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 Abstract 
Cartilage destruction in arthritic disease is characterised by irreversible collagenolysis, 
resulting in loss of efficient joint function. Of the enzymes capable of hydrolysing 
native collagen fibrils, matrix metalloproteinase-13 (MMP-13) is the major 
collagenolytic MMP in osteoarthritis (OA), making this MMP an important disease-
modifying target. Addition of interleukin-1 (IL-1) and oncostatin M (OSM) to bovine 
nasal cartilage in explant culture results in a synergistic loss of the collagen matrix, 
accompanied by a dramatic increase in the expression of collagenase enzymes. 
Interleukin-4 (IL-4) is able to ameliorate this collagen degradation by the strong 
repression of IL-1+OSM-induced MMP-13 expression. The aim of this work was to 
determine the mechanism by which IL-4 abolishes IL-1+OSM-induced MMP-13 
expression. 
 
Work examining the effect of IL-4 on the methylation status of CpG residues within the 
MMP-13 promoter failed to identify a role for epigenetic modification in the mechanism 
of action of IL-4. Subsequent cell signalling studies demonstrated Akt activation by IL-
4. Therefore, genome-wide microarray analyses of cytokine stimulated cartilage and 
chondrocytes was used to identify candidate Akt-interacting proteins involved in the 
repressive effects of IL-4 on MMP-13. Trb1 was identified as a novel gene potentially 
involved in the repression of MMP-13 by IL-4 via Akt. Gene silencing experiments in 
chondrocytes confirmed that transfection with Trb1 specific siRNA resulted in the 
rescue of IL-4 mediated repression of IL-1+OSM-induced MMP-13 expression, 
indicating an anti-inflammatory role for Trb1. Trb1 belongs to family of three tribbles 
proteins and additional studies to investigate the roles of other tribbles family members 
in MMP regulation identified Trb3 as having a potentially pro-inflammatory role in 
MMP regulation in chondrocytes. Silencing of Trb3 was reproducibly shown to abolish 
IL-1+OSM-induced MMP-13 expression. The novel data presented in this thesis 
indicate that tribbles proteins act as key regulators of catabolic and anabolic responses 
in chondrocytes. From these findings it could be hypothesised that alterations in 
functional levels of specific tribbles proteins may protect against aberrant MMP gene 
expression in chondrocytes. The identification of this potentially important regulatory 
mechanism of signalling pathways important in MMP-13 gene expression in 
chondrocytes could be translated into a tractable therapy for arthritis once the 
mechanism has been unravelled. 
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Chapter 1: Introduction 
 
 
1.1 Articular cartilage 
 
1.1.1 Structure and function 
Articular cartilage covers the articulating surfaces of bones, providing a friction-free 
surface to facilitate joint motion. This unique tissue is both avascular and aneural and 
populated by only one cell type, the chondrocyte. The absence of blood vessels and 
lymphatics means that delivery of nutrients and removal of waste products must occur by 
diffusion through the extracellular matrix (ECM) (Kuettner 1992). Like other connective 
tissues, articular cartilage derives its form and mechanical properties from its ECM 
(Buckwalter and Mankin 1997). Articular cartilage must be able to absorb and distribute 
high compressive forces. Two major macromolecules enable cartilage to provide this 
function: proteoglycan and type II collagen. Aggrecan is the predominant proteoglycan 
found in articular cartilage. It has a high sulphated glycosaminoglycan (GAG) content that, 
by nature of its negative charge, draws water into the tissue enabling it to resist 
compression. The proteoglycan is held within the cartilage by a cross-linked network of 
triple-helical type II collagen fibrils, which provide cartilage with its tensile strength (Muir 
1995; Temenoff and Mikos 2000). Other molecules such as decorin, biglycan, laminin, 
tenascin, fibromodulin and minor collagens (types VI, IX, X and XI) assist in maintaining 
the tissue through the spatial organisation of the ECM (Temenoff and Mikos 2000).  
 
Articular cartilage can be divided into four zones (superficial, transitional, middle and 
calcified) based on differences in matrix morphology and biochemical composition. The 
superficial zone (zone 1) is the thinnest zone and is located adjacent to the joint cavity. 
Within this zone there are two distinct layers. An acellular sheet of predominantly collagen 
fibers (the lamina splendens) covers the joint and underneath this is a second layer, 
composed of flattened chondrocytes and containing a high concentration of water, more 
collagen and less proteoglycan than the other zones. This combination of molecules in the 
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superficial zone imparts more tensile strength to this area of the matrix, enabling it to resist 
shearing forces from the articulating surfaces. Zone 2, known as the transitional zone, 
contains chondrocytes that are spherical and synthesise an ECM that has larger collagen 
fibrils, more proteoglycan and less collagen and water than in the previous zone. The third 
zone (middle or radial zone) contains rounded chondrocytes that are stacked in columns 
perpendicular to the articulating surface. These cells show high synthetic activity, ten times 
that of superficial zone chondrocytes (Wong et al. 1996). A tidemark separates the third 
zone from the forth zone. Zone 4 (calcified zone) lies closest to the subchondral bone and 
consists of a thin layer of calcified cartilage (Figure 1.1).  
 
Figure 1.1 The zones of articular cartilage. See section 1.1.1 for details (taken from Elliott and Cawston 
2001). 
 
1.1.2 Chondrocytes 
Chondrocytes represent only a small percentage (approximately 1%) of the total volume of 
articular cartilage, but are vital for the synthesis and maintenance of the cartilaginous 
matrix. These cells originate from mesenchymal stem cells (MSCs) found in the bone 
marrow in mature individuals. During embryogenesis, MSCs differentiate into 
chondrocytes and secrete the cartilage ECM. In the absence of a vascular supply, 
chondrocytes receive nutrients from the synovial fluid, which is synthesised by fibroblasts 
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in the synovial membrane. Maintenance of the articular cartilage requires replacement of 
matrix components. Not only can chondrocytes synthesise all the components of the ECM, 
they then must assemble and organise these components into a highly ordered framework 
(Buckwalter and Mankin 1997).  
 
Under normal circumstances, proliferation of chondrocytes is limited and it is thought they 
maintain the ECM through low-turnover replacement of certain matrix proteins. If the 
equilibrium between synthesis and degradation is disrupted, as in ageing and joint disease, 
the rate of loss of collagens and proteoglycans from the matrix exceeds the rate of 
deposition of newly synthesized molecules. Originally thought of as an inert tissue, 
cartilage is now thought to respond to extrinsic factors that regulate gene expression and 
protein synthesis in chondrocytes. Many studies over the last two decades have confirmed 
that chondrocytes are able to respond to mechanical stress and stimuli such as cytokines 
and growth factors that ultimately contribute to structural changes in the surrounding 
cartilage matrix (Goldring and Goldring 2007).  
 
1.1.3 Extracellular matrix 
The articular cartilage matrix consists of two components: the tissue fluid, which accounts 
for as much as 80% of the wet weight of the tissue, and the macromolecular framework that 
gives the tissue its form and stability and accounts for the remaining ~20% of the wet 
weight (Buckwalter et al. 1997).  
1.1.3.1 Collagen 
Articular cartilage contains various genetically distinct collagen types, specifically types II, 
VI, IX, X and XI. Together, types II, IX and XI form the cross-banded fibrils seen with 
electron microscopy of articular cartilage. It is the formation of these fibrils into a tight 
meshwork that endows articular cartilage with its tensile strength, in addition to entrapping 
the larger proteoglycans thus contributing to the cohesiveness of the cartilage (Buckwalter 
et al. 1997). Each collagen molecule is composed of three α-chains, characterised by a Gly-
Xaa-Yaa sequence, where Xaa is often proline and Yaa is hydroxyproline. Due to the high 
content of imino amino acids, the α-chains of collagen all form a left-handed α-helix. 
Furthermore, the presence of a glycine residue at every third residue allows the α-chains to 
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twist around one another to form a superhelix. The triple-helical structure is such that the 
peptide bonds linking the adjacent amino acids are buried within the molecule, making it 
highly resistant to proteolytic degradation (Cremer et al. 1998). Type II collagen is almost 
exclusively found in articular cartilage, with type I collagen predominating in other 
connective tissues such as bone, skin and tendon. In adult articular cartilage, type II 
collagen accounts for 90-95% of the collagen. The type II collagen molecule is composed 
of three identical polypeptide chains [α1(II)]3, each consisting of a single 300 nm-long 
triple helix with short telopeptides at each end (Figure 1.2).
 
 Although the functions of the 
other types of collagen present in articular cartilage are not fully understood, it is thought 
that type IX and XI are needed to stabilise the fibrillar network (Kuettner 1992). Type X 
collagen has been immunolocalised to the zone of calcified cartilage and is synthesised 
only by hypertrophic cells within this zone. Type VI collagen is thought to be localised in 
the capsular matrix around chondrocytes and chondrons (Kuettner 1992). 
 
Collagen 
fibril
Packing of 
collagen 
molecules
Collagen 
molecule
Triple 
helix
64 nm Microfibrils
Overlap zone
Hole zone
1.5 nm
280 nm
 
 
Figure 1.2 Structure and organisation of collagen. Three polypeptide α-chains assemble to form a triple 
helical precursor molecule, procollagen. After secretion, the globular regions are cleaved from each end of the 
procollagen molecule to form collagen. Collagen molecules assemble in a precise staggered arrangement, 
overlapping to give a 64 nm periodicity seen under the electron microscope (taken from Cleaver 2000). 
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1.1.3.2 Proteoglycans 
A proteoglycan is a protein which has one or more attached GAG chains. A variety of 
proteoglycans are found in articular cartilage that are essential for its normal function, 
including aggrecan, decorin, biglycan, fibromodulin and lumican. Articular cartilage is 
characterised by its high aggrecan content, which forms proteoglycan aggregates in 
association with hyaluronan (HA) and link proteins (LP) (small non-collagenous proteins). 
It is these aggregates that are crucial in distributing load in weight-bearing joints and 
providing the osmotic properties needed to resist compressive loads as well as anchoring 
the proteoglycans within the matrix. These hydrophilic proteoglycan aggregates draw water 
into the tissue, enabling it to undergo reversible deformation. Aggrecan accounts for 90% 
of the proteoglycan mass in articular cartilage. It has multiple functional domains and its 
core protein consists of three globular regions, known as G1, G2 and G3 (Figure 1.3).   
Hyaluronic
acid
Link 
protein
Keratan
sulphate 
rich region
Chondroitin sulphate 
rich region
G1
G2
G3
IGD
 
 
Figure 1.3 Structure of aggrecan. Aggrecan consists of three globular domains (G1, G2 and G3) separated 
by linear portions of polypeptide. The aggrecan interglobular domain (IGD) between G1 and G2 is 
particularly susceptible to proteolytic cleavage. The region between G2 and G3 binds highly sulphated GAGs. 
Aggrecan molecules bind to hyaluronic acid via the G1 domain and this binding is enhanced by link protein 
(taken from Pyle 2003). 
 
The interglobular domain (IGD) that links the G1 and G2 domains is a target for proteolytic 
attack and is a key site for cleavage as it separates the major GAG bearing region of 
aggrecan from the G1 domain that anchors it in the matrix. Almost 90% of the aggrecan 
mass is carbohydrate, which consists mostly of chondroitin sulphate chains, but also 
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includes keratan sulphate chains and O- and N-linked oligosaccharides (Hardingham and 
Fosang 1992; Hardingham and Fosang 1995; Roughley 2006).   
 
In addition to aggrecan, other non-aggregating proteoglycans have been identified in 
articular cartilage. These proteoglycans have shorter protein cores, fewer GAG chains and 
instead of directly contributing to the mechanical behaviour of the tissue are thought to be 
involved in the organisation of collagen molecules. Decorin, biglycan, fibromodulin and 
lumican are all small leucine-rich repeat proteoglycans (SLRPs) and are characterised by 
multiple adjacent domains possessing a common leucine-rich motif (Hocking et al. 1998). 
Decorin, fibromodulin and lumican are known to interact with type II collagen and so may 
play a role in the stabilisation of the collagen meshwork (Hedbom and Heinegard 1993).  
The interactions of biglycan are less well understood. In addition to a stabilisation role, 
SLRPs appear to help limit access of collagenases to their unique cleavage site, therefore 
they may also be important in preventing proteolytic damage (Hocking et al. 1998; 
Roughley 2006). 
 
1.2 Arthritis 
 
Despite its durability and ability to maintain itself, articular cartilage is susceptible to 
injuries and disease resulting in irreparable tissue damage. One in five adults have long-
term health problems due to arthritis (Arthritis Research Campaign 2002). Whilst many 
types of arthritis exist, the most common examples of arthritic disease are rheumatoid 
arthritis (RA) and osteoarthritis (OA).  
 
The arthritides are characterised by a progressive loss of articular cartilage and this loss of 
cartilage is associated with degradation of major ECM components. As described earlier 
(section 1.1.1), the ECM consists mainly of aggrecan and Type II collagen. Collagen 
provides cartilage with its tensile strength and aggrecan (due to its negative charge) draws 
water into the cartilage, thus enabling it to resist compression (Moore and Dalley 1999). 
The loss of aggrecan during cartilage degradation is rapid but reversible. Collagen is much 
less readily released, however when collagen degradation does occur, the tissue is 
irreversibly damaged. Collagen breakdown is therefore considered to be the key step in 
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controlling cartilage turnover (Jubb and Fell 1980). Human articular cartilage undergoes 
remodelling as a consequence of anabolic and catabolic processes. Formation and 
progression of cartilage lesions is widely accepted to be, at least partly, a consequence of 
secretion of inflammatory mediators that disrupt cartilage-matrix homeostasis, thus altering 
chondrocyte metabolism (Pelletier et al. 1993). Healthy cartilage ECM is maintained in a 
state of dynamic equilibrium, with a balance between synthetic and degradative pathways. 
However, in both RA and OA this balance is disrupted, with degradation exceeding 
synthesis. This results in breakdown of cartilage tissue and subsequent loss of joint function 
(Shingleton et al. 1996).   
 
1.2.1 Rheumatoid arthritis 
RA affects approximately 1% of adults in developed countries and is characterised by 
chronic inflammation of multiple joints and subsequent destruction of cartilage and bone 
(Figure 1.4). Genetic, environmental, infectious and hormonal factors are all thought to be 
involved in the development of RA.  Although the precise pathogenesis of RA remains 
unclear, T cells, B cells, macrophages, neutrophils and synovial fibroblasts are known to be 
central to the mechanisms of joint inflammation and disease progression.  The initiating 
trigger in RA is unclear, however the disease is generally considered to have an 
autoimmune basis. A number of potential antigens have been proposed to play a role 
including collagen type II, heat shock proteins and gp39. However, only rheumatoid factor, 
antibodies to citrullinated antigens, and antibodies to immunoglobulin binding protein have 
shown sufficient sensitivity and specificity to be considered clinically. The controversy of 
whether autoantibodies contribute to, or are secondary to, the pathogenesis of RA is still a 
matter of debate (Andersson et al. 2008).  
 
Genetic predisposition to RA is polygenic and complex. The concordance of monozygotic 
twins of 12–15% in comparison with the concordance of dizygotic twins of 2–4% provides 
evidence of a genetic contribution to the disease (Jirholt et al. 2001). In recent years there 
has been a huge increase in the number of confirmed susceptibility loci identified for RA, 
although the largest contribution to RA susceptibility remains on the HLA-DRB1 gene. A 
strong association between possession of HLA-DR haplotypes (DRB1*0101, 0401, 0405  
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Figure 1.4 Schematic representation of the joint inflammatory events in rheumatoid arthritis (RA). The 
inflammatory response in the RA joint is characterized by marked swelling and inflammation. Immune cell 
infiltration into both the synovial fluid (SF) and synovial tissue (ST) accompanies this inflammation, in 
addition to the proliferation of resident ST cells and angiogenesis. Formation of the destructive tissue front or 
pannus occurs as the ST extends over cartilage and bone. The majority of the cartilage destruction and bone 
erosion occurs at the junction with pannus (taken from Pettit and Thomas 1999). 
 
and 1402) and an increased risk of developing RA has been demonstrated. These subtypes 
were found to possess a ‘shared’ epitope (Gregerson 1997).  
 
As mentioned previously the initiating trigger in RA is unknown, however it has been 
proposed that the initiating event in RA involves an infectious agent or other environmental 
exposure. The initiating trigger is followed by the induction of an immune response that 
results in inflammation in the synovial membrane. The synovium lines the joint cavity and 
is the site of production of synovial fluid. The normal synovium is comprised of 
macrophage- and fibroblast-like cells known as synoviocytes. In RA, the lining becomes 
hyperplastic due to an increase in macrophages and fibroblasts. In addition, increased 
vascularisation is also observed. The synovial lining gradually proliferates leading to 
formation of the pannus, which extends over the articular cartilage. Although there is an 
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association between inflammation and joint damage, it is now thought that these two 
processes may not in fact be coupled. There is increasing clinical and experimental 
evidence to show that inflammation and destruction can be uncoupled and that different 
cells and mediators are important in these processes. The sustained degradation of the ECM 
may be a later consequence of the inflammatory process via stimulation of the resident 
chondrocytes (van den Berg and van Riel 2005). Cartilage destruction is mediated through 
the increased expression of degradative enzymes, resulting in breakdown of cartilage and 
erosion of the subchondral bone leading to disruption of normal joint function (Sweeney 
and Firestein 2004; Otero and Goldring 2007). 
 
1.2.2 Osteoarthritis 
OA is the most common of the arthritides, with the majority of individuals over the age of 
65 showing radiographic and/or clinical evidence of OA. The most commonly affected sites 
include the hands, knees, hips and spine (Felson 2006). OA is characterised by the 
progressive loss of articular cartilage, thickening of the subchondral plate, formation of new 
bone at the joint margins and the formation of subchondral bone cysts resulting in 
symptoms such as pain, stiffness and loss of mobility (Goldring and Goldring 2006). A 
variety of risk factors are associated with susceptibility to OA, such as increasing age, 
obesity, joint injury and genetic predisposition (Felson et al. 2000). OA can be subdivided 
into two categories; primary OA occurs in middle-aged to elderly patients and was 
considered to be a consequence of ‘wear and tear’ (although this is now known to be an 
over-simplified explanation), and secondary OA that can occur at any age as a result of 
trauma or disease.  
 
Historically, OA has been considered a process involving a disturbance of the normal 
balance between degradation and repair in the articular cartilage and subchondral bone. OA 
was therefore thought of as a primarily non-inflammatory condition as opposed to RA 
where both local and systemic inflammation is a central feature. However, this theory is 
now being reconsidered. Low-grade synovitis, increased vascularity and inflammatory-cell 
infiltration have been reported in patients with all grades of OA (Smith et al. 1997). More 
recently, magnetic resonance imaging (MRI) has reinforced the idea that synovitis is a 
frequent feature of OA (Loeuille et al. 2005). Inflammatory cytokines and mediators 
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produced by joint tissues are increasingly being shown to play a role in the pathogenesis of 
OA, perpetuating disease progression and therefore representing potential therapeutic 
targets (Abramson and Attur 2009).  
 
1.2.3 Arthritis treatment 
Treatment for OA has changed little over the last fifty years and is limited to pain relief and 
in severe cases, joint replacement. However, articular cartilage is able to provide stable 
movement with less friction than any prosthetic replacement, and can also alter its 
properties in response to differences in loading. There is no available treatment that can 
prevent or slow disease progression. RA, however, has many more treatment options 
including disease modifying anti-rheumatoid drugs (DMARDs) and the more recently 
developed anti-TNFα (Etanercept and Infliximab) and targeted B-cell (Rituximab) therapies 
(Kumar and Clark 2005). Although anti-TNFα therapy can offer significant disease 
remission in some, it is by no means effective in all patients and can cause potentially life-
threatening side effects (British Medical Association and Royal Pharmaceutical Society of 
Great Britain 2005). Hence, research into new treatments is ongoing. 
 
1.3 Proteinases 
 
The primary cause of the cartilage and bone destruction associated with the arthritides is an 
elevation of the levels of active proteinases. Proteinases are responsible for enzymatic 
cleavage of peptide bonds, a process that is an essential requirement of many biological 
processes (Rengel et al. 2007). These enzymes are secreted by various cells within the joint 
and degrade the ECM. The expression of these proteinases is regulated by various 
cytokines and growth factors acting on the cells found within the joint. 
 
Exopeptidases specifically cleave substrates at the N-terminal or C-terminal positions of 
polypeptides, whilst endopeptidases (also called proteinases) cleave internal peptide bonds. 
Proteinases can be subclassified into five main classes of proteinases. This subclassification 
is based on their mechanism of catalysis, which is related to the chemical group involved in 
the process of hydrolysis. Therefore, proteinases are described as aspartate, cysteine and 
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threonine types, which act intracellularly in an acid pH, or as serine and metallo catalytic 
types, which act extracellularly in a neutral pH (Figure 1.5) (Barrett 1980; Rengel et al. 
2007).   
 
A subdivision of the metalloproteinase superfamily is the metzincins, a structurally related 
group of zinc-dependent endoproteinases that include the serralysins, the astacins, ADAMs 
(a disintegrin and metalloproteinase), MMPs (matrix metalloproteinases) and pappalysins 
(Barrett 1980; Overgaard et al. 2001). It is now thought that the enzymes mainly 
responsible for the degradation of cartilage are the MMPs. 
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Figure 1.5 The five main classes of proteinases. Adapted from Rengel et al. (2007). 
 
1.3.1 Matrix metalloproteinases 
The MMPs are a large family of endopeptidases, which collectively are capable of 
degrading all components of the ECM and therefore have been extensively studied in 
relation to the modulation of matrix function (Nagase and Woessner 1999; Cawston and 
Young 2010). They play key roles in normal biological processes such as morphogenesis, 
wound healing, tissue repair and remodelling in response to injury. However, they are also 
central in the progression of diseases such as atheroma, arthritis, cancer and chronic tissue 
ulcers (Nagase et al. 2006). MMPs are known to be involved in the turnover and 
breakdown of the ECM, both in healthy and arthritic cartilage. MMPs are extracellular 
proteins, but recent studies have suggested that MMP-1 (Limb et al. 2005), MMP-2 (Kwan 
et al. 2004) and MMP-11 (Luo et al. 2002) are also found intracellularly and could act on 
intracellular proteins. Traditionally, MMPs have been classified according to primary 
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structure, substrate specificity and cellular location resulting in five groups; the 
collagenases, stromelysins, gelatinases, matrilysins and membrane-type (MT) MMPs, 
although several recently discovered enzymes do not fit this classification, including MMP-
12 (metalloelastase), MMP-19, MMP-20 (enamelysin), and MMP-23 (Clark and Parker 
2003) (Table 1.1). 
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MMP subfamily MMP Alternative name(s) MW 
(kDa) 
Known matrix substrates 
Collagenases MMP-1 Interstitial collagenase 
Fibroblast collagenase 
Collagenase-1 
55/45 Collagens I, II, III, VII, VIII, X; 
gelatin; aggrecan; proteoglycan link 
protein; tenascin; entactin; α1-PI; 
α2-M 
MMP-8 Neutrophil collagenase 
Collagenase-2 
75/58 Collagen types 1, IV, V, VII, X, XI, 
XIV; gelatin ;aggrecan; α1-PI; α2-
antiplasmin; fibronectin 
MMP-13 Collagenase-3 60/48 Collagens I, II, III, IV, VII, X; 
gelatin; 
plasminogen activator inhibitor 2; 
aggrecan; 
tenascin 
MMP-18 Xenopus collagenase 
Collagenase-4 
55/42 Collagen I, gelatin 
Gelatinases MMP-2 Gelatinase-A 
72 kDa gelatinase 
Type IV collagenase 
72/66 Collagens I, IV, V, VII, X, XI, XIV; 
gelatin; elastin; 
fibronectin; vitronectin; aggrecan; 
link protein; 
α1-PI; activates MMP-9 and MMP-
13 
MMP-9 Gelatinase-B 
92 kDa gelatinase 
Type V collagenase 
 
92/86 Collagens I, IV, V, VII, X, XI, XIV; 
gelatin; elastin; 
fibronectin; aggrecan; link protein; 
α1-PI 
Stromelysins MMP-3 Stromelysin-1 
Transin 
Proteoglycanase 
57/45 Collagens I, II, III, IV, V, VIII, IX, 
X, XI; gelatin; 
aggrecan; link protein; fibronectin; 
α1-PI; 
laminin; α2-M; activates MMP-1, -7, 
-8, -9 and –13. 
MMP-10 Stromelysin-2 
Transin-2 
57/44 Collagens III, IV, V; gelatin; 
aggrecan; elastin; 
link protein; fibronectin; activates 
MMP-1 and MMP-8 
MMP-11 Stromelysin-3 51/44 α1-PI 
Membrane-type MMPs MMP-14 MT1-MMP 66/56 Collagens I, II, III, IV; gelatin; 
elastin; aggrecan; 
proteoglycan; fibronectin; 
vitronectin; activates 
MMP-2 and MMP-13 
MMP-15 MT2-MMP 72/60 Collagens I, II; gelatin; fibronectin; 
tenascin; 
laminin; proteoglycan; activates 
MMP-2 
MMP-16 MT3-MMP 64/52 Activates MMP-2 
MMP-17 MT4-MMP 57/53 Gelatin 
MMP-24 MT5-MMP 63/45 Gelatin; fibronectin; proteoglycan; 
activates MMP-2 
MMP-25 MT6-MMP 
Leukolysin 
63/? Activates MMP-2 
Others MMP-7 Matrilysin 28/19 Collagens IV, X; gelatin; aggrecan; 
link protein; 
tenascin; fibronectin; laminin; 
elastin; entactin; 
α1-PI; activates MMP-1, -2 and –9 
 MMP-12 Macrophage elastase 54/45/22 Collagen IV; gelatin; elastin; α1-PI; 
fibronectin; 
vitronectin; laminin 
 MMP-19 RASI-1 54/45 Aggrecan 
 MMP-20 Enamelysin 54/22 Amelogenin 
 MMP-21 XMMP 70/53 Not known 
 MMP-22 CMMP 52/43 Gelatin 
MMP-23  ?/? Not known 
 MMP-26 Endometase 
Matrrilysin-2 
28/? Gelatin; α1-PI 
Table 1.1 Matrix Metalloproteinases. MMPs can be sub-grouped according to similarities in domain 
structure and function. Molecular weight (MW) of the latant (bold) and active forms are shown. Adapted from 
Bigg and Rowan (2001). 
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1.3.2 Structure of matrix metalloproteinases 
 
The MMPs possess a multidomain structure (Figure 1.6): 
 
Pre-domain encodes a short hydrophobic signal peptide of 18-30 residues, which is 
required for enzyme maturation and its secretion from the cell into the extracellular space. 
 
Propeptide domain is approximately 80 residues in length and contains the highly 
conserved PRCG(V/N)PD sequence motif. The cysteine residue within this motif is known 
as the ‘cysteine switch’ and ligates with the catalytic zinc to maintain the enzymes in their 
latent state (Van Wart and Birkedal-Hansen 1990). 
 
Catalytic domain is approximately 170 amino acids in length. This domain 
characteristically contains a zinc atom and is responsible for enzyme activity (Rengel et al. 
2007).  
 
Hinge domain separates the N- and C-terminal domains and is of variable length. 
 
Haemopexin domain is about 200 amino acids in length. The haemopexin domain is 
required for hydrolysis of triple helical collagens. Removal of the MMP-1, MMP-8, MMP-
13, or MMP-14 haemopexin domain results in a loss of collagenolytic activity (Lauer-
Fields et al. 2009). 
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Figure 1.6 Domain structure of MMPs. All MMPs have a catalytic domain containing the active site zinc 
(Zn). In addition, several MMPs contain a furin recognition motif (Fu), which enables intracellular activation 
by furin-like proteinases. All MMPs (with the exception of MMP-7, -23 and -26) possess a haemopexin 
domain. Several other domains are present in certain MMPs including fibronectin-like domains (F) in MMP-2 
and -9 and a vitronectin-like domain (V) in MMP-21. Some MMPs are anchored to the cell surface via a 
glycosylphosphatidyl inositol (GPI) anchor and others by a transmembrane domain (TM) with cytoplasmic 
tail (Cyt). Unlike all other MMPs, MMP-23 possesses an N-terminal TM domain, a cysteine array (CA) and 
an immunoglobulin (Ig-like) domain. Taken from Cawston and Young (2010). 
1.3.2.1 The collagenases 
Type II collagen is extremely resistant to most proteinases because of its triple helical 
structure. Thus, the only enzymes that are capable of degrading type II collagen are the 
collagenases. The three human collagenases, MMP-1, MMP-8 and MMP-13, are known to 
cleave the three α chains of types I, II and III collagen at a single site to give 3/4 and 1/4 
length products (Miller et al. 1976). MMP-2 (a gelatinase) and MMP-14 (a MT-MMP) 
have also been shown to degrade collagen (Bigg and Rowan 2001). However, the specific 
activity of MMP-14 for type II collagen is extremely weak (Ohuchi et al. 1997). The 
catalytic domains of collagenases are also capable of cleaving non-collagenous substrates, 
but they are unable to cleave native fibrillar collagens without their haemopexin domain. It 
is the cooperation between the catalytic and haemopexin domains that is thought to be 
necessary for their collagenolytic activity (Chung et al. 2004). After the collagen molecules 
have been cleaved by the collagenases, these fragments are no longer stable at body 
temperature and the helical structure is lost. The fragments then become susceptible to 
proteolytic degradation by other MMPs.  
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Collagen is not readily released from articular cartilage, however when collagen 
degradation does occur, the tissue is irreversibly damaged (Jubb and Fell 1980). MMP-1 
and MMP-13 have predominant roles in RA and OA because they are rate limiting in the 
process of collagen degradation, making these collagenase enzymes potential targets for 
therapy in arthritis. 
 
Although all the collagenases cleave collagen, it is probable that the relative importance of 
individual collagenases differs in different forms of arthritis. Current dogma suggests 
MMP-1 is the key collagenase in RA, whereas MMP-13 is thought to be the important 
collagenase in OA. MMP-8 is only a minor gene product of human articular chondrocytes 
(Stremme et al. 2003), so it is likely that MMP-8 is not involved in the cartilage destruction 
seen in OA and RA. Instead, MMP-8 is thought to be a key enzyme in septic arthritis due 
its production by neutrophils (Rajasekhar et al. 2004).  
 
MMP-1 is also known as interstitial collagenase, fibroblast collagenase and collagenase-1. 
Type III collagen is cleaved most efficiently by MMP-1, followed by type I collagen and 
then type II collagen (Welgus et al. 1981). MMP-1 is known to be expressed in many cell 
types including stromal fibroblasts, macrophages, endothelial cells, epithelial cells and 
chondrocytes (Brinckerhoff et al. 2000; Mengshol et al. 2000). Under normal physiological 
conditions the expression of MMP-1 is low, however it is readily induced under 
pathological and inflammatory conditions (Brinckerhoff et al. 2000).  
 
MMP-8, also referred to as collagenase-2 or neutrophil collagenase, was originally thought 
to be expressed solely by maturing neutrophils, and functionally restricted to ECM 
breakdown. However, in recent years it has been discovered that this protease can be 
expressed by a wide variety of cell types and plays an important regulatory role in acute 
and chronic inflammation (Van Lint and Libert 2006). Whilst MMP-8 is active against type 
II collagen, type I collagen appears to be the preferential substrate of MMP-8 (Hasty et al. 
1987). 
 
MMP-13, also known as collagenase 3, was previously thought to be associated 
exclusively with malignancy due to its discovery in breast carcinomas (Freije et al. 1994). 
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However, it has since been associated with a variety of non-malignant conditions, in 
particular arthritis (Mitchell et al. 1996). It is expressed by both chondrocytes and synovial 
cells in human OA and RA and is thought to play a critical role in cartilage destruction. 
MMP-13 preferentially degrades type II collagen (Knauper et al. 1996a) and is able to 
cleave type II collagen approximately five times faster than MMP-1 (Reboul et al. 1996). 
MMP-13 knock-out mice exhibit a normal lifespan and do not show any major phenotypic 
abnormalities. However, microscopic analysis does demonstrate defects in the growth plate 
cartilage with an increase in the hypertrophic chondrocyte zone and a delay in primary 
ossification (Takaishi et al. 2008).  To date there have been no published studies examining 
OA-like pathology in the MMP-13 knockout mouse.  
1.3.2.2 The stromelysins 
There are three stromelysins; MMP-3 (stromelysin 1), MMP-10 (stomelysin 2) and MMP-
11 (stromelysin 3). MMP-3 and MMP-10 are highly homologous, with similar structures 
and substrate specificity. MMP-3 is not constitutively expressed but can be induced by IL-1 
and TNF-α in chondrocytes and fibroblasts (MacNaul et al. 1990). MMP-3 is able to 
activate other MMPs, including the collagenases (Murphy et al. 1987). MMP-10 is also 
able to activate various MMPs, including MMP-1 and -8 (Knauper et al. 1996b). Homology 
between MMP-11 and the other stromelysins is reduced because of the presence of a 10-
amino acid insert between the pro- and catalytic domains that enables recognition of furin. 
In addition, both MMP-3 and -10 are secreted from cells as inactive pro-MMPs, whereas 
MMP-11 is activated intracellularly by furin and so is secreted from the cell as an active 
enzyme (Pei and Weiss 1995).  
1.3.2.3 The gelatinases 
This sub-group consists of MMP-2 (gelatinase A) and MMP-9 (gelatinase B). The 
gelatinases differ from the other MMPs in that they possess three repeats of a fibronectin 
type II motif inserted into their catalytic domain, which enable efficient binding to gelatin 
(Steffensen et al. 1995). These enzymes possess similar catalytic activity and are important 
in the cleavage of denatured collagen (gelatin). Their substrates also include type IV and 
type V collagen and laminin (Murphy and Nagase 2008). MMP-2 is the most widespread of 
all the MMPs and it is able to activate proMMP-9 (Fridman et al. 1995) and -13 (Knauper 
et al. 1996c). It has been suggested that MMP-2 digests native collagen in a similar manner 
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to the ‘classical’ collagenases (Patterson et al. 2001), however the collagenolytic activity of 
MMP-2 is much weaker than the other collagenases. MMP-9 is expressed in many 
transformed and tumour-derived cells as well as in chondrocytes, neutrophils, monocytes 
and alveolar macrophages (Matrisian 1992). 
1.3.2.4 The matrilysins 
This group consists of MMP-7 and MMP-26. Their structure differs from that of other 
MMPs because they lack the haemopexin domain. MMP-7 is synthesised by epithelial cells 
and MMP-26 is expressed in many cells such as those of the endometrium, but also in some 
carcinomas (Murphy and Nagase 2008).  
1.3.2.5 The membrane-type MMPs 
The membrane-type MMPs (MT-MMPs) can be further subdivided into two groups. The 
first contains four MMPs that are type I transmembrane proteins (MMP-14, -15, -16 and -
24) and the second consists of two glycosylphosphatidylinositol-anchored proteins (MMP-
17 and -25). All MT-MMPs possess a furin-like pro-protein convertase recognition 
sequence and so are activated intracellularly. With the exception of MMP-17, all MT-
MMPs can activate proMMP2 (English et al. 2001). MMP-14 is able to activate MMP-13 
on the cell surface and therefore is of particular relevance to cartilage degradation (Knauper 
et al. 1996c). The latent form of MMP-14 is activated by furin and plasmin (Okumura et al. 
1997) and once activated, is capable of degrading components of the ECM (including 
interstitial collagens) (Ohuchi et al. 1997).  
 
1.3.3 Regulation of matrix metalloproteinases 
MMPs regulate many biological processes and the production and activation of MMPs is 
strictly regulated in vivo at various critical steps (Burrage et al. 2006). Constitutive 
expression is minimal and cells within intact tissues do not usually store MMPs (with the 
exception of neutrophils) (Reunanen and Kähäri 2005). The potent proteolytic activity of 
MMPs is tightly controlled at 3 stages; synthesis, proenzyme activation and inhibition 
(Figure 1.7).  
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Figure 1.7 The regulation of MMPs occurs at three distinct levels: synthesis and secretion, activation 
and inhibition. Taken from Hochberg et al. (2003). 
1.3.3.1 Synthesis  
Within the rheumatoid joint are large numbers of inflammatory cells, T cells, macrophages 
and neutrophils. These cells interact with synovial cells, resulting in the production of 
cytokines such as IL-1 and TNF-α, which in turn stimulate many cell types to produce 
MMPs. Furthermore, certain cytokines (for example IL-1 or TNF-α in combination with 
OSM (Cawston et al. 1998) act synergistically to increase the production of MMPs by cells.  
Genetic variations can influence basal and inducible levels of MMP expression, in turn 
influencing the development of diseases such as coronary heart disease and cancers. 
Naturally occurring single-nucleotide polymorphisms (SNPs) have been detected in the 
promoter of a number of MMP genes and these sequence alterations have been shown to 
have allele-specific effects on the transcriptional activities of MMP gene promoters (Ye 
2000; Decock et al. 2008).  
1.3.3.2 Activation of proenzymes  
All MMPs are synthesised in a proenzyme form. Activation of the proenzyme requires 
proteolytic removal of the 10 kDa pro-peptide region. This process removes the conserved 
cysteine residue, which in the proenzyme, blocks the active-site zinc atom (Springman et al. 
1990). The activation of proMMPs by other active MMPs is well documented and suggests 
that carefully controlled activation cascades exist in vivo. Some MMPs, including MMP-
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14, possess a conserved sequence of 10-12 amino acids between the propeptide and N-
terminal domain that is recognised by the furin family of serine proteinases (Pei and Weiss 
1995). This enables activation of these MMPs within the Golgi. These enzymes are then 
able to arrive at the cell surface in an active form that is thought to be responsible for the 
activation of other MMPs (Cawston 1998). For those MMPs without this furin site, 
proteolytic removal of the propeptide is thought to occur close to the cell surface. Plasmin 
and other serine proteinases (such as trypsin, chymotrypsin, elastase and kallikreins) are 
able to activate certain pro-MMPs. The activators of the MMPs of particular relevance to 
the arthritides are summarized in Table 1.2.  
 
Pro-MMP Activators 
ProMMP-1 MMP-3, MMP-10, plasmin, kallikreins, 
chymase 
ProMMP-13 MMP-2, MMP-3, MMP-14, plasmin 
ProMMP-2 MMP-14, MMP-15 MMP-16 MMP-24, 
MMP-25 
ProMMP-9 MMP-1, MMP-2, MMP-3, MMP-7, MMP-
10, MMP-13, kallikreins, elastase, plasmin 
ProMMP-3 Plasmin, tryptase, chymotrypsin, neutrophil 
elastase, cathepsin G, kallikreins, 
thermolysin, chymase 
ProMMP-14 Proprotein convertases (e.g. furin), plasmin, 
urokinase 
Table 1.2 Potential activators of MMPs. Adapted from Murphy et al. (2000). 
1.3.3.3 Inhibition 
1.3.3.3.1 Natural inhibitors of MMPs 
Any disruption in the balance of active MMPs and their inhibitors can result in diseases 
associated with uncontrolled ECM turnover, such as arthritis. Tissue inhibitors of 
metalloproteinases (TIMPs) are endogenous inhibitors of MMPs and so are important 
regulators of ECM turnover (Brew and Nagase 2010). They are not only important in the 
inhibition of active enzymes, but also play a role in proMMP activation, matrix binding and 
cell growth (Brew et al. 2000). To date, four homologous TIMPs have been identified: 
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TIMP-1 (Welgus et al. 1979), TIMP-2 (Stetler-Stevenson et al. 1989), TIMP-3 (Pavloff et 
al. 1992) and TIMP-4 (Greene et al. 1996). TIMPs -1, -2, -3 and -4 inhibit MMP activity 
through noncovalent binding to the zinc-binding sites of MMPs (Reunanen and Kähäri 
2005). They bind with a 1:1 stoichiometry and this binding is essentially irreversible. 
Whilst all four TIMPs can be described as broad spectrum MMP inhibitors, their specificity 
for individual MMPs does differ (Table 1.3). TIMP-3 is thought to have the widest range of 
inhibition as it not only inhibits MMPs, but also several members of the ADAM (a protein 
with a metalloprotease and disintegrin domain) (-10, -12, -17, -28 and -33) and ADAMTS 
(an ADAM with a thrombospondin-like motif) (-1, -2, -4 and -5) families (Brew and 
Nagase 2010). The overall shape of TIMPs has been elucidated based on crystal structures 
of TIMP-MMP complexes and appears to be “wedge-like” (Nagase et al. 2006). The N-
terminal region of TIMPs is important for the inhibitory activity of the molecule and the C-
terminal is necessary for enzyme binding (Cawston 1998). TIMP-1 and TIMP-2 have been 
shown to prevent the release of collagen from bovine nasal cartilage in culture (Ellis et al. 
1994). Whilst TIMP-1 has been detected in the RA synovium (Hembry et al. 1995), the 
balance of MMPs to TIMPs appears to be altered in favour of the catabolic enzymes 
(MacNaul et al. 1990). 
 
 TIMP-1 TIMP-2 TIMP-3 TIMP-4 
Inhibition All MMPs 
except most 
MT-MMPs 
All All MMP-1, -2, -
3, -7 and -9 
Molecular mass 
(kDa) 
20.6 21.5 21.6 22.3 
Soluble Yes Yes No Yes 
Expression Inducible Constitutive Inducible ? 
Expression in 
cartilage 
Yes Yes Yes ? 
Binding to pro-
MMPs 
MMP-9 MMP-2 MMP-2,-9 MMP-2 
Table 1.3 Properties of TIMPs. Adapted from Bigg and Rowan (2001). 
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All active MMPs can also be inhibited by α2-macroglobulin, a plasma glycoprotein that 
inhibits proteinases by trapping the enzyme within the macroglobin. The complex is then 
cleared by receptor-mediated endocytosis (Strickland et al. 1990).   
 
1.3.3.3.2 Synthetic inhibitors of MMPs 
Broad spectrum MMP inhibitors have long been considered to be a possible therapeutic 
option for treatment of RA and OA. However, the use of such MMP inhibitors has been 
restricted by a toxicity known as musculoskeletal syndrome (MSS) (Clark and Parker 
2003). In an attempt to avoid MSS, low dose administration of broad spectrum MMP 
inhibitors was tried; however this resulted in a lack of efficacy. It is thought that MSS is 
probably due to the nonselective inhibition of multiple MMPs, however the exact molecular 
mechanism is unknown. As current dogma suggests MMP-13 to be the key collagenase in 
OA, the design of a highly selective MMP-13 inhibitor appears to be a good strategy for 
developing a treatment for arthritis. In recent years, Johnson et al. (2007) reported the 
generation of an orally active MMP-13 inhibitor that effectively reduced cartilage damage 
in vivo and did not induce joint fibroplasia in a rat model of MSS. A 2010 study has shown 
that fully selective MMP-13 inhibitors are able to reduce collagen degradation in human 
OA cartilage explants (Piecha et al. 2010). A reduction of 41-49% in collagen degradation 
was observed with selective MMP-13 inhibitors, compared with a reduction of 81% by the 
broad spectrum MMP inhibitor GM6001. The authors suggest that MMP-13 is therefore 
likely to be responsible for 50-60% of the increased collagenase activity in OA. The same 
study demonstrated that selective MMP-13 inhibitors were able to completely block IL-
1+OSM-induced collagen degradation in a bovine articular cartilage model. The significant 
level of inhibition by selective MMP-13 inhibitors in both the human and bovine systems 
demonstrates the integral role played by MMP-13 in cartilage degradation but highlights 
the need for further study to understand the seemingly more complex situation in human 
OA cartilage.  
Selective MMP-13 inhibitors have also been shown to reduce cartilage erosion in the SCID 
(severe combined immunodeficiency) mouse co-implantation model of RA and the 
collagen-induced arthritis (CIA) model in mice, but not in the antigen-induced arthritis 
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model (AIA) in rabbits (Jungel et al. 2010). The results of these studies taken together 
strongly support the development of this class of drugs to reduce cartilage destruction in 
arthritis patients. 
1.4 Pro-inflammatory cytokines in arthritis 
 
Cytokines are cell surface or soluble molecules that are important in mediating cell-cell 
interactions. Originally, they were classified according to their principal biological activity 
and cellular location. However, it now seems that the biological activity of particular 
cytokines can change in different situations (Goldring and Goldring 2004). Unlike 
hormones, the expression of cytokines is usually transient. The rheumatoid synovium 
contains a variety of cytokine-producing cells including macrophages, neutrophils and T 
cells. OA was traditionally thought of as non-inflammatory disease, an opinion that was 
historically based on the low numbers of leucocytes in the synovial fluid of OA patients. 
However the role of inflammatory cytokines in the pathogenesis of OA is attracting 
increased attention as inflammatory mediators are now thought to be involved in disease 
progression (Abramson and Attur 2009).  
 
Pro-inflammatory cytokines produced by the synovium and chondrocytes play a central 
role in cartilage destruction. Chronic arthritis is characterised by persistent joint 
inflammation, with IL-1 and TNF-α considered to be the key mediators in perpetuating 
cartilage and bone destruction.  Both have been found to be produced in increased 
quantities by RA synovium and can be detected in the synovial fluid of RA patients 
(Lubberts et al. 2000). OA is also characterised by an increased production of IL-1 and 
TNF-α by articular chondrocytes (Pelletier et al. 2001). Although joint swelling due to 
inflammation is a severe clinical problem, bone and cartilage destruction can occur 
uncoupled from inflammation (van den Berg 1998). Studies in experimental models have 
revealed that whilst TNF-α is an important cytokine in joint swelling, IL-1 is the dominant 
cytokine in cartilage destruction (van den Berg 1998). Cytokines are capable of acting in 
synergy, whereby the combined effects of two or more cytokines far exceeds the effects of 
either cytokine alone. For example, IL-1, when in combination with oncostatin M (OSM), 
induces a marked catabolic effect. The combination of IL-1 and OSM synergistically 
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induces the synthesis and activation of procollagenases, resulting in almost complete 
resorption of bovine nasal cartilage within a 14-day assay (Cawston et al. 1995; Cawston et 
al. 1998). Both IL-1 and OSM are relevant to the joint destruction observed in the 
arthritides as increased levels of both cytokines can be detected in the arthritic joint 
(Cawston et al. 1998). In addition, adenoviral gene transfer of IL-1 in combination with 
OSM has been shown to induce MMP production and joint damage in murine joints, 
similar to that seen in RA patients (Rowan et al. 2003).    
 
1.4.1 Interleukin-1 
IL-1 is involved in the mediation of a wide variety of biological events and has been 
implicated in the pathogenesis of several diseases, including RA. IL-1 activates important 
cell signalling pathways and is a mediator in the pathogenesis of many immunologically 
and inflammatory mediated diseases (Stylianoua and Saklatvala 1998). Prior to its 
molecular identification in the 1980s, IL-1 had been studied for many years under various 
names (such as leukocyte endogenous mediator, haematopoietin 1, endogenous pyrogen, 
catabolin and osteoclast activating factor). To date, The IL-1 family comprises eleven 
members: IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra), IL-18, IL-33 and IL-1F5–IL-
1F10. It is likely that they arose from the duplication of a common ancestral gene, as all 
eleven members possess a highly conserved gene structure (Sims and Smith 2010). IL-1α 
and IL-1β have identical biological activities because they signal through the same receptor 
complex. However, IL-1α and IL-1β differ in other respects. Both are synthesised as 
cytosolic precursors with molecular weights of 31 kDa that are cleaved to produce 17 kDa 
mature forms. However, whilst both pro- and mature forms of IL-1α are biologically active, 
IL-1β is only active after precursor cleavage by the cysteine proteinase IL-1β converting 
enzyme (ICE) (Black et al. 1988). Secondly, IL-1β is secreted and acts systemically; IL-1α 
is normally associated with the cell membrane and therefore acts locally. Thirdly, IL-1β is 
mainly produced by monocytes and macrophages, whereas IL-1α expression is more 
widespread. Lastly, the pro-domain of IL-1α has a nuclear localisation sequence. Nuclear 
IL-1α is a transcriptional transactivator and this activity is enhanced by interaction with 
histone acetyltransferases and can influence gene expression and cell survival (Sims and 
Smith 2010). 
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To date, two distinct forms of IL-1 receptor have been reported; the 80 kDa biologically 
active type I receptor (IL-1RI) and the 68 kDa biologically inert type II receptor (IL-1RII). 
The IL-1RII is thought to function as a decoy receptor, by binding IL-1 and preventing it 
from interacting with the functional IL-1RI (Colotta et al. 1994). The IL-1RI is widely 
expressed and preferentially binds IL-1α, whereas the IL-1RII preferentially binds IL-1β 
and is found mainly on B cells, neutrophils and monocytes (Stylianou and Saklatvala 
1998). The IL-1RI is able to bind the mature form of IL-1β and both forms of IL-1α. After 
binding of IL-1α or IL-1β to the single chain IL-1RI, a second subunit, called the IL-1 
receptor accessory protein (IL-1R AcP), is brought into the complex (Greenfeder et al. 
1995). The IL-1R AcP is required for internalisation of the activated IL-1R complex and 
for intracellular signalling. Signal transduction pathways activated by IL-1RI and the IL-1R 
AcP include the NF-κB, JNK/AP-1, and p38 MAP kinase pathways (Figure 1.8).  
 
A third ligand in the IL-1 family is IL-1 receptor antagonist (IL-1Ra), a structural variant of 
IL-1 that binds to both IL-1R but fails to activate cells (Arend et al. 1994). The IL-1Ra is a 
naturally occurring inhibitor of IL-1. Despite the high affinity of IL-1Ra for the IL-1RI, it is 
thought that a 10- to a 100- fold excess of the inhibitor is required to block the effect of IL-
1 due to the ability of IL-1 to activate cells at very low receptor occupancy (Arend and 
Dayer 1990). In fact, IL-1 is able to induce a biological response when less than 5% of the 
receptors are engaged.  
1.4.1.1 Interleukin-1 and arthritis 
A role for IL-1 in arthritis was first elucidated by Jubb and Fell (1980) when they identified 
a soluble factor produced by porcine synovial fragments that was able to stimulate 
chondrocytes to produce various enzymes that degraded the ECM. This soluble factor was 
shown to be IL-1. IL-1 is synthesised by articular chondrocytes and joint synovial tissue 
and can also be detected in the synovial fluid of arthritis patients (Fontana et al. 1982). It is 
able to cause cartilage degradation by stimulating the release of degradative enzymes such 
as MMPs. Inter-articular injection of IL-1 into rabbit knees led to leukocyte influx and loss 
of proteoglycans from articular cartilage (Pettipher et al. 1986) and injection of IL-1 into 
mouse knees led to similar effects with enhanced proteoglycan degradation and inhibition 
of proteoglycan synthesis (van de Loo and van den Berg 1990). Blocking IL-1 with anti-IL-
1 monoclonal antibodies or endogenous IL-1Ra has been shown to protect against cartilage  
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Figure 1.8 IL-1 signalling pathways. Of particular relevance to MMP expression are the NFκB and MAPK 
signalling pathways activated by IL-1. IL-1 binds to its receptor (IL-1R1) and receptor-associated protein (IL-
1RAcP), causing conformational changes in multiple receptor-bound proteins (MyD88, IRAK (IL-1R 
activated kinase), TRAF6 (TNF receptor-associated factor), TAB2 (Tak-binding protein)). This results in 
recruitment and activation of transforming-growth-factor-κ-activated kinase-1 (TAK1), which phosphorylates 
and activates NFκB-inducing kinase (NIK). Subsequently, NIK activates the inhibitor of κB kinase (IKK) 
complex, which is responsible for the phosphorylation of inhibitor of NFκB (IκB). Following 
phosphorylation, IκB becomes polyubiquitinated, targeting it for degradation, which allows translocation of 
NFκB subunits to the nucleus where they can bind and activate the promoters of target genes, including 
MMPs. Stimulation by IL-1 also activates the MAPKKKs, transforming-growth-factor-β-activated kinase-1 
(TAK1) and Raf, which are then able to phosphorylate and activate several MAPKKs (MKK6, MKK4, 
MKK7 and MEK1). These MAPKKs then phosphorylate and activate the MAPKs (p38, JNK and ERK), 
which translocate to the nucleus where they phosphorylate and activate various transcription factors 
(activating transcription factor 2 (ATF2), c-Jun, ETS-like gene 1 (Elk-1) and erythroblastosis twenty six (Ets-
1)) that contribute to MMP transcription. SRF (serum response factor) is a protein that regulates the activity 
of many immediate-early genes such as c-Fos. Adapted from Vincenti and Brinckerhoff (2002). 
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and bone destruction (Abramson and Amin 2002). Although elevated levels of IL-1Ra have 
been detected in RA patients, it appears these levels are not sufficiently high to inhibit IL-1-
induced inflammatory responses.  
 
1.4.2 Oncostatin M 
OSM is a member of the IL-6 family of cytokines and is produced by activated T cells and 
macrophages. IL-6 type cytokines are known to bind to plasma membrane receptor 
complexes containing the common signal transducing receptor chain glycoprotein 130 
(gp130). As the IL-6 family of receptors do not possess intrinsic kinase activity, subsequent 
signal transduction involves the activation of Janus kinases (JAK) tyrosine kinase family 
members. Following this interaction, the activated JAKs tyrosine phosphorylate both 
themselves and the cytoplasmic tail of gp130. These phosphorylated tyrosine residues act 
as docking sites for signalling molecules containing SH2 (src homology 2) domains, 
including members of the signal transducers and activators of transcription (STAT) family 
of transcription factors. Once bound, STATs also undergo tyrosine phosphorylation causing 
them to dimerise and translocate to the nucleus where they are able to bind DNA and 
regulate the transcription of target genes. In addition to the JAK/STAT signalling pathway, 
OSM can also stimulate the activation of the MAPK (mitogen-activated protein kinases) 
cascade (Gomez-Lechon 1999; Heinrich et al. 2003). MAPKs are serine-threonine kinases 
and the MAPK family includes extracellular signal-regulated kinase (ERK), p38, and c-Jun 
NH(2)-terminal kinase (JNK). Each MAPK signalling pathway consists of at least three 
components, a MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K), and a MAPK; 
MAP3Ks phosphorylate and activate MAP2Ks, which subsequently phosphorylate and 
activate MAPKs. Activated MAPKs are then able to phosphorylate numerous substrate 
proteins including transcription factors such as c-Jun (Kim and Choi 2010) (Figure 1.9). 
1.4.2.1 OSM and arthritis 
As with IL-1, elevated levels of OSM are seen in human rheumatoid synovial fluids 
(Cawston et al. 1998). Several cytokines have been shown to synergise with OSM, to 
profoundly affect MMP and TIMP levels. For example, OSM greatly exacerbates IL-1- and 
TNFα-mediated effects on cartilage (Hui et al. 2003). OSM alone is able to stimulate 
aggrecan  catabolism  in porcine cartilage  explants (Hui et al. 1996). Although OSM levels  
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Figure 1.9 OSM signalling pathways. Binding of OSM to its receptor subunits, OSM receptor (OSMR) and 
gp130, activates several signalling pathways including the PI3K/Akt pathway, the JAK/STAT pathway and 
the MAPK pathway. As the IL-6 family of receptors do not possess intrinsic kinase activity, subsequent signal 
transduction involves the activation of JAKs. The phosphorylation and activation of SHP2 (SH2 domain-
containing tyrosine phosphatase) by JAKs is thought to play a role in the PI3K signalling pathway, resulting 
in Akt activation and phosphorylation of downstream molecules. Binding of OSM to its receptor subunits also 
induces the JAK/STAT signaling pathway. Activated JAKs recruit and activate STAT proteins. 
Phosphorylated STATs then dimerise, translocate to the nucleus, bind to regulatory elements in the promoter 
of OSM-responsive genes and induce gene expression. OSM predominantly activates  STAT1, STAT3 and 
STAT5. The OSMR is also known to recruit Shc as a downstream signaling molecule, initiating MAPK 
signalling cascades via GRB2 (growth factor receptor-bound protein 2). Activated GRB2 is bound with the 
GTP-exchange factor SOS (Son of sevenless homolog). SOS interacts with Ras, which recruits Rac1 (Ras-
related C3 botulinum toxin substrate 1) and Raf-1 (a MAP3K). Activated Rac1 results in the activation of p38 
and JNK via MAP3K/MKK cascades. Activated Raf-1 transmits its signal via the MEK/ERK1/2 cascade, 
leading to alterations in gene expression. Adapted from www.genego.com (Oncostatin M signaling via 
JAK/STAT in human cells and Oncostatin M signaling via MAPK in human cells). 
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present in RA synovial fluid are thought to be too low to stimulate cartilage degradation if 
acting in isolation, this does not rule out a role for OSM alongside IL-1 in the progressive 
destruction of joint tissues (Manicourt et al. 2000). A key role for endogenously produced 
OSM as a potent mediator of joint pathology was demonstrated by a study in which mice 
with CIA treated with anti-OSM antibody showed significant amelioration of clinical 
severity and the number of affected paws compared with control animals (Plater-Zyberk et 
al. 2001). 
 
1.4.3 Other pro-inflammatory cytokines 
TNF-α is another potent pro-inflammatory cytokine implicated in the arthritides. TNF-α has 
been shown to be present at high concentrations in the synovial fluids (Tetta et al. 1990) 
and cartilage-pannus junction (Chu et al. 1991) of RA patients. TNF-α is known to act 
synergistically with IL-1 to promote cartilage damage (Henderson and Pettipher 1989). 
Alone, TNF-α has been shown to exhibit similar biological properties to IL-1, enhancing 
the resorption and inhibiting the synthesis of cartilage proteoglycan (Saklatvala 1986) and 
stimulating the release of collagenases (Dayer et al. 1985). Clinical trials of biologic anti-
TNF-α drugs performed in the late 1990s confirmed the importance of TNF-α in the 
pathogenesis of RA and these trials yielded positive results. Millions of patients worldwide 
have now received the first marketed anti-TNF-α drugs; the monoclonal anti-TNF-α 
antibodies infliximab and adalimumab and the soluble TNF-α receptor antagonist 
etanercept. However, only 60% of those patients who do not benefit from standard 
nonbiologic treatments for arthritis respond to TNF-α antagonists and so there is still a need 
for the development of new arthritis treatments (Sfikakis 2010).  
 
IL-17 has been implicated as a mediator of cartilage collagen breakdown in inflammatory 
joint disease. Animal studies have suggested a role for IL-17 in several models of arthritis 
(Bush et al. 2001; Lubberts et al. 2001; Lubberts et al. 2002). Similarly to OSM, IL-17 has 
also been shown to act in synergy with other pro-inflammatory cytokines such as IL-1 to 
promote type II collagen release from bovine nasal cartilage in an MMP-dependent manner 
(Koshy et al. 2002).  
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1.5 Anti-inflammatory cytokines in arthritis 
 
1.5.1 Interleukin-4 
Several cytokines have been shown to antagonise the effects of pro-inflammatory 
cytokines. These include IL-4 (Cawston et al. 1996), IL-10 (van Roon et al. 1996) and IL-
13 (Cleaver et al. 2001). IL-4 is a cytokine that is able to exert either stimulatory or 
suppressive effects on different cell types (Joosten et al. 1999). It was originally identified 
as a B cell growth factor (BCGF), but was subsequently revealed to be a multifunctional 
cytokine that interacts with cells of multiple lineages, including T-cells, monocytes, 
macrophages and fibroblasts. Consequently, BCGF was re-named B cell stimulatory factor, 
and later IL-4. IL-4 is produced principally by CD4+ T cells, but also by basophils, B cells, 
macrophages, monocytes, fibroblasts and endothelial cells (Paul 1991). The IL-4 gene 
resides on the long arm of chromosome 5 at q23-31 and is a 20 kDa glycosylated protein. 
Several binding sites for transcription factors have been identified in the IL-4 promoter, 
including STAT6. IL-4 stimulates the proliferation, differentiation and activation of 
multiple cell types but is known for its role as a potent anti-inflammatory cytokine, 
inhibiting the synthesis of pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6 (Hart 
et al. 1989; te Velde et al. 1990; DeKruyff et al. 1995). In addition, IL-4 stimulates the 
synthesis of a number of cytokine inhibitors including IL-1Rα, IL-1-receptor type II and 
TNF receptors (Vannier et al. 1992; Colotta et al. 1993; Cope et al. 1993). IL-4 suppresses 
metalloproteinase production, whilst increasing TIMP-1 production in cartilage explants, 
suggesting that IL-4 functions to protect the ECM (Cawston 1998). 
 
1.5.2 IL-4 in arthritis  
It has been well documented that the destructive process mediated by pro-inflammatory 
cytokines can be limited by anti-inflammatory mediators such as IL-4. Whilst upregulation 
of anti-inflammatory cytokines and inhibitory mediators does occur in chronic 
inflammatory conditions such as RA, it occurs at levels insufficient to prevent cartilage 
degradation. This imbalance between pro- and anti-inflammatory cytokines is reflected by 
an abundance of pro-inflammatory cytokines, but a virtual absence of anti-inflammatory 
cytokines such as IL-4 in RA synovium. This is despite the presence of high levels of IL-4 
in peripheral blood mononuclear cells of RA patients (Miossec et al. 1990).  Typically, 
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anti-inflammatory cytokines counteract the effects of pro-inflammatory cytokines, therefore 
promoting the synthesis of ECM components. It is thought that IL-4 fulfils its role as an 
anti-inflammatory cytokine, partly, by promoting the differentiation of T cells into Th2 
cells rather than pro-inflammatory Th1 cells. In addition to suppressing Th1 cells and 
upregulating IL-1Ra in synovial cells and chondrocytes, IL-4 also potently reduces  
inducible NO (nitric oxide) synthase (iNOS) expression (Bogdan et al. 1994). This results 
in a suppression of NO production, which is a secondary mediator in IL-1-mediated 
inhibition of proteoglycan synthesis by chondrocytes (van den Berg 1998).  
 
IL-4 is characteristically absent from the RA joint, suggesting the disease is driven 
exclusively via a Th1 response, or is not driven by T cells at all. This absence of IL-4 
makes IL-4 administration or local enrichment of IL-4 producing cells a possible 
therapeutic option (van den Berg 1998). A study by Joosten et al. (1999) demonstrated that 
systemic IL-4 treatment ameliorates disease progression of established murine CIA, a 
widely used model of arthritis that displays several features of human RA. In the same year, 
the first demonstration of the cartilage-protective effects of local IL-4 gene therapy in 
experimental arthritis were seen. Despite having only a moderate effect on inflammation, 1 
µg/day IL-4 strongly protected against cartilage and bone destruction (Joosten et al. 1999). 
A later study by van Lent et al. (2002) showed that over-expression of IL-4 in an immune 
complex (IC)-mediated arthritic knee joint protected the cartilage ECM from MMP-
mediated destruction, by preventing subsequent matrix erosion. The same study suggested 
that IL-4 does not inhibit MMP-mediated cartilage destruction by preventing MMP release 
into the cartilage, but possibly by inhibiting synovial factors involved in the activation of 
pro-MMPs.  
 
Various cytokine-based therapies are being considered to block the catabolic pathways 
thought to be responsible for the cartilage damage seen in human OA. A large amount of 
research has indicated the potential of IL-4 as a future therapeutic agent. However, it is 
important to note the pro-inflammatory role of IL-4 before considering its therapeutic use.  
Inhibition of IL-4 in diseases where IL-4 has a pro-inflammatory effect, such as asthma, has 
shown promise. However, administration of IL-4 to treat arthritis could cause potentially 
disastrous side-effects due to its pro-inflammatory effects on target cells in other parts of 
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the body. It is also possible that any beneficial effects of IL-4 may be inhibited by other 
agents. Aspirin, the most widely used non-steroidal anti-inflammatory drug, is known to 
inhibit IL-4-induced STAT6 activation (Perez et al. 2002). It is very likely that 
administration of IL-4 itself will prove too dangerous for use in vivo. Despite this, work 
currently being carried out to elucidate the protective mechanism of action of IL-4 has the 
potential to identify a vast array of targets involved in the anti-inflammatory effect of IL-4, 
leading to alternative therapeutic agents.  
 
1.5.3 Regulation of MMPs by IL-4 
It is widely accepted that production of MMPs by chondrocytes and synovial fibroblasts is 
regulated by various cytokines and growth factors. It is therefore of no surprise that IL-4 
has been implicated in the suppression of MMPs, in addition to its role in the suppression 
of pro-inflammatory mediators. IL-4 has been shown to down-regulate MMP activity in a 
number of cell types involved in arthritis. In 1996, Cawston et al. demonstrated the 
chondroprotective ability of IL-4, by showing that IL-4 specifically blocked bovine 
cartilage collagen resorption. Inhibition of collagen release was accompanied by a decrease 
in collagenase activity and an increase in TIMP levels (Cawston et al. 1996). Previously, it 
was demonstrated that IL-4 suppressed IL-1-stimulated MMP-3 protein and enzyme 
activity and was able to suppress IL-1-induced MMP-3 mRNA in human articular 
chondrocytes. In contrast, IL-4 did not alter the level of TIMP-1 protein and mRNA 
(Nemoto et al. 1997). The chondroprotective mechanism of action of IL-4 has been further 
elucidated by work carried out by the Salter group on the effect of mechanical stimulation 
on human articular chondrocytes. They have developed a technique that enables the 
application of controlled forces to cultured cells and so are able to demonstrate that 
mechanical signals can be transmitted across ECM-cell contacts. This technique was used 
to demonstrate that mechanical stimulation of human chondrocytes induced the release of 
IL-4 by human chondrocytes (Millward-Sadler et al. 1999). In 2000 it was shown that 
chondrocytes from normal and osteoarthritic human articular cartilage show differential 
responses to mechanical stimulation. Mechanical stimulation of normal human articular 
chondrocytes in vitro resulted in an increase in levels of aggrecan mRNA and a decrease in 
levels of MMP-3 mRNA. This response was shown to be dependent on IL-4. No changes in 
aggrecan or MMP-3 mRNA expression were found in OA chondrocytes, suggesting a 
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failure in the IL-4-dependent chondroprotective response (Millward-Sadler et al. 2000). A 
later study went on to show that autocrine and paracrine activity of IL-4 plays a critical role 
in the increased levels of aggrecan mRNA and decreased levels of MMP-3 mRNA seen 
after mechanical stimulation of normal human articular chondrocytes. This further adds to 
the evidence that abnormalities in mechanical signalling may contribute to disease 
progression in OA (Salter et al. 2001).  
 
As mentioned previously, collagen release is considered the key point in cartilage 
degradation. Of the three known collagenases, MMP-1 and MMP-13 are considered to be 
the most important in terms of the collagenolysis seen in the arthritides. MMP-13 is thought 
to be of greater importance in OA due to the fact that it preferentially degrades type II 
collagen (Knauper et al. 1996a) and because its expression is increased in OA (Tetlow et al. 
2001). Previous data have consistently shown IL-4 to completely inhibit MMP-13 mRNA 
expression (Cleaver 2000; Cleaver et al. 2001; Pyle 2003), but to slightly increase MMP-1 
mRNA expression (Cleaver 2000; Cleaver et al. 2001).  
 
1.5.3.1 Epigenetic regulation 
Epigenetics, literally meaning “beyond genetics”, can be defined as stable and heritable (or 
potentially heritable) changes in gene expression that do not entail a change in DNA 
sequence (Jiang et al. 2004). There are two key epigenetic modifications; DNA methylation 
and histone modifications (such as acetylation, methylation and phosphorylation). The 
methylated base 5-methylcytosine was first discovered in the calf thymus 60 years ago 
(Hotchkiss 1948). Generally, only cytosines that precede guanines can be methylated i.e. 
cytosines within CpG dinucleotides. The CpG notation (where ‘p’ represents the phosphate 
connecting the two nucleotides) is used to distinguish between a cytosine followed by a 
guanine in the DNA sequence and a cytosine base-paired to a guanine (Dahl and Guldberg 
2003). 
 
Recent studies have examined the methylation status of four degradative enzymes (MMP-3, 
MMP-9, MMP-13 and ADAMTS-4) and have shown that changes in the expression of 
these enzymes in OA correlated with demethylation of specific CpG sites within their 
promoters (Roach et al. 2005). In addition, it has been shown that one of the genes 
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upregulated in OA cartilage is leptin, a cytokine-like peptide hormone thought to act as a 
regulator of bone growth. A study by Iliopoulos et al. (2007) has shown that leptin can be 
regulated by epigenetic mechanisms in OA. Leptin was found to be methylated in normal 
chondrocytes and unmethylated in both mildly and severely affected OA chondrocytes. 
Epigenetic regulation of leptin using siRNA was found to affect MMP-13, with MMP-13 
expression down-regulated. 
 
Methylation of genomic DNA is clearly an important mechanism in the regulation of gene 
expression. DNA methylation is heritable and so any changes in methylation status are 
transmitted to daughter cells. When aberrant changes in DNA methylation occur, these 
changes are also heritable because cells have no way of “remembering” what their correct 
methylation status should be. Initial experimental evidence indicates that aberrant DNA 
methylation patterns could be responsible for at least some of the changed MMP gene 
expression patterns seen in OA.  
 
1.5.4 IL-4 in other diseases 
As mentioned previously, the effect of certain cytokines, in particular IL-4, depends greatly 
on the target cell. Recent work has provided compelling evidence that IL-4 produces a pro-
inflammatory environment via oxidative stress-mediated up-regulation of inflammatory 
mediators in vascular endothelium. In addition, IL-4 has been demonstrated to induce the 
apoptosis of human vascular endothelial cells via the caspase-3-dependent pathway. 
Vascular endothelial cell injury has been implicated in the onset and progression of 
cardiovascular diseases such as atherosclerosis (Lee and Hirani 2006). IL-4 has been well 
documented for its pro-inflammatory role in asthma, possibly being involved in the airway 
remodelling response seen in asthmatics by inducing ECM production by fibroblasts 
(Hashimoto et al. 2001).  
 
To further complicate matters, IL-4 appears to have both positive and negative effects on 
the control of tumour growth. A number of studies have assessed the impact of IL-4 on 
tumour clearance by recombinantly expressing IL-4 in tumour cell lines. Using these 
models, investigators found that IL-4 enabled the clearance of numerous tumour types 
(melanoma, renal carcinoma, colon carcinoma, plasmacytoma) in mice that had been 
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otherwise unable to clear the tumour (Tepper et al. 1989; Tepper et al. 1992; Noffz et al. 
1998). Other reports indicate that IL-4 impairs tumour clearance. Vaccination with IL-4-
expressing mesothelioma cells resulted in accelerated growth of tumour cells (Olver et al. 
2007). The same study suggests that the effect of IL-4 on tumour growth is dependent on 
the type of tumour model and the type of effector cells mediating tumour clearance.  
 
The growth of bone is a highly regulated process, involving bone-forming cells 
(osteoblasts) and bone-resorbing cells (osteoclasts). IL-4 has been shown to be an inhibitor 
of bone resorption (Watanabe et al. 1990) and so could be of therapeutic benefit in bone-
resorbing diseases such as osteoporosis and arthritis. In addition to cartilage loss, bone 
destruction is a major complication in arthritic disease. The first report demonstrating the 
bone protective effects of local IL-4 gene therapy came in 2000 (Lubberts et al. 2000). 
Local over-expression of IL-4 reduced tartrate-resistant acid phosphatase (TRAP) activity, 
suggesting that IL-4 inhibits formation of osteoclast-like cells. IL-6 and IL-12 protein 
production was also suppressed, as were mRNA levels of IL-17, IL-12 and cathepsin K. In 
vitro studies using bone samples from arthritis patients revealed suppression of type I 
collagen breakdown by IL-4, but also enhanced synthesis of type I procollagen, indicating 
that IL-4 is able to promote tissue repair. More recent work has further elucidated the 
molecular mechanism of IL-4 action on osteoclasts. It is known that IL-4 dose-dependently 
inhibits receptor activator of NFκB ligand (RANKL)-induced bone resorption by mature 
osteoclasts (Mangashetti et al. 2005). There is also evidence demonstrating how 
constitutively active STAT6 can inhibit bone erosion through blockade of JNK and NFκB 
activation (Hirayama et al. 2005). Modulation of these systems could present a novel 
approach to the alleviation of bone destruction in arthritis. 
 
1.5.5 IL-4 signalling 
IL-4 induces cellular responses by binding to a multimeric receptor. IL-4 receptors consist 
of two transmembrane proteins. IL-4 binds to the IL-4Rα chain, leading to dimerisation 
with one of two other proteins, to form either a type I or type II receptor. In haematopoietic 
cells, type I receptors are formed by the recruitment of a common gamma chain (γC). In 
cells of nonhaematopoietic lineage, the type II receptor is formed by interaction of the IL-
4Rα with IL-13Rα1 (Kelly-Welch et al. 2003). The IL-4 signalling pathway downstream of 
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the receptor involves the phosphorylation of two distinct proteins; STAT6 (Hou et al. 1994) 
and insulin receptor substrate-1/-2 (IRS1/2) (Kelly-Welch et al. 2003) (Figure 1.10). 
However, a number of other cytoplasmic signalling proteins have been demonstrated to be 
phosphorylated in response to IL-4R stimulation, including FRIP (IL-4 receptor interacting 
protein), SHIP (SH2 domain-containing inositol-5'-phosphatase) and Shp (small 
heterodimer partner) (Hou et al. 1994; Sun et al. 1995; Imani et al. 1997; Nelms et al. 1998; 
Zamorano and Keegan 1998). Type I cytokine receptors, in contrast to other receptor 
classes, do not have intrinsic kinase activity. Their initial signalling steps rely on JAKs. The 
binding of IL-4 to its receptor leads to the phosphorylation, and hence activation, of JAK1 
and JAK3.  The phosphorylation of JAKs is followed by phosphorylation of the IL-4 
receptor components and cytoplasmic signalling proteins (Hebenstreit et al. 2006). IL-4 
stimulation results in activation of JAK 1 and 3, in turn leading to phosphorylation of 
tyrosine residues in the cytoplasmic domain of the IL-4Rα chain. Once phosphorylated, 
these tyrosine residues act as docking sites for signalling molecules (Kelly-Welch et al. 
2003).  
1.5.5.1 STAT6 
STAT6 signalling is classically associated with IL-4 and IL-13 and the examination of 
STAT6-deficient mice has shown that STAT6 is essential for IL-4-dependent gene 
induction (Kuhn et al. 1991).  STAT6 is one of seven members of the STAT protein family, 
which consists of STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. 
STAT6 is recruited to the activated IL-4Rα through its SH2 domain and becomes tyrosine 
phosphorylated leading to its dimerisation and translocation to the nucleus, where the 
homodimer activates transcription of IL-4 responsive genes, in what is commonly referred 
to as the JAK-STAT pathway of signal transduction (Leonard and O'Shea 1998). A number 
of studies have demonstrated the importance of the three central tyrosine residues (Y575, 
Y603 and Y631) in the IL-4Rα chain for the activation of STAT6 (Pernis et al. 1995; Wang 
et al. 1996; Ryan et al. 1998). These three residues become phosphorylated following 
stimulation of the IL-4 receptor, thus providing docking sites for STAT6 monomers.  
Furthermore, phosphorylation of any one of these three tyrosines is sufficient for STAT6 
activation (Ryan et al. 1998).  
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Figure 1.10 IL-4 signalling pathways. A, STAT6 is the only STAT protein activated and recruited to the 
IL4Rα chain. Binding of IL-4 to the receptor complex promotes the activation of JAK1 and JAK3. Activated 
JAKs initiate intracellular signalling events by phosphorylating specific tyrosine residues in the cytoplasmic 
domain of IL-4Rα. Once phosphorylated, these tyrosine residues act as docking sites for signalling molecules. 
STAT6 is recruited to activated IL-4Rα through its SH2 domain and becomes tyrosine phosphorylated leading 
to its dimerisation and translocation to the nucleus, where the homodimer activates transcription of IL-4 
responsive genes. B, IL-4 binding induces activation of JAKs and Fes kinases. Fes in turn is responsible for 
phosphorylation of IRS-1/2. Phosphorylation of IRS-1/2 activates the PI3 kinase (PI3K) pathway by 
interacting with p85 catalytic subunit. Activated PI3K appears to regulate the pS6K pathway, resulting in 
promotion of translational process required for cell growth. Adapted from Jiang et al. (2000). 
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Although STAT6 activation in response to IL-4 has been well documented, the mechanisms 
responsible for the regulation of STAT6 signalling are less well understood. Several 
negative regulators of the JAK-STAT signalling pathway have been described. Suppressors 
of cytokine signalling (SOCS) proteins form a negative feedback loop whereby cytokine 
stimulation induces SOCS genes, which subsequently inhibit cytokine signalling. SOCS-1 
has been shown to potently inhibit the activation of JAK1 kinase and STAT6 in response to 
IL-4 (Losman et al. 1999). Protein inhibitors of activated STAT (PIAS) are thought to bind 
specifically to phosphorylated STAT dimers and prevent them from binding DNA (Liu et 
al. 1998). Chen et al. (2004) examined the effect of methylation on STAT6. It was 
discovered that in the presence of methylation inhibitors, STAT6 methylation was reduced, 
as was phosphorylation of STAT6 and STAT6 DNA binding activity.  It therefore seems 
that methylation is necessary for maximal STAT6 phosphorylation, nuclear translocation 
and DNA-binding activity (Chen et al. 2004). 
 
STAT6 binding to DNA alone is normally not sufficient to stimulate activation of 
transcription. In order to initiate transcription, STAT6 must interact with the basal 
transcription machinery via various transcriptional co-regulatory proteins. The molecular 
mechanisms by which transcription is selectively activated by STAT6 represents a key 
issue in the understanding of IL-4-mediated cellular responses. STAT6 has been shown to 
interact with NFκB (Stutz and Woisetschlager 1999), PU.1 (Pesu et al. 2003), IRF-4 (Gupta 
et al. 1999), BSAP (Thienes et al. 1997; Mikita et al. 1998) and C/EBPβ (Mikita et al. 
1998) transcription factors. The trans-activation potential of a transcription factor is 
dependent on the co-factors that it recruits; this is a key mechanism by which transcription 
factors mediate specificity for the promoters they activate. Various transcriptional co-
regulators for STAT6 have been identified, including CREB-binding protein (CBP), p300 
and NcoA1 (a member of the p160 family of coactivators). CBP/p300 stimulates the 
transcription of target genes by the regulation of chromatin remodelling through intrinsic 
histone acetyltransferase activity (Ogryzko et al. 1996; Yang et al. 1996) and by associating 
with p/CAF, another histone acetytransferase (Yang et al. 1996). Work by Silvennoinen 
and colleagues have identified several STAT6 transcriptional activation domain (TAD) 
interacting nuclear proteins. The first of these to be discovered was coactivator protein 
p100, which regulates IL-4-induced transcription by connecting STAT6 with RNA 
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polymerase II (Yang et al. 2002). A subsequent study suggested that p100 has an important 
role in the assembly of the STAT6 transcriptosome, and that p100 stimulates IL-4-
dependent transcription by mediating interaction between STAT6 and CBP and recruiting 
chromatin modifying activities to STAT6-responsive promoters (Valineva et al. 2005). It is 
now thought that p100 could also participate in mRNA splicing (Shaw et al. 2007; Yang et 
al. 2007). mRNA splicing and transcription are the two key nuclear processes in eukaryotic 
gene expression. RNA helicase A (RHA) has now also been described as a novel 
component of the STAT6 transcriptosome. Whilst RHA was found to not directly interact 
with STAT6, p100 protein was found to mediate the assembly of the ternary complex of 
STAT6-p100-RHA. RHA was found to enhance IL-4-induced transcription and the 
participation of RHA in IL-4-regulated transcription was supported by RNAi experiments 
(Valineva et al. 2006). Goenka et al (2007) have recently identified an additional novel co-
factor of STAT6. Collaborator of STAT6 (CoaSt6) was found to associate with STAT6 and 
enhance its transcriptional activity. Sequence homologies have placed CoaSt6 within the 
poly(ADP-ribosyl)polymerase (PARP)-like protein superfamily. This study also went on to 
demonstrate that PARP enzymatic activity is associated with CoaSt6 (Goenka et al. 2007).  
1.5.5.2 IRS1/-2 
The IRS proteins are cytoplasmic docking proteins that function downstream of activated 
cell surface receptors. They do not possess intrinsic kinase activity, instead functioning as 
adaptors; organising signalling complexes to initiate intracellular signalling cascades 
(White 2006). Three IRS family members are expressed in humans; IRS1, IRS2 and IRS-4. 
IRS1 and IRS2 are expressed ubiquitously and share considerable homology. The 
expression of IRS-4 is much more restricted. The importance of the activation of 
IRS1/IRS2 in IL-4 signalling was first demonstrated in the 32D myeloid progenitor cell 
line, which does not express endogenous IRS1 or IRS2. Reconstitution of these cells with 
IRS1 allowed them to proliferate in response to IL-4 (Wang et al. 1993). Following IL-4 
stimulation, IRS1 and IRS2 are recruited to the IL-4R complex by the phosphorylated 
tyrosine residue Y497 in the IL-4Rα and undergo tyrosine phosphorylation by JAK 1 (Chen 
et al. 1997) (Figure 1.10). The tyrosine-phosphorylated IRS proteins subsequently act as 
docking sites for SH2 domain-containing signalling proteins such as the p85 subunit of 
PI3K (Backer et al. 1992) and growth factor receptor-bound protein 2 (Grb-2) (Skolnik et 
al. 1993). PI3K has consistently been shown to play an important role in IL-4-mediated cell 
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proliferation (Kelly-Welch et al. 2003). The downstream effectors of activated PI3K 
include Akt/protein kinase B (PKB), PKC and p70 ribosomal protein S6 kinase (p70S6-K) 
(Pesu et al. 2000).  
 
1.5.6 Other anti-inflammatory cytokines 
IL-10 is found at increased levels in both RA synovial fluid and serum (Cush et al. 1995) 
and a strong negative correlation has been found between IL-10 production and joint 
damage in RA patients (Verhoef et al. 2001). The synthesis of pro-inflammatory cytokines 
such as IL-1, IL-8, IL-12, IL-6 and TNF-α can be inhibited by IL-10 in monocytes (de 
Waal Malefyt et al. 1991). It also is able to synergise with IL-4 to inhibit cartilage 
degradation induced by antigen-stimulated mononuclear cells of RA patients in vitro (van 
Roon et al. 1996). IL-10 is able to suppress established CIA through the inhibition of pro-
inflammatory cytokine production (Walmsley et al. 1996). In summary, IL-10 appears to 
the key in the regulation of inflammation however its inhibitory effect appears to be 
increased when in combination with IL-4 (Joosten et al. 1997).  
 
IL-13 strongly resembles IL-4, exhibiting many of the same biological activities and 
sharing approximately 30% homology at the protein level (Minty et al. 1993). IL-13 has 
been demonstrated to inhibit the production of a range of other pro-inflammatory cytokines 
including TNFα, IL-6 and IL-8. In a similar manner to IL-4, IL-13 has been shown to act in 
a chondroprotective manner by blocking collagen release from bovine nasal cartilage 
stimulated to resorb by IL-1 and OSM (Cleaver et al. 2001).  
 
1.6 Summary and aims of this study  
 
The degradation of articular cartilage and subsequent erosion of subchondral bone in the 
arthritides results in loss of joint function. Articular cartilage is composed primarily of 
collagens, proteoglycans and chondrocytes, however it is the loss of collagen from articular 
cartilage that is considered the key step in cartilage degradation. The imbalance of collagen 
synthesis and degradation has been shown in humans to correlate with disease progression. 
Pro-inflammatory cytokines, such as IL-1 and OSM, are upregulated in arthritis and 
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contribute to cartilage damage through the induction of MMPs. MMP-13, the major type II 
collagenase, is highly upregulated in arthritic diseases and therefore strongly implicated in 
the pathogenesis of OA.  
 
Studies have shown that the synergistic collagen degradation in cartilage explants by IL-1 
and OSM (Cawston et al 1995, 1998) can be ameliorated by the addition of IL-4. Further 
studies demonstrated that IL-4 is able to completely inhibit MMP-13 mRNA expression in 
both cartilage and cell culture models. The aim of this PhD was to elucidate the mechanism 
of action by which IL-4 suppresses MMP-13 expression, thereby inhibiting cartilage 
collagen breakdown.  
 
The aims of this work were to: 
 
• Determine the effect of IL-4 on IL-1+OSM-induced collagenase gene expression in 
chondrocytes. 
• Determine the time dependence of IL-4 addition on IL-1+OSM-induced collagenase 
gene expression in the bovine nasal cartilage model. 
• Examine IL-4 signalling in chondrocytes and their effect on MMP-13 expression. 
• Perform genome-wide arrays to examine global gene expression following IL-
1+OSM±IL-4 addition. 
• Attempt to recover IL-1+OSM+IL-4-induced MMP-13 expression through gene 
silencing experiments. 
 
Chapter 2 
 - 42 - 
Chapter 2: Materials and Methods 
 
 
2.1 Materials 
2.1.1 Antibodies 
All antibodies are rabbit polyclonal, unless otherwise stated. Phospho-Akt (Ser473) 
(#4060), phospho-Akt (Thr308) (#4056), phospho-STAT6 (Tyr641) (#9361), phospho-
GSK-3-beta (Ser9) (#9336), Histone H3 (#9717B), Lamin A/C (#2032) and Caveolin 1 
(#3267B) were purchased from Cell Signaling Technology (Danvers, MA, USA). Trb1 
polyclonal antibody (#09-126) was purchased from Millipore (MA, USA). Trb3 (#2488-1) 
and MEK2 (#04-377) monoclonal antibodies and β-tubulin polyclonal antibody (#1799-1) 
were purchased from Epitomics (Insight Biotech, Wembley). STAT6 (#sc-981) polyclonal 
antibody, mouse monoclonal Trb2 antibody (#sc-100878) and mouse monoclonal c-Myc 
antibody (#sc-40) were purchased from Santa Cruz (California, USA).  
2.1.2 Cell lines 
The human chondrosarcoma cell line, SW1353, was purchased from the American Type 
Culture Collection (ATCC). Cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) in a 1:1 ratio with Ham’s F-12 medium (DMEM:F12) as described in section 
2.2.3. 
2.1.3 Cell culture reagents 
DMEM, DMEM-F12, and foetal bovine serum (FBS) were obtained from Invitrogen 
(Paisley, UK). Phosphate buffered saline (PBS) was from Lonza (Wokingham, UK). 
Penicillin-streptomycin solution (10 000 U/ml and 10 mg/ml, respectively), L-glutamine 
solution (200 mM), Nystatin suspension (10,000 U/ml), trypsin-EDTA 
(ethylenediaminetetraacetic acid) solution (0.5 g porcine trypsin and 0.2 g/L EDTA), 
hyaluronidase (from bovine testes, 439 U/mg), trypsin (from porcine pancreas, 1020 U/mg) 
and collagenase (from Clostridium histolyticum type I) were obtained from Sigma-Aldrich 
(Poole, UK). Tryptone, yeast extract and bacto-agar were purchased from Difco 
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Laboratories (Detroit, MI, USA). Syringe filters (0.2 µm) were purchased from Pall Life 
Sciences (Portsmouth, UK). Cell strainers (100 micron) were from Scientific Laboratory 
Supplies (Hessle, UK). 
2.1.4 Commercially available kits 
RNeasy® Mini Kit, Qiaprep Spin Midi/Maxi Kit and Epitect® Bisulphite Kit were 
purchased from Qiagen (Crawley, UK). PureLinkTM Genomic DNA MiniPrep Kit and the 
TOPO TA Cloning® Kit with Dual Promoter pCR®II-TOPO® vector were purchased from 
Invitrogen. Subcellular Protein Fractionation Kit was purchased from ThermoScientific 
(Loughborough, UK).  
2.1.5 Biochemical Biology Reagents 
Bovine serum albumin (BSA), chondroitin sulphate A (from bovine trachea), collagenase 
(type I from Clostridium histolyticum), L-cysteine hydrochloride, p-
dimethylaminobenzaldehyde (DAB), 4-aminophenylmercuric acetate (APMA) and 
ethylenediamine tetraacetic acid (EDTA) were obtained from Sigma-Aldrich. Chloramine T 
and papain were purchased from BDH (Poole, UK).  
2.1.6 Molecular Biology Reagents 
DharmafectTM 1 lipid reagent and SMARTpool® small interfering RNA (siRNA) were from 
Dharmacon (Cramlington, UK). Trb-1 MISSION® Lentiviral Transduction Particles and 
hexadimethrine bromide were from Sigma-Aldrich. FuGene HD Transfection Reagent was 
purchased from Roche (Burgess Hill, UK) and Lipofectamine 2000 Reagent from 
Invitrogen (Paisley, UK). Trb1, Trb2 and Trb3 over-expression plasmids (see appendix A 
for plasmid maps) and GFP constructs were a kind gift from Dr Endre Kiss-Toth (Sheffield 
University, UK). SidestepTM Lysis and Stabilization Buffer was purchased from Agilent 
Technologies, Stratagene Product Division (CA, USA). Real-time reverse transcriptase 
polymerase chain reaction (RT-PCR) primers and probes were purchased from Sigma-
Genosys (Poole, UK). SuperscriptTM II reverse transcriptase, Moloney Murine Leukamiea 
Virus (M-MLV) reverse transcriptase and RNaseOut Recombinant Ribonuclease Inhibitor 
were purchased from Invitrogen. SYBR Green and TitaniumTM Taq DNA Polymerase were 
purchased from TaKaRa Bio Inc (Shiga, Japan). Jumpstart Taq Ready Mix was purchased 
from Sigma. EcoR1 was purchased from Fermentas Life Sciences (York, UK). Agarose 
Chapter 2 
 - 44 - 
(electophoretic grade) and TRIzol® Reagent were purchased from Invitrogen. 
VECTASHIELD mounting medium with DAPI was purchased from Vector Labs. RNase- 
and DNase-free H2O was from Sigma-Aldrich.  
2.1.7 Immunoblotting reagents 
Ammonium peroxodisulphate (APS) and gelatin were obtained from BDH. β-
mercaptoethanol, N,N,N’N’-tetramethylenediamine (TEMED), 1,10-phenanthroline and 
polyoxyethylenesorbitan monolaurate (Tween 20) were obtained from Sigma-Aldrich. 40% 
(w/v) acrylamide/bis-acrylamide (37.5:1) solution was obtained from Amresco (Solon, OH, 
USA). PageRulerTM prestained protein ladder and GeneRulerTM 1 kb DNA ladder were 
purchased from Fermentas Life Sciences. Enhanced chemiluminescence (ECL) western 
blot detection reagents were obtained from Amersham Biosciences (Little Chalfont, UK).  
2.1.8 Inhibitors 
LY294002 (selective PI3K inhibitor), TGX-221 (selective PI3K p110β inhibitor) and 
compound 15e (selective PI3K p110α inhibitor) were purchased from Calbiochem 
(Nottingham, UK). All inhibitors were reconstituted in sterile filtered DMSO. All inhibitors 
were screened for cytotoxicity using the ToxiLightTM Bioassay Kit according to the 
manufacturer’s instructions (Lonza). Briefly, the assay quantitatively measured the release 
of adenylate cyclase (AK) from damaged cells. Cell supernatant (20 µl) was transferred to a 
luminescence compatible 96-well plate. AK Detection Reagent (100 µl) was added to each 
well. After 5 minutes, a 1 second integrated reading was taken using a MicroLumatPlus LB 
96V (Berthold Technologies UK Ltd, Hertfordshire). 
2.1.9 Cytokines 
Recombinant human IL-1α was a kind gift from GlaxoSmithKline (Stevenage, UK) and 
was stored at -20oC prior to formulation at the appropriate concentration in the relevant 
culture medium. Recombinant OSM was prepared in-house and stored at a stock 
concentration of 85 µg/ml at -80oC prior to formulation at the appropriate concentration in 
the relevant culture medium. Recombinant human IL-4 was purchased from R&D Systems 
(Abington, UK) and diluted from powder form in sterile PBS containing 1% BSA (Sigma 
Aldrich) to a stock concentration of 50 µg/ml, aliquoted and stored at -80oC prior to 
formulation at the appropriate concentration in the relevant culture medium. 
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All other standard laboratory chemicals and reagents, unless otherwise indicated, were 
commercially available from Sigma-Aldrich, Invitrogen or BDH Chemicals. 
2.2 Methods 
2.2.1 Cartilage Sample Collection 
Human articular cartilage samples were obtained from patients undergoing whole joint 
replacement surgery due to end-stage OA in accordance with university ethical guidelines 
(All subjects gave informed consent and the study performed with Newcastle and North 
Tyneside Research Ethics Committee 1 approval (Reference 09/H0906/72),  
as well as Newcastle upon Tyne Hospitals NHS Trust Research and Development approval 
(Reference 5044)). Cartilage was processed to extract chondrocytes. Bovine cartilage was 
obtained from a local abattoir.  
2.2.2 Chondrocyte Extraction and Culture 
Bovine nasal septum cartilage was used as a source of primary chondrocytes. Human 
articular cartilage obtained from patients undergoing joint replacement was also used as a 
source of chondrocytes. A three-step enzymatic digest of cartilage was used to isolate 
chondrocytes.  
2.2.2.1 Bovine nasal chondrocyte extraction 
Reagents: 
• PBS containing 200 IU/ml penicillin, 200 ug/ml streptomycin and 40 IU/ml 
Nystatin. 
• DMEM culture medium containing 10% (w/v) FBS, 2 mM L-glutamine, 200 IU/ml 
penicillin, 200 ug/ml streptomycin and 40 IU/ml Nystatin. 
• Hyaluronidase (1 mg/mL in PBS, 5 ml/g cartilage) 
• Trypsin (2.5 mg/mL in PBS, 5 ml/g cartilage) 
• Collagenase (2.5 mg/mL in DMEM containing 10% FBS, 3 ml/g cartilage) 
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Method: 
Cartilage was removed from bovine nasal septum, either on the day of slaughter or the 
following day after storage at 4oC, and cut into small pieces. Pieces were washed 3 x 15 
minutes in PBS containing antibiotics. Samples were placed in a pre-weighed 50 ml Falcon 
tube. Cartilage was then incubated for 15 minutes with hyaluronidase at 37oC with rotation. 
Supernatant was removed and cartilage washed 3 times with PBS (+ antibiotics). Cartilage 
was then incubated with trypsin for 30 minutes at 37oC with rotation. The supernatant was 
removed and the cartilage was washed twice with DMEM+FBS. Cartilage was then 
incubated with collagenase for 15-20 hours at 37oC with rotation. Falcon tubes were left 
upright for 15 minutes to allow undigested cartilage to settle at the bottom of the Falcon 
tube. The supernatant (containing chondrocytes) was removed and passed through a cell 
strainer (0.2 µm) and centrifuged at 112 x g for 10 minutes in sterile Falcon tubes to obtain 
the cell pellet. Pellets were combined and washed with PBS, spun at 112 x g for 10 minutes 
and the final pellet resuspended in 20 ml DMEM+FBS.  
2.2.2.2 Human articular chondrocyte extraction 
Residual, macroscopically normal cartilage was removed from the subchondral bone and 
washed in PBS. Cartilage was cut into small pieces and sequentially digested as described 
in section 2.2.2.1.  
2.2.3 Cell culture 
Reagents: 
• For bovine nasal chondrocyte and human articular chondrocyte culture: DMEM 
culture medium containing 10% (w/v) FBS, 2 mM L-glutamine, 200 IU/ml 
penicillin, 200 µg/ml streptomycin and 40 IU/ml Nystatin. 
• For SW1353 culture: DMEM:F12 culture medium containing 10% (w/v) FBS, 2 
mM L-glutamine, 200 IU/ml penicillin and 200 µg/ml streptomycin. 
 
Method: 
Cells were counted and seeded at a density of 40 000 cells/cm2 into 96-well plates, 6-well 
plates or T75 cm2 flasks. Cells were grown to 70-80% confluence at 37oC in 5% (v/v) 
CO2/humidified air.  SW1353 monolayers were washed with PBS before incubation with 
Chapter 2 
 - 47 - 
trypsin-EDTA solution to release cells. Cells were then split into appropriate culture vessels 
for experimentation or into further T75 cm2 flasks to continue the cell line. 
2.2.4 Bovine nasal cartilage explant culture 
As a model of cartilage degradation, bovine nasal cartilage in explant culture was 
stimulated to resorb with the pro-inflammatory cytokines IL-1 and OSM. Serum was 
excluded from cartilage explants as it has been shown to increase cartilage metabolism in 
the absence of exogenous cytokine(s) (Sah et al. 1994). The absence of serum has been 
shown not to affect the viability of the tissue and previous studies have shown that cartilage 
in serum-free culture for 8-9 days can still respond to serum and other growth factors 
(Hascall et al. 1983). 
 
Reagents: 
• For bovine nasal cartilage culture: DMEM culture medium containing 2 mM L-
glutamine 200 IU/ml penicillin, 200 µg/ml streptomycin, 40 IU/ml Nystatin and 100 
µg/ml gentamicin.  
2.2.4.1 Bovine nasal cartilage degradation assay 
Bovine nasal cartilage in explant culture was stimulated to resorb with the cytokines IL-1 ± 
OSM. Bovine nasal septum was obtained from a local abattoir after slaughter and stored at 
4oC overnight. The cartilage from four separate cartilage samples was cut into 2 mm thick 
slices. One slice was taken from each cartilage sample and the four slices were cut into 2 
mm x 2 mm pieces. These pieces of cartilage were then mixed and divided between 4 wells 
of a 6-well tissue culture plate. This process was repeated until all wells were filled. To 
each well, 6 ml of bovine nasal cartilage culture medium were added and the plates were 
incubated overnight at 37°C. Media were removed from each well and replaced with 6 ml 
fresh culture medium containing the appropriate cytokine(s) (day 0). For RNA extraction, 
cartilage and culture supernatants were harvested at specific days, according to the 
experiment. Harvested cartilage was placed in RNAlater (Ambion), stored at 4oC overnight 
and stored at -80oC until RNA extraction. At day 7, media were removed and replenished 
with identical cytokine(s) to day 0. At day 14, the remaining cartilage was digested with 
papain to release any remaining proteoglycan and collagen. Cartilage was placed in capped 
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bijoux tubes with 5.5 ml phosphate buffer (137 ml 0.1M NaH2PO4 and 63 ml 0.1 M 
NaHPO4, pH 6.5) containing papain (4.5 mg/ml), cysteine-HCl (5 mM) and EDTA (5 mM). 
Following overnight (20 hours) digestion at 65°C, cartilage digests were frozen at -20oC 
until assayed. 
2.2.4.2 Hydroxyproline assay 
The amino acid sequence glycine-proline-hydroxyproline occurs frequently in collagen and 
hydroxyproline is found in very few other proteins. Therefore, hydroxyproline was assayed 
as a measure of collagen. Protein was hydrolysed to its constituent amino acids. The assay 
is based on the oxidation of hydroxyproline by chloramine T to a compound related to 
pyrrole, and the subsequent condensation of this intermediate with DAB to produce a red 
colour, which is measured at A560 nm. Hydroxyproline present in samples was assayed 
using a microtitre modification of the assay described by Bergman and Loxley (1963). 
 
Reagents:  
• Acetate-citrate buffer: 420 mM sodium acetate, 130 mM tri-sodium citrate, 26 mM 
citric acid and 38.5% (v/v) propan-2-ol, pH 6. 
• DAB: 4.5 M stock in 70% (v/v) perchloric acid, stored 4°C. 
• Chloramine T: 250 mM in dH2O, made fresh. 
 
Method: 
The media or cartilage digests (200 µl) to be assayed were mixed with 200 µl of 12 M HCl 
in 2 ml capped Sarstedt tubes. Samples were then hydrolysed in a hot-block overnight at 
105°C. The hydrolysates were dried in a centrifugal evaporator using an acid-resistant 
integrated Savant Speed Vac (Life Sciences International, Basingstoke, UK) for 1-2 hours. 
The residue was resuspended in 200 µl dH2O and stored at room temperature until assayed. 
Standards (0-30 µg/ml) were produced by diluting hydroxyproline (1 mg/ml) in dH2O. On 
the day of use, chloramine T (250 mM) was diluted 1:4 in acetate-citrate buffer and DAB 
was diluted 1:3 in propan-2-ol. To a 96-well microtitre plate, 40 µl of sample or standard 
was added in duplicate (neat or diluted in dH2O). Using a stopwatch, 25 µl of 62.5 mM 
chloramine T was added at time 0 minutes. After 4 minutes, 150 µl of 1.5 M DAB was 
added in the same order. The plate was then incubated for 35 minutes at 65°C, allowed to 
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cool and the absorbance measured at 560 nm (Sunrise multilabel counter, TECAN, 
Reading, UK). The standard curve was used to calculate the hydroxyproline content of the 
samples. The release of hydroxyproline from the cartilage was then calculated using the 
following equation: 
 
% hydroxyproline release =  
[hydroxyproline in supernatants (µg/ml)]/[total hydroxyproline (µg/ml)] x 100 
 
Where total hydroxyproline is the amount of hydroxyproline in supernatants and cartilage 
digests. The % release of hydroxyproline was considered to be representative of the % 
release of collagen. 
2.2.4.3 Collagenase assay 
Collagenolytic activity present in supernatants from bovine nasal cartilage explant cultures 
was determined using a 96-well plate modification (Koshy et al. 1999) of the diffuse fibril 
assay (Cawston and Barrett, 1979). Collagen at neutral pH and at temperatures above 25°C 
forms into fibrils where the individual collagen molecules associate to form a viscous gel. 
In this assay, collagen, which has been acetylated with [3H]-acetic anhydride, is allowed to 
form fibrils. At the end of the assay, undigested collagen fibrils are spun down in the 
centrifuge and the amount of [3H] in the supernatant gives a measure of the amount of 
collagen digested. As well as measuring active collagenase activity, a measure of total 
collagenase activity can be obtained by adding APMA (0.67 mM) to the assay, which 
activates latent proMMPs. 
 
Reagents: 
• Tris assay buffer: 100 mM TrisHCl, pH 7.6, 15 mM CaCl2 and 0.02% (w/v) NaN3. 
• 10 mM stock solution APMA: 35.2 mg APMA was dissolved in 200 µl DMSO and 
diluted to 10 ml with 100 mM TrisHCl, pH 8.5. This was stored at 4°C in a foil-
wrapped container for up to 3 months.  
• Tris-APMA assay buffer: At the time of assay, APMA was diluted to 2 mM in Tris 
assay buffer. 
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• Cacodylate buffer: 25 mM sodium cacodylate, pH 7.6, 0.05% (w/v) Brij-35 and 
0.02% (w/v) NaN3. 
• [3H]-acetylated collagen: Acid-soluble type I collagen was extracted and purified 
from calf skin using the method previously described (Cawston and Barrett, 1979). 
The purified collagen was freeze-dried and stored at -20°C. When required the 
collagen was thawed and redissolved in 0.2 M acetic acid at 4°C. Collagen was 
radiolabelled with [3H]-acetic anhydride (925 MBq; Amersham Pharmacia Biotech 
Ltd. (Buckinghamshire, UK)) to a high specificity as described (Cawston et al. 
2001). For the assay, a 1 mg/ml solution (50 mM TrisHCl pH 7.6, containing 200 
mM NaCl and 0.02% (w/v) NaN3) with a specific activity of approximately 1 x 105 
dpm/mg was used.  
• Trypsin: 100 µg/ml trypsin in 1 mM HCl. Stored -20°C. 
• Bacterial collagenase: 100 µg/ml bacterial collagenase in cacodylate buffer. Stored -
20°C. 
 
Controls: 
Total lysis of collagen was obtained by the addition of bacterial collagenase. 
Negative control (cacodylate buffer) was used to determine the background counts. 
Trypsin control was used to determine maximum susceptibility of the labelled non-helical 
telopeptides to non-specific proteolytic cleavage and to identify if denaturation of the triple 
helix had occurred before the assay. Trypsin activity of between 10-20% lysis of total 
collagen was acceptable. The linear range of the assay was between 10-80% lysis of total 
collagen. 
 
Method:  
A measure of total collagenase activity was obtained by adding APMA (0.67 mM) to the 
assay. APMA activates the pro-form of MMPs by destabilising the propeptide, making it 
accessible to autolytic cleavage (Koshy et al. 1999). 50 µl of Tris assay buffer (100 mM 
Tris/HCl and 15 mM CaCl2, pH 7.6 at room temperature) ± APMA was added to each well 
of a V-bottomed 96-well plate. At the time of assay, APMA was diluted to 2 mM in Tris 
assay buffer. This was followed by 40 µl cacodylate buffer (CCA) (25 mM sodium 
cacodylate, 0.05% (w/v) Brij 35 and 0.02% (w/v) azide; pH 7.5) + 10 µl sample or standard 
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in duplicate (neat or diluted in cacodylate buffer). Three sets of controls (in duplicate) were 
also included 1) CCA (50 µl) (negative control to determine the background counts 
obtained in the assay); 2) 10 µl trypsin (100 µg/ml in 1 mM HCl) + 40 µl CCA (used to 
ensure the collagen has not been denatured and thus become susceptible to non-specific, 
non-collagenolytic proteolytic cleavage); 3) 50 µl bacterial collagenase (100 µg/ml in CCA) 
(the total lysis control is used to determine the counts obtained if all the collagen is 
cleaved). This was followed by the addition of 50 µl of [3H]-acetylated collagen (1 mg/ml) 
(50 mM TrisHCl, pH 7.6, 200 mM NaCl, 0.02% (w/v) NaN3). The 96-well plate was 
incubated at 37°C (16-20 hours) then centrifuged at 1056 x g, 4°C for 30 minutes in a 
Sorvall RC5C Plus centrifuge. Supernatant (50 µl) was removed and placed in a flexible 
96-well sample plate with 200 µl of Optiphase “Supermix” scintillation fluid. Counts were 
read in a 1450 Micro-Beta Trilux liquid scintillation and luminescence counter (Wallac). 
Collagenase activity was measured in units/ml, where one unit can degrade 1 µg of 
collagen per minute at 37°C.  
 
Equation for calculating collagenase activity (units/ml):  
= 50/(total lysis-blank) x 1000/(sample volume (µl)) x 1/(time (minute)) x (sample - blank) 
2.2.5 RNA isolation and real-time polymerase chain reaction 
2.2.5.1 Extraction of RNA from bovine nasal cartilage 
During cartilage experiments, RNA was extracted from powdered cartilage using TRIzol® 
Reagent. This extraction procedure is a modification of the single-step acid-phenol 
guanidinium extraction method developed by (Chomczynski and Sacchi 2006). Cartilage 
stored in RNAlater at -80oC was thawed and RNAlater removed. Cartilage was snap-frozen 
in liquid nitrogen and immediately ground (10 minutes pre-cool, 5 cycles of 2 minutes of 
grinding and 2 minutes of cooling, impact frequency of 10 Hz) in a SPEX CertiPrep 6750 
freezer mill (Glen Creston, Stanmore, UK). 3 ml TRIzol® Reagent was added to the 
powdered cartilage, shaken vigorously, incubated at room temperature for 10 minutes and 
centrifuged at maximum speed for 10 minutes at 4oC to remove insoluble material. 
Chloroform (450 µl chloroform per 750 µl TRIzol) was added to the supernatant, the 
samples were vortexed and incubated at room temperature for 10 minutes. Samples were 
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then centrifuged at maximum speed for 15 minutes at 4oC. The aqueous phase was allowed 
to separate for up to 3 days at 4oC. The aqueous phase was removed and mixed with a half 
volume of 100% ethanol. Total cellular RNA was extracted and purified using the RNeasy 
kit. This included an on-column DNase step, as per the manufacturer’s instructions. Total 
RNA (1 µg) was reverse transcribed in a 20 µl reaction using superscript II reverse 
transcriptase (Invitrogen) according to the manufacturer’s instructions. cDNA was stored at 
-20oC until use in downstream real-time RT-PCR. 
2.2.5.2 Reverse Transcription 
RNA extracted using RNeasy® Mini Kit: RNA was quantified by spectrophotometry 
(Nanodrop ND 1000 spectrophotometer) and complementary DNA (cDNA) was 
synthesised from 1 µg of total RNA. RNA was combined with 2 µg of random hexamers (1 
µg/ml) (GE Healthcare, Little Chalfont, UK) in a final volume of 12.5 µl and heated at 
70oC for 10 minutes. Samples were chilled immediately on ice and the following was added 
to each well: 4 µl 5x First Stand Synthesis Buffer, 2 µl DTT (0.1 M), 0.5 µl Superscript II 
(200 U/µl), 0.5 µl RNaseOut (40 U/µl) and 0.5 µl dNTPs (10 mM). Samples were then 
incubated at 42oC for 1 hour. cDNA diluted 1:100 in dH2O for target gene quantification or 
1:500 for housekeeping gene quantification and stored at -20oC until required. 
 
RNA extracted using SideStepTM Kit: Cells were seeded into 96-well plates at a density of 
10,000 cells per well and grown until 70-80% confluent. After the desired period of 
cytokine incubation, culture medium was removed and cells were washed once with ice-
cold PBS. 10 µl SideStepTM Lysis and Stabilization Buffer was added to each well and the 
plate was then vortexed for 2 minutes to ensure complete cell lysis. 5 µl cell lystate was 
transferred to a new 96-well plate and diluted with 15 µl dH20. 4 µl of the diluted cell lysate 
was transferred to a new 96-well plate for reverse transcription. To each well of the 96-well 
plate 1 µl random hexamers (0.2 µg/ml) and 3 µl dNTPs (2.5 mM) were added and the plate 
heated at 70oC for 5 minutes. The plate was immediately placed on ice where 4 µl 5x First 
Strand Synthesis Buffer, 2 µl DTT (0.1 M), 0.125 µl RNaseOut (40 U/µl) and 0.5 µl 
MMLV (200 U/µl) were added to each well. The plate was incubated at 37oC for 50 
minutes, followed by 70oC for 15 minutes. Bovine cDNA was diluted 1:100 and human 
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cDNA was diluted 1:20 for housekeeping gene quantification. All cDNA was stored at -
20oC until required. 
2.2.5.3 Taqman® Probe-Based Real-Time RT-PCR 
Oligonucleotide primers and probes were designed using Primer Express 1.0 (Applied 
Biosystems, Warrington, UK) (Table 2.1) and were used to measure mRNA expression in 
human articular chondrocytes and SW1353. Relative quantification of genes was performed 
using the ABI prism 7900HT sequence detection system (Applied Biosystems, Foster City, 
Ca, USA).  To a 96-well microtitre plate 5 µl of real-time RT-PCR mix containing the 
following was added: 3.3 µl Jumpstart Taq Readymix, 0.8 µl MgCl2 at a final concentration 
of 2 mM, 0.3 µl each of forward and reverse primer (final concentration 300 nM), 0.1 µl 
probe (final concentration 150 nM) and 0.2 µl ROX reference dye. 5 µl of cDNA was then 
added to each well, to make a final volume of 10 µl per well. Conditions for real-time RT-
PCR were as follows: for 18S, MMP-1, MMP-13, Trb2 and Trb3, 2 minutes at 50oC, 10 
minutes at 95°C, then 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. To normalise 
for different amounts of total RNA present in each sample, 18S rRNA was used as an 
endogenous control. 
Gene Sequence (5’-3’) Length (bp) 
18S CGAATGGCTCATTAAATCAGTTATGG 
TATTAGCTCTAGAATTACCACAGTTATCC 
FAM-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-TAMRA 
26 
29 
32 
MMP-1 AAGATGAAAGGTGGACCAACAATT 
CCAAGAGAATGGCCGAGTTC 
FAM-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-TAMRA 
24 
20 
32 
MMP-13 AAATTATGGAGGAGATGCCCATT 
TCCTTGGAGTGGTCAAGACCTAA 
FAM-CTACAACTTGTTTCTTGTTGCTGCGCATGA-TAMRA  
23 
23 
30 
Trb2 CATACACAGGTCTACCCCC 
TCCGCGGACCTTATAGAC 
FAM-CTTCGAAATCCTGGGTTTT-TAMRA 
19 
18 
19 
Trb3 CTGCCCGCTGTCTGGTTC 
GGGCATCGGGTCCTGTCG 
FAM-TGCCTCCTTCGTCGGGAG-TAMRA 
18 
18 
18 
Table 2.1 Human Taqman® probe-based real-time PCR primers and probes. 
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2.2.5.4 SYBR® Green Real-Time PCR 
Oligonucleotide primers were designed using DNAstar (DNASTAR, Inc, Madison, WI, 
USA) (Table 2.2). Relative quantification of genes was performed using the ABI prism 
7900HT sequence detection system (Applied Biosystems, Foster City, Ca, USA). Bovine 
MMP gene expression was determined using SYBR Green. Takara SYBR Green mixtures 
contained 50% SYBR Green PCR mix (Takara) and 1 pmole of each primer in a total 
volume of 10 µl. Conditions for real-time RT-PCR were as follows: for MMP-1 and 18S, 
10 seconds at 95oC, then 40 cycles consisting of 5 seconds at 95oC and 30 seconds at 60oC, 
followed by a dissociation plot; for MMP-13, 10 seconds at 95oC, then 40 cycles consisting 
of 5 seconds at 95oC, 15 seconds at 55oC and 20 seconds at 72oC, followed by a 
dissociation plot; and for Trb1 and STAT6 10 seconds at 95oC, then 40 cycles consisting of 
15 seconds at 95oC and 1 minute at 60oC, followed by a dissociation plot. To normalise for 
different amounts of total RNA present in each sample, 18S rRNA was used as an 
endogenous control. 
 
 
Gene                    Sequence (5’-3’)                                                                                          Length    (bp) 
Bovine  
MMP-1 
GATGCCGCTGTTTCTGAGGA 
GACTGAGCGACTAACACGACACAT 
  20 
  24 
Bovine 
MMP-3 
 
TTAGAGAACATGGGGACTTTTTG  
CGGGTTCGGGAGGCACAG 
23 
18 
 
Bovine 
MMP-13 
CCCTCTGGTCTGTTGGCTCAC  
CTGGCGTTTTGGGATGTTTAGA 
21 
22 
Bovine 
MMP-14 
AGGCCGACATCATGATCTTCTTTG  
CTGGGTTGAGGGGGCATCTTAGTG 
24 
24 
 
Human 
STAT6 
TTCTCTGCCAGCTTCACACTT 
CACCAGGGGCAGAGACAG 
21 
18 
Human 
Trb1 
CCCCAAAGCCAGGTGCCT 
TACCCGGGTTCCAAGACG 
 
18 
18 
 
Table 2.2 SYBR® Green primers for real-time RT-PCR. 
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2.2.6 Preparation of total cell lysates 
Reagents: 
• Lysis buffer (50 mM Tris, pH 7.4, 10% (v/v) glycerol, 1 mM EDTA, 1 mM EGTA, 
1 mM Na3VO4, 5 mM NaF, 10 mM β glycerol phosphate, 5 mM Na4P2O7, 1%  (v/v) 
Triton X-100, 1µM microcystin-LF and 1 Complete protease inhibitor Mini tablet 
from (Roche Diagnostics, Burgess Hill, UK) for 50 ml buffer). 
 
Method:  
Cells were plated in 6-well plates or 25 cm2 flasks at a density of 25 000 cells/cm2.  After 
the desired period of cytokine incubation, culture medium was removed and cells rinsed 
with ice-cold PBS.  The PBS was then removed and replaced with ice-cold Lysis buffer at 
the following volumes: 150 µl/well of a 6-well plate and 200 µl/75 cm2 flask.  The cells 
were scraped into the lysis buffer then transferred to an Eppendorf tube on ice.  Samples 
were vortexed for 10 seconds and incubated on ice for 20 minutes, followed by 
centrifugation at 10,000 x g at 4ºC for 3 minutes.  The supernatant was then removed, snap 
frozen on dry ice and stored immediately at -80ºC. 
2.2.7 Subcellular protein fractionation 
The Subcellular Protein Fractionation Kit from ThermoScientific was used to separate the 
cytoplasmic, membrane, soluble nuclear, chromatin-bound nuclear and cytoskeletal 
fractions. The first reagent added to the cell pellet causes selective membrane 
permeabilisation, releasing soluble cytoplasmic contents. The second reagent dissolves 
plasma, mitochondria and ER/golgi membranes but does not solubilise the nuclear 
membranes. After recovering intact nuclei by centrifugation, a third reagent yields the 
soluble nuclear extract. An additional nuclear extraction with micrococcal nuclease is 
performed to release chromatin-bound nuclear proteins. The recovered insoluble pellet is 
then extracted with the final reagent to isolate cytoskeletal proteins. 
 
Reagents: 
• Ice-cold PBS 
• Subcellular Protein Fractionation Kit containing: 
• Cytoplasmic Extraction Buffer (CEB), stored at -20oC 
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• Membrane Extraction Buffer (MEB) ), stored at 4oC 
• Nuclear Extraction Buffer (NEB) ), stored at 4oC 
• Pellet Extraction Buffer (PEB) ), stored at room temperature 
• Micrococcal Nuclease ≥ 100 units/µl), stored at -20oC 
• CaCl2 (100 mM), stored at 4oC 
• HaltTM Protease Inhibitor Cocktail (100X), stored at 4oC 
 
Method:  
SW1353 cells were cultured as described in section 2.2.3. Following cytokine stimulation, 
cells were washed once with ice-cold PBS. Cells were scraped into 1 ml ice-cold PBS and 
centrifuged at 500 x g for 3 minutes to pellet. The supernatant was discarded.  Protease 
inhibitors were added to required volume of reagents as per Table 2.3. 
 
Packed cell 
volume (µl) 
CEB (µl) MEB (µl) NEB (µl) NEB (µl) + 
CaCl2, 
MNase* 
PEB (µl) 
10 100 100 50 50 50 
20 200 200 100 100 100 
50 500 500 250 250 250 
* MNase = Micrococcal nuclease 
Table 2.3 Subcellular protein fractionation reagent volumes for different packed cell volumes. 
 
Ice-cold CEB buffer containing protease inhibitors was added to the cell volume (Table 
2.3) and the tube incubated at 4oC for 10 minutes with gentle mixing.  The tube was 
centrifuged at 500 x g for 5 minutes at 4oC and the supernatant (cytoplasmic extract) 
transferred to a clean pre-chilled tube on ice. Ice-cold MEB buffer containing protease 
inhibitors was added to the pellet and vortexed for 5 seconds on highest setting. The tube 
was then incubated at 4oC for 10 minutes with gentle mixing and centrifuged at 3000 x g 
for 5 minutes at 4oC. The supernatant (membrane extract) was transferred to a clean pre-
chilled tube on ice. Ice-cold NEB containing protease inhibitors was added to the pellet and 
vortexed for 15 seconds on the highest setting, then incubated at 4oC for 30 minutes with 
gentle mixing. The tube was centrifuged at 5000 x g for 5 minutes at 4oC and the 
supernatant (soluble nuclear extract) transferred to a clean pre-chilled tube on ice. The 
Chapter 2 
 - 57 - 
chromatin-bound extraction buffer was prepared by adding 5 µl 100 mM CaCl2 and 3 µl of 
Micrococcal Nuclease (300 units) per 100 µl of room temperature NEB and added to the 
pellet. The tube was vortexed for 15 seconds on the highest setting, incubated at room 
temperature for 15 minutes and centrifuged at 16000 x g for 5 minutes at 4oC. The 
supernatant (chromatin-bound nuclear extract) was transferred to a clean pre-chilled tube 
on ice. Room temperature PEB containing protease inhibitors was added to the pellet, 
vortexed at the highest setting for 15 seconds and incubated at room temperature for 10 
minutes. The tube was centrifuged at 16000 x g for 5 minutes at 4oC and the supernatant 
(cytoskeletal extract) transferred to clean tube. Fractions were snap frozen and stored at –
80oC until required. 
2.2.8 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated based on size by SDS-PAGE performed under reducing conditions 
(Laemmli 1970). The polymerisation of acrylamide is initiated by the addition of APS and 
TEMED. TEMED catalyses the decomposition of the persulphate ion to give a free radical 
which initiates the polymerisation reaction. Samples were prepared by boiling in β-
mercaptoethanol and SDS. β-mercaptoethanol reduces any disulphide bridges and the SDS, 
an anionic detergent, denatures proteins. The bound SDS masks the charge of the proteins, 
forming anionic complexes with constant net negative charge per unit mass. The purpose of 
the stacking gel is to concentrate the protein sample into a sharp band before it enters the 
main separating gel. This is achieved by utilising differences in ionic strength and pH 
between the electrophoresis buffer and the stacking gel. The stacking gel has a large pore 
size, allowing the proteins to move freely and stack under the effect of the electric field. 
The band-sharpening effect relies on the fact that negatively charged glycinate ions (in the 
electrophoresis buffer) have a lower electrophoretic mobility than the protein-SDS 
complexes, which, in turn, have lower mobility than the chloride ions of the loading buffer 
and the stacking gel. Proteins are separated by their size, with smaller proteins moving 
more easily through the pores of the gel and larger proteins moving more slowly. After the 
tracking dye (bromophenol blue) reaches the bottom of the gel, electrophoresis is stopped.  
 
 
 
Chapter 2 
 - 58 - 
Reagents: 
• 4 x Lower gel buffer (LGB): 1.5 M TrisHCl pH 8.8, 0.4% (w/v) SDS. 
• 4 x Upper gel buffer (UGB): 0.5 M Tris HCl pH 6.8, 0.4% (w/v) SDS. 
• Stacking gel: 40% bis/acrylamide diluted to 4.5% with water and 4 x UGB. 
• 5 x Final sample buffer (FSB): 0.625 mM Tris HCl pH 6.8, 40% (v/v) glycerol, 
10% (w/v) SDS, 0.5% (w/v) bromophenol blue, 5% (v/v) β-mercaptoethanol. 
• 10 x Running Buffer: 250 mM Tris, 2 M glycine, 10% (w/v) SDS. 
 
Method: 
Electrophoresis was performed in a Bio-Rad Mini-Protean II apparatus with 1.0 mm 
spacers and combs. Polyacrylamide-bis-acrylamide was purchased as a 40% (w/v) (37.5:1 
acrylamide:bis) solution, diluted with water and 3 ml of 4 x LGB  to the required 
percentage (Table 2.4). Gel mixture (12 ml) was polymerised by the addition of 20 µl 
TEMED and 60 µl APS (0.2% w/v) immediately before pouring the gel. The lower gel was 
overlaid with propan-2-ol to exclude oxygen and allowed to polymerise. Once set, propan-
2-ol was washed off the gel and a 4.5% bis/acrylamide stacking gel laid on top, combs 
inserted and the stacker allowed to set. Upper gel (5 ml) was set with 10 µl TEMED and 30 
µl 0.2% (w/v) APS. The gel kit was assembled and filled with 1 x Running Buffer. Cell 
lysate samples were prepared as follows: 1 ml of 5 x sample buffer was mixed with 250 µl  
β-mercaptoethanol. Sample buffer (4 µl) was added to 20 µl of each cell lysate sample and 
heated to 105°C for 5 minutes. Molecular weight markers were PageRuler pre-stained 
protein standards (Fermentas). Proteins were electrophoresed at a constant 80 V in Running 
Buffer for approximately 1 hour 30 minutes, until the dye front had run to the end of the 
separating gel. 
 
Percentage gel 
(%) 
40% (w/v) acryl/bis solution 
(37.5:1) (ml) 
dH2O         
(ml) 
4x LGB    
(ml) 
12.5 3.75 5.25 3.0 
10 3.0 6.0 3.0 
7.5 2.25 6.75 3.0 
Table 2.4 Preparation of SDS-PAGE gels (volumes for 2 gels). 
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2.2.9 Western blotting 
Reagents: 
• Transfer Buffer: 39 mM glycine, 48 mM Tris, 0.0375% (w/v) SDS and 20% (v/v) 
methanol. 
• Tris Buffered Saline (TBS): 10 mM TrisHCl pH 7.4, 0.15 M NaCl. 
 
Method: 
Proteins were separated by SDS-PAGE (section 2.2.8) and semi-dry blotted onto PVDF 
membrane essentially according to the method of (Towbin et al. 1979). Proteins were 
transferred from SDS gels to PVDF membrane (0.2 µm pore size) (Millipore) using a semi-
dry transfer unit (Bio-Rad). The gel, PVDF membrane and 4 sheets of filter paper were 
soaked in transfer buffer. A sandwich was made on the anode plate consisting of 2 sheets of 
filter paper followed by the PVDF membrane, the gel and the remaining 2 sheets of filter 
paper. The sandwich was rolled gently to remove any air bubbles and the cathode plate 
lowered on top. Transfer was allowed to proceed for 1 hour 30 minutes at a current of 80 
mA per gel (35 V, 200 W). Following transfer, the blot was blocked with TBS containing 
0.2% Tween 20 (TBS-T) containing 5% (w/v) non-fat dried milk in blocking buffer for 1 
hour at room temperature. The blot was incubated overnight at room temperature with 
primary antibody diluted in TBS-T (containing 5% BSA). The blot was then washed three 
times in 20 ml TBS/0.05% Tween for 5 minutes in a small dish on a rocking table. The blot 
was incubated for 1-2 hours with a secondary antibody conjugated with HRP. The blot was 
then washed three times in TBS-T for 5 minutes.  
 
Towards the end of this PhD, the above method was replaced by the iBlot® Dry Blotting 
System (Invitrogen), carried out according to manufacturer’s instructions. The iBlot® Dry 
Blotting System blots proteins from polyacrylamide gels in 7 minutes, without the need for 
additional buffers or an external power supply. Briefly, the iBlot™ Gel Transfer Device is a 
self-contained blotting unit with an integrated power supply that allows for fast, dry 
blotting of proteins. The iBlot™ Gel Transfer Stacks are disposable stacks with an 
integrated nitrocellulose transfer membrane to perform dry blotting of proteins. Each 
iBlot™ Gel Transfer Stack contains a copper electrode and appropriate cathode and anode 
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buffers in the gel matrix to allow fast dry blotting of proteins without the need to prepare 
buffers.   
 
Protein detection by enhanced chemiluminescent (ECL) was carried out according to the 
manufacturer‘s instructions.  
2.2.10 Gelatin zymography 
Proteins were separated on an SDS-PAGE gel, co-polymerised with 0.1% w/v gelatine. 
SDS was then washed from the gel to allow proteins to refold and become active. Gels 
were incubated overnight in Tris/Triton/Ca2+/Zn2+ buffer to allow gelatin digestion to 
occur. The gels were stained with Coomassie blue and destained. Clear bands on a blue 
background indicated the presence of gelatin activity.  
 
Reagents: 
• 5 x sample buffer: 10 ml 10 x Upper Gel Buffer (UGB), 2 g SDS, 8 ml glycerol, 2 
ml bromophenol blue (0.1% (w/v) in ethanol). 
• 10 x zymography buffer: 200 mM Tris pH 7.8. 
• Tris/Triton buffer: 20 mM Tris pH 7.8, 2.5% (w/v) Triton-X100. 
• Tris/Triton/Ca2+/Zn2+ buffer: 20 mM Tris pH 7.8, 10 mM CaCl2, 5 µM ZnCl2, 1% 
Triton-X100. 
• Coomassie stain: 2.5 g Coomassie G250, 400 ml methanol, 100 ml acetic acid, 500 
ml H2O.  
• Destain: 800 ml methanol, 100 ml acetic acid, 1100 ml H2O. 
 
Method: 
Gelatin zymography was used to assay gelatinase activity in the culture supernatants. 
Samples were electrophoresed under non-reducing conditions by SDS-PAGE in 7.5% 
polyacrylamide gels copolymerised with 0.1% (w/v) gelatin. To remove SDS, gels were 
washed twice for 1 hour in Tris/Triton buffer, then incubated overnight (16 hours) in 
Tris/Triton/Ca2+/Zn2+ buffer at 37oC. Coomassie Brilliant Blue was used to stain gels. 
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2.2.11 RNAi and over-expression plasmid assays 
2.2.11.1 RNAi assays 
Reagents: 
• Dharmacon siGENOMETM SMARTpools®  
• siCONTROL (non-targeting siRNA #2, Cat: 001210-02)  
• DharmafectTM 1 lipid reagent  
Method: 
Primary human chondrocytes or SW1353 cells were prepared and cultured as described in 
sections 2.2.2.2 and 2.1.2, respectively. For siRNA transfections, cells were trypsinized and 
re-seeded at approximately 50% confluency. Dharmacon siGENOMETM SMARTpools® of 
4 specific siRNA duplexes (total of 100 nM siRNA) were used to transfect SW1353 cells 
using DharmafectTM 1 lipid reagent. siRNA pools were used to target Trb1 (NM_025195, 
Cat: 003633); Trb2 (NM_021643, Cat: 005391); Trb3 (NM_021158, Cat: 003754), STAT6 
(NM_003153, Cat: 006690); S100A8 (NM_002964, Cat: 011770); S100A9 (NM_002965, 
Cat: 011384); SNFT (NM_018664, Cat: 003633); IRS1 (NM_005544, Cat: 003015) and 
IRS2 (NM_003749, Cat: 003554).  
 
96-well plate format: Several hours prior to transfection, all medium was removed from the 
human articular chondrocytes or SW1353 cells and replaced with 50 µl of FBS-containing 
DMEM or DMEM-F12, respectively. For each well, 100 nM siRNA in a total volume of 15 
µl FBS-free DMEM or DMEM-F12 and 0.26 µl DharmafectTM 1 lipid reagent in a total 
volume of 15 µl of FBS-free DMEM or DMEM:F12 was prepared. These two mixes were 
combined and incubated at room temperature for 20 minutes before addition to cells, to 
allow complex formation. Cells were transfected for 28 hours and serum starved for 20 
hours prior to the addition of cytokines for a further 24 hours. Total RNA was isolated and 
reverse-transcribed as described in section 2.2.5.2. Expression of genes of interest was 
measured by real-time PCR as described in section 2.2.5.3.1. Changes in gene-specific 
mRNA levels were calculated by comparison of expression levels with cells transfected 
with 100 nM siCONTROL. 
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6-well plate format: Several hours prior to transfection, all media was removed from the 
SW1353 cells and replaced with 500 µl of serum-containing DMEM-F12. For each well, 
100 nM siRNA in a total volume of 250 µl serum-free DMEM-F12 and 3.25 µl 
DharmafectTM 1 lipid reagent in a total volume of 250 µl of DMEM:F12 was prepared. 
These two mixes were combined and incubated at room temperature for 20 minutes before 
addition to cells, to allow complex formation. Cells were transfected for 28 hours and 
serum starved for 20 hours prior to the addition of cytokines for a further 24 hours. Total 
cell lysates were prepared as described in section 2.2.6 and proteins were separated by 
SDS-PAGE as described in section 2.2.8. Protein fractions were transferred to PVDF 
membranes (as described in section 2.2.9) and blots were probed with the relevant antibody 
to confirm successful knock-down of genes by siRNA at the protein level. 
2.2.11.2 Over-expression plasmid assays 
 
Preparation of plasmid DNA:  
Reagents: 
• Luria broth (LB) containing 10 g NaCl, 10 g tryptone and 5 g yeast extract per litre 
dH2O. 
• LB Agar containing 10 g NaCl, 10 g tryptone, 5 g yeast extract and 15 g agar per 
litre dH2O. 
• Qiaprep Spin Midi/Maxi Kit. 
 
Reagents were autoclaved prior to use and ampicillin added at a final concentration of 100 
µg/ml in filter-sterilised water for selection. Standard aseptic technique was used 
throughout the cloning procedure. 
 
Mach1TM-T1® chemically competent E.coli (30 µl) and 0.5 µl plasmid (see appendix A for 
plasmid maps) was added to a 1.5 ml Eppendorf tube and swirled to mix. The tube was then 
incubated on ice for 30 minutes and heat shocked at 42oC for 30 seconds. The tube was 
incubated on ice for 2 minutes before the addition of 500 µl pre-warmed LB (37oC). Tubes 
were incubated for 1 hour in a 37oC water bath. On pre-warmed agar plates containing 
ampicillin (100 µg/ml), 20 µl and 50 µl volumes were streaked out. Plates were allowed to 
dry for 5 minutes before incubation at 37oC overnight. One colony for each plasmid was 
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picked and placed in a universal with 2 ml LB containing 100 µg/ml ampicillin. This was 
shaken at 37oC for 8 hours at 250 rpm before transferring the 2 ml culture to a conical flask 
containing 250 ml LB (plus 100 µg/ml ampicillin). The conical flasks were shaken at 37oC 
overnight (16 hours) at 250 rpm.  Overnight cultures were centrifuged at 6000 x g for 15 
minutes at 4oC to pellet cells. The supernatant was discarded and the bacterial pellet 
resuspended in 10 ml Buffer P1 (Qiagen) and vortexed until the pellet was fully 
resuspended. Buffer P2 (Qiagen) (10 ml) was added and inverted 6 times to mix and 
incubated for 5 minutes at room temperature. Buffer P3 (Qiagen) (10 ml) was added and 
incubated on ice for 20 minutes before centrifuging at 20000 x g for 30 minutes at 4oC.  
The supernatant was transferred a clean bottle and centrifuged again at 20000 x g for 30 
minutes at 4oC. Qiagen MaxiPrep columns were equilibrated by applying 10 ml Buffer 
QBT. The supernatant was applied to the column. Columns were then washed with 2 x 30 
ml Buffer QC and the plasmid DNA was eluted with 15 ml Buffer QF. Plasmid DNA was 
precipitated by adding 10.5 ml propan-2-ol and centrifuging at 15000 x g for 30 minutes at 
4oC. The supernatant was discarded and 350 µl dH20 was added to resuspend pellet. This 
was transferred to a 2 ml screw-cap tube. dH20 (150 µl) was added to the original tube to 
resuspend any remaining DNA and then transferred to the same 2 ml tube. Ethanol (100%, 
1125 µl) was added to the 2 ml tube and centrifuged at maximum speed for 10 minutes. The 
supernatant was discarded and the pellets air-dryed. Pellets were resuspended in 300 µl 
dH20 and plasmid DNA was quantified by spectrophotometry (Nanodrop ND 1000 
spectrophotometer) and stored at -20oC until required.   
 
Over-expression plasmid assay: 
Reagents: 
• FuGene HD Transfection Reagent 
• Lipofectamine 2000 Reagent 
 
Method: 
SW1353 cells were prepared and cultured as described in section 2.1.2. For over-expression 
plasmid transfections, cells were trypsinized and re-seeded at approximately 50% 
confluency. Trb1 (c-Myc tagged), Trb3 (c-Myc tagged) and STAT6 over-expression 
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plasmids were used to transfect SW1353 cells using FuGene HD Transfection Reagent or 
Lipofectamine 2000 Reagent (see individual experiments).  
 
96-well plate format: Several hours prior to transfection, all media was removed from the 
SW1353 cells and this was replaced with 100 µl serum-containing DMEM:F12. Cells were 
then transfected with 0.1 µg of plasmid DNA and 0.3 µl of transfection reagent in a total 
volume of 3 µl serum-free DMEM:F12. This mix was incubated for 20 minutes at room 
temperature before addition to cells to allow for complex formation. Cells were transfected 
for 28 hours and serum starved for 20 hours prior to the addition of cytokines for a further 
24 hours. Total RNA was isolated and reverse-transcribed as described in section 2.2.5.2. 
Expression of genes of interest was measured by real-time RT-PCR as described in section 
2.2.5.3.1. Changes in gene-specific mRNA levels were calculated by comparison of 
expression levels with cells transfected with the empty vector, pcDNA3.1. 
 
6-well plate format: Several hours prior to transfection, all media was removed from the 
SW1353 cells and this was replaced with 1 ml serum-containing DMEM:F12. Cells were 
then transfected with 1 µg of plasmid DNA and 3 µl of transfection reagent in a total 
volume of 20 µl serum-free DMEM:F12. This mix was incubated for 20 minutes at room 
temperature before addition to cells to allow for complex formation. Cells were transfected 
for 28 hours before preparation of total cell lysates (as described in section 2.2.6) and 
separation of proteins by SDS-PAGE (as described in section 2.2.8). Protein fractions were 
transferred to PVDF membranes (as described in section 2.2.9) and blots were probed with 
c-Myc or STAT6 antibody to confirm protein over-expression. 
2.2.11.3 GFP-based protein fragment complementation assay 
 
To assess any physical interactions between the tribbles and MAPKKs, a green fluorescent 
protein (GFP)-based protein fragment complementation assay was used. The venus variant 
of GFP was used in this assay. MEK1, MKK4, MKK6 and MKK7 were fused to the N-
terminal fragment of Venus GFP (V1) and Trb1 and Trb3 were fused to the C-terminal 
fragment of Venus GFP (V2). Various combinations of expression constructs were co-
transfected and the GFP signal was visualised by fluorescent microscopy. Plasmids for the 
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GFP-based protein fragment complementation assay were a kind gift of Endre Kiss-Toth 
(Sheffield University).  
 
Reagents:  
• FuGene HD Transfection Reagent 
 
Method: 
SW1353 cells were prepared and cultured as described in section 2.1.2. Cells were 
trypsinized and re-seeded in 8-well chamber slides at approximately 50% confluency. 
Several hours prior to transfection, all media was removed and replaced with 250 µl serum-
containing DMEM:F12. Cells were then transfected with 0.1 µg of plasmid DNA and 0.3 µl 
of FuGene HD Transfection Reagent in a total volume of 3 µl serum-free DMEM:F12. This 
mix was incubated for 20 minutes at room temperature before addition to cells to allow for 
complex formation. After 28 hours incubation, cells were washed twice with PBS and fixed 
in 4% paraformaldehyde for 10 minutes. Cells were washed a further 2 times in PBS and 
slides mounted in VECTASHIELD with DAPI. All fluorescent images of cells were taken 
using a Leica DM LB microscope (Leica Microsystems, Milton Keynes, UK). Images were 
captured using a RTKE SPOT™ camera and SPOT™ Advanced imaging software from 
Diagnostic Instruments Inc. (Sterling Heights, MI, USA). Cell fixing was performed by 
Beth Gibson and microscopy was performed with the assistance of Christos Gabrielides.  
2.2.11.4 shRNA assays 
Reagents: 
• MISSION® Lentiviral Transduction Particles  
• Hexadimethrine bromide  
 
Method: 
SW1353 cells were prepared and cultured in 96-well plates as described in section 2.1.2. 
For shRNA transfections, cells were trypsinized and re-seeded at approximately 50% 
confluency. MISSION® Lentiviral Transduction Particles for trb1 (Clone IDs 
TRCN0000001535, TRCN0000001536, TRCN0000001537, TRCN0000001538, 
TRCN0000001539) were used to transduce SW1353 cells. Several hours prior to 
transduction, all media was removed from the SW1353 cells and this was replaced with 100 
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µl serum-containing DMEM:F12. Immediately prior to transduction, hexadimethrine 
bromide was added to the cells at a final concentration of 8 µg/ml. The appropriate amount 
of viral particles was then added at a suitable multiplicity of infection (MOI) (10 or 25), 
where the MOI is the number of lentiviral transducing particles per cell.  The volume of 
lentiviral particles required for the desired MOI depends on the number of transducing units 
(TU) in the provided solution and is determined using the calculation ((No. of cells x 
M.O.I) / TU per mL reported).  The cell-viral particle mix was then incubated at 37oC for 
28 hours. The cells were serum starved for 20 hours prior to the addition of cytokines for a 
further 24 hours. Total RNA was isolated and reverse-transcribed as described in section 
2.2.5.2. Expression of genes of interest was measured by real-time RT-PCR as described in 
section 2.2.5.3.1. Changes in gene-specific mRNA levels were calculated by comparison of 
expression levels with untransduced cells. 
2.2.12 Genome-wide Arrays 
2.2.12.1 Affymetrix Bovine GeneChip Array 
The GeneChip® Bovine Genome Array allows the gene expression of over 23,000 bovine 
transcripts to be analysed.  
 
Preparation of RNA: 
A 14-day bovine nasal cartilage degradation assay was performed to generate RNA for the 
GeneChip® Bovine Genome Array. Bovine nasal cartilage was stimulated with control 
media ± IL-1 ± OSM ± IL-4 (added at day 7 of timecourse only) for 14 days as described in 
section 2.2.4.1. RNA was extracted from the bovine cartilage as described in section 
2.2.5.1. 
 
Data normalisation: 
Data normalisation was performed by Dr Daniel Swan (Newcastle University). Affymetrix 
Bovine GeneChip CEL files were imported into GeneSpring 10 (Agilent). An experiment 
was created where the chips were normalised with MAS5 expression algorithm to produce 
Present, Marginal or Absent flag data.  A list was derived where a probeset had to have a 
present or marginal signal in 3/4 samples in order to be included, reducing the probeset list 
to 15367 entities (reduced from 24128 entities). Data were then renormalised in an 
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independent experiment using GCRMA. A list of Affymetrix control probes (denoted by an 
AFFX_ prefix) was generated. From the MAS5 generated list, the Affymetrix control 
probesets were subtracted, leaving a final quality controlled list of probesets with 14928 
entities for further analysis. Chips were then compared on a pairwise basis to generate lists 
of probesets for each comparison which had a fold change greater than 2. 
 
2.2.12.2 Sentrix Human-6 Expression BeadChip 
The Sentrix Human-6 Expression BeadChip contains 6 arrays on a single BeadChip, each 
with >46,000 probes derived from human genes in the National Center for Biotechnology 
Information (NCBI) Reference Sequence (RefSeq) and UniGene databases.  
 
Preparation of RNA: 
Human articular chondrocytes and SW1353 cells were cultured as described in 2.2.3. 
Following 24 hour cytokine stimulation, RNA was extracted as described in section 2.2.5.2.  
 
Data normalisation: 
Data normalisation was carried out by the Centre for Microarray Resources (Cambridge, 
UK). The selection of the data removed non-expressed genes or data that were too close to 
the background to be distinguished. Not removing these genes would add noise to the data. 
 
The selection was done using the following criteria: 
• Threshold for selection: detection p-value inferior to 0.01 for a measurement to be 
selected. 
• The selection is applied so that a gene must be present on all the samples used. 
• The set is then use to generate the raw data plot present in the archive. 
 
Once the raw data plot has been generated, the data are re-selected using a less stringent 
parameter: 
• the genes must be present on at least one of the array/samples analysed.  
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The data were then transformed using a variance stabilisation algorithm (Lin et al. 2008) 
and then normalised using quantile normalisation. All of this was performed using the lumi 
package (Du et al. 2008). 
 
Analysis results: 
Number of genes selected after normalisation: 15184 of the 48804, which represents 31% 
of the total genes. 
2.2.13 DNA methylation analysis 
Methylation is the most widely studied type of epigenetic modifications of DNA. The 
development of bisulphite sequencing PCR (BSP) by Frommer et al. (1992) greatly 
advanced the study of DNA methylation and is now one of the most frequently used 
techniques in the field. This method begins with the bisulphite treatment of genomic DNA 
(to convert unmethylated cytosine bases to uracil), followed by PCR amplification of the 
region of interest within the modified DNA. Conventional sequencing of the amplified 
product can then be carried out to specifically evaluate DNA methylation within a 
particular DNA sequence (Reed et al. 2009). 
2.2.13.1 Isolation of DNA from Primary Cells 
Method: DNA was isolated from primary cells using the PureLinkTM Genomic DNA Kit 
according to the manufacturer’s instructions. Briefly, cells were harvested in PBS and 
centrifuged at 250 x g for 5 minutes to pellet the cells. PBS was removed and the cells 
resuspended in 200 µl PBS. Proteinase K (20 µl) (>600 mAU/ml) was added, followed by 
20 µl RNaseA and the sample was mixed well by vortexing and incubated at room 
temperature for 2 minutes. PureLinkTM Genomic Lysis/Binding Buffer (200 µl) was added 
and the sample mixed by vortexing to obtain a homogenous solution and incubated at 55oC 
for 10 minutes to promote protein digestion. Ethanol (100%, 200 µl) was added to the 
lysate and vortexed for 5 seconds. The lysate was then added to a PureLinkTM Spin Column 
and centrifuged at 10,000 x g for 1 minute at room temperature. The collection tube was 
discarded and the spin column placed into a clean PureLinkTM collection tube. Wash Buffer 
1 (500 µl) prepared with ethanol was added to the column and the column was centrifuged 
at room temperature at 10,000 x g for 1 minute. The column was placed into a clean 
PureLinkTM collection tube and 500 µl Wash Buffer 2 prepared with ethanol was added. 
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The column was centrifuged at maximum speed for 3 minutes at room temperature. The 
column was then placed in a sterile 1.5 ml Eppendorf tube and 100 µl PureLinkTM Genomic 
Elution Buffer was added to the column, which was then incubated at room temperature for 
1 minute. To recover the genomic DNA, the column was centrifuged at maximum speed for 
1.5 minutes at room temperature. The purified DNA was stored at -20oC until bisulphite 
conversion. 
2.2.13.2 Primer design and optimisation 
Bisulphite conversion of bovine nasal chondrocyte DNA: Total DNA was isolated as 
described in section 2.2.12.1. To provide DNA for primer optimisation, 1 µg aliquots of 
bovine nasal chondrocyte DNA were subject to bisulphite conversion using the Epitect® 
Bisulphite Kit according to manufacturer’s instructions. Bisulphite reactions were prepared 
by combining 1 µg bovine nasal chondrocyte DNA, 85 µg bisulphite mix and 35 µg DNA 
protect buffer in a final volume of 140 µl. Bisulphite conversion was carried out using a 
PTC-200 DNA Engine Thermal Cycler (Bio-Rad). Cycling conditions were 99oC for 5 
minutes, 60oC for 25 minutes, 99oC for 5 minutes, 60oC for 85 minutes, 99oC for 5 minutes 
and 60oC for 175 minutes. Clean up of bisulphite converted DNA was performed using 
Epitect® spin columns according to manufacturers instructions. Purified DNA was eluted in 
20 µl dH2O and stored at -20oC prior to analysis by PCR. 
 
Primer design: Primers were designed to amplify a region of the bovine MMP-13 promoter 
containing 7 CpG sites. Primers were designed using the MethPrimer software (available at 
www.urogene.org/methprimer), which identifies suitable regions of DNA in a bisulphite 
converted sequence against which primers can be designed. All primer sequences are 
shown in Table 2.5. 
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Primer name Sequence 
Bovine MMP-13 Forward TAGTTGTTTTTTTGTAAAGGGGAAA 
 
Bovine MMP-13 Reverse AAACCAACCAAAACCCTTAAAC 
 
Pyrosequencing PCR bovine MMP-13 Forward GAGGTTGTTATTTTGTAAGA 
 
Pyrosequencing PCR bovine MMP-13 Reverse AACCAACCAAAACCCTTA  
 
Pyrosequencing sequencing primer 1 GTTGAAAGGAGAGAAGTTT 
 
Pyrosequencing sequencing primer 2 TTGTTTGGGAAAAGATAG 
 
Table 2.5 DNA methylation analysis primers. 
 
Optimisation of cycling conditions: 6 identical 20 µl reactions were prepared by combining 
2 µl TitaniumTM Taq buffer, 0.4 µl forward primer, 0.4 µl reverse primer, 0.4 µl Taq, 0.4 µl 
dNTPs (2.5 mM) and 1 µl bisulphite treated genomic DNA in a final reaction volume of 20 
µl in dH2O. Optimal annealing temperatures were determined using a TaKaRa PCR 
Thermal Cycler Dice (SANYO E&E Europe Ltd., Loughbourgh, UK). Cycling conditions 
were: 95oC for 1 minute, 40 cycles of [95oC for 15 seconds, 50-65oC gradient for 30 
seconds, 68oC for 1 minute], 68oC for 7 minutes. A 5 µl aliquot of each reaction was run 
out on a 1.2% agarose gel to determine the optimal annealing temperature required to 
amplify the desired PCR product. 
 
Once primer optimisation had been carried out, bovine nasal chondrocytes were grown to 
80-90% confluency as described in section 2.2.3, serum-starved overnight and stimulated 
with DMEM ± IL-1 (1 ng/µl) ± OSM (10 ng/µl) ± IL-4 (20 ng/µl). Total DNA was isolated 
as in section 2.2.12.1 and bisulphite conversion of this DNA was carried out as in section 
2.2.13.2. 
2.2.13.3 Amplification and purification of PCR products 
Bisulphite treatment of DNA from bovine DNA: DNA was obtained from and extracted as 
described in section 2.2.2.1. Approximately 1 µl DNA was subject to bisulphite conversion 
as described in section 2.2.13.2. 
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PCR analysis: PCR was performed using bovine MMP-13 primers (Table 2.5) to amplify a 
369 base pair (bp) region of the MMP-13 promoter. The PCR was carried as described in 
section 2.2.13.2. Optimised PCR cycling conditions for bovine MMP-13 primers were: 
95oC for 1 minute, 40 cycles of [95oC for 15 seconds, 65oC for 30 seconds, 68oC for 1 
minute], 68oC for 7 minutes.  
2.2.13.4 Cloning of PCR products 
Reagents: 
• Luria broth (LB) containing 10 g NaCl, 10 g tryptone and 5 g yeast extract per litre 
dH2O. 
• LB Agar containing 10 g NaCl, 10 g tryptone, 5 g yeast extract and 15 g agar per 
litre dH2O. 
 
Reagents were autoclaved prior to use and ampicillin added at a final concentration of 100 
µg/ml in filter-sterilised water for selection. Standard aseptic technique was used 
throughout the cloning procedure. 
 
Method: 
Ligation and transformation: Purified PCR products were cloned using the TOPO TA 
cloning® kit and Dual Promoter pCR®II-TOPO® vector according to manufacturer’s 
instructions. Briefly, ligation reactions were prepared by combining 4 µl PCR product, 1 µl 
salt solution and 0.5 µl pCR®II-TOPO® in a final volume of 6 µl in dH2O. Ligations were 
incubated at room temp for 20 minutes then placed on ice and 2 µl of the reaction added to 
25 µl Mach1TM-T1® chemically competent E.coli. Reactions were incubated on ice for 10 
minutes prior to transformation by heat shock at 42oC for 30 seconds followed by 
immediate removal to ice. A 250 µl aliquot of SOC medium (Invitrogen) was added to each 
vial and cultures were shaken (200 rpm) at 37oC for 1 hour. A 100 µl aliquot of each 
transformation was spread onto a pre-warmed agar plate containing 40 µg/ml 5-bromo-4-
chloro-3-indolyl-b-D-galactopyranoside (X-GAL) in dimethylformamide (DMF) and 100 
µg/ml ampicillin to allow blue/white screening. Plates were incubated at 37oC for 16 hours 
for colonies to develop. 
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Preparation of overnight cultures: White colonies were selected and added to 5 ml LB 
containing 100 µg/ml ampicillin. Cultures were shaken at 200 rpm at 37oC for 16 hours in 
an orbital shaker. 
 
Quick MiniPreps of plasmid DNA: A 1.5 ml aliquot of culture was transferred to a 1.5 ml 
Eppendorf tube and centrifuged at 20 seconds at 9500 x g. The supernatant was discarded 
and cells resuspended in 100 µl Buffer P1 (Qiagen) by vortexing. Subsequently, 200 µl 
Buffer P2 (Qiagen) was added to cells and mixed thoroughly by inverting 10 times. A 150 
µl aliquot of Buffer P3 (Qiagen) was then added and mixed immediately by inverting 10 
times. Lysates were centrifuged for 3 minutes at 9500 x g and the supernatant removed to a 
new Eppendorf tube containing 1 ml 100% ethanol. Samples were vortexed for 10 seconds 
to mix thoroughly and centrifuged for 10 minutes at 9500 x g. All ethanol was removed and 
pellets were air-dryed before resuspension in 50 µl dH2O. 
 
Restriction digests: A 2 µl aliquot of each miniprep was digested using the restriction 
enzyme EcoR1. Plasmid DNA was combined with 5 U EcoR1 (0.5 µl), 1.5 µl 10x EcoR1 
buffer and dH2O in a final volume of 15 µl and incubated at 37oC for 1 hour. A 10 µl 
aliquot of each digest was electrophoresed on a 1.2% agarose gel, as described in section 
2.2.13.6 to determine if it contained an insert of the correct size. 
2.2.13.5 Analysis of DNA methylation 
The inserts of numerous colonies were sequenced via the AP6 promoter until 20 unique 
clones from each treatment group were obtained. DNA methylation analysis was performed 
using BiQ analyzer software (available at http://biq-analyzer.bioinf.mpiinf.mpg.de/). 
Sequences were required to be 80% identical to the original sequence and have >90% C-T 
conversion (excluding CpG). Any potential sequence clones identified by the software were 
also removed to ensure only unique sequences were analysed. 
2.2.13.6 Agarose Gel Electrophoresis 
Reagents: 
• 1 x Tris-acetate-ethylenediamine tetraacetic acid (TAE) containing 0.04 M Tris (pH 
8), 5.7% (v/v) glacial acetic acid and 0.1 mM EDTA. 
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• Loading buffer containing Tris 0.125 M (pH 6.8), 2% (w/v) SDS, 10% (v/v) 
glycerol and 0.001% (w/v) bromophenol blue. 
 
Method: 
Agarose gels were prepared at 1.2% (w/v) by dissolving the required amount of agarose in 
1 x TAE buffer through boiling. Ethidium bromide (3,8-Diamino-5-ethyl-6-
phenylphenanthridinium bromide) solution was added to cooled agarose at a final 
concentration of 0.2 µg/ml. Gels were poured, allowed to set and the required amount of 
DNA loaded in loading buffer. Bands were separated at 100 V for approximately 40 
minutes and visualised on a ChemiGenius II Biolmager (Syngene, Cambridge, UK) using 
GeneRulerTM 1 kb DNA ladder to assess product size. 
2.2.13.7 Pyrosequencing 
Pyrosequencing was recently adapted to study DNA methylation and is now an alternative 
to conventional bisulphite-sequencing PCR (BSP). This technique also requires the 
bisulphite treatment of genomic DNA and PCR amplification of the target sequence, but 
this is followed by pyrosequencing rather than conventional sequencing methods (Reed et 
al 2009). Pyrosequencing is a sequencing-by-synthesis method that quantitatively monitors 
the real-time incorporation of nucleotides through the enzymatic conversion of released 
pyrophosphate into a proportional light signal (Tost and Gut 2007). Incorporation of a 
cytosine is indicative of a methylated residue, whereas the incorporation of a thymine 
indicates an originally unmethylated cytosine. Therefore, the methylation status of a CpG 
site can be determined from the ratio of T and C. 
 
Method: 
2.2.13.7.1 Assay design and optimisation  
Bisulphite conversion of bovine nasal chondrocyte DNA: Bovine nasal chondrocytes were 
grown to 80-90% confluency as described in section 2.2.3, serum-starved overnight and 
stimulated with DMEM ± IL-1 (1 ng/µl) ± OSM (10 ng/µl) ± IL-4 (20 ng/µl). Total DNA 
was isolated as in section 2.2.12.1 and bisulphite conversion of this DNA was carried out as 
in section 2.2.13.2.  
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Primer design: PCR primers and sequencing primers were designed using 
PyrosequencingTM Assay Design Software, which automatically designed both 
pyrosequencing PCR primers and pyrosequencing sequencing primers. All primer 
sequences are shown in table 2.4. The PCR primers were designed to amplify the region of 
the bovine MMP-13 promoter containing 6 of the 7 CpG sites analysed in section 2.2.13.5. 
The reverse primer was biotinylated to facilitate immobilization onto streptavidin-coated 
beads and to render the PCR product single stranded. 
 
Positive and negative controls: Positive and negative controls were picked from clones 
generated in section 2.2.13.4. The positive control was a clone in which all 7 CpG sites 
were methylated and the negative control was a clone in which all 7 CpG sites were 
unmethylated. 
 
Optimisation of cycling conditions: Primer cycling condition optimisation was carried out 
as in section 2.2.13.2. Control bisulphite-treated bovine DNA was used for primer 
optimisation. Optimised PCR cycling conditions for pyrosequencing PCR bovine MMP-13 
primers were: 95oC for 1 minute, 40 cycles of [95oC for 15 seconds, 65oC for 30 seconds, 
68oC for 1 minute], 68oC for 7 minutes. A 5 µl aliquot of each reaction was run out on a 
1.2% agarose gel to determine the optimal annealing temperature required to amplify the 
desired PCR product. 
2.2.12.7.2 Amplification and purification of PCR products 
PCR analysis: PCR was performed using pyrosequencing PCR bovine MMP-13 primers to 
amplify a 240 bp region of the bovine MMP-13 promoter. The PCR was carried as 
described in section 2.2.13.2. Optimised PCR cycling conditions for MMP-13 primers 
were: 95oC for 1 minute, 40 cycles of [95oC for 15 seconds, 65oC for 30 seconds, 68oC for 
1 minute], 68oC for 7 minutes.  
2.2.13.7.3 Pyrosequencing 
Reagents: 
• Binding buffer: 10 mM Tris, 2 M NaCl, 1 mM EDTA, 0.1% (v/v) Tween 20, pH 7.6 
• Denaturing Solution: 0.2 M NaOH 
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• Wash buffer: 10 mM Tris, pH 7.6 
• Annealing buffer: 20 mM Tris, 2 mM Mg-acetate, pH 7.6 
• Streptavidin-coated sepharose beads 
 
Preparation of single-stranded DNA template: The single stranded DNA template was 
prepared using immobilisation on streptavidin-coated sepharose beads. The following was 
added to individual wells of a 96-well PCR plate (binding mix): 10 µl PCR product, 2 µl 
streptavidin-coated sepharose beads, and 38 µl binding buffer made up to a total volume of 
80 µl with dH2O. The plate was sealed and vortexed for 5 minutes.  
 
Next, 0.5 µl sequencing primer (10 µM) and 11.5 µl annealing buffer was added to each 
well of a 96-well pyrosequencing plate (annealing mix). 
 
A PyroMark Vacuum Prep Workstation (Qiagen) is a sample preparation terminal designed 
to batch process up to 96 DNA samples in parallel. The Vacuum Prep Workstation consists 
of a hand-held Vacuum Prep Tool and a Vacuum Prep Worktable, connected to a vacuum 
source, containing four solution troughs. The Vacuum Prep Tool consists of a hand-grip 
with 96 replaceable filter probes, which is connected to a vacuum source. The binding mix 
was aspirated from the wells of the PCR plate by placing the hand-grip block into the PCR 
plate resulting in the capture of the beads on the filter probes. The hand-grip filter tips were 
then immersed in three successive baths for 5 seconds each as follows: 70% (v/v) ethanol, 
denaturing buffer and wash buffer. At this point the vacuum was switched off and the hand-
grip block immersed in the annealing mix of the pyrosequencing plate and gently agitated 
to release the beads. The pyrosequencing plate was then heated at 80oC for 2 minutes. The 
plate was then cooled to room temperature to allow annealing of the primers to the PCR 
product.  
 
Pyrosequencing: The sequencing run was programmed into the pyrosequencer (PyroMark 
Q96  MD, Qiagen) using the Pyro Q-CpGTM software. The reagents (nucleotides, substrate 
and enzyme mix (Qiagen)) were dispensed into the appropriate wells of the cartridge 
according to the volume calculation of the software. The pyrosequencing plate and the 
reagent cartridges were placed in the pyrosequencer and the software run.  
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Analysis of methylation: Analysis of methylation status was performed by the Pyro Q-
CpGTM software.  
2.2.14 Statistical analysis 
The difference between sample group means was tested for statistical significance using 
ANOVA (analysis of variance) with a posthoc Bonferroni multiple comparison test. For 
hydroxyproline and collagenase assay data, values are given as mean and standard 
deviation (S.D.), where *p≤0.05, **p≤0.01 and ***p≤0.001. Real-time RT-PCR data were 
normalised against 18S rRNA, then plotted as the fold induction of the target gene 
expression over control levels. Levels of statistical significance are shown as *p≤0.05, 
**p≤0.01 and ***p≤0.001. For clarity, only selected comparisons are presented in some 
figures. 
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Chapter 3:  Investigations into the effects of IL-4 on IL-
1+OSM-induced cartilage collagen release and 
collagenase expression in chondrocytes and 
cartilage 
 
 
 
3.1 Introduction 
 
Arthritic disease is characterised by the irreversible loss of the cartilage matrix resulting in 
the loss of normal joint function and disability. Degradation of proteoglycan is rapid yet 
reversible (Dingle et al. 1987); collagen loss occurs more slowly but this loss irreversibly 
compromises the structural integrity of the tissue (Jubb and Fell 1980).  Cartilage collagen 
loss is therefore regarded as being the key control point in cartilage breakdown. 
 
The bovine nasal cartilage explant culture model has provided a valuable system for 
studying collagen loss and identifying factors that contribute to the breakdown of the tissue 
(Cawston et al. 1995). It has also facilitated the investigation of chondoprotective agents 
such as IL-4 and IL-13 (Cawston et al. 1996; Cleaver et al. 2001). Addition of the pro-
inflammatory cytokine combination of IL-1 and OSM to bovine nasal cartilage induces 
collagen release through the increase in synthesis of collagenases. In 1996, Cawston et al. 
reported that IL-4 acted as a protective factor by specifically blocking the release of 
collagen from bovine nasal cartilage stimulated to resorb with IL-1+OSM, preventing pro-
inflammatory cytokine-induced cartilage breakdown. Subsequent data from the department 
have indicated that IL-4 mediates its protective effect by reducing the levels of active 
collagenase and that this was most likely due to a reduction in MMP-13 expression (Pyle 
2003). Furthermore, these studies demonstrated that MMP-1 expression was seemingly 
unaffected by IL-4 in stimulated cartilage. These key observations, firstly that IL-4 was 
able to block pro-inflammatory cytokine-induced collagen release and secondly that IL-4 
differentially regulated MMP-1 and MMP-13, formed the basis of this PhD project.  
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The bovine nasal cartilage model has been used to investigate the chondroprotective effect 
of IL-4 on cartilage as opposed to a human cartilage model because bovine tissue is 
conveniently available in large quantities. Human articular cartilage is very difficult to 
obtain in amounts large enough for such experiments. Resorption of human articular 
cartilage in explant culture treated with IL-1 and OSM is variable with only approximately 
50% of samples responding with the release of collagen and even in those samples the 
levels of collagen release are low (Cawston et al. 1998). The reasons for this low response 
are currently unclear. However, the lack of response in terms of collagen release may be 
explained by the fact that the majority of human articular cartilage samples are from elderly 
patients, which are suspected to have low numbers of chondrocytes. Whilst the levels of 
collagen release from the bovine nasal cartilage model can also be variable, the majority of 
samples release typically ≥60% of their collagen. 
 
Pro-inflammatory cytokines are well understood to stimulate the production of MMPs, 
including the collagenases. IL-1 is a potent inducer of MMP-13 expression in chondrocytes 
(Borden et al. 1996). The combination of IL-1 and OSM has been shown to synergistically 
promote the expression of MMP-1 mRNA in human articular chondrocytes (Cawston et al. 
1998). It is also known that IL-1+OSM-induced collagen degradation in bovine nasal 
cartilage is MMP-dependent (Cawston et al. 1995). Given that IL-4 acts as a protective 
factor in the bovine nasal cartilage model by preventing IL-1+OSM-induced collagen 
breakdown, this chapter aims to elucidate the effect of IL-4 on collagenase expression at 
the transcriptional level. Previous studies (Cleaver 2000, Pyle 2003) addressed the effect of 
IL-4 on IL-1+OSM-induced MMP-1 and MMP-13 mRNA expression by Northern blot. IL-
4 was shown to increase IL-1+OSM-induced MMP-1 expression in bovine nasal 
chondrocytes, human articular chondrocytes and SW1353 cells and decrease MMP-13 
expression in human articular chondrocytes and SW1353 cells. Data regarding the effect of 
IL-4 on IL-1+OSM-induced MMP-13 expression in bovine nasal chondrocytes was 
inconclusive (Pyle 2003). This chapter will address the effect of IL-4 on IL-1+OSM-
induced MMP-1 and MMP-13 mRNA expression using the more sensitive technique of 
real-time RT-PCR.  
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The aims of this chapter were to: 
• Confirm the original findings of Cawston et al. (1996) demonstrating that IL-4 was 
able to block IL-1+OSM-induced collagen release in the bovine nasal cartilage 
model. 
• Determine the effect of delayed IL-4 addition to bovine nasal cartilage stimulated to 
resorb with IL-1+OSM.  
• Investigate the effect of IL-4 on IL-1+OSM-induced collagenase gene expression in 
bovine nasal chondrocytes, human articular chondrocytes and SW1353 cells. 
• Profile collagenase expression in resorbing bovine nasal cartilage. 
 
3.2 Results 
 
3.2.1 The effect of IL-4 on the release of collagen from bovine cartilage treated 
with IL-1±OSM. 
Experiments were performed using bovine nasal cartilage in culture to recapitulate the 
findings of Cawston et al. (1996) that originally showed IL-4 specifically blocked collagen 
release in this model. Cartilage stimulated with IL-1 alone resulted in 14.8% total collagen 
release over 14 days (Figure 3.1). In response to the pro-inflammatory combination of IL-
1+OSM, 78.3% of the collagen was released. The addition of IL-4 to IL-1+OSM 
significantly inhibited collagen release, reducing the total collagen release to 3.7 %. These 
data demonstrate that the previous results of Cawston et al. (1996) are indeed reproducible.  
 
3.2.2 The effect of delayed addition of IL-4 on IL-1+OSM-induced collagen and 
active collagenase levels in bovine nasal cartilage.  
Previous work in the department (Pyle 2003) has shown that IL-4 does not need to be 
present for the full 14 days of culture in order to protect against IL-1+OSM-induced 
cartilage degradation. Experiments demonstrated that addition of IL-4 as late as day 8 of 
culture still significantly inhibited IL-1+OSM (0.2 and 2 ng/ml respectively)-induced 
cartilage degradation. The concentrations of IL-1 and OSM were reduced from the normal 
1 and 10 ng/ml, respectively, to allow resorption to proceed at a slower rate. This  
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Figure 3.1 The effect of IL-4 on the release of collagen from the bovine nasal cartilage model treated 
with IL-1±OSM. Bovine nasal cartilage chips were cultured in medium + IL-1 (1 ng/ml) ± OSM (10 ng/ml) 
± IL-4 (20 ng/ml) for 14 days. At day 7, medium was removed and replenished with identical cytokines. 
Media were harvested at days 7 and 14 and cartilage was harvested at day 14. As a measure of collagen 
release, the levels of hydroxyproline released into the media were assayed as described in section 2.2.4.4. The 
cumulative levels (day 7 + day 14) of hydroxyproline released in the medium were expressed as a % of the 
total collagen. Values are the mean ± standard deviation (n=4). *** = p ≤ 0.001. This experiment is 
representative of three separate cartilages. 
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experiment aimed to confirm the findings that delayed IL-4 addition could still protect 
against collagen release, but with IL-1 and OSM used at the standard concentrations of 1 
and 10 ng/ml, respectively, in order to enable greater overall % collagen release and to 
standardise experiments. In this experiment, IL-1+OSM (1 and 10 ng/ml respectively) 
stimulated a 53% collagen release (Figure 3.2a). The levels of collagen release induced by 
IL-1+OSM is known to vary between experiments. Tests to determine if this is due to a loss 
of cytokine activity have shown that this is not the reason behind reduced levels of collagen 
release in certain experiments (data not shown). It is thought that these differences can be 
explained by the cartilage explant model being a variable biological system and 
susceptibility to resorption is bound to vary between different cartilage samples, just as 
susceptibility to OA differs between different humans. The addition of IL-4 to IL-1+OSM 
from day 0 of the timecourse reduced the collagen release to 1%. Delayed addition of IL-4 
to IL-1+OSM until day 7 still dramatically reduced collagen release (2%) (Figure 3.2a). 
Active collagenase (Figure 3.2b) was reduced to levels that were undetectable by the 
collagenase assay following addition of IL-4 at both day 0 and day 7 of the timecourse.  
 
3.2.3 The effect of IL-4 on IL-1+OSM–induced gene expression of MMP-1 and 
MMP-13 in bovine chondrocytes.  
This was the first opportunity to look at gene expression in bovine chondrocytes using the 
sensitive technique of real-time RT-PCR. Whilst previous studies have looked at MMP 
mRNA expression in bovine chondrocytes, gene expression in these studies was analysed 
using Northern blots (Pyle 2003). Both MMP-1 and MMP-13 mRNA were synergistically 
induced by IL-1+OSM when compared with IL-1 alone (Figure 3.3). Addition of IL-4 to 
the pro-inflammatory combination of IL-1+OSM was able to substantially block the 
induction of MMP-13 mRNA (Figure 3.3b), whilst this addition of IL-4 to IL-1+OSM had 
no significant effect on MMP-1 mRNA levels (Figure 3.3a). 
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Figure 3.2 The effect of delayed addition of IL-4 on IL-1+OSM-induced collagen and active collagenase 
levels in bovine nasal cartilage. Bovine nasal cartilage chips were cultured in medium + IL-1 (1 ng/ml) + 
OSM (10 ng/ml) ± IL-4 (20 ng/ml, added at day 0 or day 7) for 14 days. At day 7, medium was removed and 
replenished. Media were harvested at days 7 and 14 and cartilage was harvested at day 14. As a measure of 
collagen release, the levels of hydroxyproline released into the media were assayed as described in section 
2.2.4.4. The cumulative levels (day 7 + day 14) of hydroxyproline released in the medium were expressed as a 
% of the total collagen. Day 14 medium was assayed for active collagenase activity as described in section 
2.2.4.5. Values are the mean ± standard deviation (n=4). *** = p ≤ 0.001 compared to IL-1+OSM in the 
absence of IL-4. This experiment was performed three times with tissue from three different animals. The 
results shown are representative of all three experiments. 
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Figure 3.3 The effect of IL-4 on IL-1+OSM–induced gene expression of MMP-1 and MMP-13 in bovine 
nasal chondrocytes. Bovine nasal chondrocytes were stimulated for 24 hours with medium ± IL-1 (1 ng/ml) 
± OSM (10 ng/ml) ± IL-4 (20 ng/ml). Following treatment, total RNA was isolated from cells, reverse 
transcribed and the cDNA was used in real-time RT-PCR reaction assays, as described in section 2.2.5, to 
examine MMP-1 and MMP-13 gene expression. Data are presented as fold induction relative to the basal 
expression and represent mean ± SEM (n=4). and are representative of four independent experiments. ** = p 
≤ 0.01; ns = not significant.  
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3.2.4 The effect of IL-4 on IL-1+OSM–induced gene expression of MMP-1 and 
MMP-13 in human articular chondrocytes and SW1353 cells.  
The induction of MMP-1 and MMP-13 mRNA in both human articular chondrocytes and 
SW1353 by IL-1+OSM (Figure 3.4) and particularly the synergy observed, was not as 
strong as that observed in bovine chondrocytes (Figures 3.2 and 3.3). Consequently, the 
inhibition of MMP-13 by IL-4 in both human cell types (Figure 3.4) was not as complete as 
that observed in bovine nasal chondrocytes (Figure 3.3). Whilst the inhibition of MMP-13 
in SW1353 cells was not significant when compared with IL-1+OSM-treated cells due to 
the large standard error, the inhibition of MMP-13 by IL-4 in human articular chondrocytes 
was significant. The effect of IL-4 on IL-1+OSM-induced MMP-1 expression in human 
articular chondrocytes and SW1353 cells was consistent with the results observed in bovine 
chondrocytes, where the addition of IL-4 to IL-1+OSM had no significant effect on MMP-1 
mRNA expression.  
 
3.2.5 The effect of different concentrations of IL-4 on MMP-1 and MMP-13 
mRNA expression in bovine chondrocytes.  
A titration of IL-4 between 20 and 0.02 ng/ml was performed in bovine chondrocytes to 
determine the concentration dependence for the effects of IL-4 on MMP-13 repression. The 
data show that the repression of MMP-13 by IL-4 was less complete at decreasing 
concentrations of IL-4 (Figure 3.5b). Concentrations below 2 ng/ml of IL-4 were unable to 
significantly repress IL-1+OSM-induced MMP-13 expression. As observed in previous 
experiments, the effect of IL-4 on IL-1+OSM-induced MMP-1 expression was generally 
insignificant. However, IL-4 is often seen to slightly increase IL-1+OSM-induced MMP-1 
mRNA expression, although this increase is less frequently significant. Figure 3.5a shows a 
concentration-dependent decrease in MMP-1 expression with decreasing concentrations of 
IL-4, although none of these decreases were statistically significant.   
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Figure 3.4 The effect of IL-4 on IL-1+OSM–induced gene expression of MMP-1 and MMP-13 in human 
articular chondrocytes and SW1353 cells. Human articular chondrocytes were stimulated for 24 hours with 
medium ± IL-1 (0.02 ng/ml) ± OSM (10 ng/ml) ± IL-4 (20 ng/ml). SW1353 were stimulated for 24 hours with 
medium ± IL-1 (0.5 ng/ml) ± OSM (10 ng/ml) ± IL-4 (20 ng/ml). Following treatment, total RNA was 
isolated from cells, reverse transcribed and the cDNA was used in real-time RT-PCR reaction assays, as 
described in section 2.2.5, to examine MMP-1 and MMP-13 gene expression. Data are presented as fold 
induction relative to the basal expression and represent mean ± SEM (n=4) and are representative of two 
independent experiments. *** = p ≤ 0.001; ns = not significant for IL-1+OSM vs IL-1+OSM+IL-4.  
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Figure 3.5 The effect of different concentrations of IL-4 on MMP-1 and MMP-13 mRNA expression in 
bovine nasal chondrocytes. Bovine nasal chondrocytes were stimulated for 24 hours with medium ± IL-1 (1 
ng/ml) ± OSM (10 ng/ml) ± IL-4 (0.02 - 20 ng/ml). Following treatment, total RNA was isolated from cells, 
reverse transcribed and the cDNA was used in real-time RT-PCR reaction assays, as described in section 
2.2.5, to examine MMP-13 gene expression. Data are presented as fold induction relative to the basal 
expression and represent mean ± SEM (n=4). ** = p ≤ 0.01; * = p ≤ 0.05; ns = not significant.  
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3.2.6 Profiling the effect of IL-4 on collagenase gene expression and 
collagenolysis in resorbing cartilage.  
Experiments performed in monolayer bovine chondrocytes have shown that IL-4 blocks IL-
1+OSM-induced MMP-13 expression, but not MMP-1 expression. To confirm this, MMP 
expression was examined in the bovine nasal cartilage explant culture system, a more 
biologically relevant model. The expression and regulation of MMPs in response to pro-
inflammatory cytokines in chondrocytes have been profiled in two previous studies (Koshy 
et al. 2002; Barksby et al. 2006). However, both these studies were restricted to examining 
gene expression in isolated chondrocyte monolayers. Work by (Milner et al. 2006) has 
enabled the profiling of gene expression of multiple MMPs in actively resorbing cartilage 
by real-time RT-PCR. 
 
Figure 3.2 demonstrated that IL-4 does not need to be present for the full 14 days of culture 
in order to protect against IL-1+OSM-induced cartilage degradation. Previous work has 
demonstrated that addition of IL-4 as late as day 8 of culture still significantly inhibited IL-
1+OSM-induced cartilage degradation. Experiments were performed to confirm these 
findings and to examine the effect of delayed addition of IL-4 on collagenase mRNA 
expression. Both MMP-1 and MMP-13 were markedly and rapidly induced by IL-1+OSM, 
as reported previously (Milner et al. 2006) (Figures 3.6a and 3.6b). With IL-4 present in the 
culture from day 0, MMP-13 gene expression was completely inhibited. After day 3, the 
expression of MMP-1 reaches a plateau and IL-4 appears to have no overall effect during 
the remainder of the culture period. Following addition of IL-4 at day 7 of culture, MMP-
13 gene expression was immediately down-regulated. MMP-1 gene expression remained 
constant after addition of IL-4, with neither a significant increase nor decrease in 
expression levels. Procollagenases were first detected in the culture medium at day 3 
(Figure 3.6e). However, active collagenase (Figure 3.6d) was not detected until day 10 of 
culture and collagenolysis (Figure 3.6c) was not detected until day 12 of culture. In the 
presence of IL-4, procollagenases were detected in the culture medium, although at reduced 
levels compared to IL-1+OSM culture medium. Despite the presence of procollagenases, 
active collagenases and collagenolysis were both completely inhibited.      
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Figure 3.6 Profiling the effect of IL-4 on collagenase gene expression and collagenolysis in resorbing 
cartilage. Bovine nasal cartilage pieces were cultured in medium + IL-1 (1 ng/ml) + OSM (10 ng/ml) ± IL-4 
(20 ng/ml) for 14 days. At day 7, medium was removed and replenished with identical cytokines. Each time 
point and condition were performed in quadruplicate. RNA was extracted from the cartilage and collagenase 
gene expression determined by real-time RT-PCR as described in section 2.2.5. Data are presented as fold 
induction relative to the basal expression (a and b). As a measure of collagen release, the levels of 
hydroxyproline (OHPro) released into the media were assayed as described in section 2.2.4.3; cumulative 
OHPro is release is shown (c). Levels of active collagenase were measured (d) and APMA was used to 
activate pro-collagenases to provide a measure of total collagenase activity (pro+active) (e) as in section 
2.2.4.4. Values are the mean ± standard error of the mean. *** = p ≤ 0.001; ** = p ≤ 0.01; * = p ≤ 0.05 for IL-
1+OSM vs IL-1+OSM(+IL-4 at day 7). ### = p ≤ 0.001; ## = p ≤ 0.01; # = p ≤ 0.05 for IL-1+OSM vs IL-
1+OSM+IL-4. 
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3.2.7 Profiling the effect of IL-4 on gelatinolytic activity in resorbing cartilage.  
Previous work has shown IL-4 to have potent effects on the gelatinases MMP-2 and MMP-
9. IL-4 did not appear to have a significant effect on either pro or active MMP-2 
expression. Active MMP-9 however, was almost completely inhibited by the presence of 
IL-4 and proMMP-9 was barely detectable (data not shown). These observations appeared 
to support the findings of Milner et al. (2006) that MMP-9 is the predominant gelatinase in 
actively resorbing cartilage. Figure 3.7 shows the effect of delayed IL-4 addition on 
gelatinase activity. ProMMP-2 was expressed constitutively, regardless of cytokine 
treatment. In IL-1+OSM-treated cartilage, active MMP-2 was detectable from day 3 of 
culture and increased thereafter. Both pro and active MMP-2 were inhibited by IL-4, but 
this inhibition was not complete. ProMMP-9 was induced by IL-1+OSM and was 
detectable by day 3 of culture, however the addition of IL-4 strongly inhibited proMMP-9 
(Figure 3.7b and 3.7c). Active MMP-9 was first detected at day 7 of culture in IL-1+OSM-
treated cartilage (Figure 3.7a), but completely undetectable in IL-1+OSM+IL-4-treated 
cartilage (Figure 3.7b). The addition of IL-4 at day 7 of culture resulted in strong inhibition 
of active MMP-9 (Figure 3.7c), however this inhibition was slightly less complete than in 
cartilage in which IL-4 had been present from day 0 of culture. The data presented in 
Figure 3.7 support previous real-time RT-PCR data, which showed a complete inhibition of 
IL-1+OSM-induced MMP-9 mRNA by IL-4, but a lesser inhibition of IL-1+OSM-induced 
MMP-2 mRNA.  
 
3.2.8 Profiling the effect of IL-4 on IL-1+OSM-induced non-collagenolytic 
MMP expression in resorbing cartilage.  
MMP-3 is known to activate several proMMPs, including the collagenases proMMP-1 and 
13 (Murphy et al. 1987; Knauper et al. 1996b). IL-4 downregulated IL-1+OSM-induced 
MMP-3 mRNA expression by day 8 of the bovine nasal cartilage timecourse, regardless of 
whether IL-4 was present from day 0 or day 7 (Figure 3.8). It has been suggested that 
MMP-14 is able to degrade type II collagen (Ohuchi et al. 1997), although to a much lesser 
degree than either MMP-1 or MMP-13. Figure 3.8 demonstrates that IL-4 does not 
significantly alter the expression of IL-1+OSM-induced MMP-14 expression at any point in 
the 14-day timecourse.  
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Figure 3.7 Profiling the effect of IL-4 on gelatinolytic activity in resorbing cartilage. Bovine nasal 
cartilage chips were cultured in medium + IL-1 (1 ng/ml) + OSM (10 ng/ml) ± IL-4 (20 ng/ml) for 14 days. 
At day 7, medium was removed and replenished with identical cytokines. Cartilage and media were harvested 
at days 1, 3, 7, 8, 10, 12 and 14. Each time point and condition were performed in quadruplicate and 
representative data is shown. Gelatin zymography was performed as in section 2.2.4.2. 
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Figure 3.8 Profiling the effect of IL-4 on IL-1+OSM-induced non-collagenolytic MMP expression in 
resorbing cartilage. Bovine nasal cartilage pieces were cultured in medium + IL-1 (1 ng/ml) + OSM (10 
ng/ml) ± IL-4 (20 ng/ml) for 14 days. At day 7, medium was removed and replenished with identical 
cytokines. Each time point and condition were performed in quadruplicate. RNA was extracted from the 
cartilage and MMP-3 (a) and MMP-14 (b) gene expression were determined by real-time RT-PCR as 
described in section 2.2.5. Data are presented as fold induction relative to the basal expression and represent 
mean ± SEM (n=4). ** = p ≤ 0.01; * = p ≤ 0.05 for IL-1+OSM vs IL-1+OSM(+IL-4 at day 7). ## = p ≤ 0.01; 
# = p ≤ 0.05 for IL-1+OSM vs IL-1+OSM+IL-4. 
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3.3 Discussion 
 
Collagen breakdown is considered to be a key step in cartilage destruction. This chapter 
investigated the mechanism of IL-4 in the protection of bovine nasal cartilage from IL-
1+OSM-induced degradation, specifically its effect on the two key collagenases, MMP-1 
and MMP-13.  Previous work demonstrated that bovine nasal cartilage stimulated with IL-
1+OSM synergistically promoted cartilage collagen release, which was accompanied by a 
large increase in collagenolytic activity (Cawston et al. 1995).  IL-13, a related anti-
inflammatory cytokine, has likewise been shown to inhibit IL-1+OSM-induced collagen 
release from bovine nasal cartilage (Cleaver et al. 2001).  
 
The first results in this chapter confirmed the findings of Cawston et al. (1996), 
demonstrating that IL-4 was able to act in a chondroprotective manner by blocking the 
release of collagen from bovine nasal cartilage stimulated with the pro-inflammatory 
combination of IL-1+OSM. IL-4 was shown to be equally chondroprotective when addition 
was delayed until day 7 of the 14 day timecourse. IL-1+OSM-induced active collagenase 
was completely inhibited by the addition of IL-4, both at day 0 and day 7. This 
demonstrates that the protective mechanism of action of IL-4 is extremely effective.  
 
MMPs have been extensively studied in relation to the modulation of matrix function; 
between them they are able to degrade all ECM components. It is widely accepted that 
production of MMPs by chondrocytes and synovial fibroblasts is regulated by various 
cytokines and growth factors. It is therefore of no surprise that IL-4 has been implicated in 
the suppression of MMPs. IL-4 has been shown to downregulate MMP activity in a number 
of cell types involved in arthritis. Nemoto et al. (1997) demonstrated that IL-4 suppressed 
IL-1 stimulated MMP-3 protein and enzyme activity and was able to suppress IL-1-induced 
MMP-3 mRNA in human articular chondrocytes. As mentioned previously, collagen 
release is considered a key point in cartilage degradation. Of the three known collagenases, 
MMP-1 and MMP-13 are considered to be the most important in terms of the 
collagenolysis seen in the arthritides. MMP-13 is thought to be of greater importance in OA 
due to the fact that it preferentially degrades type II collagen (Knauper et al. 1996a) and 
because its expression is increased in OA (Tetlow et al. 2001). A key aim of this chapter 
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was to assess the effect of IL-4 on the regulation of MMP-1 and MMP-13 in both human 
and bovine chondrocytes. Due to the difficulties in obtaining sufficient quantities of human 
articular cartilage, it was necessary to use a human chondrocyte cell line in addition to 
primary human articular chondrocytes. The human chondrosarcoma SW1353 cell line is 
frequently used as a model for primary OA chondrocytes (Borden et al. 1996, Mengshol et 
al. 2000). IL-4 was found to inhibit IL-1+OSM-induced MMP-13 in bovine nasal 
chondrocytes and, albeit to a slightly lesser extent, in human articular chondrocytes and 
SW1353 cells (although this did not reach significance in the latter cell line). In contrast, 
IL-4 appeared to have no significant effect on IL-1+OSM-induced MMP-1 expression in 
any of the three cell types. If anything, a pattern of increasing MMP-1 expression in the 
presence of IL-4 was observed in all three cell types, although these increases were not 
always statistically significant. The apparent lack of effect of IL-4 on IL-1+OSM-induced 
MMP-1 expression compared with the potent inhibitory effect on IL-1+OSM-induced 
MMP-13 expression demonstrates differential regulation of the collagenases by IL-4. 
Indeed, this observation also further supports the observations of differential regulation of 
MMP-1 and -13 by IL-1+OSM (Litherland et al. 2008, 2010). 
 
The inhibitory effect of IL-4 on MMP-13 has been documented by other groups. El 
Mabrouk et al. (2008) reported a strong inhibition of OSM-induced MMP-13 gene 
expression by IL-4 in chondrocytes. Doi et al. (2008) found that IL-4 was able to 
downregulate mechanical stress-induced MMP-13 in chondrocytes. There have been 
differing reports in the literature regarding the effect of IL-4 on MMP-1 expression. A 
study by Chizzolini et al. (2000) found that IL-4 specifically enhanced MMP-1 production 
by mononuclear phagocytes at various stages of differentiation with the exception of freshly 
isolated PBMC (peripheral blood mononuclear cells), in which IL-4 was found to inhibit 
MMP-1 activity. The type I IL-4 receptor consists of IL-4Rα and γc chain. Bonder et al. 
(1998) have already demonstrated that the culturing of monocytes in GM-CSF (granulocyte 
macrophage colony-stimulating factor) results in the loss of the γc chain and that this loss is 
accompanied by decreased STAT6 activity. Therefore, Chizzolini et al. (2000) 
hypothesised that the ability of IL-4 to inhibit MMP-1 production is dependent on γc 
expression and γc-dependent intracellular signalling. When γc is no longer expressed, IL-4 
enhances rather than suppresses MMP-1 production.  
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Importantly, the data presented in this chapter demonstrates that IL-4 has similar effects on 
MMP expression in the SW1353 cell line as it does in primary human chondrocytes, 
supporting the use of SW1353 cells when large amounts of material are required. 
Additionally, the effects of IL-4 on MMP expression in primary bovine chondrocytes are 
very similar to those observed in human chondrocytes. As human articular cartilage is 
unavailable in quantities large enough to perform explant culture experiments for RNA 
extraction, these data suggest that the use of bovine nasal cartilage in such experiments is a 
biologically relevant alternative.  
 
Experiments utilising the 14 day bovine nasal explant culture model have demonstrated that 
strong down-regulation of MMP-13 mRNA by IL-4 is rapid, occurring within 24 hours of 
IL-4 addition. As collagen release does not occur until at least day 10 of culture in this 
model, IL-4 is able to completely block cartilage collagen degradation when addition is 
delayed until day 7 of culture. IL-1+OSM stimulate the production of active collagenases in 
bovine nasal cartilage; previous data and results in this chapter demonstrate that this 
activity can be inhibited by IL-4. Activation of any latent proenzymes with APMA allows 
total (pro + active) collagenolytic activity to be measured. The presence of IL-4 throughout 
all 14 days of culture significantly inhibits IL-1+OSM-induced levels of total collagenase, 
however the levels of total collagenase are not significantly inhibited if addition of IL-4 is 
delayed until day 7 of culture. Despite this, levels of active collagenase are virtually 
undetecable throughout the 14 day culture regardless of whether addition of IL-4 is delayed 
until day 7. Despite the presence of procollagenases in IL-1+OSM+IL-4 conditioned media, 
active collagenases and collagenolysis were both completely inhibited. These data give 
further support to the hypothesis Milner et al. (2001) that activation of procollagenases is a 
key control point in cartilage collagen degradation. It is possible that IL-4 could function by 
inhibiting the activation of procollagenases. Further evidence supporting this hypothesis is 
provided in a study by Cleaver et al. (2001), which showed that addition of MMP-3, a 
known activator of proMMPs, resulted in the recovery of collagen release in the presence 
of IL-1+OSM+IL-4, demonstrating that sufficient levels of procollagenases are present to 
promote extensive collagen loss if activated. 
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Previous work in the department (Pyle 2003) led to the hypothesis that IL-4 acts by 
inhibiting the activation of procollagenases in the bovine nasal cartilage system, in 
particular, by blocking serine proteinase activity. It has previously been shown that serine 
proteinase inhibitors can block IL-1+OSM-induced cartilage collagenolysis, implicating 
serine proteinases in the activation cascades that lead to the generation of active 
collagenases (Milner et al. 2003). These findings have yet to be pursued further. Thus, IL-4 
appears to be chondroprotective by two distinct, but possibly inter-related mechanisms; 
MMP-13 repression and blockade of serine proteinase activity. It could be that the 
downregulation of MMP-13 mRNA by IL-4 is incidental and it is the inhibition of 
proMMP-1 activation by IL-4 that explains the chondroprotective effects of IL-4. However, 
data presented in this chapter and by other groups suggest this is probably not the case. 
Previous data (Pyle 2003) had indicated that IL-4 can be added as late as day 8 or 9 of 
culture in the bovine nasal cartilage model and still protect against cartilage degradation. 
This could have been due to rapid repression of MMP-13 or via the hypothesised ability of 
IL-4 to prevent procollagenase activation. A key experiment in this chapter demonstrated 
the effect of delayed addition of IL-4 on IL-1+OSM-induced MMP-13 mRNA expression. 
By day 7 of culture in the bovine nasal cartilage model, MMP-13 expression had been 
strongly induced. Addition of IL-4 at day 7 resulted in rapid repression of MMP-13, 
providing a strong indicator of the protective mechanism of action of IL-4. Studies 
involving selective MMP-13 inhibitors (Johnson et al. 2007, Jungel et al. 2010, Piecha et al. 
2010) have demonstrated a reduction in collagen degradation with these inhibitors. These 
studies, along with the data presented in this chapter and the fact that MMP-13 is known to 
cleave type II collagen five times faster than MMP-1, strongly suggest that MMP-13 plays 
an integral role in collagen degradation and supports the development of selective MMP-13 
inhibitors to reduce cartilage destruction in arthritis patients.   
 
Analysis of the effect of IL-4 on non-collagenolytic MMPs provided further evidence that 
MMP-13 is central to the collagen degradation observed in the bovine nasal cartilage 
model. It has been suggested that both MMP-2 and MMP-14 possess collagenolytic activity 
(Ohuchi et al. 1997). However, data presented in this chapter demonstrated that whilst IL-4 
appears to slightly inhibit both IL-1+OSM-induced MMP-2 (both pro and active) and 
MMP-14 mRNA expression, this inhibition is by no means complete and certainly not 
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comparable to the level of inhibition of MMP-13. These data would suggest that neither of 
these enzymes are responsible for the collagen degradation in this model as active MMP-2 
and MMP-14 mRNA have been shown to be present in the assay at timepoints where 
collagenolysis was completed inhibited. Of more relevance is the inhibition of IL-1+OSM-
induced MMP-3 by IL-4. MMP-3 is a known activator of numerous MMPs, including the 
collagenases (Murphy et al. 1987). IL-4 was shown to significantly inhibit IL-1+OSM-
induced MMP-3 mRNA expression when present from day 0 or day 7 of the timecourse. 
These findings support those of Nemoto et al. (1997), who found that IL-4 was able to 
suppress IL-1-induced MMP-3 expression in human articular chondrocytes. The inhibition 
of MMP-3 mRNA by IL-4 could explain why MMP-1 mRNA is present throughout the 
timecourse and yet does not result in any collagenolysis.  
 
Despite the established chondroprotective effects of IL-4, the use of IL-4 as a therapeutic 
agent would not be recommended. IL-4 is known to have strong pro-inflammatory effects 
in other diseases, in particular asthma. Therefore, the direct administration of IL-4 would 
undoubtedly result in unwanted side effects. Therefore it is vitally important to establish the 
exact protective mechanism of action of IL-4 so that this protective pathway may be 
targeted at a more specific level. The most significant finding of this chapter is that IL-4 is 
able to strongly and reproducibly downregulate IL-1+OSM-induced MMP-13 expression in 
both primary chondrocytes and bovine cartilage. This suggests that MMP-13 could be the 
key collagenase in IL-1+OSM-induced cartilage collagen breakdown and therefore an 
important therapeutic target. The aim of the following studies is to further elucidate the 
mechanism by which IL-4 so effectively inhibits MMP-13.  
 
3.4 Summary 
 
Studies in this chapter have shown that: 
 
• IL-4 specifically blocked collagen release from bovine nasal cartilage stimulated to 
resorb with IL-1+OSM, in agreement with reports by Cawston et al. (1996). 
• Delayed addition of IL-4 until day 7 of culture still completely blocked IL-1+OSM-
induced cartilage collagen release. 
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• Prevention of collagen loss was accompanied by a concomitant reduction in active 
collagenase levels. The presence of IL-4 throughout the 14 days of culture significantly 
reduced total collagenase levels and to a lesser extent when addition of IL-4 was 
delayed. 
• IL-4 differentially regulated IL-1+OSM-induced MMP-1 and MMP-13 mRNA 
expression in bovine nasal chondrocytes, human articular chondrocytes and SW1353 
cells. IL-4 reproducibly down-regulated MMP-13 mRNA expression in all three cell 
types, whereas MMP-1 mRNA expression remained unchanged.  
• Addition of IL-4 to IL-1+OSM in the bovine nasal cartilage model resulted in a rapid 
down-regulation of MMP-13 mRNA but no overall effect on MMP-1 mRNA, 
suggesting MMP-13 is the key collagenase in cartilage collagen degradation. 
• Addition of IL-4 to IL-1+OSM in the bovine nasal cartilage model resulted in a strong 
down-regulation of active MMP-9. 
• IL-1+OSM-induced MMP-2 and MMP-14 were only partially inhibited by IL-4 in the 
bovine nasal cartilage model, suggesting neither are responsible for cartilage 
degradation in this model. 
• IL-1+OSM-induced MMP-3 mRNA expression was repressed by IL-4 in the bovine 
nasal cartilage model. 
 
Chapter 4 
 - 98 - 
Chapter 4: Assessment of epigenetic regulation of MMP-13 
by DNA methylation in bovine chondrocytes 
 
4.1 Introduction  
 
Data presented in Chapter 3 of this thesis demonstrated that IL-4 is able to rapidly repress 
IL-1+OSM-induced MMP-13 expression. One possible explanation for this rapid 
repression is that IL-4 induces epigenetic changes in the MMP-13 promoter, thereby 
leading to reduced gene expression. This hypothesis was examined in this chapter. 
 
There is a growing awareness that individual characteristics can be determined by factors 
other than genetic sequences. Epigenetics, literally meaning “beyond genetics”, can be 
defined as stable and heritable (or potentially heritable) changes in gene expression that do 
not entail a change in DNA sequence (Jiang et al. 2004). Essentially, epigenetic 
modifications provide information as to where and when a gene should be expressed as 
opposed to altering the structure or function of a gene. There are two key epigenetic 
modifications; DNA methylation and histone modifications (such as acetylation and 
phosphorylation). Over recent years there has been considerable progress in the 
understanding of DNA methylation, the predominant epigenetic modification of DNA in 
mammalian genomes, and the importance of this process in both normal cellular function 
and disease. 
 
The methylated base 5-methylcytosine was first discovered in the calf thymus 60 years ago 
(Hotchkiss 1948). It was subsequently discovered that methylcytosines are nonrandomly 
distributed throughout the genome (Razin and Cedar 1977).  Unlike the other four bases in 
the genome, 5-methylcytosine does not exist as a free nucleotide in the cellular 
environment. Instead, methylation of cytosine residues occurs after DNA replication. With 
few exceptions, only cytosines that precede guanines can be methylated i.e. cytosines 
within CpG dinucleotides. The CpG notation (where ‘p’ represents the phosphate 
connecting the two nucleotides) is used to distinguish between a cytosine followed by a 
Chapter 4 
 - 99 - 
guanine in the DNA sequence and a cytosine base-paired to a guanine (Dahl and Guldberg 
2003). Low levels of DNA methylation correlate with active gene expression and high 
levels of DNA methylation result in gene silencing (Jaenisch and Bird 2003). The process 
of DNA methylation is mediated by the DNA methyltransferases (DNMT), which catalyse 
the transfer of a methyl group from the methyl-donor S-adenosylmethionine (SAM) to the 
cytosine residue (Pradhan and Esteve 2003) (Figure 4.1).  
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Figure 4.1 The formation of 5-methylcytosine. A DNA methyltransferase catalyses the transfer of a methyl 
group (CH3) from S-adenosylmethionine (SAM) to cytosine producing 5-methylcytosine and S-
adenosylhomocysteine (SHC). Adapted from Roach and Aigner (2007). 
 
CpG sites are not evenly distributed throughout the genome and sequences containing CpG 
sites can be divided into two groups: those which are CpG rich and those which are CpG 
poor or sparse (McClelland and Ivarie 1982). The CpG-rich regions became known as CpG 
islands and they constitute between 1 and 2% of the genome and account for virtually all 
the unmethylated CpG dinucleotides. Any remaining CpG dinucleotides are found outside 
of CpG islands and the majority of these are methylated. CpG islands are defined as being 
longer than 500 bp and having a GC content of greater than 55% (Takai and Jones 2002). 
The promoter region of the collagenase MMP-13 is a so called ‘sparse CpG’ promoter as it 
contains only six CpG sites (Roach et al. 2005). In healthy cells, CpG sparse regions are 
generally methylated, whereas CpG islands are usually hypomethylated. During cancer 
development, the converse occurs, with CpG islands becoming hypermethylated and sparse 
CpG regions undergoing hypomethylation. This change in DNA methylation ultimately 
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resulting in, for example, the silencing of tumour suppressor genes (Jones and Baylin 
2002). Until recently, the methylation status of ‘sparse CpG’ promoters has not been 
examined because it was widely believed that the methylation of many CpGs within a 
promoter was required to repress gene transcription. Whilst it is thought that this remains 
true for promoters with enhancer elements, it is now thought that silencing of genes with 
sparse CpG promoters by DNA methylation is feasible and that the chance of pathological 
demethylation is in fact increased in sparse CpG promoters (Roach and Aigner 2007).   
 
There are two methods available for the analysis of methylation status: cleavage with 
specific methylation-sensitive restriction enzymes (MSREs) (Singer-Sam et al. 1990) and 
bisulphite modification (Frommer et al. 1992). Bacterial restriction endonucleases with 
varying sensitivities to 5-methylcytosine have been widely used to analyse the methylation 
status of cytosine at specific sites. If the cytosines of interest are methylated, then post-
restriction PCR amplification produces a band equivalent to that of untreated control 
samples. If the cytosines are unmethylated and cleavage by the restriction enzyme induces 
DNA strand breaks, no band will be detected. MSRE-based analysis is limited because it 
can only provide information about CpGs within the cleavage sites of specific enzymes and 
is also prone to false positives due to incomplete digestion. Bisulphite treatment has one 
major advantage over the use of MSREs; it enables the methylation status of virtually all 
CpGs in the genome to be determined (Dahl and Guldberg 2003).  Bisulphite treatment of 
genomic DNA results in the conversion of unmethylated cytosine residues to uracil, leaving 
any methylated cytosines unchanged according to the protocol originally developed by 
(Frommer et al. 1992). Hence, bisulphite treatment gives rise to different DNA sequences 
for methylated and unmethylated DNA (Figure 4.2).  
Unmethylated DNA     N-C-G-N-C-G-N-C-G-N N-U-G-N-U-G-N-U-G-N
Methylated DNA         N-C-G-N-C-G-N-C-G-N                              N-C-G-N-C-G-N-C-G-NBisulphite 
treatment
 
Figure 4.2 Bisulphite treatment of DNA. Incubation of target DNA with sodium bisulphite results in the 
conversion of unmethylated cytosines to uracil, leaving methylated cytosines unchanged, hence, giving rise to 
different DNA sequences for methylated and unmethylated DNA. 
Whilst the CpG methylation pattern within the genome is relatively stable and clonally 
inherited (Leonhardt et al. 1992), pathological alterations are known to occur in cells as 
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they age (Richardson 2003). The examination of the DNA methylation status of 
chondrocytic genes has not been extensively studied, however several studies have 
indicated that DNA methylation may play a part in OA development. During OA, it is 
thought that increasing numbers of chondrocytes undergo a phenotypic modulation, 
producing ‘degradative’ chondrocytes or chondrocytes with hypertrophic characteristics. 
As with all adult somatic cells, the phenotype of chondrocytes is stabilised by the 
epigenetic status of the DNA within the cell. It is therefore likely that the destabilisation of 
the chondrocyte phenotype in OA is at least partly due to epigenetic changes (Aigner and 
Dudhia 1997; Spector and MacGregor 2004). Recent work has shown that various genes 
are up- or down-regulated in OA chondrocytes compared to normal chondrocytes (Burrage 
et al. 2006; Eleswarapu et al. 2007), indicating that OA chondrocytes have a modulated 
phenotype. One of the most recent studies examining the role of DNA methylation in OA 
demonstrated that DNA methylation had been lost at specific CpG residues in the 
ADAMTS-4 promoter. ADAMTS-4 is known to contribute to aggrecan degradation in 
human OA. The results of this study indicate that the upregulation of ADAMTS-4 in OA 
involves loss of DNA methylation at these specific CpG sites resulting in a permanent 
expression of ADAMTS-4 in OA chondrocytes (Cheung et al. 2008). OA chondrocytes that 
have been shown to exhibit changes in gene expression appear to be mainly confined in 
clusters in the superficial zone of OA cartilage. These clusters of chondrocytes are thought 
to result from the clonal expansion of a single chondrocyte in an attempt to repair cartilage 
damage (Sandell and Aigner 2001).  The presence of such clusters is indicative of gene 
expression changes being under epigenetic control (Roach and Aigner 2007). The first, and 
currently only study to investigate whether abnormal gene expression seen in OA is due to 
epigenetic “unsilencing” was by Roach et al. (2005). This study investigated whether the 
abnormal expression of MMPs 3, 9 and 13 and ADAMTS-4 by human OA chondrocytes is 
associated with demethylation. The methylation status of the promoter regions of these 
genes were analysed using MSREs and it was found that the overall percentage of 
nonmethylated sites was increased in OA patients (48.6%) compared with controls (20.1%). 
It was also discovered that for each enzyme, there was one specific CpG site where the 
demethylation in OA patients was significantly higher than that in controls.  
If alterations in DNA methylation are responsible for aberrant gene expression in OA, it is 
possible that a random loss of methylation occurs simply with aging. In fact, binding of 
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transcription factors to both promoter and nonpromoter sequences is sufficient to cause 
passive demethylation of nearby CpG dinucleotides. However, it is also possible that active 
demethylation mechanisms exist, which target specific genes. Active demethylation would 
require a demethylase to remove the associated methyl group. However, whilst several 
putative demethylases have been described, none of the current candidates appear to exhibit 
the required characteristics to explain demethylation patterns observed in vivo (Ooi and 
Bestor 2008). DNA methylation is heritable and so any changes in methylation status are 
transmitted to daughter cells. When aberrant changes in DNA methylation occur, these 
changes are also heritable because cells have no way of “remembering” what their correct 
methylation status should be. Initial experimental evidence indicates that aberrant DNA 
methylation patterns could be responsible for at least some of the changed gene expression 
patterns seen in OA. Whether these DNA methylation patterns can be influenced 
therapeutically will undoubtedly be a major future research interest, as although heritable, 
DNA methylation is potentially reversible.  
 
The aim of this chapter was to: 
 
• Determine if IL-4 (in combination with IL-1+OSM) decreases IL-1+OSM-induced 
MMP-13 mRNA expression by increasing MMP-13 promoter methylation. 
 
4.2 Results 
 
4.2.1 MMP-13 promoter methylation in bovine nasal chondrocytes 
 
4.2.1.1 Optimisation of Primers for Bisulphite PCR 
Preliminary experiments to determine if IL-4 (in combination with IL-1+OSM) decreased 
MMP-13 mRNA expression by increasing MMP-13 promoter methylation were performed 
using bovine nasal chondrocytes. The predicted bovine MMP-13 promoter sequence was 
obtained by performing a BLAST search with the human MMP-13 promoter (U52692.1) 
against the Bos Taurus genome. The PCR was initially performed on control bisulphite 
treated bovine nasal chondrocyte DNA using primers and conditions as described 
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previously (section 2.2.12). Methprimer was used to design primers to amplify a 369 bp 
region of the MMP-13 promoter between - 325 and + 47 (Li and Dahiya 2002) (Figure 4.3). 
Primer pairs 4 and 5 (Figure 4.3) were tested using bisulphite-treated control bovine nasal 
chondrocyte DNA (as described in section 2.2.12). A band of the correct size was observed 
with both primer pairs (data not shown). In order to amplify the longest possible section of 
the MMP-13 promoter (369 bp), primer F5 (from this point referred to as bovine MMP-13 
F) and R4 (from this point referred to as bovine MMP-13 R) were used (Figure 4.3). The 
annealing temperature was optimised using bisulphite-treated control bovine nasal 
chondrocyte DNA over a temperature gradient of 50 - 65oC (described in section 2.2.12.2). 
The optimum annealing temp for the MMP-13 primers was shown to be 65oC (Figure 4.4). 
The 369 bp region of the MMP-13 promoter was shown to be specifically amplified at 
these temperatures with no contaminating non-specific PCR products.  
 
4.2.1.2 Bisulphite sequencing of MMP-13 promoter in treated DNA 
The MMP-13 primers were used to amplify the -325 to +47 region of the bovine MMP-13 
promoter in bisulphite treated DNA samples isolated from bovine nasal chondrocytes. The 
PCR products were then transformed into chemically competent E.coli and the resultant 
colonies sequenced until twenty non-clonal sequences were obtained for each treatment 
group as described in section 2.2.12. The bisulphite sequence data were then analysed to 
compare the methylation status of control, IL-1, IL-1+OSM and IL-1+OSM+IL-4-treated 
bovine nasal chondrocytes (after a 24 hour cytokine stimulation). Fisher’s exact test was 
used to determine any significant difference in methylation pattern. 
 
Sequencing of twenty non-clonal sequences for each treatment group showed no 
statistically significant difference in methylation status between different treatment groups. 
However, a pattern of altered methylation status was observed in five out of the seven (CpG 
sites 2 and 4-7) CpG sites analysed (Figure 4.5, Table 4.1). IL-1+OSM increased the level 
of demethylation compared with control and IL-1+OSM+IL-4 decreased the level of 
demethylation compared with IL-1+OSM. Despite the lack of statistical differences in this  
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experiment, it was felt that the pattern of altered methylation observed, albeit limited, 
warranted further investigation. 
 
4.2.2 Analysis of DNA methylation by pyrosequencing 
 
As described previously, pyrosequencing is a sequencing-by-synthesis method that 
quantitatively monitors the real-time incorporation of nucleotides through the enzymatic 
conversion of released pyrophosphate into a proportional light signal (Tost and Gut 2007). 
After bisulphite treatment and PCR, the percentage methylation at each CpG site in a 
sequence is determined from the ratio of T and C. The ability of pyrosequencing to reliably 
detect differences in DNA methylation across cell populations without requiring the 
cloning of bisulphite-treated DNA into bacterial expression vectors gives pyrosequencing a 
major advantage over the bisulphite-treated PCR technique. 
  
Bovine nasal chondrocytes were treated with control, IL-1, IL-1+OSM or IL-1+OSM+IL-4 
for 24 hours. The DNA was then extracted and bisulphite treated (as described in section 
2.2.12). The pyrosequencing bovine MMP-13 primers (see Table 2.5) were then used to 
amplify the -234 to +46 region of the bovine MMP-13 promoter in these samples. The 
reverse pyrosequencing primer was biotinylated at its 5’ terminus. The biotinylated primer 
is required for the PCR product to be immobilised on streptavidin-coated beads, which 
renders the PCR product single-stranded. A sequencing primer (see Table 2.5) 
complementary to the single-stranded template was then hybridised to the single-stranded 
template. The pyrosequencing reaction was then performed as described in section 
2.2.12.7.3. 
 
The results from the pyrosequencing reaction failed to show any significant difference in 
methylation status between the different cytokine combinations at any of the six CpG sites 
analysed (Figure 4.7). Due to the greater statistical power of the pyrosequencing method, it 
was therefore concluded that there was no evidence of a role for alterations in MMP-13 
promoter methylation in the regulation of MMP-13 gene expression by IL-1, IL-1+OSM or 
IL-1+OSM+IL-4.   
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Figure 4.4 Optimisation of primers designed to amplify a 369 bp region of the MMP-13 promoter in 
bisulphite treated bovine DNA: agarose gel analysis of PCR products generated using bovine MMP-13 
F and bovine MMP-13 R. Lane A shows the 1 kb ladder, lanes B to G show the products amplified in 
bisulphite treated BNC DNA over a temperature gradient of 50-65oC. The optimal annealing temperature and 
corresponding PCR product is indicated by a black box. Lane H shows the water control.   
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Figure 4.5 The effect of IL-1, IL-1+OSM and IL-1+OSM+IL-4 on bovine MMP-13 promoter 
methylation. DNA methylation analysis of a 369 base pair region of the bovine MMP-13 promoter in DNA 
isolated from bovine nasal chondrocytes. DNA from bovine nasal chondrocytes treated with control, IL-1, IL-
1+OSM or IL-1+OSM+IL-4 was analysed to determine the methylation status of the 7 CpG sites within the 
sequenced section. For each treatment group, 20 non-clonal sequences were sequenced. Each dot represents a 
CpG site from one clone with black dots representing methylated CpG sites and white dots representing 
unmethylated CpG sites.  
Table 4.1 The effect of IL-1, IL-1+OSM and IL-4 on the percentage of unmethylated CpG sites. 
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  -353 GATAGTCTTATCAGAAAAAAAAAAAAAAAGTAGTTGCTCTCCTGCAAAGGGGAAAGTTTT 
       ||||||:||||:||||||||||||||||||||||||:|:|::||:||||||||||||||| 
  -353 GATAGTTTTATTAGAAAAAAAAAAAAAAAGTAGTTGTTTTTTTGTAAAGGGGAAAGTTTT 
                                    >>>>>>>>>>>>>>>>>>>>>>>>                              
                                                                1 
  -293 TTTGCCAAGTGAAGTGAAAATTTTACTCTCTGGTTTTTCCCACAATAGCCATAAATACGC 
       ||||::|||||||||||||||||||:|:|:||||||||:::|:|||||::|||||||++: 
  -293 TTTGTTAAGTGAAGTGAAAATTTTATTTTTTGGTTTTTTTTATAATAGTTATAAATACGT 
                                                                   
                                                                2 
  -233 TGAGGCTGTTATTTTGCAAGATGGTTTTTGAGACCCTGCTGAAAGGAGAGAAGCCCTCGT 
       |||||:||||||||||:||||||||||||||||:::||:||||||||||||||:::|++| 
  -233 TGAGGTTGTTATTTTGTAAGATGGTTTTTGAGATTTTGTTGAAAGGAGAGAAGTTTTCGT 
        >>>>>>>>>>>>>>>>>>                  S1                 
                                              3                 4 
  -173 ATTAGATTTCCCTCAAATTCTACCACAAACCACACTTCTCGGGAGGAAAAAAAAAGGCGC 
       |||||||||:::|:|||||:||::|:|||::|:|:||:|++||||||||||||||||++: 
  -173 ATTAGATTTTTTTTAAATTTTATTATAAATTATATTTTTCGGGAGGAAAAAAAAAGGCGT 
                                                                   
 
  -113 AATGTAAGCATGTTTACCTTTAACTGACTAGGAAGTTGAAACTTGTCCATAACTGATGAC 
       ||||||||:|||||||::|||||:|||:|||||||||||||:||||::||||:||||||: 
  -113 AATGTAAGTATGTTTATTTTTAATTGATTAGGAAGTTGAAATTTGTTTATAATTGATGAT 
                                                                   
 
  -53  TCACCACAGTAGGTCTATAAAAGTAAAGGTACTTGTCTGGGAAAAGACAGCTGCCTCCAG 
       |:|::|:|||||||:||||||||||||||||:||||:||||||||||:||:||::|::|| 
  -53  TTATTATAGTAGGTTTATAAAAGTAAAGGTATTTGTTTGGGAAAAGATAGTTGTTTTTAG 
                                       S2                            
        5    6          7 
    8  GCGGATCGTCCAAGATGCGCCCAAGGGTCCTGGCTGGCTT 
       |++|||++|::||||||++:::||||||::|||:|||:|| 
    8  GCGGATCGTTTAAGATGCGTTTAAGGGTTTTGGTTGGTTT 
                        <<<<<<<<<<<<<<<<<<<<<< 
                        <<<<<<<<<<<<<<<<<<<<< 
 
 
 
Figure 4.6 The bovine MMP-13 promoter. The DNA sequence is numbered with respect to the 
predicted transcription start site (+1). >>> highlighted green shows the positions of bovine MMP-13 F 
and bovine MMP-13 R (as designed by Methprimer).  >>> highlighted red show the positions of F and 
R primers used for pyrosequencing. Underlined sections show the positions of the two sequencing 
primers (S1 and S2) used for pyrosequencing. Blue highlighted areas show the positions of CpG sites.  
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4.3 Discussion 
 
Methylation is the most widely studied type of epigenetic modification of DNA. The 
development of bisulphite sequencing PCR by Frommer et al. (1992) greatly advanced the 
study of DNA methylation and is now one of the most frequently used techniques in the 
field. The aim of these experiments was to determine if IL-4 (in combination with IL-
1+OSM) decreased MMP-13 mRNA expression by increasing MMP-13 promoter 
methylation in bovine nasal chondrocytes. Prior studies of DNA methylation within 
cartilage are very limited. Until recently, the methylation status of ‘sparse CpG’ promoters 
has not been examined because it was widely believed that the methylation of many CpGs 
was required to repress gene transcription. However, preliminary evidence has suggested 
that changes in DNA methylation with age not only affect transcription of genes that 
contain CpG islands, but also genes that are considered CpG poor (such as MMP-13) 
(Richardson 2002). 
 
Recent studies have shown that changes in the expression of MMP-13 correlated with 
demethylation of specific CpG sites within its promoter (Roach et al. 2005). This study 
examined the methylation status of four degradative enzymes (MMP-3, MMP-9, MMP-13 
and ADAMTS-4) in human OA chondrocytes and normal human chondrocytes. The 600 bp 
of the human MMP-13 promoter examined in this report was found to contain six CpG 
sites. Loss of methylation was detected in OA chondrocytes at sites -134 and -110. This 
provided the first evidence that changes in the expression of the matrix-degrading enzyme 
MMP-13 may occur as a result of changes in DNA methylation. The induction of MMP-13 
expression by the pro-inflammatory cytokine combination of IL-1+OSM and the rapid 
repression (within 24 hours) of IL-1+OSM-induced MMP-13 mRNA expression by IL-4 
was clearly demonstrated in this chapter. Low levels of DNA methylation correlate with 
active gene expression and high levels of DNA methylation result in gene silencing. It was 
therefore hypothesised that the pro-inflammatory cytokines IL-1+OSM could cause 
demethylation of the MMP-13 promoter, thereby resulting in active MMP-13 gene 
expression and IL-4 may act by preventing this demethylation or causing unmethylated 
CpG sites to be re-methylated, hence preventing expression of MMP-13. Due to the ease in 
obtaining bovine nasal cartilage for bovine nasal chondrocyte extraction and the difficulty 
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in obtaining normal human articular cartilage, these experiments were carried out in bovine 
nasal chondrocytes with the view to repeating any positive results in human articular 
chondrocytes. 
 
Bisulphite sequencing is one of the best available methods currently available for detailed 
studies of DNA methylation as it allows analysis of all CpGs in a specific sequence. The 
bisulphite conversion generally produces a C-T conversion rate of over 95%, indicating that 
the results obtained in this chapter were an accurate measure of the methylation status of 
MMP-13. Other methods such as cleavage with MSREs are restricted to a specific number 
of sites within the genome. The study by Roach et al. (2005) employed the use of MSREs. 
In contrast to the bisulphite sequencing technique used in this chapter, the MSRE method is 
only able to provide information about CpGs within the cleavage sites of the restriction 
enzymes. In addition, false positives are common place in MSRE-based analysis due to 
incomplete digestion, resulting in the false conclusion that some CpGs in the target 
sequence were methylated (Dahl and Guldberg 2003). However, the paper by Roach et al. 
(2005) acknowledges the problem of false positives and addressed this by comparing the 
intensity of the PCR band with the no-enzyme control.  
 
Use of the bisulphite sequencing PCR technique to sequence twenty non-clonal sequences 
for each treatment group (control, IL-1, IL-1+OSM and IL-1+OSM+IL-4) showed no 
significant difference in methylation status between different treatment groups. 
Unfortunately, the -110 CpG site in the human MMP-13 promoter (where a statistically 
significant loss of methylation was detected in OA chondrocytes when compared to normal 
chondrocytes (Roach et al. 2005)) is not present in the bovine MMP-13 promoter, therefore 
it is impossible to compare the results with the data presented in this chapter. However, the 
CpG located at position -134 is present in both the human and bovine MMP-13 promoters. 
Data presented in this chapter show a decrease in methylation at this site in the bovine 
MMP-13 promoter following IL-1+OSM stimulation, which is in concordance with the loss 
of methylation detected at this site in OA chondrocytes by the Roach study (Roach et al. 
2005). As the pro-inflammatory cytokine combination of IL-1+OSM is used to mimic the 
degradation that would occur in an arthritic joint, this is not an unexpected result. However, 
treatment with IL-1+OSM+IL-4 failed to result in any re-methylation at this site, implying 
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that IL-4 does not repress MMP-13 gene expression by increasing MMP-13 promoter 
methylation. 
 
The bisulphite sequencing method of analysing methylation status is very laborious, 
therefore in order to obtain statistically significant data, pyrosequencing was used to 
analyse methylation status on a larger scale. Pyrosequencing enables the reliable detection 
of differences in DNA methylation across cell populations without requiring the cloning of 
bisulphite-treated DNA into bacterial expression vectors. The limitation of the read-length 
is the main disadvantage of the pyrosequencing technology for DNA methylation analysis. 
This means that multiple sequencing primers must be designed and multiple reactions 
performed in order to analyse the whole sequence of interest (in the case of the bovine 
MMP-13 promoter, two sequencing primers had to be designed in order to analyse the 
methylation status of the desired number of CpGs). The methylation status of the CpG sites 
was further analysed by pyrosequencing, however this also failed to show any significant 
difference in methylation status between the different cytokine treatments. Both positive 
and negative controls were included in the pyrosequencing experiment to ensure the 
method was working as expected. These controls were selected from clones produced 
during the bisulphite sequencing experiment. The negative control consisted of a control in 
which, following sequencing, all seven CpG sites were known to be unmethylated. 
Similarly, the positive control consisted of a clone in which all seven CpG sites were 
known to be methylated. Due to the greater statistical power of the pyrosequencing method, 
it was concluded from the results that there was no evidence of a role for MMP-13 
promoter methylation in the regulation of MMP-13 gene expression by IL-1, IL-1+OSM or 
IL-1+OSM+IL-4.   
 
Whilst there was no literature available at the time of writing on the role of IL-4 in 
epigenetic modifications in the MMP-13 promoter or in arthritis generally, IL-4 has been 
implicated in epigenetic changes in other cell types.  A 2009 study found that continuous 
IL-4 treatment led to decreased histone H3 lysine-27 methylation in activated macrophages 
(Ishii et al. 2009). In relation to the epigenetic regulation of MMP-13, it has been shown 
that one of the genes upregulated in OA cartilage is leptin, a cytokine-like peptide hormone 
thought to act as a regulator of bone growth by inducing osteoblast proliferation, collagen 
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synthesis and bone mineralisation. A study by Iliopoulos et al. (2007) has shown for the 
first time that leptin can be regulated by epigenetic mechanisms in OA. Leptin was found to 
be methylated in normal chondrocytes and unmethylated in both mildly and severely 
affected OA chondrocytes. Epigenetic regulation of leptin using siRNA was found to affect 
MMP-13, with MMP-13 expression down-regulated. Interestingly, this had no effect on the 
expression levels of other MMPs. Studies have shown that promoter methylation is 
important in the regulation of other MMPs. For example, the treatment of lymphoma cells 
with a DNA methylation inhibitor was found to decrease MMP-9 promoter methylation and 
increase MMP-9 messenger RNA and protein secretion (Chicoine et al. 2002). The 
expression of MMP-2, -7 and -9 and has been demonstrated to be associated with DNA 
methylations in pancreatic adenocarcinoma cells (Sato et al. 2003). DNA hypomethylation 
of normal synovial fibroblasts has been found to induce changes resulting in them 
resembling RA synovial fibroblasts (RASFs). RASFs are known to exhibit aggressive 
behaviour resulting in the upregulation of matrix-degrading enzymes and cytokines. This 
study suggests that DNA hypomethylation may play a role in the pathogenesis of RA by 
resulting in the activation of normally silenced genes, explaining the aggressive nature of 
RASFs (Karouzakis et al. 2009). Therefore, whilst the preliminary data presented in this 
chapter imply that changes in MMP-13 gene expression in response to IL-4 are not caused 
by epigenetic modifications, there is evidence to suggest that changes in genomic 
methylation play a role in the pathogenesis of arthritis in general.  
 
The data presented in this chapter are by no means sufficient to completely exclude 
possible epigenetic regulation of IL-1+OSM-induced MMP-13 expression by IL-4. The 
MMP-13 promoter contains relatively few CpG sites, a property that could well favour a 
loss of methylation in disease and studies indicate that epigenetic mechanisms will no 
doubt be found to play an important role in the pathology of OA. Preliminary data would 
suggest that the chondroprotective nature of IL-4 is not due to it inducing any changes in 
the methylation status of the MMP-13 promoter. However, given more time, multiple 
experiments to assess the methylation status of the MMP-13 promoter would need to be 
performed in bovine chondrocytes, and more importantly in human chondrocytes to fully 
rule out the epigenetic regulation of MMP-13 as an explanation for the chondroprotective 
abilities of IL-4.   
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4.4 Summary 
 
• Data presented in this chapter found no evidence of a role for changes in MMP-13 
promoter methylation in the regulation of MMP-13 gene expression by IL-1, IL-
1+OSM or IL-1+OSM+IL-4 in bovine chondrocytes. 
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Chapter 5: The effect of IL-4 on PI3K-dependent signalling 
in chondrocytes 
 
 
5.1 Introduction 
 
The chondroprotective effect of IL-4 in IL-1+OSM-induced cartilage collagen degradation 
is strongly thought to be due to the repression of MMP-13 mRNA expression and/or the 
inhibition of activation of latent MMPs. Data presented in Chapter 3 strongly suggests that 
it is the rapid repression of MMP-13 by IL-4 that is responsible for the protective effect of 
IL-4 on cartilage. Chapter 4 investigated changes in the DNA methylation status of the 
MMP-13 promoter by IL-4 as a possible mechanism of action for the rapid repression of 
MMP-13 mRNA. These data failed to show any role for epigenetic regulation by IL-4 in 
the regulation of MMP-13 mRNA expression, therefore, the next logical line of 
investigation was to examine the effect of IL-4 on cell signalling in chondrocytes.  
 
The binding of IL-4 to its receptor leads to the phosphorylation, and hence activation, of 
JAK1 and JAK3.  The phosphorylation of JAKs is followed by phosphorylation of the IL-4 
receptor components and cytoplasmic signalling proteins (Hebenstreit et al. 2006). Once 
phosphorylated, these tyrosine residues act as docking sites for signalling molecules. 
STAT6 signalling is classically associated with IL-4 and the examination of STAT6-
deficient mice has shown that STAT6 is essential for IL-4-dependent gene induction (Kuhn 
et al. 1991).  STAT6 is recruited to the activated IL-4Rα through its SH2 domain and 
becomes phosphorylated on tyrosine 641 by JAKs leading to its dimerization and 
translocation to the nucleus, where the homodimer activates transcription of IL-4 
responsive genes (Leonard and O'Shea 1998). IL-4 is also known to signal through IRS2, 
resulting in the activation of PI3K and its downstream target Akt. However, the role of this 
pathway in IL-4-induced gene expression is still unclear. This chapter details investigations 
of the involvement of PI3K in IL-4-induced Akt activation. 
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Previous work in the group (Litherland et al. 2008) has demonstrated that OSM stimulates 
Akt phosphorylation at both Thr308 and Ser473 in human articular chondrocytes, 
indicating Akt activation. In addition, the same study showed that PI3K inhibition was able 
to block both IL-1+OSM-induced cartilage degradation and IL-1+OSM-induced 
collagenase expression. Stimulation with IL-1 does not result in Akt activation and so 
experiments in this chapter have focused on the effect of OSM alone as opposed to the 
usual combination of IL-1+OSM. As mentioned previously, IL-4 has been shown to signal 
via the PI3K/Akt pathway, in addition to the JAK/STAT pathway (Kaminski et al. 2010). 
However, the effect of IL-4 on the PI3K/Akt pathway in chondrocytes has yet to be 
examined. This is therefore one of the key aims of this chapter.  
 
Activation of the PI3K signalling pathway is now known to be one of the central pathways 
by which cellular functions are controlled. The PI3Ks are a group of enzymes that catalyse 
the phosphorylation of the 3’-position of the inositol ring in phosphoinositides. They have 
been classified into three major classes on the basis of their structural and functional 
homologies: I, II and III (Hawkins et al. 2006). Activation of class I PI3Ks, in particular, is 
known to be very important in the control of various cellular processes by cytokines and 
growth factors. The Class I PI3Ks consist of four closely related approximately 110 kDa 
catalytic subunits and two distinct families of regulatory subunits, which form the basis of 
their further subdivisions into Class IA and IB. Class IA PI3Ks comprise heterodimers 
consisting of a p110 catalytic subunit (p110α, β or δ), associated with a p50, p55 or p85 
regulatory subunit. The class IB PI3Ks consist of dimers of the p110γ catalytic subunit 
paired with either a p84 or p101 regulatory subunit. Akt is a serine/threonine kinase that 
acts downstream of PI3K and is known to be of vital importance to PI3K signalling 
pathway events. The Akt kinase family is comprised of three highly homologous isoforms: 
Akt1, Akt2 and Akt3 (Gonzalez and McGraw 2009). They are regulated by 
phosphoinositide-dependent kinase-1 (PDK1), a PH (plekstrin homology) domain-
containing kinase downstream of PI3K, which phosphorylates all three Akt isoforms 
(Franke 2008). Maximum activation of Akt requires phosphorylation at two different sites, 
Thr308 (by phosphoinositide-dependent kinase 1 (PDK1)) and Ser473 (by PDK2) (Liang 
and Slingerland 2003). Many findings have pointed to functional differences between the 
Akt isoforms and it is widely suspected that different Akt isoforms are associated with 
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different disease processes (Franke 2008). Another downstream substrate of the PI3K 
signalling pathway is GSK-3 (glycogen synthase kinase-3), a serine/threonine kinase.  
GSK-3 is unusual in that it is active in unstimulated cells and its activity is reduced during 
cellular responses. GSK-3 is negatively regulated by PI3K-mediated activation of Akt 
(Doble and Woodgett 2003). Two homologous isoforms of GSK-3 exist, GSK-3α and 
GSK-3β. Whilst they both have similar functions, gene knockout studies have shown they 
are not functionally redundant (Rayasam et al. 2009). 
 
The PI3K/Akt signalling pathway has been implicated in the pathogenesis of many diseases 
and the modulation of specific PI3K isoform activity is already a well-established 
therapeutic target. Many mutations in the PI3K/Akt pathway have been found to be 
common in human malignancies (Carnero 2010). Of particular relevance to this thesis, was 
the finding that blockade of PI3Kγ can ameliorate joint damage in mouse models of RA 
(Camps et al. 2005).  
 
This chapter aimed to further investigate the mechanism of MMP-13 repression by IL-4 by 
examining the role of the PI3K/Akt pathway in IL-4 signalling. Data presented in Chapter 3 
of this thesis demonstrated that bovine nasal chondrocytes appear to behave very similarly 
to human articular chondrocytes. For this reason, bovine nasal chondrocytes were used in 
the majority of the experiments in this chapter due to their availability and plentiful supply.  
 
The aims of this chapter were to: 
• Determine the optimum timepoint for examination of STAT6 phosphorylation by 
IL-4 in bovine nasal chondrocytes. 
• Assess Akt involvement in IL-4 signalling, by determining the effect of IL-4 on 
OSM-stimulated Akt and GSK-3 phosphorylation in bovine nasal chondrocytes. 
• Determine if IL-4-mediated Akt phosphorylation is PI3K-dependent and if so, 
which isoform(s) of PI3K are involved in IL-4-dependent Akt phosphorylation. 
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5.2 Results 
 
5.2.1 The effect of different concentrations of IL-4 on STAT6 and Akt 
phosphorylation in bovine chondrocytes 
STAT6 signalling is classically associated with IL-4 and the examination of STAT6-
deficient mice has shown that STAT6 is essential for IL-4-dependent gene induction (Kuhn 
et al. 1991).  Previous investigations into IL-4 signalling in chondrocytes used IL-4 at a 
concentration of 50 ng/ml (Pyle 2003). However, Chapter 3 in this thesis demonstrated that 
IL-4 could be used at 20 ng/ml in chondrocytes to repress MMP-13 mRNA expression. The 
purpose of this experiment was to examine if this correlated with the concentration 
dependence of cell signalling experiments. Figure 5.1 clearly demonstrates the 
phosphorylation of both STAT6 and Akt (Ser473) at both 5 ng/ml and 20 ng/ml, however 
the phosphorylation was stronger when IL-4 was used at 20 ng/ml. Therefore, in further 
signalling experiments, IL-4 was used at 20 ng/ml.  
 
5.2.2 Timecourse to investigate the effect of IL-4 on STAT6 activation in 
primary bovine and human articular chondrocytes 
The examination of IL-4-induced STAT6 phosphorylation over a timecourse was 
performed twice. Previous work in the department has shown latent STAT6 to be present at 
all timepoints (Pyle 2003). Both bovine nasal (Figure 5.2a) and human articular 
chondrocytes (Figure 5.2b) demonstrated weak tyrosine phosphorylation of STAT6 after a 
5 minute stimulation with IL-4. In bovine nasal chondrocytes, this increased to a maximum 
at 20 minutes and decreased thereafter. The maximum timepoint of STAT6 
phosphorylation by IL-4 in human articular chondrocytes was more sustained, but reached 
a maximum around 10-20 minutes. 
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phospho-STAT6 
(Tyr641)
phospho-Akt
(Ser473)
β-tubulin
IL-4 (ng/ml)                     0              0.05           0.2      1              5              20
 
Figure 5.1 The effect of different concentrations of IL-4 on STAT6 and Akt phosphorylation in bovine 
nasal chondrocytes, as determined by Western blot. Primary bovine nasal chondrocytes were treated with 
medium containing IL-4 (0-20 ng/ml) for 20 minutes at 37oC. Total cell lysates were prepared and separated 
by SDS-PAGE on a 10% polyacrylamide gel with a molecular weight marker. Protein fractions were 
transferred to PVDF membranes. Blots were probed with phospho-STAT6 (Tyr641), phospho-Akt (Ser473) 
and β-tubulin followed by goat anti-rabbit HRP. The blots were visualised using ECL. Results are 
representative of two independent experiments. 
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Figure 5.2 Timecourse to investigate the effect of IL-4 on STAT6 activation in primary bovine nasal 
and human articular chondrocytes, as determined by Western blot. Primary bovine nasal chondrocytes 
(a) and human articular chondrocytes (b) were treated with medium containing IL-4 (20 ng/ml) for 0-120 
minutes at 37oC. Total cell lysates were prepared and separated by SDS-PAGE on a 10% polyacrylamide gel 
with a molecular weight marker. Protein fractions were transferred to PVDF membranes. Blots were probed 
with phospho-STAT6 (Tyr641) and β-tubulin followed by goat anti-rabbit HRP. The blots were visualised 
using ECL. Results are representative of two independent experiments. 
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5.2.3 The effect of IL-4 on OSM-stimulated Akt and GSK-3 phosphorylation in 
bovine chondrocytes 
One potential mechanism to explain the effects of IL-4 in negating IL-1+OSM-dependent 
MMP-13 induction (which is dependent on Akt (Litherland et al. 2008)) is that IL-4 
stimulation of Akt may lead to a state of resistance of Akt to further stimulation by OSM. 
To test this possibility, the effect of IL-4 on OSM-stimulated Akt and GSK-3 
phosphorylation was examined. As already demonstrated in Figures 5.1 and 5.2, IL-4 
induced tyrosine phosphorylation of STAT6. It has previously been reported that OSM 
stimulates Akt phosphorylation in human chondrocytes at both Thr308 and Ser473 
(Litherland et al. 2008) and Figure 5.3 confirmed that the same was true in bovine nasal 
chondrocytes. Interestingly, the effects of IL-4 on Akt phosphorylation was much weaker 
than that of OSM but the combination of IL-4 and OSM was seen to enhance Akt 
phosphorylation. Pretreatment of bovine nasal chondrocytes with IL-4 was shown to reduce 
phosphorylation of Akt and GSK-3 in response to IL-4+OSM, suggesting that pre-
incubation with IL-4 in some way inhibits the OSM-stimulated phosphorylation of Akt and 
GSK-3. This interference is a common phenomenon and has been observed for stimuli such 
as insulin in other systems (Litherland et al. 2007). 
 
5.2.4 Stimulation of Akt and GSK-3 by IL-4 is PI3K-dependent in bovine 
chondrocytes 
Previous data presented in this chapter have shown that stimulation of bovine nasal 
chondrocytes with IL-4 resulted in both Akt and GSK-3 phosphorylation. Therefore, the 
next aim was to determine if this phosphorylation was PI3K-dependent as is the case for 
OSM-dependent Akt phosphorylation (Litherland et al. 2008). Experiments were performed 
using the selective PI3K inhibitor, LY294002. Figure 5.4 clearly shows that the PI3K 
inhibitor inhibited IL-4-stimulated phosphorylation of both Akt and GSK-3 in a 
concentration-dependent manner, therefore showing that IL-4-stimulation of Akt/GSK-3 is 
dependent on PI3K. STAT6 phosphorylation, which is not thought to be PI3K-dependent 
was unaffected by LY294002. 
 
Chapter 5 
 - 122 - 
OSM                                             - - +               +                 +           +
IL-4                                               - +                  - +                 +                + 
IL-4 pretreatment (hours)         - - - - 1                2
phospho-Akt
(Ser473)
phospho-Akt
(Thr308)
phospho-STAT6 
(Tyr641)
phospho-GSK-3β
(Ser9)
β-tubulin
 
 
Figure 5.3 The effect of IL-4 on OSM-stimulated Akt and GSK-3 phosphorylation in bovine nasal 
chondrocytes, as determined by Western blot. Primary bovine nasal chondrocytes were treated with 
medium containing ± OSM (10 ng/ml) ± IL-4 (20 ng/ml) for 20 minutes at 37˚C. Total cell lysates were 
prepared and separated by SDS-PAGE on a 10% polyacrylamide gel with a molecular weight marker. Blots 
were probed with phospho-STAT6 (Tyr641), phospho-Akt (Thr308), phospho-Akt (Ser473), phospho-GSK-
3β (Ser9) and β-tubulin followed by goat anti-rabbit HRP. Protein fractions were transferred to PVDF 
membranes. The blots were visualised using ECL. Results are representative of two independent experiments. 
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Figure 5.4 Stimulation of Akt and GSK-3 by IL-4 is PI3K-dependent in bovine nasal chondrocytes, as 
determined by Western blot. Primary bovine nasal chondrocytes were treated with medium containing IL-4 
(20 ng/ml) ± LY294002 (1-10 µM) for 20 minutes, with a 30 minute pretreatment with LY294002 at 37oC. 
Total cell lysates were prepared and separated by SDS-PAGE on a 10% polyacrylamide gel with a molecular 
weight marker. Protein fractions were transferred to PVDF membranes. Blots were probed with phospho-
STAT6 (Tyr641), phospho-Akt (Thr308), phospho-Akt (Ser473), phospho-GSK-3β (Ser9) and β-tubulin 
followed by goat anti-rabbit HRP. The blots were visualised using ECL. Results are representative of two 
independent experiments. 
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5.2.5 The effect of selective PI3K 110β inhibition on IL-4- and OSM-induced 
Akt and phosphorylation in bovine chondrocytes 
Given that the phosphorylation of Akt and GSK-3 has been shown to be PI3K-dependent 
(Figure 5.4), the next step was to determine if this phosphorylation was dependent on a 
particular isoform of PI3K. Treatment with TGX-221 (3 µM) partially blocked OSM- and 
IL-4-dependent Akt phosphorylation (Ser473), suggesting that phosphorylation by either 
stimulus is partly PI3K p110β-dependent (Figure 5.5). The effects of PI3K p110β inhibition 
on Akt308 were not reproducible and so are not shown. PI3K p110β inhibition had no 
effect on IL-4-induced STAT6 phosphorylation.  
 
5.2.6 The effect of PI3K p110α inhibition on IL-4- and OSM-induced Akt 
phosphorylation in bovine chondrocytes 
This experiment demonstrated a concentration-dependent, but incomplete, inhibition of IL-
4-stimulated Akt (Ser473) phosphorylation by compound 15e (Figure 5.6). The p110α is 
thought to be the major PI3K isoform involved in OSM-induced Akt activation in human 
chondrocytes (Litherland et al. 2008). The strong inhibition of OSM-stimulated Akt 
(Ser473) phosphorylation by compound 15e at all concentrations supports this. IL-4-
dependent Akt phosphorylation can be inhibited by compound 15e, but was less sensitive to 
compound 15e than OSM-dependent Akt phosphorylation, which remained inhibited at 
lower concentrations of compound 15e. This suggests that IL-4-stimulated Akt 
phosphorylation is only partially dependent on the p110α isoform in bovine chondrocytes. 
PI3K p110α inhibition had no effect on IL-4-induced STAT6 phosphorylation. 
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Figure 5.5 The effect of TGX-221, a selective PI3K p110β inhibitor, on IL-4- and OSM-induced Akt 
phosphorylation in bovine chondrocytes, as determined by Western blot. Primary bovine nasal 
chondrocytes were treated with medium containing IL-4 (20 ng/ml) or OSM (10 ng/ml) for 20 minutes, with a 
30 minute pretreatment with TGX-221 (0.1-3 µM) at 37oC. Total cell lysates were prepared and separated by 
SDS-PAGE on a 10% polyacrylamide gel with a molecular weight marker. Protein fractions were transferred 
to PVDF membranes. Blots were probed with phospho-STAT6 (Tyr641), phospho-Akt (Ser473) and β-
tubulin followed by goat anti-rabbit HRP. The blots were visualised using ECL. Results are representative of 
two independent experiments. 
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Figure 5.6 The effect of compound 15e, a PI3K p110α specific inhibitor, on IL-4- and OSM-induced 
Akt phosphorylation in bovine chondrocytes, as determined by Western blot. Primary bovine nasal 
chondrocytes were treated with medium containing IL-4 (20 ng/ml) or OSM (10 ng/ml) for 20 minutes, with a 
30 minute pretreatment with compound 15e (0.1-3 µM) at 37oC. Total cell lysates were prepared and 
separated by SDS-PAGE on a 10% polyacrylamide gel with a molecular weight marker. Protein fractions 
were transferred to PVDF membranes. Blots were probed with phospho-STAT6 (Tyr641), phospho-Akt 
(Thr308), phospho-Akt (Ser473) and β-tubulin followed by goat anti-rabbit HRP. The blots were visualised 
using ECL. Results are representative of two independent experiments.  
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5.2.7 The effect of PI3K p110 α, β and δ silencing on OSM- and IL-4-induced 
Akt phosphorylation in SW1353 cells 
Following experiments into the effect of PI3K p110 inhibitors on IL-4-dependent Akt 
phosphorylation, siRNA was used in order to validate these results and investigate a 
possible role for PI3K p110δ, for which there were no inhibitors available commercially. 
Previous work within the group meant that siRNAs specific for the human α, β and δ 
isoforms of PI3K p110 had been validated (Litherland et al. 2008) and were available. This 
work was performed in the chondrocyte cell line SW1353 as SW1353 cells are transfected 
more readily than human articular chondrocytes. Data presented in Chapter 3 demonstrated 
that SW1353 appeared to be an appropriate alternative to primary human chondrocytes. 
This experiment was performed only once and therefore cannot be interpreted robustly.  
 
As expected, transfection with siCon had no effect on OSM- or IL-4-induced Akt 
phosphorylation. Both cytokines stimulated an increase in Akt phosphorylation, with the 
increase in phosphorylation stronger in the presence of OSM (Figure 5.7).  As mentioned 
previously, the p110α is thought to be the major PI3K isoform involved in OSM-induced 
Akt activation in human chondrocytes (Litherland et al. 2008). Figure 5.7 shows a slight 
reduction in OSM-induced phosphorylation following PI3K p110α silencing. However, 
silencing of PI3K p110α would have been expected to have a more pronounced effect on 
Akt phosphorylation and so this result could suggest some inefficiency in p110α 
knockdown or differences in the involvement of particular p110 isoforms between primary 
chondrocytes and the SW1353 cell line. In contrast to the results shown in Figure 5.6, 
silencing of PI3K p110α appears to have no apparent effect on IL-4-induced Akt 
phosphorylation. Unexpectedly, silencing of PI3K p110β strongly reduced both OSM- and 
IL-4-induced Akt phosphorylation, which is in contrast to the results obtained in Figure 5.5, 
where only OSM-induced Akt phosphorylation was effected by inhibition of PI3K p110β. 
Silencing of PI3K p110δ was shown to strongly inhibit both OSM- and IL-4-induced Akt 
phosphorylation, suggesting that the δ isoform of PI3K p110 is important in Akt 
phosphorylation by both OSM and IL-4. Overall, these results do not highlight one specific 
PI3K isoform as being crucial for IL-4-induced Akt phosphorylation; instead the data 
suggest interplay between several isoforms, but caution should be exercised as this 
experiment was performed only once. 
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Figure 5.7 The effect of PI3K p110 α, β and δ silencing on OSM- and IL-4-induced Akt 
phosphorylation in SW1353 cells. SW1353 cells were stimulated with media ± OSM (10 ng/ml) ± IL-4 (20 
ng/ml) for 20 minutes at 37oC following a 48 hour transfection with siRNA specific to PI3K p110α, PI3K 
p110β, PI3K p110δ or siCon (100 nM). Total cell lysates were prepared and separated by SDS-PAGE on a 
10% polyacrylamide gel with a molecular weight marker. Protein fractions were transferred to PVDF 
membranes. Blots were probed with phospho-Akt (Thr308), phospho-Akt (Ser473) and β-tubulin followed by 
goat anti-rabbit HRP. The blots were visualised using ECL. Data are from a single experiment only. 
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5.2.8 The effect of PI3K p110 isoform silencing on IL-1+OSM ± IL-4-induced 
MMP-13 expression in SW1353 cells 
Given that siRNA specific to the PI3K isoforms was already available, a logical experiment 
was to assess the effect of PI3K p110 isoform silencing on IL-1+OSM ± IL-4-induced 
MMP-13 expression in SW1353 cells by real-time RT-PCR. Data presented in Figure 5.7 
suggest that the δ isoform of PI3K p110 plays an important role in IL-4-induced Akt 
phosphorylation. The aim of this experiment was to determine if the repression of IL-
1+OSM-induced MMP-13 expression is dependent on any particular PI3K isoform. It has 
already been shown that the specific PI3K inhibitor, LY294002, significantly inhibits IL-
1+OSM-induced MMP-1 and MMP-13 expression in human articular chondrocytes 
(Litherland et al. 2008). The same study suggested that p110α and p110δ are involved in 
IL-1+OSM-stimulated collagenase induction in human chondrocytes. Figure 5.8 shows that 
silencing of the p110δ isoform significantly reduces IL-1+OSM-induced MMP-13 
expression. Unfortunately, as silencing of p110δ prevented the induction of MMP-13 by 
IL-1+OSM, it is impossible to tell whether p110δ is important in the repression of MMP-13 
by IL-4. Silencing of the p110α isoform did not reduce IL-1+OSM-induced MMP-13 
expression, as was reported in human articular chondrocytes (Litherland et al. 2008). This 
could suggest a difference in signalling mechanisms between primary chondrocytes and 
SW1353 cells. However, silencing of p110α did significantly reduce the ability of IL-4 to 
suppress IL-1+OSM-induced MMP-13 expression, suggesting a possible role for p110α in 
the chondroprotective effect of IL-4. As reported previously (Litherland et al. 2008), 
silencing of p110β had no significant effect on the induction of MMP-13.  
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Figure 5.8 The effect of PI3K p110 isoform silencing on IL-1+OSM ± IL-4-induced MMP-13 expression 
in SW1353 cells. SW1353 were stimulated with control, IL-1+OSM (0.5 and 10 ng/ml, respectively) or IL-
1+OSM+IL-4 (0.5, 10 and 20 ng/ml, respectively) for 24 hours following a 28 hour transfection with siRNA 
specific to p110α, p110β, p110δ or siCon (100 nM). Real-time RT-PCR of the isolated RNA was performed 
for MMP-13 72 hours after the start of transfection. Data are presented as fold induction relative to the siCon 
basal expression (mean ± S.E.M, n = 6). ** = p ≤ 0.01; * = p ≤ 0.05; ns = not significant. Data are from a 
single experiment only. 
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5.3 Discussion 
 
Little is currently known about the possible function of PI3K/Akt signalling in 
chondrocytes and cartilage degradation in arthritis. Recent data published by this laboratory 
(Litherland et al. 2008) demonstrated a requirement for PI3K/Akt signalling in ECM 
catabolism via a role in IL-1+OSM-induced collagenase gene expression in human articular 
chondrocytes. This study indicated a role for p110α and Akt1 in collagenase (MMP-1 and 
MMP-13) gene induction by IL-1+OSM. In addition, involvement of p110δ and Akt3 were 
implicated in MMP-13 induction.  
 
This chapter has confirmed the rapid tyrosine phosphorylation of STAT6 in response to IL-
4 stimulation in chondrocytes. Maximal phosphorylation of STAT6 was shown to occur at 
20 minutes in bovine nasal chondrocytes and as such this timepoint was used to examine 
STAT6 phosphorylation in further experiments. Previous work within the department had 
already established that 20 minutes was the most appropriate timepoint for examination of 
OSM-induced Akt phosphorylation. 
 
The role of STAT6 in IL-4 signalling has been well documented. Whilst it has been known 
for some time that IL-4 can also signal through the PI3K/Akt pathway, the effect of IL-4 on 
Akt and GSK-3 phosphorylation had yet to be examined in chondrocytes. Data presented in 
this chapter demonstrate the phosphorylation, and hence activation, of Akt at both the 
Thr308 and Ser473 sites in response to IL-4. OSM is now strongly indicated in the 
pathological destruction of cartilage (Cawston et al. 1998; Hui et al. 2003; Rowan et al. 
2003), in particular when in combination with other pro-inflammatory mediators such as 
IL-1. The report by Litherland et al. (2008) strongly suggested a role for OSM-mediated 
PI3K/Akt signalling in the synergistic induction of collagenase genes. OSM is known to 
stimulate Akt phosphorylation in human chondrocytes at both Thr308 and Ser473 
(Litherland et al. 2008) and the combination of IL-4 and OSM was seen to enhance Akt 
phosphorylation. Pretreatment of bovine nasal chondrocytes with IL-4 was shown to reduce 
phosphorylation of Akt and GSK-3 in response to IL-4+OSM, suggesting that pre-
incubation with IL-4 in some way inhibits the subsequent OSM-stimulated phosphorylation 
of Akt and GSK3. One possible explanation for this may be that IL-4 effects the 
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localisation of certain signalling molecules, resulting in them being unavailable for use by 
OSM in the phosphorylation of Akt. In many cases, the PI3K/Akt signalling pathway has 
been shown to be responsible for GSK-3 phosphorylation. Unusually, phosphorylation of 
GSK-3 by Akt results in the inactivation of GSK-3. Given that the phosphorylation of other 
proteins by GSK-3 often results in their inactivation, phosphorylation of GSK-3 by Akt 
results in the activation of many downstream pathways normally blocked by active GSK-3 
(Doble and Woodgett 2003). Very few studies have investigated the cytokine-mediated 
phosphorylation of GSK-3 and only one other study has examined (and reported) the 
phosphorylation of GSK-3 by IL-4 (Vilimek and Duronio 2006). The data presented in this 
chapter have demonstrated that the phosphorylation, and hence inactivation, of GSK-3 by 
IL-4 is PI3K dependent. This would suggest that IL-4 stimulation, via the PI3K/Akt 
signalling pathway, results in the activation of various signalling pathways downstream of 
GSK-3 that would be kept inactivated by a normally constitutively active GSK-3. GSK-3 is 
known to participate in the insulin signalling pathway and Wnt signalling pathway, with its 
downstream targets including glycogen synthase and β-catenin (Rayasam et al. 2009).  
 
At the time of writing, there was no literature available on the effect of IL-4 on the 
PI3K/Akt pathway in chondrocytes or in relation to arthritis. However, several reports have 
investigated the role of IL-4 in this signalling pathway in other cell types or in relation to 
other biological pathways. A recent report demonstrated an increased phosphorylation of 
Akt in pancreatic beta-cells following IL-4 incubation (Kaminski et al. 2010). Another 
study has shown that IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-
induced growth arrest and apoptosis, with the Akt pathway thought to play a major role in 
the suppression of the apoptotic pathway activated by IgM (Carey et al. 2007).  Treatment 
with the Akt inhibitor, Akt1, blocked the IL-4-mediated protection of CH31 cells from anti-
IgM-induced apoptosis, indicating that Akt plays a central role in the signals generated by 
IL-4 that protect these cells from apoptosis. 
 
Having established that stimulation of bovine nasal chondrocytes with IL-4 results in 
phosphorylation of Akt and GSK-3, the next aim of this chapter was to investigate whether 
this phosphorylation was PI3K-dependent. Experiments performed in bovine nasal 
chondrocytes using the selective PI3K inhibitor, LY294002, clearly showed that the PI3K 
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inhibitor inhibited IL-4-stimulated phosphorylation of both Akt and GSK-3 in a 
concentration-dependent manner, therefore showing that IL-4-stimulation of Akt/GSK-3 is 
dependent on PI3K in bovine chondrocytes. Inhibition of the PI3K signalling pathway was 
shown to have no effect on STAT6 phosphorylation, confirming that IL-4 signals through 
at least two independent pathways.  
 
Whilst LY294002 is a selective PI3K inhibitor, it does not distinguish between the four 
Class I PI3Ks. As discussed previously, the Class I PI3Ks consist of four closely related 
approximately 110 kDa catalytic subunits, namely α, β, δ and γ. To date there is little 
evidence that there are any significant preferences for specific catalytic subunit/regulatory 
subunit pairs. For that reason, the classification of a PI3K isoform in the literature generally 
refers only to the catalytic subunit present in the dimer. No doubt as our knowledge of 
PI3K signalling increases, specific functions of the regulatory subunits will be revealed 
(Hawkins et al. 2006). PI3K p110α and β are known to be ubiquitously expressed in 
mammalian tissues whereas δ and γ expression was thought to be localised to leukocytes 
(Rommel et al. 2007). The study by Litherland et al. (2008) was the first to find evidence of 
p110δ expression in primary human chondrocytes. Expression of all four class I PI3K 
isoforms has been reported in the pre-chondrogenic cell line ATDC5 (Fujita et al. 2004). 
 
Experiments using p110 isoform-specific inhibitors were performed to investigate the roles 
of specific p110 isoforms in IL-4-mediated Akt phosphorylation. These experiments 
demonstrated that IL-4-dependent Akt activation is largely not PI3K p110β-dependent, but 
may be partially dependent on p110α. In order to investigate the role, if any, of PI3K p110δ 
in IL-4-dependent Akt phosphorylation an siRNA approach was used as no P110δ-selective 
inhibitors were commercially available at the time of this study. Silencing of the α, β and δ 
isoforms of p110 has been shown previously to be effective (≥75 % mRNA reduction) and 
selective in human chondrocytes (data not shown).  Experiments utilising siRNA against 
the PI3K p110 isoforms in SW1353 cells demonstrated that silencing of both p110β and 
p110δ reduced both OSM- and IL-4-induced Akt phosphorylation. This was in contrast to 
inhibitor data presented earlier in the chapter that indicated IL-4-dependent Akt activation 
was not p110β-dependent in bovine nasal chondrocytes. Data presented in Chapter 3 of this 
thesis demonstrated that the effect of IL-1+OSM and IL-1+OSM+IL-4 on collagenase gene 
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expression was very similar in bovine nasal chondrocytes, human articular chondrocytes 
and SW1353 cells. However, these results could indicate subtle differences in PI3K p110 
isoform involvement in OSM-induced Akt phosphorylation in different types of 
chondrocytes.  
 
Previous reports have indicated a role for p110α and p110δ in the induction of MMP-13 by 
IL-1+OSM (Litherland et al. 2008) in human chondrocytes. Data presented in this chapter 
show a significant reduction in MMP-13 induction by IL-1+OSM in SW1353 cells 
following p110δ silencing, but not following p110α silencing. Again, this could be 
indicative of differences in PI3K signalling in primary chondrocytes and the SW1353 cell 
line. Interestingly, silencing of p110α appeared to reduce the ability of IL-4 to repress IL-
1+OSM-induced MMP-13 expression. Unfortunately, due to time constraints, siRNA work 
was not extended to bovine chondrocytes. In addition, the siRNA experiments were only 
performed once. In order to confirm the results obtained in this chapter, it would be 
necessary to perform several repeats of these experiments. As optimisation of p110 
silencing was originally performed in human chondrocytes, it would also be necessary to 
perform optimisation experiments in SW1353 cells to confirm the effectiveness and 
selectivity of gene knockdown. 
 
The data presented in this chapter further highlight the complexity of the PI3K/Akt 
signalling pathway. Further work is needed to better understand the importance of specific 
isoforms in IL-4-induced Akt phosphorylation. Unfortunately, given that the induction of 
MMP-13 by IL-1+OSM has been shown to be PI3K-dependent (Litherland et al. 2008), 
investigating the effect of PI3K inhibition on IL-1+OSM+IL-4-mediated MMP-13 
repression will clearly be problematic.   
 
Whilst the results presented in this chapter are mostly preliminary, an important finding 
was that stimulation of chondrocytes with the pro-inflammatory cytokine OSM and the 
chondroprotective cytokine IL-4, both resulted in Akt phosphorylation, indicating Akt 
activation. The study by Litherland et al. (2008) also suggested that Akt activation in 
chondrocytes may mediate different downstream signalling events, depending on the nature 
of the stimulus. As mentioned previously, the three different Akt isoforms are suspected of 
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having different biological functions, suggesting that additional mechanisms exist to fine-
tune the downstream effects following Akt phosphorylation. Numerous Akt-interacting 
proteins have been identified, some of which appear to lack any intrinsic kinase activity, 
suggesting they modulate the activity of Akt by affecting enzymatic activity or cellular 
localisation and distribution (Franke 2008). One of the aims of the remainder of this PhD is 
to investigate candidate Akt-interacting proteins that could be responsible for the 
dramatically different downstream effects of OSM and IL-4 following Akt activation.  
 
5.4 Summary 
 
• IL-4 induces the tyrosine phosphorylation of STAT6 in bovine and human 
chondrocytes. 
• Phosphorylation of Akt and GSK-3 by IL-4 is PI3K-dependent in bovine nasal 
chondrocytes. 
• Phosphorylation of Akt by IL-4 is partially dependent on p110α in bovine nasal 
chondrocytes. 
• Preliminary results suggest that silencing of both p110β and p110δ appears to 
inhibit IL-4-induced Akt phosphorylation in SW1353 cells, and silencing of p110δ 
inhibits the induction of MMP-13 by IL-1+OSM in SW1353 cells. 
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Chapter 6: Assessment of altered gene expression following 
IL-4 stimulation of cartilage and chondrocytes 
by genome-wide microarray analysis 
 
 
 
6.1 Introduction 
 
IL-4 has been shown to act as a protective factor in cartilage, preventing pro-inflammatory 
cytokine-induced cartilage breakdown (Cawston et al. 1996). Data indicate that IL-4 
mediates its effect by reducing levels of active collagenase, in particular MMP-13. In order 
to provide clues to the protective mechanism of action of IL-4, whole genome-wide arrays 
were performed to assess the effect of IL-4 and the pro-inflammatory cytokines IL-1±OSM 
on global gene expression in cartilage and chondrocytes.  
 
Genome-wide microarray analysis is an extremely powerful technique that enables the 
examination of the gene expression of thousands of transcripts in one single experiment. 
Several research groups have used this technique to increase understanding regarding the 
molecular changes observed in OA (Aigner et al. 2006; Sato et al. 2006; Appleton et al. 
2007; Fukui et al. 2008; Geyer et al. 2009; Karlsson et al. 2010). These studies compared 
gene expression levels in normal cartilage to OA cartilage as well as in cartilage from 
animals with experimentally-induced arthritis. The data presented in this chapter are the 
first to examine the effect of pro- and anti-inflammatory cytokine treatment in the context 
of arthritis on a genome-wide basis.  
 
In this chapter, global gene expression following cytokine stimulation was examined in 
bovine nasal cartilage, primary human articular chondrocytes and SW1353 cells. Analysis 
of three independent systems was performed to assess similarity in gene expression profiles 
between the three different systems and to aid validation and the robustness of results. 
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The aim of this chapter was to: 
• Perform genome-wide microarray analyses of stimulated cartilage and chondrocytes 
(control, IL-1, IL-1+OSM and IL-1+OSM+IL-4) in order to identify genes 
potentially involved in the chondroprotective action of IL-4 and hence the 
repression of MMP-13. 
 
6.2 Results 
 
6.2.1 Preliminary data 
6.2.1.1 Preliminary data from the bovine nasal cartilage model used to generate RNA for 
use on the GeneChip® Bovine Genome Array.  
The GeneChip® Bovine Genome Array allows the gene expression of over 23,000 bovine 
transcripts to be analysed. A 14-day bovine nasal cartilage degradation assay was 
performed to generate RNA for the GeneChip® Bovine Genome Array. Bovine nasal 
cartilage was stimulated with control medium ± IL-1 ± OSM ± IL-4 (added at day 7 of 
timecourse only) for 14 days. Figure 6.1 shows a variety of preliminary data from the 
bovine nasal cartilage experiment that was used to generate RNA for the genome-wide 
microarray. Due to the quantity of RNA required for the array, it was not possible to 
perform replicates in this experiment (the size of the experiment was limited by the size of 
the bovine nasal septum used) and so all the data presented in Figure 6.1 are representative 
of a single data set only. A hydroxyproline assay was performed to confirm that IL-4 had 
effectively protected the bovine nasal cartilage from IL-1+OSM-induced collagen release. 
Figure 6.1a shows that IL-1+OSM stimulated a 54% collagen release and the protective 
effect of IL-4 reduced this collagen release to 2.5%. Ordinarily in a 14-day timecourse, 
cartilage is harvested and RNA extracted at regular timepoints throughout the 14-days in 
order to provide an overall view of collagen release and gene expression during cartilage 
degradation. However, due to cost, it was only possible to perform genome-wide arrays on 
four samples. As four different cytokine treatments were included in the experiment 
(control, IL-1, IL-1+OSM and IL-1+OSM+IL-4), it was necessary to select only one 
timepoint for genome-wide analysis. Collagen release occurs during a very short timeframe 
and so a “snapshot” of the gene profile immediately preceding this collagen release was 
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judged to be the most appropriate use of the arrays. Previous experiments using the bovine 
nasal cartilage model have reproducibly demonstrated that collagen release occurs between 
day 11 and day 12 of the 14-day timecourse and as such the experiment was performed so 
that cartilage was harvested at days 10, 11, 12 and 14 of the timecourse. Figure 6.1b clearly 
shows that collagen release began between day 11 and day 12 of the timecourse and so 
RNA from the cartilage harvested on day 11 of the assay was selected for use in the array. 
 
Before the RNA from day 11 of the timecourse was used on the genome-wide array, it was 
important to perform several other preliminary checks to act as internal controls. Active and 
total collagenase levels were examined to confirm that IL-4 had suppressed levels of active 
collagenase, as previously observed in data presented in Chapter 3 of this thesis. IL-4 was 
shown to completely inhibit IL-1+OSM-induced active collagenase levels (Figure 6.1c) and 
strongly reduce the levels of total collagenase (Figure 6.1d). Real-time RT-PCR was 
performed to confirm the effect of IL-4 on the collagenases was as expected i.e. to confirm 
that IL-1+OSM-induced MMP-13 was completely repressed by IL-4 and MMP-1 was 
slightly up-regulated (Figure 6.1e and f). All the preliminary experiments performed on the 
RNA produced the expected results and so the four samples of bovine RNA from day 11 of 
the assay were sent to Geneservice (Nottingham, UK) for completion of the array.  
 
6.2.1.2 Preliminary data from human articular chondrocytes and SW1353 cells used to 
generate RNA for the Sentrix Human-6 Expression BeadChip.  
The majority of the work presented in this thesis has involved either bovine cartilage or 
bovine chondrocytes, hence the decision to perform genome-wide screening in the bovine 
model. However, a human genome-wide array would be more relevant to human disease 
and so it was decided to also generate human RNA for use on an Illumina Array.  The 
Sentrix Human-6 Expression BeadChip contains six arrays on a single BeadChip, each with 
>46,000 probes derived from human genes in the National Center for Biotechnology 
Information (NCBI) Reference Sequence (RefSeq) and UniGene databases. Again, due to 
cost, only six RNA samples could be selected for the array. RNA generated from a 
combination of both human articular chondrocytes and SW1353 cells was used. Due to the 
inherent variability in cultures of primary human osteoarthritic chondrocytes, if a genome-
Chapter 6 
 - 139 - 
wide array showed a similar gene expression profile between human articular chondrocytes 
and SW1353 cells, this would increase the confidence with which highlighted potential 
targets could be pursued. As only six samples could be chosen, it was necessary to 
eliminate one of the four cytokine treatments that had been included on the bovine array, 
for both human articular chondrocytes and SW1353 cells. For human articular 
chondrocytes, control, IL-1+OSM and IL-1+OSM+IL-4 treatments were selected. It was 
decided not to select a control sample for  the SW1353 cells as well, but instead to select 
IL-1, IL-1+OSM and IL-1+OSM+IL-4 as this might provide additional data regarding the 
mechanism of synergy between IL-1+OSM in a model where this feature is more robust. 
Human articular chondrocytes and SW1353 cells were stimulated with the appropriate 
cytokines for 24 hours, at which point they were lysed and the RNA extracted. As with the 
bovine RNA, several preliminary checks were performed to assess the effect of IL-4 on the 
collagenase genes prior to it being sent for microarray analysis. For both human articular 
chondrocytes and SW1353 cells, cells were seeded in both T25 flasks (to provide sufficient 
RNA for the array) and 96-well plates (to enable real-time RT-PCR to be performed). 
Figure 6.2 confirms that in the RNA used for the array, IL-4 was able to significantly 
inhibit IL-1+OSM-induced MMP-13 expression in human articular chondrocytes (Figure 
6.2c and d), but had no significant effect on IL-1+OSM-induced MMP-1 expression 
(Figure 6.2a and b). Figure 6.3 confirmed the same to be true in the RNA extracted from 
SW1353 cells to be used in the array. As all preliminary experiments produced the 
expected results, the RNA was sent to the Centre for Microarray Resources (Cambridge, 
UK) for completion of the Illumina array.  
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Figure 6.1 Preliminary data from the bovine nasal cartilage model used to generate RNA for use on the 
GeneChip® Bovine Genome Array. Bovine nasal cartilage chips (n=1) were cultured in DMEM ± IL-1 (1 
ng/ml) ± OSM (10 ng/ml) ± IL-4 (20 ng/ml, added at day 7 of culture) for 14 days. At day 7, medium was 
removed and replenished. Cartilage and media were harvested at days 10, 11, 12 and 14. As a measure of 
collagen release, the levels of hydroxyproline (OHPro) released into the media were assayed; percentage 
collagen release at day 14 and cumulative OHPro release are shown (a and b). Levels of active collagenase 
were measured (c) and APMA was used to activate pro-collagenases in order to measure the total collagenase 
activity (pro+active) (d). RNA was extracted from the cartilage and collagenase gene expression was 
determined by real-time RT-PCR (e and f). The real-time RT-PCR data are presented relative to 18S rRNA. 
Key:   = control, ■ = IL-1, ▲ = IL-1+OSM,  = IL-1+OSM+IL-4.  
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Figure 6.2 Preliminary data from human articular chondrocytes used to generate RNA for the Sentrix 
Human-6 Expression BeadChip. Human articular chondrocytes were seeded in 96-well plates and T25 
flasks according to section 2.2.3 of Materials and Methods and stimulated for 24 hours with DMEM ± IL-1 
(0.02 ng/ml) ± OSM (10 ng/ml) ± IL-4 (20 ng/ml). Following treatment, total RNA was isolated from cells, 
reverse transcribed and the cDNA was used in real-time RT-PCR reaction assays, as described in Materials 
and Methods section 2.2.5, to examine MMP-1 and MMP-13 gene expression. RNA was extracted from 
human articular chondrocytes in 96-well plates using the SideStepTM Kit to confirm the expected MMP-1 and 
MMP-13 expression (n=6) and from human articular chondrocytes in T25 flasks using the RNeasy® Mini Kit 
to prepare RNA for the Sentrix Human-6 Expression BeadChip (n=1). Results from 96-well plate experiments 
were normalised to 18S rRNA and expressed as mean ± SEM (n=6). *** = p ≤ 0.001; ** = p ≤ 0.01; ns = not 
significant. 
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Figure 6.3 Preliminary data from SW1353 cells used to generate RNA for the Sentrix Human-6 
Expression BeadChip. SW1353 cells were seeded in 96-well plates and T25 flasks according to section 2.2.3 
of Materials and Methods and stimulated for 24 hours with DMEM:F12 ± IL-1 (0.5 ng/ml) ± OSM (10 ng/ml) 
± IL-4 (20 ng/ml). Following treatment, total RNA was isolated from cells, reverse transcribed and the cDNA 
was used in real-time RT-PCR reaction assays, as described in Materials and Methods section 2.2.5, to 
examine MMP-1 and MMP-13 gene expression. RNA was extracted from SW1353 cells in 96-well plates 
using the SideStepTM Kit to confirm the expected MMP-1 and MMP-13 expression (n=6) and from SW1353 
cells in T25 flasks using the RNeasy® Mini Kit to prepare RNA for the Sentrix Human-6 Expression 
BeadChip (n=1). Results from 96-well plate experiments were normalised to 18S rRNA and expressed as 
mean ± SEM (n=6). ** = p ≤ 0.01; ns = not significant. 
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6.2.2 Analysis of genome-wide microarray results 
 
Gene expression analysis was carried out using GeneSpring GX software. Due to the vast 
amount of data generated by the microarrays, thresholds of fold change were set to produce 
more manageable sized gene lists. For unknown reasons, Affymetrix arrays (GeneChip® 
Bovine Genome Array) characteristically produce higher fold changes than Illumina arrays 
(Sentrix Human-6 Expression BeadChip) (personal communication, Dr Daniel Swan, 
Newcastle University). As such only genes with ≥2 fold change in the bovine array were 
examined (see appendix B for full gene lists). This threshold was lowered to ≥1.5 fold 
change for the Illumina array data (human articular chondrocytes and SW1353 cells) (see 
appendices C and D for full gene lists). Figures 6.4, 6.5 and 6.6 show the gene trees 
generated by the GeneSpring software, with red bars indicating up-regulated genes and blue 
bars indicating down-regulated genes.  
 
One of the aims of the microarray analysis was to examine the similarity in gene profiles 
between the three different models used in this thesis, namely, bovine nasal cartilage, 
human articular chondrocytes and SW1353 cells. Venn diagrams were used to show the 
number of overlapping up- or down-regulated genes between the different models (Figures 
6.7 and 6.8) The lack of similarity between up and down-regulated genes shown in the ≥ 2 
fold change Venn diagram (Figure 6.7) was not unexpected and highlights the difference 
between 3D tissue and cells in monolayer. When the fold change threshold was lowered to 
include all genes which were up or down-regulated by ≥1.5 fold, the number of common 
genes between human articular chondrocytes and SW1353 cells increased (Figure 6.8).  
 
Following examination of the gene profiles produced by GeneSpring, a thorough literature 
search was performed to shortlist genes for further study.  
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IL-1                     IL-1 +OSM           IL-1+OSM+IL-4
 
Figure 6.4 Gene tree: GeneChip® Bovine Genome Array. Coloured according to expression versus control 
samples, with red bars indicating up-regulated genes, blue bars indicating down-regulated genes and white 
bars representing genes with no change in expression versus control.  
Chapter 6 
 - 145 - 
IL-1 +OSM              IL-1+OSM+IL-4
 
Figure 6.5 Gene tree: Human articular chondrocyte Sentrix Human-6 Expression BeadChip. Coloured 
according to expression versus control samples, with red bars indicating up-regulated genes,  blue bars 
indicating down-regulated genes and white genes representing a gene with no change in expression versus 
control.  
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IL-1 +OSM                    IL-1+OSM+IL-4
 
Figure 6.6 Gene tree: SW1353 cells Sentrix Human-6 Expression BeadChip. Coloured according to 
expression versus IL-1-treated samples, with red bars indicating up-regulated genes, blue bars indicating 
down-regulated genes and white bars representing genes with no change in expression versus IL-1-treated 
samples.  
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Figure 6.7 Venn diagrams showing the overlap of genes up- or down-regulated ≥ 2 fold in IL-
1+OSM+IL-4-stimulated bovine cartilage, human articular cartilage and SW1353 cells compared to 
IL-1+OSM-stimulated bovine cartilage, human articular chondrocytes and SW1353 cells. 
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Figure 6.8 Venn diagrams showing the overlap of genes up- or down-regulated ≥ 1.5 fold in IL-
1+OSM+IL-4-stimulated human articular cartilage and SW1353 cells compared to IL-1+OSM-
stimulated human articular chondrocytes and SW1353 cells. 
 
 
 
 
 
 
 
Chapter 6 
 - 149 - 
6.2.3 Candidate genes selected for further study 
 
The primary aim of this study was to increase the understanding of the chondroprotective 
mechanism of action of IL-4 and in particular, how IL-4 is able to strongly repress IL-
1+OSM-induced MMP-13 expression. Therefore, this section focuses on the differences in 
gene expression profiles between IL-1+OSM-stimulated cartilage/cells and IL-1+OSM+IL-
4-stimulated cartilage/cells. After examination of the most highly up- or down-regulated 
genes (IL-1+OSM+IL-4 vs IL-1+OSM) and a thorough literature search, the genes listed in 
section 6.2.3.1 and Table 6.1 were selected as candidate genes in the protective mechanism 
of action of IL-4 and therefore shortlisted for further study (Figures 6.9, 6.10 and 6.11).  
6.2.3.1 Reasoning behind selection of shortlisted genes 
 
Genes up-regulated by IL-1+OSM+IL-4 vs IL-1+OSM 
A newly induced gene, and thus a gain of function, could help to explain the mechanism of 
MMP-13 repression following inclusion of IL-4. 
 
Chemokine ligand 26 (CCL26) 
• CCL26, also known as eotaxin-3, is a small cytokine belonging to the CC 
chemokine family.   
• Highest up-regulated gene in both human articular chondrocytes and SW1353 
cells. 
• CCL26 contains two STAT6 binding sites (through which IL-4 is known to signal) 
(Blanchard et al. 2005).  
• Polymorphisms of CCL26 may be associated with susceptibility to RA (Chae et al. 
2005).  
Protein kinase C zeta (PKCζ) 
• PKCζ is a serine/threonine kinase involved in the regulation of various signalling 
pathways, including the NFκB pathway. 
• Indicated in previous literature (Hussain et al. 2002) and current studies in the lab to 
be important in collagenase expression. 
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Regulator of G-protein signalling 4 (RGS4) 
• RGS4 belongs to the RGS family of proteins, which act as negative regulators of G-
protein mediated signalling by increasing the intrinsic GTPase activity of 
heterotrimeric G proteins (Bansal et al. 2007). 
• Up-regulated in both human articular chondrocytes and SW1353 cells. 
• Involvement of G proteins such as PAR is suspected to be important in collagenase 
gene expression. 
Basic leucine zipper transcription factor (BATF3/SNFT) 
• BATF3 is a small nuclear factor originally isolated from T cells, the over-
expression of which leads to the repression of transcription from several AP-1-
driven promoters (Bower et al. 2004). 
• Up-regulated in both human articular chondrocytes and SW1353 cells. 
• Over-expression of p21SNFT had been shown to repress MMP-1 expression 
(Bower et al. 2004). 
Tribble 1 (Trb1) 
• Trb1 is one of three members of a newly identified family of proteins, thought to 
play a role in regulating cell signalling pathways (Hegedus et al. 2007). 
• Up-regulated in human articular chondrocytes, SW1353 cells and bovine cartilage. 
• Trb3 is a known regulator of Akt (Matsumoto et al. 2006), which is involved in 
collagenase expression and Akt is known to be activated by IL-4. 
 
Genes down-regulated by IL-1+OSM+IL-4 vs IL-1+OSM 
A newly down-regulated gene, and thus a loss of function, could also help explain the 
mechanism of MMP-13 repression following inclusion of IL-4. 
 
Autotaxin (ENNP2) 
• ENPP2 is a secreted glycosylated enzyme that exhibits lysophospholipase D 
activity, hydrolyzing lysophosphatidylcholine to lysophosphatidic acid. 
• Over-expressed in RA patients (Kehlen et al. 2001). 
• Important in the generation of lysophosphatidic acid (LPA), which plays a critical 
role in the induction of COX-2 in collaboration with inflammatory cytokines in RA 
synovial cells (Nochi et al. 2008). 
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Growth arrest-specific 1 (GAS1) 
• GAS1 is an integral membrane protein. 
• Down-regulated in both human articular chondrocytes and SW1353. 
• Chondrocytes over-expressing GAS1 are unable to participate in cartilage formation 
(Lee et al. 2001) therefore down-regulation of GAS1 may be part of the protective 
mechanism of action of IL-4. 
Phosphodiesterase 5 (PDE5) 
• PDE5 belongs to a family of enzymes that degrade the phosphodiester bond in 
cAMP and cGMP, thereby acting as important regulators of signal transduction 
mediated by these molecules.  
• PDE5 specific inhibitors suppress IL-1-induced nitric oxide (NO) release and 
inducible nitric oxide synthase (iNOS) mRNA expression (Geng et al. 1998) and 
NO has previously been linked to collagenase expression (Zaragoza et al. 2002; 
Zaragoza et al. 2006). 
S100A8/S100A9 
• S100A8 and S100A9 are calcium binding proteins that are important pro-
inflammatory mediators in acute and chronic inflammation. 
• Inflammatory cytokines such as IL-1 have been shown to upregulate 
S100A8/S100A9, which are both found in and around chondrocytes in experimental 
models of arthritis. Stimulation of chondrocytes with S100A8 has been shown to 
significantly upregulate various MMPs, including MMP-13 (van Lent et al. 2008). 
• RAGE (receptor for advanced glycation end products)-mediated signalling cascades 
are known to lead to increased production of MMP-13 (Yammani et al. 2006). 
S100A8 and S100A9 have been shown to interact with RAGE (Boyd et al. 2008) 
and therefore a decrease in S100A8/S100A9 could be at least partly responsible for 
the repression of MMP-13 by IL-4.  
Syndecan 1 (SDC1) 
• SDC1 is a transmembrane heparan sulphate proteoglycan important in cell binding, 
cell signalling and cytoskeletal organisation.  
• Down-regulated in human articular chondrocytes, SW1353 cells and bovine 
cartilage. 
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• SDC1 is up-regulated in articular cartilage during early stages of cartilage 
degeneration suggesting it is involved in attempted repair (Salminen-Mankonen et 
al. 2005). 
• Expression of SDC1 is higher in chondrocytes derived from OA cartilage than in 
those from normal cartilage (Barre et al. 2000). 
Thrombospondin 1 (THBS1) 
• THBS1 is a large glycoprotein that is secreted in response to cell injury and various 
growth factors. 
• Down-regulated in human articular chondrocytes, SW1353 cells and bovine 
cartilage. 
• Increased plasma levels of THBS1 correlate with increased levels of pro-
inflammatory cytokines in RA patients (Rico et al. 2008). 
 
Genes up-regulated by 
IL-1+OSM+IL-4 vs IL-1+OSM 
Genes down-regulated by 
IL-1+OSM+IL-4 vs IL-1+OSM 
Gene Fold Change Gene Fold Change 
HAC SW Bovine HAC SW Bovine 
CCL26 88 21 N/A ENPP2 2.1 1.2 N/A 
PKCζ 2 N/A N/A GAS1 4 1.8 N/A 
RGS4 8.6 4.7 N/A PDE5 2 N/A N/A 
SNFT 15.3 4.7 N/A S100A8 1.1 3.7 1.9 
TRIB1 1.2 1.6 3.9 S100A9 1.1 4.9 3.7 
    SDC1 2.6 1.5 2 
    THBS1 2.2 2.5 2 
Table 6.1 List of genes selected for further study from microarray data. HAC = human articular 
chondrocyte array results, SW = SW1353 cells array results and bovine = bovine articular cartilage array 
results. N/A refers to a gene either not being present on the array or to a gene failing to pass the normalisation 
process. 
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Figure 6.9 Scatter plot showing genes up- or down-regulated >2 fold (IL-1+OSM+IL-4 versus IL-
1+OSM) on the GeneChip® Bovine Genome Array. Coloured according to expression versus control 
samples, with red dots representing up-regulated genes and blue dots representing down-regulated genes. 
Genes of interest have been circled. 
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Figure 6.10 Scatter plot showing genes up- or down-regulated >1.5 fold (IL-1+OSM+IL-4 versus IL-
1+OSM) on the Sentrix Human-6 Expression BeadChip (human articular chondrocytes). Coloured 
according to expression versus IL-1+OSM+IL-4 samples, with red dots representing up-regulated genes and 
blue dots representing down-regulated genes. Genes of interest have been circled. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 - 155 - 
MMP-13TRB1CCL26
RGS4
SNFT
ENPP2
GAS1
S100A8 S100A9
SDC1
THBS1
IL-1+OSM
IL
-
1+
O
SM
+
IL
-
4
Figure 6.11 Scatter plot showing genes up- or down-regulated >1.5 fold (IL-1+OSM+IL-4 versus  
 
Figure 6.11 Scatter plot showing genes up- or down-regulated >1.5 fold (IL-1+OSM+IL-4 versus IL-
1+OSM) on the Sentrix Human-6 Expression BeadChip (SW1353 cells). Coloured according to 
expression versus IL-1+OSM+IL-4 samples, with red dots representing up-regulated genes and blue dots 
representing down-regulated genes. Genes of interest have been circled. 
 
 
 
 
 
 
Chapter 6 
 - 156 - 
6.3 Discussion 
 
In this chapter the genome-wide effects of various cytokine combinations (control, IL-1, 
IL-1+OSM and IL-1+OSM+IL-4) were compared in three different systems; bovine nasal 
cartilage, human articular chondrocytes and SW1353 cells. In order to identify genes 
potentially involved in the repression of MMP-13 by IL-4, this chapter focused on the 
differences in gene expression profiles between IL-1+OSM-treated cells/cartilage and IL-
1+OSM+IL-4-treated cells/cartilage. However, the data generated by this screen have also 
provided information regarding the genes involved in synergy between IL-1 and OSM. 
 
Whilst several groups have examined differences in gene expression profiles between 
normal and OA cartilage, this is the first genome-wide array to examine the specific effects 
of certain cytokine combinations (known to be relevant to arthritic disease) on global gene 
expression. One problem encountered by groups examining gene profiles from both OA 
and normal cartilage has been the high variability of gene expression levels between 
different donors. This is perhaps not surprising in OA tissue; however the large difference 
in gene expression in normal donors indicates that a wide range of gene expression is 
compatible with normal joint function. Unfortunately, this also suggests that complicated 
networks of genes are responsible for abnormal joint changes, rather than single 
components (Aigner et al. 2006). As no replicates were performed in the genome-wide 
screens performed in this chapter, it is impossible to comment on any variation between 
different bovine or human cartilage donors. However, as three different systems were 
examined, it is acceptable to presume that any similarity in up- or down-regulation of 
particular genes found in all three models represents an accurate result.  
 
Previous genome-wide analyses have identified many differentially expressed genes in OA 
cartilage. Many of these genes, such as those involved in matrix synthesis, were expected to 
be differentially expressed. Some of the newly identified differentially expressed genes 
include those involved in oxidative stress defence (down-regulation of superoxide 
dismutases (SOD) 2 and 3 and glutathione peroxidase 3), indicating that continuous 
oxidative stress to the cells and the matrix is one major underlying pathogenic mechanism 
in OA (Aigner et al. 2006). As the major feature of arthritic disease is cartilage destruction, 
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many proteases (DKFZP586H2123, ADAMTS6, ADAM12, and PRSS11) are known to be 
up-regulated in damaged vs intact cartilage (Sato et al. 2006). The same study also found 
the expression levels of three genes known to inhibit degradation of the ECM (TNFAIP6, 
SERPINE1, and TIMP3) to be increased in damaged vs intact cartilage, indicating an 
attempt by the body to halt cartilage destruction. Several serpin peptidase inhibitors were 
shown to be dramatically up-regulated in IL-1+OSM+IL-4 vs IL-1+OSM cells/cartilage in 
the data presented in this chapter. Appleton et al. (2007) identified dysregulation of 
members of the insulin-like growth factor (IGF) family, including increased levels of 
expression of IGF binding proteins, which sequester IGFs and prevent their anabolic 
influences in chondrocytes. This study also reported the modulation of oxidative defense 
genes (e.g. SOD2). Another study examined the differential gene expression profile of 
damaged vs intact cartilage areas within the same joint of patients with OA of the knee and 
found several genes to be up-regulated in all patients (IGF binding protein 3 (IGFBP-3), 
wnt-1-inducible signalling protein 1 (WISP-1), aquaporin 1 (AQP-1), delta/notch-like EGF-
repeat containing (DNER), decay accelerating factor (DAF), complement factor I (IF)) 
(Geyer et al. 2009). In agreement with this study, IGFBP-3 was up-regulated in both bovine 
cartilage (5.99 fold) and SW1353 cells (2.28 fold) in the data presented in this chapter. In 
addition, DAF was up-regulated 2.81 fold in bovine cartilage. These similarities indicate 
that the cytokine treatments used in this array, do appropriately mimic the in vivo action of 
cytokines in OA.  
 
The most recent genome-wide analysis identified several genes that had not previously 
been associated with OA (Karlsson et al 2010). These included an up-regulation in OA 
cartilage of TFPI2 (tissue factor pathway inhibitor 2), a gene previously demonstrated to 
reduce the ability of MMP-1 and -13 to degrade collagen and also reduce the activity of 
MMP-2 and -9. This finding again suggests the presence in OA cartilage of a mechanism to 
counteract matrix degradation. TFPI2 was up-regulated 7.69 fold in bovine cartilage (IL-
1+OSM+IL-4 vs IL-1+OSM), indicating the presence of a similar mechanism. Increased 
expression of SGPP1 was also observed in OA cartilage compared to normal. SGPP1 
regulates sphingolipid biosynthesis and is known to be involved in programmed cell death 
(Johnson et al. 2003).     
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After examination of the genome-wide array data and extensive literature searches, a 
number of genes that were differentially regulated between IL-1+OSM+IL-4- vs IL-
1+OSM-treated cells/cartilage were selected as potential candidates for further study. The 
decision as to whether a gene warranted further study was based on a number of factors; (1) 
the fold change up or down regulation of a particular gene, (2) if existing literature had 
identified a particular gene as playing a role in arthritic disease or MMP regulation, and (3) 
whether a particular gene was up or down regulated in at least two out of the three systems 
examined. Unlike previous genome-wide studies (Aigner et al. 2006; Sato et al. 2006; 
Appleton et al. 2007; Fukui et al. 2008; Geyer et al. 2009; Karlsson et al. 2010) that were 
interested in genes differentially expressed in OA vs normal cartilage, the more specific 
aim of this chapter (to identify genes involved in the repression of MMP-13 by IL-4) made 
selection of genes for further study more complicated. Many of the most highly up or 
down-regulated genes were not selected for further study because there was no evidence 
that they played a role in the repression of MMP-13 by IL-4 and therefore the 
chondroprotective mechanism of action of IL-4. In addition, many genes involved in, for 
example, the general inflammatory process (such as C-reactive protein) or genes involved 
in matrix synthesis (such as the collagens) were discounted from further study. Instead, 
genes that were potentially involved in cell signalling pathways (such as Trb1) were 
selected as being more likely to be involved in the repression of MMP-13 by IL-4. 
Moreover, relatively subtle changes in cell signalling molecules could have significant 
effects on MMP expression (Litherland et al. 2008, Litherland et al. 2010).  
 
All genome-wide screens in relation to arthritis to date have utilised OA cartilage or 
cartilage from animal models. This analysis of disease ‘end-point’ may not reflect gene 
expression patterns during the initiation of cartilage destruction. An advantage of the screen 
performed in this chapter is that the stimulation of cartilage with cytokines enabled a 
snapshot of gene expression changes immediately preceding collagen loss and cartilage 
degradation, and for isolated chondrocytes at a timepoint during which MMP-13 expression 
was marked. 
 
One of the reasons behind performing genome-wide arrays in three different systems 
(bovine cartilage, human articular chondrocytes and SW1353 cells) was to assess the 
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similarity in gene expression profiles. A strong similarity would validate the use of bovine 
cartilage and the cell line SW1353 cells as an alternative to primary human chondrocytes 
when the latter was unavailable. At the time of writing, a large proportion of the genes 
included on the bovine Affymetrix array had yet to be transcribed and this explains the lack 
of similarity in gene profiles between the Affymetrix and Illumina array data. Illumina 
arrays are known to produce smaller fold changes than Affymetrix arrays so; again, this 
goes some way as to explaining the lack of common genes between the three models. The 
Venn diagrams presented in this chapter may actually underestimate the number of 
common genes, as they do not include genes encoding different protein isoforms (for 
example IGFBP-3 was up-regulated in SW1353 cells and bovine cartilage and IGFBP-5 
was up-regulated in human articular chondrocytes and bovine cartilage). Therefore, these 
genes do not count as common genes, despite the fact that similar processes are obviously 
occurring in all three models, albeit by slightly different mechanisms. Despite the lack of 
similarity between the bovine and human gene expression data (for reasons explained 
previously), the data presented in this chapter suggest that human articular chondrocytes 
and SW1353 cells are appropriate complementary model systems as their gene expression 
profiles are very similar. This in agreement with studies by another group, which also 
demonstrated similarity between SW1353 cells and human articular chondrocytes 
(following IL-1β treatment) (Gebauer et al. 2005). 
 
Unfortunately due to the cost of performing genome-wide arrays, it was not possible to 
include replicates on any of the arrays. As no statistical analysis could be performed on the 
resulting data, these arrays acted as a basic screen to identify genes that could be involved 
in the chondroprotective action of IL-4. Despite this obvious drawback to the study, the 
extensive preliminary experiments performed on the RNA used for the arrays does increase 
the confidence in the gene expression data. Additionally, the expression levels of genes that 
have been extensively studied previously in response to these cytokine combinations acted 
as positive internal controls. The gene expression profile of these internal controls was 
found to follow the same pattern of up- or down-regulation in the array results as in 
previous data (Chapter 3 of this thesis). For example, MMP-13 was down-regulated by IL-
1+OSM+IL-4 compared with IL-1+OSM in bovine cartilage, human articular chondrocytes 
and SW1353 cells (-10.5, -2.1 and -2.63 fold, respectively). These results correlate strongly 
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to those presented in Chapter 3 of this thesis, whereby IL-4 repressed IL-1+OSM-induced 
MMP-13 expression in all systems, but to a greater extent in the bovine system. The fact 
that the gene expression data for MMP-13 from all three arrays corresponds so closely to 
data obtained from numerous previous experiments, strengthens the confidence in the 
results for other genes on the array, despite the lack of replicates and therefore statistical 
power. Furthermore, the genome wide arrays were performed in three different models. 
Therefore any up- or down-regulation of genes observed in two or three of the models can 
confidently be viewed as an accurate observation.  
 
The remainder of this study will examine the role of candidate genes identified in this 
chapter, in the repression of MMP-13 by IL-4. RNA interference-mediated knockdown of 
up-regulated genes in IL-1+OSM+IL-4 treated cells/cartilage will be used to determine if 
this recovers MMP-13 expression. In down-regulated genes, siRNA will be used in IL-
1+OSM treated cells/cartilage to determine if knockdown of these genes mimics the effect 
of IL-4 (i.e. blocks MMP-13 expression). 
 
The data presented in this chapter provide a basis for future studies on the function of 
certain genes in the chondroprotective mechanism of action of IL-4. Many of the genes 
highlighted in this chapter have not before been implicated in arthritic disease and so any 
involvement will be a novel finding. 
 
6.4 Summary 
 
• Genome-wide microarray analysis of bovine cartilage, human articular 
chondrocytes and SW1353 cells provided data on the gene expression profile 
differences between IL-1+OSM+IL-4 vs IL-1+OSM. 
• These data, along with an extensive literature search, enabled a shortlist of genes, 
with a possible involvement in the repression of MMP-13 by IL-4, to be selected for 
further study. 
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Chapter 7: The role of the Tribbles family of proteins in 
MMP-13 expression in chondrocytes 
 
 
7.1 Introduction 
 
 
Data presented in this thesis have demonstrated that IL-4 prevents cartilage destruction via 
MMP-13 repression. Transcriptome analyses of stimulated cartilage and chondrocytes to 
provide clues to the mechanism of action of IL-4 revealed numerous genes with potential 
involvement in the chondroprotective action of IL-4. An RNA interference approach was 
used to further investigate the involvement of genes highlighted in Chapter 6 as having a 
potential role in the mechanism of action of IL-4. It was hypothesised that silencing (via 
siRNA) of genes up-regulated by IL-4 might rescue IL-4-mediated repression of IL-
1+OSM-induced MMP-13. In genes down-regulated by IL-1+OSM+IL-4, gene silencing 
would mimic the effect of IL-4 (i.e. block MMP-13 expression by IL-1+OSM). This 
approach was used against several genes and preliminary results indicated a role for Trb1 in 
the repression of MMP-13 by IL-4. This chapter examines the role of the tribbles (trb) 
family of proteins in MMP-13 expression in chondrocytes. 
 
Regulators of cellular signalling have evolved to regulate and integrate the huge variety of 
extracellular signals, ultimately determining the cellular response. The recent identification 
of tribbles as regulators of cell signalling pathways has generated a large amount of interest 
in this family of proteins. An expanding literature on tribbles indicates that the proteins 
encoded by these genes play an important role in the regulation and modulation of 
numerous signalling pathways and transcription factors, perhaps affecting the balance of 
activation between key signalling pathways. These regulatory mechanisms usually involve 
enzymes with catalytic activity. However, this unusual family of signalling regulatory 
proteins appear to be catalytically inactive, despite resembling Ser/Thr kinases. Instead, it is 
thought that tribbles evolved as adaptor proteins with a scaffold-like regulatory function. It 
is widely believed that these proteins do have an important physiological function, despite 
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their apparent lack of kinase activity, however the molecular basis of tribbles function is 
still poorly understood (Hegedus et al. 2007).  
 
In mammals, three tribbles proteins have been described to date. The three human tribbles 
share 45% sequence similarity and bear a strong resemblance to tribbles, a Drosophila 
protein that inhibits mitosis early in development (Mata et al. 2000; Seher and Leptin 
2000). 
 
Trb1 
Trb1, originally named c8fw, was first identified as a homologue of Trb2 (first called 
c5fw). In a yeast two-hybrid screen, LOX-12 (an enzyme that metabolises arachidonic acid) 
was found to be a Trb1 interacting protein (Tang et al. 2000). Trb1 was subsequently found 
to regulate the activity of stress kinase pathways through interaction with MAPKKs 
(mitogen-activated protein kinase kinase) (Kiss-Toth et al. 2004). Activation of MAPK 
pathways can occur in response to a wide range of stimuli, such as stress, pro-inflammatory 
cytokines and growth factors. MAPKs are subdivided into 3 groups, namely Jun kinases 
(JNK), p38 and extracellular signal-regulated protein kinases (ERK) and are activated by 
upstream kinases called MAPKKs. Co-immunoprecipitation experiments in HeLa cells 
with over-expressed Trb1, MAPKs, MAPKKs and MAPKK kinases revealed specific 
interactions of Trb1 with MEK1 and MKK4/SEK1 (a Jun activator kinase) (Sung et al. 
2007). This study evaluated the importance of Trb proteins in the cellular responses of 
vascular smooth muscle cells to inflammatory stimuli. Trb1 was found to control vascular 
smooth muscle cell proliferation and chemotaxis through the JNK pathway via direct 
interactions between Trb1 and MKK4/SEK1.  
 
Trb2 
Trb2 has been identified as a candidate autoantigen in autoimmune uveitis (Zhang et al. 
2005). Several studies have investigated the binding partners of Trb2. The first reported the 
interaction of Trb2 with over-expressed Akt in co-immunoprecipitation assays (Du et al. 
2003). The second showed that Trb2 appears to have anti-adipogenic effects (Naiki et al. 
2007). Both Trb2 and Trb3 were shown to exhibit anti-adipogenic effects through 
inhibition of Akt activation. However, Trb2 only partially inhibited Akt phosphorylation 
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suggesting that Trb2 inhibits adipogenensis through an additional mechanism to Akt 
inhibition. Trb2 was shown to also interact with C/EBPβ (CCAAT-enhancer-binding 
protein β, a transcription factor required for an early stage of adipogenesis) and block 
adipogenesis through proteosome-dependent degradation of C/EBPβ. A later study 
demonstrated that Trb2 associated with and inhibited C/EBPα. Trb2 expression was found 
to be elevated in a subset of human acute myelogenous leukemia (AML) patient samples 
suggesting that Trb2 is an oncogene that induces AML through a mechanism involving 
inactivation of C/EBPα (Keeshan et al. 2006). Trb2 has been also been described as a pro-
apoptotic molecule, inducing the apoptosis of cells mainly of hematopoietic origin (Lin et 
al. 2007). In 2009, Trb2 was identified as a highly regulated gene in vulnerable 
atherosclerotic lesions (Deng et al. 2009). Inhibition of macrophage IL-10 biosynthesis 
appeared to be a potential consequence of high Trb2 expression, which the authors suggest 
may contribute to plaque instability. Trb2 has been identified as a novel regulator of 
inflammatory activation of monocytes (Eder et al. 2008). Most recently, anti-Trb2 
antibodies have been associated with narcolepsy (Toyoda et al. 2010).  
 
Trb3 
Trb3 is the most studied member of the mammalian Trb family. Two separate groups 
reported the identification of Trb3 in 1999. Mayumi-Matsuda et al. (1999) identified a 
kinase-like protein involved in neuronal cell death and designated this protein NIPK 
(Neuronal cell death Inducible Putative Kinase). The second study by Klingenspor et al. 
(1999) analysed the altered pattern of gene expression in the fatty liver of fld (fatty liver 
dystrophy) mice and found a novel Ser/Thr kinase, which they called Ifld2.  
 
In 2003, Trb3 was reported to be a negative regulator of Akt (Du et al. 2003). In order to 
identify additional proteins that modulate Akt activity, a yeast two-hybrid assay was used to 
screen for proteins from a preadipocyte F422A cDNA library that interacted with a GAL4-
Akt PH construct lacking the NH2-terminal pleckstrin homology domain of Akt1. Twenty-
five independent transformants from a screen of 2 x 106 cDNAs were found to encode a 
protein recently identified as Trb3. Interaction between endogenous Trb3 and Akt was 
confirmed by co-immunoprecipitation assays using HepG2 cell extracts. To determine 
whether the association of Akt with Trb3 modulated the activity of Akt, Akt 
Chapter 7 
 - 164 - 
phosphorylation in response to IGF-1 was monitored. IGF-1 induced phosphorylation of 
Akt at Thr308 and Ser473 in human embryonic kidney 293 (HEK293) cells within 15 minutes, 
however expression of Trb3 inhibited Akt phosphorylation at both sites without altering 
total amounts of Akt protein. This study therefore demonstrated that Trb3 appears to block 
Akt activity by disrupting its phosphorylation without reducing the abundance of the 
protein (Du et al. 2003). The same study investigated possible mechanisms by which Trb3 
inhibits Akt phosphorylation. A phosphorylation-defective T308A mutant Akt was shown 
to associate more efficiently with Trb3 when compared to wild-type protein. Conversely, 
substitution of Thr308 with Asp to mimic Thr308 phosphorylation was shown to strongly 
inhibit the interaction between Trb3 and Akt, suggesting that Trb3 preferentially binds to 
the unphosphorylated form of Akt. Akt is a principal target of insulin signalling that inhibits 
hepatic glucose output when glucose is available from food and so the conclusion of this 
study was that Trb3 may contribute to insulin resistance by interfering with Akt activation. 
Trb3 has also been shown to inhibit the phosphorylation of Akt at Thr308 in FGC-4 cells, a 
highly differentiated rat hepatoma cell line (He et al. 2006). However, a contradictory study 
by Iynedjian (Iynedjian 2005) failed to find any evidence of a role for Trb3 as an inhibitor 
of Akt-mediated insulin signalling in primary rat hepatocytes. These opposing findings 
could suggest that the function of Trb3 varies depending on experimental procedures and/or 
cell type. A 2006 study identified Trb3 as a transcriptional target of PI3K (Schwarzer et al. 
2006). Inhibition of PI3K in the prostate cancer cell line, PC-3, reduced Trb3 expression.  
 
To date, only one study has looked at the role of tribbles in the context of OA (Cravero et 
al. 2009). As mentioned previously, Trb3 has been shown to inhibit IGF-1-mediated 
activation of Akt in HEK 293 cells (Du et al. 2003). It is known that the chondrocyte 
response to IGF-1 is reduced both with ageing and in OA chondrocytes. The study by 
Cravero et al. (2009) first confirmed the expression of Trb3 in human articular 
chondrocytes. It went on to demonstrate that a significantly higher level of Trb3 was found 
in OA chondrocytes when compared to age-matched control chondrocytes. Over-expression 
of Trb3 in normal chondrocytes was found to block IGF-1 stimulation of proteoglycan 
synthesis and reduce cell survival by almost 40%. IGF-1-mediated production of 
proteoglycan by chondrocytes has previously been shown to be dependent on the PI3K 
signalling pathway (Starkman et al. 2005). Cravero et al. (2009) suggest that an increase in 
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the level of Trb3 in OA chondrocytes may be partly responsible for the decreased response 
of OA chondrocytes to IGF-1 and the cell death and cell matrix loss that occurs during OA 
progression. Cravero et al. (2009) also found that an increase in endoplasmic reticulum 
(ER) stress resulted in increased chondrocyte Trb3 levels. Yang et al. (2007) demonstrated 
that ER stress in chondrocytes decreases the expression of cartilage matrix genes. Taken 
together, it appears Trb3 could play a role in causing the imbalance between anabolic and 
catabolic activity associated with the development of OA.  
 
Tribbles structure 
The kinase-like domain of tribbles proteins is located in the middle of the protein, flanked 
by relatively short N- and C-terminal sequences. The N-terminal segment of human tribbles 
proteins is approximately 60–80 residues long (Hegedus et al. 2007). A notable feature of 
the N-terminal portion of tribbles is a very high serine (7-24%) and proline (6-23%) 
content, predominantly in the section of sequence adjacent to the kinase-like domain. This 
is of note because a high level of these particular amino acids is an important feature of 
PEST regions (a polypeptide sequence that is enriched in proline (P), glutamic acid (E), 
serine (S) and threonine (T)). The presence of these regions is thought to result in the rapid 
intracellular degradation of the proteins containing them (Rogers et al. 1986; Rechsteiner 
and Rogers 1996). This observation corroborates the findings of a previous report that 
demonstrated Trb2 to be an unstable protein (Wilkin et al. 1997). It also adds weight to the 
growing hypothesis that tribbles are regulators of cell division and cell signalling, both of 
which often involve proteins with a rapid turnover. In addition, the presence of a proline-
rich region is potentially associated with other functions such as the anchoring of SH3 or 
WW domains of other proteins (Macias et al. 2002) or as substrates for proline-dependent 
phosphorylation (MAP and CDK-like proteins phosphorylated a Ser/Thr residue preceding 
a Pro residue).  
 
The importance of tribbles in various physiological processes is now well accepted; 
however the cellular and molecular basis for their action is poorly understood. The three 
tribbles proteins have been implicated in the control of stress response, cell viability and 
metabolic processes, and have been linked to medical conditions such as insulin resistance 
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and diabetes. Therefore, the understanding of mechanisms that regulate tribbles expression 
is of considerable importance. 
 
The aims of this chapter were to: 
 
• Determine the involvement of the tribbles protein family in IL-1+OSM- and IL-
1+OSM+IL-4-induced MMP-13 expression/repression through gene silencing and 
over-expression experiments. 
• Determine the subcellular localisation of tribbles proteins under basal conditions in 
chondrocytes and examine the effect of cytokine stimulation on this localisation. 
• Examine the physical interactions of tribbles proteins with MAPKKs. 
 
7.2 Results 
 
7.2.1 The effect of various gene silencing on IL-1+OSM-induced MMP-13 
expression in SW1353 cells 
Of the genes selected in Chapter 6 as being potentially involved in the repression of MMP-
13 by IL-4, several were selected for preliminary RNA interference experiments using 
siRNA (S100A8, S100A9 and Trb1). Along with these genes, three other targets were 
selected for RNA interference due to their known involvement in IL-4 signalling pathways; 
namely, STAT6, IRS1 and IRS2. Of the genes investigated in these experiments, silencing 
of STAT6 and Trb1 appeared to rescue IL-4-mediated repression of IL-1+OSM-induced 
MMP-13 (Figure 7.1). IL-1+OSM-induced S100A8 and S100A9 expression was down-
regulated by IL-4 in the microarray performed in Chapter 6. Therefore, silencing of 
S100A8 and S100A9 would have been expected to abolish IL-1+OSM-induced MMP-13 
expression if these genes were involved in the mechanism of action of IL-4. Surprisingly, 
silencing of S100A9 was found to rescue IL-4-mediated repression of IL-1+OSM-induced 
MMP-13 (Figure 7.1a). Silencing of neither IRS-1 nor IRS-2 significantly interfered with 
the ability of IL-4 to repress IL-1+OSM-induced MMP-13 (Figure 7.1b). As IL-4 signalling 
is known to involve either STAT6 or IRS-1/-2, these observations would suggest that the 
repression of MMP-13 by IL-4 is solely mediated through the STAT6 signalling pathway. 
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Figure 7.1 The effect of various gene silencing on IL-1+OSM-induced MMP-13 expression in SW1353 
cells. SW1353 cells were stimulated with control, IL-1+OSM (0.5 and 10 ng/ml, respectively) or IL-
1+OSM+IL-4 (0.5, 10 and 20 ng/ml, respectively) for 24 hours following a 28 hour transfection with siRNA 
specific to STAT6, S100A8, S100A9, IRS1, IRS2, Trb1 or siCon (100 nM). Real-time RT-PCR of the 
isolated RNA was performed for MMP-13 72 hours after the start of transfection. Data are presented as fold 
induction relative to the basal siCon-transfected expression (mean ± S.E.M, n = 8) and are representative of 
two independent experiments. * = p ≤ 0.05; ns = not significant.  
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7.2.2 The effect of Trb1 and STAT6 gene silencing on MMP-13 expression in 
SW1353 cells and human articular chondrocytes  
The significant involvement of STAT6 and Trb1 in the repression of MMP-13 by IL-4 
demonstrated in Figure 7.1 warranted further experiments to investigate the reproducibility 
of these findings. A further experiment in SW1353 cells (Figure 7.2a) and in human 
articular chondrocytes (Figure 7.2b), again, demonstrated that silencing of Trb1 rescued IL-
4-mediated repression of IL-1+OSM-induced MMP-13. Silencing of STAT6 did not appear 
to rescue IL-4-mediated repression of IL-1+OSM-induced MMP-13 in these experiments. 
However, the repression of MMP-13 observed with the inclusion of IL-4 was no longer 
observed when compared to IL-1+OSM-treated cells following STAT6 siRNA treatment. 
Alternatively, this could be due to the fact that repression of IL-1+OSM-induced MMP-13 
expression by IL-4 was not as strong as observed in previous experiments. Interestingly, in 
both cell types (Figure 7.2a and b) MMP-13 expression following Trb1 silencing was 
greater than that induced by IL-1+OSM. This suggests alterations in Trb1 levels regulate 
the magnitude of the resultant pro-inflammatory stimulus in terms of MMP expression. 
 
7.2.3 IL-4-induced Trb1 expression is STAT6-dependent 
Examination of Trb1 gene expression via real-time RT-PCR demonstrated that IL-4-
induced Trb1 expression is STAT6-dependent in both SW1353 cells and human articular 
chondrocytes (Figure 7.3). STAT6 gene silencing significantly inhibits IL-1+OSM+IL-4-
induced Trb1 expression in both cell types. Bioinformatic examination of the Trb1 
promoter region revealed a STAT6-binding element (5’-TTC(N)2-4GAA-3’). These data 
suggest that the Trb1-dependent MMP-13 repression by IL-4 is STAT6-dependent 
suggesting STAT6 is upstream of Trb1, with increased Trb1 transcription occurring via 
STAT6-binding to the Trb1 promoter.  
 
7.2.4 The effect of STAT6 and Trb1 gene silencing on STAT6 and phospho-
STAT6 abundance 
Silencing of STAT6 via siRNA is shown to virtually eliminate STAT6 protein levels 
(confirming that the gene silencing is effective) (Figure 7.4). IL-4 stimulated the  
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Figure 7.2 The effect of Trb1 and STAT6 gene silencing on MMP-13 expression in SW1353 cells (a) and 
human articular chondrocytes (b). SW1353 cells were stimulated with control, IL-1+OSM (0.5 and 10 
ng/ml, respectively) or IL-1+OSM+IL-4 (0.5, 10 and 20 ng/ml, respectively) and human articular 
chondrocytes were stimulated with control, IL-1+OSM (0.02 and 10 ng/ml, respectively) or IL-1+OSM+IL-4 
(0.02, 10 and 20 ng/ml, respectively) for 24 hours following a 28 hour transfection with siRNA specific to 
STAT6, Trb1 or siCon (100 nM). Real-time RT-PCR of the isolated RNA was performed for MMP-13 72 
hours after the start of transfection. Data are presented as fold induction relative to the basal siCon-transfected 
expression (mean ± S.E.M, n = 8). Data are representative of two independent experiments in SW1353 cells 
and human articular chondrocytes. * = p ≤ 0.05; ns = not significant.  
Chapter 7 
 - 170 - 
 
 
0
2
4
6
8
10
12
14
Fo
ld
 
Ch
an
ge
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Fo
ld
 
Ch
an
ge
a) SW1353 cells
b) Human articular chondrocytes
IL-1+OSM             - +                         +            - +                        +
IL-4                        - - +                        - - +                
siRNA Con                STAT6     
**
**
 
 
Figure 7.3 The effect of STAT6 gene silencing on Trb1 expression in SW1353 cells (a) and human 
articular chondrocytes (b). SW1353 cells were stimulated with control, IL-1+OSM (0.5 and 10 ng/ml, 
respectively) or IL-1+OSM+IL-4 (0.5, 10 and 20 ng/ml, respectively) and human articular chondrocytes were 
stimulated with control, IL-1+OSM (0.02 and 10 ng/ml, respectively) or IL-1+OSM+IL-4 (0.02, 10 and 20 
ng/ml, respectively) for 24 hours following a 28 hour transfection with siRNA specific to STAT6 or siCon 
(100 nM). Real-time RT-PCR of the isolated RNA was performed for Trb1 72 hours after the start of 
transfection. Data are presented as fold induction relative to the basal siCon-transfected expression (mean ± 
S.E.M, n = 8) and are taken from a single experiment. ** = p ≤ 0.01. 
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phosphorylation of STAT6 as expected and silencing of STAT6 reduced phospho-STAT6 
protein expression. However, silencing of Trb1 did not prevent the phosphorylation of 
STAT6 by IL-4. This, along with the data presented in Figure 7.3, suggests that Trb1 acts 
downstream of STAT6.  
 
7.2.5 The effect of STAT6 and Trb1 gene silencing on MMP-1 mRNA 
expression in SW1353 cells 
Data presented in this thesis have consistently demonstrated a differential regulation of 
MMP-13 and MMP-1 by IL-4. IL-4 appears to increase IL-1+OSM-induced MMP-1 
expression in many experiments, therefore the effect of STAT6 and Trb1 gene silencing on 
IL-1+OSM-induced MMP-1 expression was examined. Figure 7.5 demonstrates that 
increased MMP-1 expression with IL-1+OSM+IL-4 appears to be STAT6-dependent. 
Whilst Trb1 gene silencing significantly reduces IL-1+OSM+IL-4-induced MMP-1 
expression, MMP-1 expression remains greater in the presence of IL-4 than in the absence 
of IL-4 (as has been consistently observed before).  
 
7.2.6 The effect of tribbles protein family gene silencing on IL-1+OSM-induced 
collagenase gene expression in SW1353 cells 
Trb1 is one of three members of the tribbles protein family and so it was important to 
assess the effect of Trb2 and Trb3 (in addition to Trb1) gene silencing on MMP-13 mRNA 
expression. Further attempts to replicate the preliminary findings of the effect of Trb1 gene 
silencing on MMP-13 gene expression (Figures 7.1 and 7.2) yielded inconsistent results. 
For unknown reasons, Trb1 gene silencing did not consistently rescue IL-4-mediated 
repression of IL-1+OSM-induced MMP-13 (Figure 7.6a). Silencing of Trb2 consistently 
had no significant effect on IL-1+OSM or IL-1+OSM+IL-4-induced MMP-13 expression, 
suggesting that Trb2 is not involved in either the induction of MMP-13 by pro-
inflammatory cytokines or the repression of MMP-13 by anti-inflammatory cytokines. 
Despite problems with the reproducibility of the rescue of IL-4-mediated repression of IL-
1+OSM-induced MMP-13 following Trb1 gene silencing, tribbles-regulated MMP 
expression is further supported in that Trb3 silencing abolished IL-1+OSM-induced MMP-
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13 expression (Figure 7.6a and b). This finding was highly reproducible (representative of 
four independent experiments) and suggests that individual tribbles may have opposing 
roles in MMP regulation. These preliminary data support a pro-inflammatory role for Trb3.  
 
In order to extend these initial observations, Figure 7.7 confirms that other pro-
inflammatory stimuli (TNFα+OSM) are also Trb3-dependent for MMP-13. Taken together, 
these preliminary data are suggestive of a model whereby Trb1 and Trb3 regulate MMP-13 
gene expression during pro-inflammatory signalling, with a pro-inflammatory role for Trb3 
and a possible anti-inflammatory role for Trb1.  
 
7.2.7 Transfection timecourse to determine the efficiency of Trb1 and Trb3 
gene silencing in SW1353 cells 
After problems with the reproducibility of the rescue of IL-4-mediated repression of IL-
1+OSM-induced MMP-13 following Trb1 gene silencing, a Trb1 and Trb3 siRNA 
transfection timecourse was performed in SW1353 cells. The purpose of this experiment 
was to determine, not only if the Trb1 gene silencing was effectively reducing Trb1 protein 
expression but also to examine the most appropriate timepoint for examination of the effect 
of Trb1 gene silencing on MMP-13 expression. Figure 7.8 clearly shows that whilst Trb3 
gene silencing via siRNA was effective at reducing Trb3 protein expression (at all 
timepoints tested). Trb1 silencing was less effective, although appeared to reduce Trb1 
protein expression at 48 hours by approximately 50%. This experiment suggests that the 
problems encountered in reproducing the preliminary findings of Trb1 gene silencing on 
IL-4-mediated repression of IL-1+OSM-induced MMP-13 are due to the Trb1 siRNA 
producing only a partial knock-down, thereby resulting in poor reproducibility.  
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Figure 7.4 The effect of STAT6 and Trb1 gene silencing on STAT6 and phospho-STAT6 abundance. 
SW1353 cells were stimulated with control or IL-4 (20 ng/ml) for 20 minutes following a 48 hour transfection 
with siRNA specific to STAT6, Trb1 or siCon (100 nM). Total cell lysates were prepared and separated by 
SDS-PAGE on a 10% polyacrylamide gel with a molecular weight marker. Protein fractions were transferred 
to PVDF membranes. Blots were probed with STAT6, phospho-STAT6 and β-tubulin followed by goat anti-
rabbit HRP. The blots were visualised using ECL and are representative of two independent experiments.  
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Figure 7.5 The effect of STAT6 and Trb1 gene silencing on MMP-1 mRNA expression in SW1353 cells. 
SW1353 cells were stimulated with control, IL-1+OSM (0.5 and 10 ng/ml, respectively) or IL-1+OSM+IL-4 
(0.5, 10 and 20 ng/ml, respectively) for 24 hours following a 28 hour transfection with siRNA specific to 
STAT6, Trb1 or siCon (100 nM). Real-time RT-PCR of the isolated RNA was performed for MMP-1 72 
hours after the start of transfection. Data are presented as fold induction relative to the basal siCon-transfected 
expression (mean ± S.E.M, n = 8). Data are representative of two independent experiments. *** = p ≤ 0.001; 
** = p ≤ 0.01. 
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Figure 7.6 The effect of Trb protein family gene silencing on IL-1+OSM-induced collagenase gene 
expression in SW1353 cells. SW1353 cells were stimulated with control, IL-1+OSM (0.5 and 10 ng/ml, 
respectively) or IL-1+OSM+IL-4 (0.5, 10 and 20 ng/ml, respectively) for 24 hours following a 28 hour 
transfection ± siRNA specific to Trb1, Trb2, Trb3 or siCon (100 nM). Real-time RT-PCR of the isolated 
RNA was performed for MMP-13 (a) and MMP-1 (b) 72 hours after the start of transfection. Data are 
presented as fold induction relative to the basal siCon-transfected expression (mean ± S.E.M, n = 6) and are 
representative of four independent experiments. *** = p ≤ 0.001; * = p ≤ 0.05. 
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Figure 7.7 The effect of Trb protein family gene silencing on TNFα+OSM-induced collagenase gene 
expression in SW1353 cells. SW1353 cells were stimulated with control, TNFα+OSM (10 and 10 ng/ml, 
respectively), TNFα+OSM+IL-4 (10, 10 and 20 ng/ml, respectively) for 24 hours following a 28 hour 
transfection ± siRNA specific to Trb1, Trb2, Trb3 or siCon (100 nM). Real-time RT-PCR of the isolated 
RNA was performed for MMP-13 (a) and MMP-1 (b) 72 hours after the start of transfection. Data are 
presented as fold induction relative to the basal siCon-transfected expression (mean ± S.E.M, n = 6) and are 
taken from a single experiment. *** = p ≤ 0.001; ** = p ≤ 0.01; ns = not significant.  
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7.2.8 Investigations into the efficiency of Trb1 gene silencing 
7.2.8.1 The effect of Trb1 gene silencing using siRNA on MMP-13 expression in SW1353 
cells  
The siRNA used to silence Trb1 in Figures 7.1 - 7.8 was SMARTpool® small interfering 
RNA (siRNA) from Dharmacon. This SMARTpool® siRNA consists of a mixture of four 
siRNA provided as a single reagent, so whilst the total Trb1 siRNA concentration in 
experiments was 100 nM, the actual concentration of each individual siRNA was only 25 
nM. The first theory tested as to why Trb1 SMARTpool® siRNA was ineffective in 
reproducibly silencing Trb1 gene expression was that perhaps only one of the four siRNAs 
provided in the SMARTpool® was effectively silencing Trb1. To test this hypothesis, the 
four single siRNAs were purchased individually from Dharmacon and used separately in 
SW1353 cells at four times the concentration they had been present at in previous 
experiments. However, none of the four individual Trb1 siRNAs were able to rescue IL-4-
mediated repression of IL-1+OSM-induced MMP-13 (Figure 7.9). 
 
7.2.8.2 The effect of Trb1 gene silencing using shRNA on MMP-13 expression in SW1353 
cells  
The failure to observe consistent knockdown of Trb1 using siRNA purchased from 
Dharmacon led to the use of Trb1 shRNA in an attempt to produce efficient knockdown of 
Trb1 and reproducible rescue of IL-4-mediated repression of IL-1+OSM-induced MMP-13. 
MISSION shRNA clones were purchased from Sigma-Aldrich. Each clone was constructed 
within the lentivirus plasmid vector pLKO.1-Puro followed by transformation into E. coli. 
All five clones available from Sigma-Aldrich were purchased, each of which targeted a 
different region of the Trb1 gene sequence. Previous work in the department (Scott, 2009) 
had determined that the optimal multiplicity of infection (M.O.I.) for human articular 
chondrocytes was 15. As SW1353 cells are characteristically transfected more efficiently 
than primary chondrocytes, the initial experiment in SW1353 cells used an M.O.I of 10 
(Figure 7.10a). Out of the five clones tested, only one (Trb1 1535) produced promising 
results in the rescue of IL-4-mediated repression of IL-1+OSM-induced MMP-13 (p=0.08). 
Whilst this result was not statistically significant, it was felt that the finding warranted 
further investigation. A second experiment was performed using an M.O.I of 25 (Figure 
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7.10b). The M.O.I was increased from 10 to 25 in order to try and maximise any effects of 
the Trb1 shRNA. Unfortunately the first shRNA experiment (Figure 7.10a) used the entire 
stock of Trb1 1539 and so this clone was not included in the second experiment (Figure 
7.10b). Figure 7.10b showed a statistically significant rescue of IL-4-mediated repression of 
IL-1+OSM-induced MMP-13 by Trb1 1535. Again, none of the other clones were able to 
rescue IL-4-mediated repression of IL-1+OSM-induced MMP-13. IL-1+OSM-stimulated 
levels of MMP-13 were reduced following transduction with some shRNA clones. This 
made the effect of the shRNA clones on IL-1+OSM+IL-4-induced MMP-13 expression 
difficult to interpret. Despite this, the preliminary work with shRNA identified one 
commercially available Trb1 shRNA clone that appeared to successfully rescue IL-4-
mediated repression of IL-1+OSM-induced MMP-13. Further work would be needed to 
assess the reproducibility of this finding. 
 
Taken together, the preliminary experiments involving siRNA and shRNA would suggest 
that effective silencing of Trb1 is much more complex than silencing of Trb3. However, the 
data suggest that when Trb1 is effectively silenced, this knockdown is able to effectively 
rescue IL-4-mediated repression of IL-1+OSM-induced MMP-13. Further work is needed 
to understand the reproducibility issues concerning Trb1 gene silencing.  
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Figure 7.8 Transfection timecourse to determine the efficiency of Trb1 and Trb3 gene silencing in 
SW1353 cells, as determined by Western blot. Following transfection with siRNA specific to Trb1, Trb3 or 
siCon (100 nM) for 24, 48 or 72 hours, total cell lysates were prepared and separated by SDS-PAGE on a 
10% polyacrylamide gel with a molecular weight marker. Protein fractions were transferred to PVDF 
membranes. Blots were probed with Trb1, Trb3 and β-tubulin followed by goat anti-rabbit HRP. The blots 
were visualised using ECL and are representative of two independent experiments.  
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Figure 7.9 The effect of Trb1 gene silencing on MMP-13 expression in SW1353 cells. SW1353 cells were 
stimulated with control, IL-1+OSM (0.5 and 10 ng/ml, respectively) or IL-1+OSM+IL-4 (0.5, 10 and 20 
ng/ml, respectively) for 24 hours following a 28 hour transfection with siRNA specific to Trb1 (Dharmacon 
SMARTpool), individual Dharmacon Trb1 siRNA (07-10) or siCon (100 nM). Real-time RT-PCR of the 
isolated RNA was performed for MMP-13 72 hours after the start of transfection. Data are presented as fold 
induction relative to the basal siCon-transfected expression (mean ± S.E.M, n = 4). *** = p ≤ 0.001; ** = p ≤ 
0.01; * = p ≤ 0.05, ns = not significant. Data are from a single experiment only. 
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Figure 7.10 The effect of shRNA Trb1 gene silencing on MMP-13 expression in SW1353 cells. SW1353 
cells were stimulated with control, IL-1+OSM (0.5 and 10 ng/ml, respectively) or IL-1+OSM+IL-4 (0.5, 10 
and 20 ng/ml, respectively) for 24 hours following a 28 hour transduction with various shRNA specific to 
Trb1 (1535 - 1539) (MOI 10 (a) or 25 (b)). Real-time RT-PCR of the isolated RNA was performed for MMP-
13 72 hours after the start of transduction. Data are presented as fold induction relative to the mock-
transduced expression (mean ± S.E.M, n = 4). *** = p ≤ 0.001; ** = p ≤ 0.01; * = p ≤ 0.05; ns = not 
significant.  
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7.2.9 The effect of over-expression of Trb1, 2 or 3 on MMP-13 expression in 
SW1353 cells 
Gene silencing data presented in this chapter have indicated a potential anti-inflammatory 
role for Trb1 (rescue of IL-4-mediated repression of IL-1+OSM-induced MMP-13 
following Trb1 silencing) and a pro-inflammatory role for Trb3 (inhibition of IL-1+OSM-
induced MMP-13 expression following Trb3 silencing). Experiments were performed using 
over-expression plasmids for the tribble proteins to assess the effect of over-expression of 
these proteins on MMP-13 expression. It was hoped that over-expression of tribbles might 
result in converse effects to siRNA, thereby validating the interpretation. However, over-
expression of Trb1 and Trb2 had no significant effect on IL-1+OSM+IL-4-induced MMP-
13 expression. Over-expression of Trb3 was shown to enhance IL-1+OSM-induced MMP-
13 expression when compared to pcDNA3.1 transfected SW1353 cells (Figure 7.11). The 
data presented here, along with those presented in Figure 7.6, support a pro-inflammatory 
role for Trb3 as over-expression resulted in a super-induction of MMP-13 (by IL-1+OSM) 
and silencing of Trb3 abolished IL-1+OSM-induced MMP-13 expression. Whilst this 
experiment was repeated three times, over-expression of Trb3 at the protein level (as 
demonstrated by Western blot) was only demonstrated in a single experiment (data not 
shown) and so it was assumed the over-expression was ineffective in the other two 
experiments. For this reason, the data from the other two experiments were not included.  
 
7.2.10 The effect of IL-1+OSM and IL-1+OSM+IL-4 on the subcellular 
localisation of Trb1 and Trb3 
At the time of study, no information existed on the subcellular localisation of tribbles 
proteins in chondrocytes. These experiments aimed to determine the subcellular localisation 
of tribbles proteins under basal conditions in SW1353 cells. In addition, they examined the 
effect of IL-1+OSM and IL-1+OSM+IL-4 treatment on the localisation of tribbles. Only 
one Trb2 antibody was available commercially at the time of study and this was ineffective 
in my experiments (data not shown). Various control antibodies were used to assess the 
purity of each fraction, for example MEK-2 was used as a marker of the cytoplasmic 
fraction, lamin A/C for the soluble nuclear fraction and histone H3 for the chromatin-bound 
nuclear fraction.  The localisation of Akt was examined in order to provide another control  
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Figure 7.11 The effect of over-expression of Trb1, 2 or 3 on MMP-13 expression in SW1353 cells. 
SW1353 cells were stimulated with control, IL-1+OSM (0.5 and 10 ng/ml, respectively) or IL-1+OSM+IL-4 
(0.5, 10 and 20 ng/ml, respectively) for 24 hours following a 28 hour transfection with over-expression 
plasmids specific to Trb1, Trb2, Trb3 or pcDNA3.1. Real-time RT-PCR of the isolated RNA was performed 
for MMP-13 following stimulation. Data are presented as fold induction relative to the pcDNA3.1-transduced 
basal expression (mean ± S.E.M, n = 6) and are taken from a single experiment. ** = p ≤ 0.01. 
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for the experiment. Akt is known to be mainly localised to the cytoplasmic fraction, which 
is demonstrated in Figure 7.12. In addition, data presented in Chapter 3 of this thesis 
showed that both OSM and IL-4 increase phosphorylation of Akt when compared to basal. 
This is also shown in Figure 7.12, indicating that cytokine stimulations worked as expected.    
Figure 7.12 demonstrates that Trb1 is principally cytoplasmic under basal and stimulated 
conditions. However, IL-1+OSM was shown to slightly enrich Trb1 in the membrane-
bound fraction and IL-1+OSM+IL-4 increased this enrichment even more so. Trb3 was 
shown to be localised to the soluble-nuclear fraction under all conditions, but was also 
present in the cytoplasmic fraction under all conditions and to a lesser extent in the 
membrane-bound fraction. IL-1+OSM+IL-4 also increased Trb3 in the membrane-bound 
fraction, as was the case with Trb1.  
7.2.11 MKK-Trb1 and –Trb3 interactions in SW1353 cells 
The tribbles family of proteins has been identified as regulators of MAPK pathways (Kiss-
Toth et al. 2006). They have been shown to interact with MAPK activators, MAPKKs and, 
in turn, modulate the activity of these MAPKKs (Kiss-Toth et al. 2004; Kiss-Toth et al. 
2006). To assess any physical interactions between the tribbles and MAPKKs in SW1353 
cells, a green fluorescent protein (GFP)-based protein fragment complementation assay 
(PCA) was used (as described in section 2.2.10.3). Multiple controls (MEK1 V1-
pcDNA3.1, MKK4 V1-pcDNA3.1, MKK6 V1-pcDNA3.1, MKK7 V1-pcDNA3.1, Trb1 
V2-pcDNA3.1, Trb3 V2-pcDNA3.1 and pcDNA3.1-pcDNA3.1) were included in the 
experiment to exclude false positive results. All controls were negative, however, for clarity 
only one example is shown in each figure (Figure 7.13 and 7.14). Data presented in Figure 
7.13 demonstrate a physical interaction between Trb1 and MEK1, MKK4, MKK6 and 
MKK7. These data demonstrated that the MKK6-Trb1 and MKK7-Trb1 complexes are 
primarily located in the nucleus, whereas the MEK1-Trb1 and MKK4-Trb1 complex are 
primarily cytoplasmic. Given that subcellular localisation data in Figure 7.12 indicated that 
Trb1 is primarily cytoplasmic, data in Figure 7.13 suggests that Trb1 relocates to the 
nucleus when complexed with MKK6 and MKK7. Trb3 was also shown to form complexes 
with MEK1, MKK4, MKK6 and MKK7 (Figure 7.14). All the MKK-Trb3 complexes 
appeared to be nuclear, with the exception of MKK6-Trb3, which may be partially 
cytoplasmic.   
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Figure 7.12 The effect of IL-1+OSM and IL-1+OSM+IL-4 on the subcellular localisation of Akt, Trb1 
and Trb3, as determined by Western blot. SW1353 cells were stimulated with control, IL-1+OSM (0.5 and 
10 ng/ml, respectively) or IL-1+OSM+IL-4 (0.5, 10 and 20 ng/ml, respectively) for 20 minutes. A subcellular 
protein fractionation kit was used to separate the cytoplasmic, membrane, soluble nuclear, chromatin-bound 
nuclear and cytoskeletal fractions. These lysates were separated by SDS-PAGE on a 10% polyacrylamide gel 
with a molecular weight marker. Protein fractions were transferred to PVDF membranes. Blots were probed 
with phospho-Akt (Thr308), phospho-Akt (Ser473), Trb1, Trb3, β-tubulin, lamin A/C, Mek-2 and histone H3 
followed by goat anti-rabbit HRP. The blots were visualised using ECL and are representative of three 
independent experiments.  
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Figure 7.13 MEK1- and MKK-Trb1 interactions in SW1353 cells. Physical interaction between Trb1 and 
MKKs was investigated by GFP-based protein fragment complementation assay. MEK1, MKK4, MKK6 and 
MKK7 were fused to the N-terminal fragment of Venus GFP (V1) and Trb1 was fused to the C-terminal 
fragment of Venus GFP (V2). Various combinations of expression constructs were co-transfected and the 
GFP signal was visualised by fluorescence microscopy. Representative cells show the interaction between 
Trb1 and MKKs.  
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Figure 7.14 MEK1- and MKK-Trb3 interactions in SW1353 cells. Physical interaction between Trb3 and 
MKKs was investigated by GFP-based protein fragment complementation assay. MEK1, MKK4, MKK6 and 
MKK7 were fused to the N-terminal fragment of Venus GFP (V1) and Trb3 was fused to the C-terminal 
fragment of Venus GFP (V2). Various combinations of expression constructs were co-transfected and the 
GFP signal was visualised by fluorescence microscopy. Representative cells show the interaction between 
Trb3 and MKKs.  
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7.3 Discussion 
Genome-wide microarrays described in Chapter 6 of this thesis highlighted numerous genes 
that were differentially expressed in IL-1+OSM+IL-4-treated cells/cartilage compared to 
IL-1+OSM-treated cells/cartilage, one of which was Trb1. This initial screen demonstrated 
Trb1 induction following IL-1+OSM stimulation of human chondrocytes and bovine 
cartilage, and this induction was further augmented following the inclusion of IL-4. This 
suggested that “anti-inflammatory” agents, such as IL-4, may mediate their repressive 
effects on MMP gene expression via increased Trb1 expression. Preliminary gene silencing 
experiments using siRNA specific to Trb1 provided more evidence that Trb1 may indeed 
be an important protein in mediating the chondroprotective effects of IL-4. Silencing of 
Trb1 was found to rescue IL-4-mediated repression of IL-1+OSM-induced MMP-13 
expression, suggesting an anti-inflammatory role for Trb1. STAT6 is a major IL-4 
signalling molecule and further experiments confirmed IL-4-mediated repression of IL-
1+OSM-induced MMP-13 was STAT6-dependent. This indicated that STAT6 is upstream 
of Trb1, with increased Trb1 transcription resulting from STAT6-binding to the Trb1 
promoter (bioinformatics confirmed there is a STAT6 binding element within the Trb1 
promoter sequence).  
 
In many instances MMP-13 expression following Trb1 silencing was found to be equal to, 
or greater than, that induced by IL-1+OSM. This phenomenon suggests that alterations in 
tribbles levels regulate the magnitude of the resultant pro-inflammatory stimulus in terms of 
MMP expression. This hyper-inducement of MMP expression has been observed 
previously. The IL-1+OSM+IL-4 stimulus consistently results in increased MMP-1 gene 
expression when compared to IL-1+OSM-induced MMP-1 expression. This IL-1+OSM-IL-
4-induced increase in MMP-1 expression has also been shown to be STAT6-dependent. 
Previously, the potential mechanism for the observations that suggest pro-inflammatory 
stimuli are regulated in terms of the magnitude of MMP expression was unknown. The data 
presented here indicate that alterations in tribbles levels may impact upon this. 
 
A recent study had suggested a role for Trb1 in the control of adipose tissue inflammation 
(Ostertag et al. 2010). Trb1 was found to be specifically up-regulated during acute and 
chronic inflammation in the white adipose tissue of mice. In adipocytes, Trb1 was found to 
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act as a nuclear transcriptional coactivator for the NFκB subunit RelA, thereby promoting 
the induction of pro-inflammatory cytokines. It is not without precedent that this reported 
pro-inflammatory role for Trb1 is in apparent conflict with the anti-inflammatory role of 
Trb1 in chondrocytes. Indeed, IL-4 itself is known to be both pro- and anti-inflammatory 
depending on the circumstances and cell-type. Discrepancies in the function of mammalian 
and Drosophila tribbles have been reported (Kiss-Toth et al. 2004). It is thought that 
tribbles function in Drosophila is cell-type specific (Seher and Leptin 2000) and it is 
speculated that the same applies to the mammalian tribbles (Kiss-Toth et al. 2004).  
 
Trb1 belongs to a family of three tribbles proteins and further gene silencing identified a 
novel role for Trb3 in IL-1+OSM-induced MMP-13 expression. Knockdown of Trb3 gene 
expression was shown to reproducibly abolish IL-1+OSM-induced MMP-13 expression, 
indicating a possible pro-inflammatory role for Trb3. Experiments involving TNFα+OSM, 
another pro-inflammatory cytokine combination known to synergistically induce cartilage 
degradation, extended these initial observations by also proving to be Trb3-dependent for 
MMP-13 induction. This suspected pro-inflammatory role for Trb3 was further confirmed 
by over-expression experiments, demonstrating that over-expression of Trb3 enhanced IL-
1+OSM-induced MMP-13 expression. This apparently pro-inflammatory role for Trb3 is in 
agreement with the study by Cravero et al. (2009), which demonstrated that a significantly 
higher level of Trb3 was found in OA chondrocytes when compared to age-matched control 
chondrocytes. Taken together, these novel findings suggest individual tribbles may have 
opposing roles in MMP regulation. 
 
The effects of Trb3 gene silencing on IL-1+OSM-induced MMP-13 expression were highly 
reproducible. However, problems were encountered with Trb1 gene silencing. Data 
presented in this chapter found that silencing of Trb1 was not always effective, leading to 
differing results when examining the effects of Trb1 knockdown on MMP-13 expression. 
Attempts to rationalise this ineffective silencing through the use of several different gene 
silencing reagents proved unsuccessful. It seems evident that extensive optimisation of the 
Trb1 silencing protocol is necessary in order to obtain reproducible gene knockdown. 
Despite problems with reproducibility, preliminary data suggest that when Trb1 gene 
silencing is effective, IL-4-mediated repression of IL-1+OSM-induced MMP-13 is rescued. 
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This finding has been replicated in both SW1353 cells and primary human articular 
chondrocytes, indicating that this is a valid result.  
 
The function(s) of the tribbles proteins is still poorly understood. They have been identified 
as regulators of MAPK pathways (Kiss-Toth et al. 2006) and are known to interact with 
MAPK activators and MAPKKs, to modulate the activity of MAPKKs. Tribbles have also 
been shown to interact with components of the PI3K pathway (including Akt) as well as the 
transcription factors C/EBP, ATF4 and p65, thus enabling them to regulate the level of 
activation within these signalling systems (Hegedus et al. 2006). However, many aspects of 
the molecular basis of tribbles action remain unclear. Previous data revealed that in OA 
chondrocytes, specific Akt3 silencing repressed cytokine-induced MMP-13 expression but 
not MMP-1 (Litherland et al. 2008). Furthermore, Trb3 has been shown to bind to Akt and 
inhibit its phosphorylation in hepatocytes (Du et al. 2003), and Trb3 expression appears 
elevated in OA chondrocytes when compared to normal chondrocytes (Cravero et al. 2009). 
These findings, in addition to the data presented here, suggest a definite role for tribbles in 
MMP regulation. It is possible that the apparent regulation by tribbles of the magnitude of 
specific MMP induction demonstrated in this chapter may be related to their ability to 
regulate MAPK cascades. Previous work by the Kiss-Toth group (Kiss-Toth et al. 2004) 
investigated the physical interactions of Trb1/3 and various members of the MAPK 
signalling pathway in HeLa cells. This study found that MEK-1 interacts with both Trb1 
and Trb3, whereas MKK7 specifically interacted with Trb-3 and MKK4 specifically 
interacted with Trb1. No interactions between Trb1 or 3 were detected between MEKK-1, 
MLK-3, ERK-2, JNK-1 or p38. In contrast to the 2004 study by Kiss-Toth et al., data 
presented in this chapter demonstrated that physical interactions could be detected between 
both Trb1 and Trb3 and MEK1, MKK4, MKK6 and MKK7 in SW1353 cells. Although not 
all cells exhibited fluorescence in this assay, punctate nuclear staining was indicative of the 
predicted localisation of these complexes. Due to time contraints, this assay was completed 
only once and so repeats are necessary to confirm the findings reported here. However, 
multiple controls were included in the experiment to exclude false positive results and 
fluorescence can only occur when two proteins physically interact within the same cell, and 
so the findings can be viewed with some confidence. The demonstration of these physical 
interactions in chondrocytes suggests that tribbles impact on pro-inflammatory MMP 
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regulation by controlling the balance of key signalling pathways through interactions with 
central components in the MAPK and PI3K pathway (interactions between tribbles and Akt 
have been previously documented (Cravero et al. 2009)).  
 
Subcellular localisation data presented in this chapter found Trb1 to be mainly cytoplasmic 
in SW1353 cells, which is in contrast to data presented by other groups. Kiss-Toth et al. 
(2006) found Trb1 to be localised to the nucleus of HeLa cells. However, it is quite possible 
that the subcellular localisation of tribbles proteins is cell-type dependent. Trb3 was shown 
to be predominantly localised to the soluble-nuclear fraction in SW1353 cells, which is in 
agreement with previous reports (Ord and Ord 2003; Kiss-Toth et al. 2006). Indeed, some 
tribbles have been shown to possess nuclear localisation sequences (personal 
communication, Endre Kiss-Toth, Sheffield University). All the studies that have 
investigated the subcellular localisation of tribbles (to date) have been based upon the use 
of over-expression plasmids, therefore their conclusions should be regarded with some 
caution. The majority of signalling molecules act as part of a multiprotein complex, 
therefore higher than normal levels of a particular protein can lead to non-physiological 
intracellular localisation (Hegedus et al. 2007). When expressed as GFP fusion proteins, 
both Trb1 and Trb3 were localised to the nucleus of HeLa cells (Kiss-Toth et al. 2006). 
Trb3-GFP fusion protein has also been shown to be nuclear in GT1-7, Cos-7 and CHO cells 
(Ord and Ord 2003). Conversely, studies investigating the cellular localisation of Trb2 have 
suggested that Trb2 is found mainly in the cytoplasm (Wilkin et al. 1997; Saka and Smith 
2004). A more recent paper agreed with these findings (Kiss-Toth et al. 2006).  
 
Data presented in Chapter 5 of this thesis clearly showed the phosphorylation, and hence 
activation, of Akt by both OSM and IL-4. This finding posed the question of how two 
cytokines with opposing effects on cartilage (OSM being catabolic and IL-4 being 
anabolic), can both activate the same signalling molecule. The finding that tribbles proteins 
appear to play an important role in the regulation of cytokine-induced MMP expression 
may explain the activation of Akt in both OSM- and IL-4-signalling pathways. The 
important physiological function of tribbles proteins is now widely accepted; however, the 
molecular basis of tribbles function is still poorly understood. The presence of a kinase-like 
domain in tribbles proteins that appears to be catalytically inactive suggests that tribbles are 
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‘kinase-dead’ proteins. One hypothesis put forward by a recent review (Hegedus et el. 
2007) suggests that tribbles may function as decoy proteins, by competing with active 
protein kinases for binding partners, thereby affecting the activation of downstream 
signalling pathways. One hypothesis that may explain the activation of Akt by both OSM 
and IL-4 could be that following either OSM-mediated Akt activation or IL-4-mediated Akt 
activation, tribbles proteins act to sequester either activated Akt or signalling molecules 
downstream of Akt, thereby altering downstream signalling events. This could mean that 
relatively subtle changes in tribbles expression, as demonstrated for Trb1 in this thesis,  
may still result in marked alterations in downstream signalling events and resultant MMP 
expression. 
 
The observation that the magnitude of specific MMP induction appears to be regulated by 
tribbles suggests that alterations in functional levels of specific tribbles proteins may 
protect against aberrant MMP gene expression in chondrocytes. Future work should 
concentrate on identifying how individual tribbles mediate their effects. As tribbles are 
thought to be pseudo-kinases, protein interactions are likely to be their mechanism of action 
for regulating MMP-13 expression. In fact, it is likely that tribbles regulate signalling cross-
talk, especially within an inflammatory environment. The consequences of specific tribbles 
over-expression or deletion in animal models of arthritis would need to be examined, in 
addition to molecular approaches to identify the mechanism by which tribbles regulate 
MMP-13. The data presented in this chapter represent highly novel data, which could lead 
to the development of a therapy to specifically target MMP-13, potentially ameliorating 
joint damage in arthritis.    
 
7.4 Summary 
 
• Individual tribbles may have opposing roles in MMP regulation 
• Data indicate a possible anti-inflammatory role for Trb1 as gene silencing of 
Trb1 results in the rescue of IL-4-mediated repression of IL-1+OSM-induced 
MMP-13. 
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• Data indicate a possible pro-inflammatory role for Trb3 as gene silencing of 
Trb3 abolishes IL-1+OSM-induced MMP-13 expression and over-expression of 
Trb3 enhances IL-1+OSM-induced MMP-13 expression. 
• Under basal conditions Trb1 appears to be primarily cytoplasmic, whereas Trb3 
appears to be predominantly nuclear.  
• Both Trb1 and Trb3 interact with MEK1, MKK4, MKK6 and MKK7 in SW1353 
cells. 
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Chapter 8: General discussion 
 
 
 
Cartilage degradation in arthritic disease is characterised by irreversible collagenolysis. Of 
the enzymes capable of hydrolysing native collagen fibrils, MMP-13 is considered the 
major collagenolytic MMP in OA, whilst MMP-1 is thought to be the major destructive 
collagenase in RA. Inhibiting the action of these enzymes to prevent cartilage destruction is 
a highly sought after aim in arthritis research.  
 
OA has historically been considered a ‘wear and tear’ process involving an imbalance 
between degradation and repair of the articular cartilage and subchondral bone favouring 
gradual catabolism. OA was originally thought of as a primarily non-inflammatory 
condition as opposed to RA where both local and systemic inflammation is a central 
feature. However, this theory is now being reconsidered as inflammatory cytokines and 
mediators produced by joint tissues are increasingly being shown to play a role in the 
pathogenesis of OA, perpetuating disease progression and therefore representing potential 
therapeutic targets (Goldring and Goldring 2007, Abramson and Attur 2009). The 
destructive process mediated by pro-inflammatory cytokines can be limited by anti-
inflammatory mediators such as IL-4. Whilst up-regulation of some anti-inflammatory 
cytokines and inhibitory mediators does occur in chronic inflammatory conditions such as 
RA, it occurs at levels insufficient to prevent cartilage degradation. This imbalance between 
pro and anti-inflammatory cytokines is reflected by an abundance of pro-inflammatory 
cytokines, but a virtual absence of anti-inflammatory cytokines such as IL-4 in RA 
synovium. This is despite the presence of high levels of IL-4 in peripheral blood 
mononuclear cells of RA patients (Miossec et al. 1990).  In 1996, Cawston et al. reported 
that IL-4 acted as a protective factor by specifically blocking the release of collagen from 
bovine nasal cartilage stimulated to resorb with IL-1+OSM, preventing pro-inflammatory 
cytokine-induced cartilage breakdown. However, direct administration of IL-4 to treat 
arthritis would undoubtedly result in potentially disastrous side-effects due to its known 
pro-inflammatory effects on target cells in other parts of the body. The aim of this PhD was 
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to further understand the protective mechanism of action of IL-4 in order to identify more 
specific therapeutic targets.  
 
A bovine nasal cartilage explant model was used to investigate the effect of IL-4 on 
cartilage degradation and collagenase expression. The addition of the pro-inflammatory 
combination of IL-1+OSM to bovine nasal cartilage in explant culture induced an increase 
in the synthesis of procollagenases and a release of collagen fragments. This study 
corroborated the original findings of Cawston et al (1996), demonstrating that IL-4 was 
able to prevent IL-1+OSM-mediated cartilage collagen breakdown. Expanding on this 
original finding, data presented in Chapter 3 demonstrated that IL-4 was equally 
chondroprotective when addition of IL-4 was delayed until day 7 of the 14 day bovine nasal 
cartilage timecourse. IL-4 was shown to strongly and reproducibly down-regulate IL-
1+OSM-induced MMP-13 expression in both primary chondrocytes and bovine nasal 
cartilage. For the first time, data presented in Chapter 3 demonstrated that complete 
repression of IL-1+OSM-induced MMP-13 expression occured within 24 hours of IL-4 
addition to bovine nasal cartilage. It has been suspected for some time that the 
chondroprotective effect of IL-4 in IL-1+OSM-induced cartilage collagen degradation was 
due to the strong repression of MMP-13 mRNA expression and/or the inhibition of 
activation of latent MMPs. Data presented in this thesis strongly suggest that it is the 
repression of MMP-13 that is responsible for the protective effect of IL-4 on cartilage 
degradation. The specific repression of MMP-13 by IL-4 is an important finding in relation 
to possible future therapies. Understanding the mechanism by which MMP-13 is 
specifically repressed could lead to a therapy with minimal side effects. Also reported in 
Chapter 3 was the finding that IL-4 differentially regulated MMP-1 and MMP-13 
expression in bovine cartilage, primary chondrocytes and the chondrosarcoma cell line 
SW1353. IL-4 reproducibly inhibited IL-1+OSM-induced MMP-13 in bovine nasal 
chondrocytes and, albeit to a slightly lesser extent, in human articular chondrocytes and 
SW1353 cells. In contrast, IL-4 appeared to have no significant effect on IL-1+OSM-
induced MMP-1 expression in any of the three cell types. If anything, a pattern of 
increasing MMP-1 expression in the presence of IL-4 was observed in all three cell types, 
although these increases were rarely statistically significant. This differential expression 
had been previously reported after examination of MMP expression by Northern blot (Pyle 
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2003), however this was the first study to examine MMP expression by real-time RT-PCR. 
These findings of differential collagenase gene expression in chondrocytes indicate that the 
signalling that drives collagenase transcriptional activation and subsequent production, 
especially of MMP-13, represents a therapeutic target that could have significant benefits 
for OA.  
 
As IL-4 was shown to rapidly repress IL-1+OSM-induced MMP-13 expression, Chapter 4 
sought to investigate the possibility that IL-4 induces epigenetic changes in the MMP-13 
promoter, thereby leading to reduced gene expression. Epigenetic modifications provide 
information as to where and when a gene should be expressed as opposed to altering the 
structure or function of a gene. The predominant epigenetic modification of DNA in 
mammalian genomes is DNA methylation. Previous work by Roach et al. (2005) suggested 
that the increase in MMP-13 expression observed in OA cartilage correlated with 
demethylation at specific sites within the MMP-13 promoter. It was therefore hypothesised 
that IL-4 (in combination with IL-1+OSM) could decrease IL-1+OSM-induced MMP-13 
mRNA expression by increasing MMP-13 promoter methylation. However, examination of 
the methylation status of the MMP-13 promoter via two different methods (bisulphite 
sequencing and pyrosequencing) found no evidence of a role for changes in MMP-13 
promoter methylation in the regulation of MMP-13 gene expression by IL-1, IL-1+OSM or 
IL-1+OSM+IL-4 in bovine chondrocytes. 
 
IL-4 is known to signal through IRS2, resulting in the activation of PI3K and its 
downstream target Akt. However, the role of this pathway in IL-4-induced gene expression 
is still unclear. Previous work in the group (Litherland et al. 2008) has demonstrated that 
OSM stimulates Akt phosphorylation in human articular chondrocytes, indicating Akt 
activation. Studies into PI3K signalling in chondrocytes in Chapter 5 confirmed that both 
OSM and IL-4 stimulation of chondrocytes resulted in the phosphorylation and hence 
activation of Akt. Due to the completely opposing effects of these two cytokines on 
cartilage destruction, this finding posed an interesting question. That is, how do the 
signalling pathways induced by two cytokines with opposing effects on cartilage 
degradation, both result in Akt activation? This question was further investigated in 
Chapter 7 of this thesis. Following the confirmation of PI3K-dependent Akt activation by 
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IL-4 in chondrocytes, Chapter 5 sought to examine the roles of PI3K p110 isoforms in IL-
4-dependent Akt phosphorylation. The study by Litherland et al. (2008) indicated a role for 
p110α and Akt1 in MMP-1 gene induction by IL-1+OSM. In addition, involvement of 
p110δ and Akt3 were implicated in MMP-13 induction. No particular PI3K p110 isoform 
was found to have a clear role in IL-4-dependent Akt activation. In fact, data presented in 
Chapter 5 highlighted possible differences in PI3K p110 isoform involvement in different 
cell types. The involvement of specific PI3K p110 isoforms was difficult to interpret due to 
the same molecules (i.e. Akt) apparently being utilised by OSM (pro-inflammatory) and IL-
4 (anti-inflammatory). Despite the uncertainty in the involvement of any specific PI3K 
p110 isoform in IL-4-dependent Akt activation, data presented in Chapter 5 did corroborate 
the findings of Litherland et al. (2008), indicating that p110δ is required for MMP-13 
induction by IL-1+OSM in chondrocytes. In support of this apparently pro-inflammatory 
role for PI3K p110δ in chondrocytes, a 2006 study demonstrated a role for PI3K p110δ in 
allergic airway inflammation in a murine asthma model (Lee et al. 2006).  
 
Chapter 6 presented the findings of genome-wide screens following cytokine-treatment of 
bovine nasal cartilage, human articular chondrocytes and the chondrosarcoma cell line 
SW1353. The aim of this study was to identify candidate genes involved in the repression 
of MMP-13 by IL-4, and therefore the chondroprotective action of IL-4. A number of 
similarities were observed in the gene expression profiles of the three different systems and 
this, along with an extensive literature search, formed the basis of the selection of genes for 
further study. The results of this genome-wide study were limited due to the lack of 
replicates. However, the inclusion of numerous internal controls strengthened the reliability 
of the results. Indeed, the intention here was to generate new leads for investigations into 
the mechanism of action of IL-4, rather than generate publishable data. 
 
One of the genes selected for further study following the genome-wide screen was Trb1. 
Preliminary studies into the role of tribbles in MMP regulation in chondrocytes revealed 
several novel findings. Gene silencing of Trb1 via siRNA resulted in the rescue of IL-4-
mediated repression of IL-1+OSM-induced MMP-13 expression, indicating an anti-
inflammatory role for Trb1 in the context of MMP regulation in chondrocytes. As the 
tribbles family of proteins are a relatively newly discovered family of proteins, there is 
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currently no literature available on the role of Trb1 in chondrocytes. However, a recent 
paper identified Trb1 as a tumour suppressor gene in acute myeloid leukaemia, with 
reduced Trb1 activity resulting in enhanced cell survival, thereby contributing to the 
pathogenesis of the disease (Gilby et al. 2010). Conversely, Trb1 has been shown to be up-
regulated in acute and chronic inflammation in the white adipose tissue of mice (Ostertag et 
al. 2010). The genome-wide analysis described in Chapter 6 of this thesis reported an up-
regulation of Trb1 by the pro-inflammatory cytokines IL-1+OSM, in agreement with the 
findings of Ostertag et al. (2010). However, the addition of the anti-inflammatory cytokine 
IL-4 to IL-1+OSM was shown to further increase Trb1 expression, indicating that Trb1 can 
dictate both pro- and anti-inflammatory responses depending on the functional levels of 
Trb1 within a cell. Expanding on the initial finding of Trb1 involvement in repression of 
MMP-13 by IL-4, further gene silencing experiments revealed a completely novel role for 
Trb3 in the pro-inflammatory induction of MMP-13 by IL-1+OSM. In support of a pro-
inflammatory role for Trb3, experiments demonstrated that over-expression of Trb3 
enhanced IL-1+OSM-induced MMP-13 expression. Trb3 has been linked to various 
pathological conditions including insulin resistance, diabetes and cardiovascular disease 
(Ord et el. 2009) and therefore a potentially pathogenic role for Trb3 in chondrocytes is not 
unexpected. Moreover, Trb3 is known to be expressed at higher levels in OA chondrocytes 
than in normal chondrocytes (Cravero et al. 2009), further supporting a pathogenic role for 
Trb3 in the development of OA.  
 
These novel findings suggest that tribbles family members are integral to MMP regulation 
in chondrocytes. IL-4-mediated repression of IL-1+OSM-induced MMP-13 was shown to 
be STAT6-dependent. Previous work indicated that the chondroprotective nature of IL-4 
was due to the expression of a STAT6-reponsive gene (Pyle 2003). The data presented in 
Chapter 7 appear to confirm this. The tribbles are a relatively newly discovered family of 
proteins and so their role in cell signalling and gene regulation in response to inflammatory 
stimuli has not been well investigated. Therefore, the model proposed in this thesis 
whereby Trb1 and Trb3 regulate MMP-13 gene expression during pro- and anti-
inflammatory signalling is speculative and further work is required to confirm this 
hypothesis.  
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As tribbles have been previously implicated in the control of MAPK signalling pathways 
(Kiss-Toth et al. 2004), further work examined physical interactions between tribbles 
proteins and MAPKKs. A GFP-based PCA assay demonstrated physical interactions 
between Trb1/Trb3 and MEK-1, MKK4, MKK6 and MKK7 in chondrocytes. The 
involvement of MAPKs in MMP signalling is well established, although not clearly 
understood (Rowan and Young 2007). For example, activation of the JNK and ERK 
pathways by IL-1 is known to result in the phosphorylation and activation of the activating 
protein-1 (AP-1) family member c-Jun, which subsequently dimerizes with c-Fos to drive 
transcription of various MMP genes, including MMP-1 and -13 (Vincenti and Brinckerhoff 
2002). For that reason, the demonstration of these interactions between tribbles and 
MAPKKs is an important finding in relation to MMP regulation in chondrocytes. 
Following on from these preliminary findings, the suspected involvement of tribbles in the 
regulation of MAPK signalling pathways would need to be assessed in relation to pro- and 
anti-inflammatory stimuli. The phosphorylation status of various signalling molecules 
within the MAPK signalling pathway would be assessed following tribbles gene silencing, 
to identify any altered phosphorylation events following tribbles interaction. However, it 
may well be that phosphorylation events are unaltered by tribbles and instead the 
intracellular sequestration of signalling molecules could be responsible for the alteration of 
downstream signalling events following Akt activation, resulting in either the enhancement 
or abolishment of MMP expression. Co-immunprecipitation experiments using tribbles 
antibodies, combined with mass spectrometry, could be used to identify tribbles-interacting 
proteins in stimulated chondrocytes. Following this, the subcellular localisation in which 
tribbles and identified binding partners are located would be determined under both basal 
and stimulated conditions. 
 
One of the questions posed by data presented in Chapter 5 of this thesis was how do two 
cytokines (namely, OSM and IL-4) both activate Akt and yet have completely opposing 
effects on cartilage degradation and MMP regulation. The finding that the tribbles family of 
proteins appear to play an important role in MMP regulation in chondrocytes could partly 
explain this. It has been suggested that tribbles may function as decoy proteins (Hegedus et 
el. 2007), affecting the outcome of signalling pathways by competing with active protein 
kinases for binding partners. Trb3 is known to inhibit Akt in chondrocytes (Cravero et al.  
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Figure 8.1 Diagram summarising the possible involvement of Trb proteins in MMP-13 expression and 
repression. Gene-silencing of Trb1 (via siRNA) has been shown to rescue IL-4-mediated repression of IL-
1+OSM-induced MMP-13. This repression has been shown to be STAT6-dependent, suggesting STAT6 is 
upstream of Trb1, with increased Trb1 transcription via STAT6-binding to the Trb1 promoter. Tribbles-
regulated MMP expression is further supported in that Trb3 silencing abolishes MMP-13 expression, 
supporting a pro-inflammatory role for Trb3. OSM and IL-4 signalling are both known to result in Akt 
activation and Trb proteins are known Akt-binding partners. It is hypothesised that IL-4 functions to repress 
MMP-13 expression via an upregulation of Trb1. Trb1 is then thought to (a) sequester activated Akt 
molecules, thereby preventing downstream signalling and inhibiting MMP-13 transcription and/or (b) act as a 
decoy protein for protein kinases downstream of Akt, again inhibiting MMP-13 transcription. 
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2009), and previous work within the department has provided compelling evidence that 
Akt-dependent signalling is critical for MMP expression in chondrocytes (Litherland et al. 
2008). As Trb3 appears to play an important role in the pro-inflammatory cytokine 
induction of MMP-13, it could be hypothesised that following OSM-mediated Akt 
activation, tribbles proteins act to sequester activated Akt or signalling molecules 
downstream of Akt, thereby altering downstream signalling events in favour of MMP 
activation and therefore matrix catabolism. Data presented in Chapters 6 and 7 of this thesis 
have shown levels of Trb1 to be up-regulated in response to IL-4 in chondrocytes. 
Therefore, downstream signalling events following IL-4-mediated Akt activation could be 
hypothesised to be altered by the involvement of Trb1 (as opposed to Trb3), thereby 
preventing the induction of MMPs and resulting in the inhibition of cartilage degradation 
observed in the presence of IL-4. Given more time, experiments using a Trb3-deficient 
mouse model could be used to further examine the role of Trb3 in IL-1+OSM-induced 
MMP-13 induction in cartilage. The hypothesis described here would predict that Trb3-
deficiency would protect against IL-1+OSM-induced arthritis following inter-articular 
over-expression of IL-1+OSM via adenoviral gene transfer. Previous studies have 
successfully used adenoviral gene transfer to over-express murine IL-1 and murine OSM 
intraarticularly in the knees of C57BL/6 mice resulting in increased MMP expression and 
cartilage destruction (Rowan et al. 2003). In addition, a Trb1 over-expression mouse model 
could be used to test the hypothesis that cartilage-specific Trb1 over-expression would 
result in fewer arthritic changes. Both transgenic animals are now available for these 
studies (A D Rowan and E Kiss-Toth, personal communication). C-myc tagged Trb1 and 
Trb3 over-expression constructs are available and so the hypothesised modulation of 
PI3K/Akt signalling pathways by tribbles would be examined using co-
immunoprecipitation.  
 
There are currently no treatments for OA that block cartilage destruction, and treatments for 
RA are expensive and ineffective in some patients. The increasing ageing population is 
resulting in a mounting disease burden that requires the development of new therapies. The 
success of current biological therapies indicates that targeting key mediators is a viable and 
important therapeutic strategy. Data presented in this thesis have demonstrated that IL-4 is 
able to specifically inhibit MMP-13 expression, a finding which opens up the possibility of 
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designing a drug to mimic this action. However, a better understanding of the mechanisms 
by which MMP genes are regulated is required to minimise potential side effects. The 
highly novel observations presented in this thesis demonstrating the involvement of the 
tribbles family of proteins in both pro- and anti-inflammatory MMP-13 regulation could 
provide a detailed understanding of the molecular mechanisms by which a key MMP gene 
is regulated in disease. Further work to unravel the mechanism of action by which tribbles 
regulate MMP expression could result in new therapies. Arthritic disease results in severe 
and prolonged disability and so any new therapy to limit cartilage destruction would 
dramatically reduce the escalating burden on the health services. 
 
Summary of possible future studies: 
 
• Characterise the impact of Trb1 over-expression and Trb3 deletion in arthritis 
models. 
• Determine what factors regulate tribbles expression and identify their binding 
partners in chondrocytes. 
• Investigate the molecular mechanisms of tribbles-controlled MMP-13 gene 
expression. 
• Determine what other, if any, genes (including MMPs) are also regulated in a 
similar manner by tribbles. 
• Examine which signalling pathways tribbles regulate and, to what extent tribbles 
impact on these signalling pathways in pro-inflammatory cytokine-stimulated 
chondrocytes. 
• Investigate the binding partners of individual tribbles; and whether re-
compartmentalisation of signalling molecules explains tribbles function in 
regulating MMP expression. 
 
The most significant finding of this thesis is that IL-4 appears to prevent IL-1+OSM-
induced cartilage destruction by specifically repressing MMP-13. Genome-wide 
microarrays identified Trb1 as a potential gene involved in the repression of MMP-13 by 
IL-4. Gene silencing experiments in chondrocytes confirmed that transfection with Trb1 
specific siRNA resulted in the rescue of IL-4 mediated repression of IL-1+OSM-induced 
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MMP-13 expression, indicating an anti-inflammatory role for Trb1. Trb1 belongs to family 
of three tribbles proteins and additional studies to investigate the roles of other tribbles 
family members in MMP regulation identified Trb3 as having a potentially pro-
inflammatory role in MMP regulation in chondrocytes. Silencing of Trb3 was reproducibly 
shown to abolish IL-1+OSM-induced MMP-13 expression. The novel preliminary data 
presented in this thesis indicate that tribbles proteins act as key regulators of catabolic and 
anabolic responses in chondrocytes. From these findings it could be hypothesised that 
alterations in functional levels of specific tribbles proteins may protect against aberrant 
MMP gene expression in chondrocytes. The identification of this potentially important 
regulatory mechanism of signalling pathways important in MMP-13 gene expression in 
chondrocytes could be translated into a tractable therapy for arthritis. 
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pCDNA3.1-trb1-mycHis
6560 bp
 
 
pCDNA3.1-trb3-mycHis
6515 bp
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Genome-wide microarray results 
  
     
Bovine nasal cartilage: IL-1+OSM+IL-4 vs IL-1+OSM 
     
Affymetrix ID 
Fold 
change Regulation Symbol Gene name 
Bt.958.1.A1_at 157.97 up  
Transcribed sequence with strong similarity to protein sp:P98066 
(H.sapiens) TSG6_HUMAN Tumor necrosis factor-inducible protein 
TSG-6 precursor 
Bt.19204.1.S1_at 44.89 up  Transcribed sequences 
Bt.9202.1.S1_at 29.08 up  
Transcribed sequence with strong similarity to protein sp:Q14314 
(H.sapiens) FGL2_HUMAN Fibroleukin precursor 
Bt.5362.1.S1_at 24.17 up SERPINA3 
serine (or cysteine) proteinase inhibitor, cladeA (alpha-1 
antiproteinase, antitrypsin), member 3 
Bt.4321.1.S1_at 23.31 up  
Transcribed sequence with strong similarity to protein sp:Q9NSE2 
(H.sapiens) CISH_HUMAN Cytokine-inducible SH2-containing 
protein 
Bt.13556.2.A1_x_at 18.60 up HF1 H factor 1 (complement) 
Bt.13556.2.A1_at 18.27 up HF1 H factor 1 (complement) 
Bt.3307.1.A1_at 17.83 up  
Transcribed sequence with strong similarity to protein pir:A57005 
(H.sapiens) A57005 Norrie disease candidate protein - human 
Bt.17331.1.A1_at 17.74 up  Transcribed sequence 
Bt.13556.1.S1_a_at 16.96 up HF1 H factor 1 (complement) 
Bt.25478.1.A1_at 16.84 up  
Transcribed sequence with strong similarity to protein 
ref:NP_066025.1 (H.sapiens)  CEGP1 protein [Homo sapiens] 
Bt.25236.1.A1_at 12.06 up  Transcribed sequences 
Bt.13892.1.S1_at 11.71 up  Transcribed sequences 
Bt.26538.1.S1_at 11.02 up  
Transcribed sequence with moderate similarity to protein sp:Q15884 
(H.sapiens) X123_HUMAN Putative protein X123 
Bt.17780.1.A1_at 10.34 up  
Transcribed sequence with weak  similarity to protein sp:P14784 
(H.sapiens) IL2B_HUMAN Interleukin-2 receptor beta chain 
precursor 
Bt.23514.1.S1_at 9.88 up  
Transcribed sequence with moderate similarity to protein sp:P01023 
(H.sapiens) A2MG_HUMAN Alpha-2-macroglobulin precursor 
Bt.28182.1.A1_at 9.82 up  Transcribed sequences 
Bt.22545.2.S1_at 9.72 up  
Transcribed sequence with strong similarity to protein pir:B36346 
(H.sapiens) B36346 fibulin 1 precursor, splice form B - human 
Bt.26803.1.A1_at 9.31 up  Transcribed sequences 
Bt.8124.1.S2_at 9.18 up COL1A2 collagen, type I, alpha 2 
Bt.1929.1.S1_at 9.16 up  Transcribed sequences 
Bt.9062.1.S1_at 9.13 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_071420.1 (H.sapiens)  secreted modular calcium-binding 
protein 1 [Homo sapiens] 
Bt.14209.1.A1_at 9.08 up  Transcribed sequences 
Bt.15488.1.A1_at 8.77 up  Transcribed sequence 
Bt.17517.1.S1_at 8.60 up  Transcribed sequences 
Bt.19231.1.S1_at 8.39 up  
Transcribed sequence with strong similarity to protein sp:Q99574 
(H.sapiens) NEUS_HUMAN Neuroserpin precursor 
Bt.4063.1.S1_at 8.12 up PLA2G7 
phospholipase A2, group VII (platelet-activatingfactor 
acetylhydrolase, plasma) 
Bt.7176.1.S1_at 7.84 up SPON1 spondin 1, (f-spondin) extracellular matrixprotein 
Bt.2017.1.S1_at 7.69 up TFPI2 tissue factor pathway inhibitor 2 
Bt.17036.1.A1_s_at 7.69 up  
Transcribed sequence with strong similarity to protein pir:A41706 
(H.sapiens) A41706 tryptophan--tRNA ligase 
Bt.2236.1.S1_at 7.57 up  Transcribed sequences 
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Bt.19866.1.A1_at 7.44 up  
Transcribed sequence with strong similarity to protein sp:Q9P2J9 
(H.sapiens) PDP2_HUMAN [Pyruvate dehydrogenase [Lipoamide]]-
phosphatase 2, mitochondrial precursor 
Bt.8124.1.S1_at 7.23 up COL1A2 collagen, type I, alpha 2 
Bt.13482.1.S1_at 7.03 up  
Transcribed sequence with moderate similarity to protein sp:P48745 
(H.sapiens) NOV_HUMAN NOV protein homolog precursor 
Bt.1736.1.A1_at 6.90 up  
Transcribed sequence with strong similarity to protein 
ref:NP_003736.1 (H.sapiens)  JAK binding protein [Homo sapiens] 
Bt.2841.1.S1_at 6.77 up WARS tryptophanyl-tRNA synthetase 
Bt.5530.1.S1_at 6.76 up SDR1 short-chain dehydrogenase/reductase 1 
Bt.4209.2.S1_a_at 6.73 up C3 component 3 
Bt.13526.1.S1_at 6.58 up  Transcribed sequences 
Bt.982.1.S1_at 6.46 up SERPINA1 
serine (or cysteine) proteinase inhibitor, cladeA (alpha-
1antiproteinase, antitrypsin), member 1 
Bt.17881.1.S1_at 6.40 up  Transcribed sequences 
Bt.4209.2.S1_at 6.39 up C3 component 3 
Bt.15298.1.A1_at 6.37 up  Transcribed sequences 
Bt.3595.1.S1_at 6.27 up MGP matrix Gla protein 
Bt.12440.1.A1_at 6.13 up  Transcribed sequence 
Bt.422.1.S1_at 5.99 up IGFBP-3 insulin-like growth factor binding protein-3 
Bt.9421.1.S1_at 5.99 up VIT vitrin 
Bt.26813.1.S1_at 5.86 up  Transcribed sequences 
Bt.28209.1.S1_at 5.81 up  Transcribed sequences 
Bt.3100.1.A1_at 5.77 up  Transcribed sequence 
Bt.20745.1.A1_at 5.72 up  Transcribed sequences 
Bt.24212.1.S1_at 5.60 up  Transcribed sequences 
Bt.3247.1.S1_at 5.56 up  
Transcribed sequence with moderate similarity to protein pir:T46488 
(H.sapiens) T46488 hypothetical protein DKFZp434J065.1 - human 
Bt.16048.1.S1_at 5.32 up  
Transcribed sequence with weak  similarity to protein sp:P10124 
(H.sapiens) PGSG_HUMAN Secretory granule proteoglycan core 
protein precursor 
Bt.22699.2.A1_at 5.26 up  
Transcribed sequence with strong similarity to protein sp:Q12857 
(H.sapiens) NFIA_HUMAN Nuclear factor 1 A-type 
Bt.5598.1.S1_at 5.25 up  
Transcribed sequence with strong similarity to protein 
ref:NP_064515.1 (H.sapiens)  chromosome 8 open reading frame 4; 
C8ORF4 protein [Homo sapiens] 
Bt.719.1.A1_at 5.23 up  Transcribed sequences 
Bt.27202.1.A1_at 5.21 up  Transcribed sequences 
Bt.390.1.S1_at 5.14 up CALB3 calbindin 3, (vitamin D-dependent calciumbinding protein) 
Bt.23864.1.A1_at 5.12 up  Transcribed sequences 
Bt.24898.1.S1_at 5.09 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_076973.1 (H.sapiens)  hypothetical protein MGC2731 [Homo 
sapiens] 
Bt.2638.1.S1_at 5.02 up SERPINF1 
serine (or cysteine) proteinase inhibitor, cladeF (alpha-2 antiplasmin, 
pigment epithelium derivedfactor), member 1 
Bt.4939.1.S1_at 5.02 up  
Transcribed sequence with strong similarity to protein pir:JE0174 
(H.sapiens) JE0174 frizzled protein-2 - human 
Bt.5861.1.S1_at 5.00 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_005935.3 (H.sapiens)  OX-2 membrane glycoprotein 
precursor; MRC OX-2 antigen; antigen identified by monoclonal 
antibody MRC OX-2  
Bt.982.1.S1_a_at 4.99 up SERPINA1 
serine (or cysteine) proteinase inhibitor, cladeA (alpha-
1antiproteinase, antitrypsin), member 1 
Bt.1855.1.S1_at 4.97 up CST3 cystatin C (amyloid angiopathy and cerebralhemorrhage) 
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Bt.17865.1.A1_at 4.90 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_443178.1 (H.sapiens)  hypothetical protein MGC20702 
[Homo sapiens] 
Bt.25733.1.A1_at 4.82 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_000203.1 (H.sapiens)  integrin beta chain, beta 3 precursor; 
platelet glycoprotein IIIa precursor [Homo sapiens] 
Bt.23354.1.S1_at 4.77 up  
Transcribed sequence with moderate similarity to protein pir:A29939 
(H.sapiens) A29939 epoxide hydrolase 
Bt.4627.1.S1_at 4.72 up SLC6A8 
solute carrier family 6 (neurotransmittertransporter, creatine), member 
8 
Bt.4844.1.S1_at 4.71 up PTN 
pleiotrophin [heparin binding growth factor 8,neurite growth-
promoting factor 1] 
Bt.28162.3.S1_at 4.70 up  
Transcribed sequence with strong similarity to protein pir:A40424 
(H.sapiens) A40424 phospholamban - human 
Bt.5847.1.S1_at 4.66 up  Transcribed sequence 
Bt.555.1.S1_at 4.58 up CA4 carbonic anhydrase IV 
Bt.1319.1.S1_at 4.54 up  Transcribed sequences 
Bt.21284.2.S1_at 4.53 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_057525.1 (H.sapiens)  cysteine-rich motor neuron 1; cysteine-
rich repeat-containing protein S52 precursor, [Homo sapiens] 
Bt.26774.1.S1_at 4.50 up  Transcribed sequences 
Bt.4209.1.S1_a_at 4.47 up C3 component 3 
Bt.6321.1.S1_at 4.44 up  Transcribed sequences 
Bt.11679.1.S1_at 4.37 up  Transcribed sequences 
Bt.18634.2.S1_at 4.36 up  Transcribed sequences 
Bt.12694.1.S1_at 4.24 up  
Transcribed sequence with strong similarity to protein 
ref:NP_055267.1 (H.sapiens)  death receptor 6 [Homo sapiens] 
Bt.27778.1.A1_at 4.23 up  Transcribed sequences 
Bt.272.1.S1_at 4.23 up PIM1 pim-1 oncogene 
Bt.9379.1.S1_at 4.22 up MAOA monoamine oxydase A 
Bt.25009.1.S1_at 4.21 up  Transcribed sequences 
Bt.24211.1.A1_at 4.21 up  
Transcribed sequence with strong similarity to protein 
ref:NP_060150.2 (H.sapiens)  asporin 
Bt.4627.1.S2_at 4.18 up SLC6A8 
solute carrier family 6 (neurotransmitter transporter, creatine), 
member 8 
Bt.6802.1.S1_at 4.17 up  Transcribed sequences 
Bt.28583.1.S1_s_at 4.16 up LOC404102 similar to pro alpha 1(I) collagen 
Bt.27543.1.A1_at 4.15 up  Transcribed sequences 
Bt.376.1.S2_at 4.10 up NPR3 natriuretic peptide receptor C [atrionatriureticpeptide receptor C] 
Bt.9412.1.S1_at 4.10 up  
Transcribed sequence with moderate similarity to protein pir:S46657 
(H.sapiens) S46657 collagen alpha 1 
Bt.23575.1.A1_at 4.08 up  Transcribed sequences 
Bt.24452.1.S1_at 4.07 up  
Transcribed sequence with strong similarity to protein 
ref:NP_004782.1 (H.sapiens)  integrin, beta-like 1 
Bt.28651.1.S1_at 4.05 up  
Transcribed sequence with strong similarity to protein 
ref:NP_443083.1 (H.sapiens)  similar to RhoGAP [Homo sapiens] 
Bt.15939.1.A1_at 4.04 up  Transcribed sequences 
Bt.6408.2.A1_at 4.01 up  Transcribed sequences 
Bt.24904.1.A1_at 3.97 up  
Transcribed sequence with strong similarity to protein sp:Q9H324 
(H.sapiens) AT10_HUMAN ADAMTS-10 precursor 
Bt.15828.2.S1_at 3.94 up  
Transcribed sequence with strong similarity to protein 
ref:NP_079471.1 (H.sapiens)  G-protein-coupled receptor induced 
protein [Homo sapiens] 
Bt.15908.1.S1_at 3.94 up  
Transcribed sequence with moderate similarity to protein pir:T08785 
(H.sapiens) T08785 hypothetical protein DKFZp586A0522.1 - human 
Bt.4394.1.S1_at 3.93 up GUCY1B3 guanylate cyclase 1, soluble, beta 3 
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Bt.18264.1.A1_at 3.92 up  Transcribed sequences 
Bt.632.1.S1_at 3.90 up TIMP1 
tissue inhibitor of metalloproteinase 1[erythroid potentiating activity, 
collagenase inhibitor] 
Bt.22974.1.S1_at 3.90 up SYNE1 spectrin repeat containing, nuclear envelope 1 
Bt.14369.1.A1_at 3.86 up  Transcribed sequences 
Bt.13780.1.A1_at 3.85 up  
Transcribed sequence with strong similarity to protein sp:O43609 
(H.sapiens) SPY1_HUMAN Sprouty homolog 1 
Bt.27990.1.S1_at 3.84 up 5htr2a 5-hydroxytryptamine receptor 2A 
Bt.24328.1.S1_at 3.83 up  Transcribed sequences 
Bt.8549.1.S2_at 3.83 up LOC404067 similar to pro alpha 1(I) collagen 
Bt.29718.1.A1_a_at 3.83 up  
Clone bghrmv3 growth hormone receptor mRNA, variant 5  UTR and 
partial cds 
Bt.23042.1.S1_at 3.81 up MT-1A metallothionein-1A 
Bt.24881.1.S1_at 3.78 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_036204.1 (H.sapiens)  complement component C1q receptor 
[Homo sapiens] 
Bt.16382.1.A1_at 3.78 up  Transcribed sequences 
Bt.29718.1.S1_a_at 3.78 up  
Clone bghrmv3 growth hormone receptor mRNA, variant 5  UTR and 
partial cds 
Bt.13306.2.S1_at 3.76 up  Transcribed sequences 
Bt.17518.1.S1_at 3.75 up  Transcribed sequences 
Bt.13290.1.S1_at 3.73 up  
Transcribed sequence with moderate similarity to protein pir:I38891 
(H.sapiens) I38891 hypothetical protein - human 
Bt.12606.1.S1_a_at 3.72 up  Transcribed sequences 
Bt.22538.1.A1_at 3.72 up  
Transcribed sequence with strong similarity to protein 
ref:NP_114072.1 (H.sapiens)  frizzled homolog 8; frizzled 
Bt.6483.1.A1_at 3.66 up  Transcribed sequences 
Bt.3964.1.S1_at 3.61 up SLC2A3 solute carrier family 2 (facilitated glucosetransporter), member 3 
Bt.632.1.S1_s_at 3.60 up TIMP1 
tissue inhibitor of metalloproteinase 1[erythroid potentiating activity, 
collagenase inhibitor] 
Bt.8549.1.S1_at 3.59 up LOC404067 similar to pro alpha 1(I) collagen 
Bt.15828.1.S1_at 3.55 up  
Transcribed sequence with strong similarity to protein 
ref:NP_079471.1 (H.sapiens)  G-protein-coupled receptor induced 
protein [Homo sapiens] 
Bt.18581.1.A1_at 3.55 up  Transcribed sequence 
Bt.8486.1.S1_at 3.50 up  Transcribed sequences 
Bt.7393.1.S1_at 3.47 up  Transcribed sequences 
Bt.1807.1.A1_at 3.47 up  Transcribed sequences 
Bt.20404.1.S1_at 3.46 up  Transcribed sequences 
Bt.27976.1.S1_at 3.44 up  
MRNA for similar to tissue inhibitor of metalloproteinases, partial 
cds, clone: ORCS11139 
Bt.16381.1.S1_at 3.43 up  Transcribed sequences 
Bt.6556.1.S1_at 3.43 up  
Transcribed sequence with weak  similarity to protein prf:2208449A 
(H.sapiens) 2208449A eotaxin [Homo sapiens] 
Bt.11599.1.S1_at 3.41 up  Transcribed sequences 
Bt.4653.1.S2_at 3.41 up PECAM1 platelet/endothelial cell adhesion molecule [CD31 antigen] 
Bt.20979.1.S1_at 3.40 up  Transcribed sequences 
Bt.21284.1.A1_at 3.38 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_057525.1 (H.sapiens)  cysteine-rich motor neuron 1; cysteine-
rich repeat-containing protein S52 precursor, [Homo sapiens] 
Bt.13849.1.S1_at 3.38 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_067017.1 (H.sapiens)  solute carrier family 30 
Bt.13306.1.S1_at 3.37 up  Transcribed sequences 
Bt.26053.1.A1_at 3.37 up  
Transcribed sequence with moderate similarity to protein pir:A40970 
(H.sapiens) A40970 undulin 1 - human 
Bt.8948.1.S1_at 3.36 up LOX lysyl oxidase 
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Bt.22735.1.S1_at 3.35 up  
Transcribed sequence with strong similarity to protein 
ref:NP_115755.2 (H.sapiens)  synaptotagmin-like 2, isoform b; 
chromosome 11 synaptotagmin [Homo sapiens] 
Bt.28162.1.S1_at 3.34 up  
Transcribed sequence with strong similarity to protein pir:A40424 
(H.sapiens) A40424 phospholamban - human 
Bt.13387.1.S1_at 3.33 up  
Transcribed sequence with weak  similarity to protein sp:P05156 
(H.sapiens) CFAI_HUMAN Complement factor I precursor 
Bt.21540.1.S1_at 3.31 up FGFR2 FGF-receptor 
Bt.26971.1.S1_at 3.31 up  Transcribed sequences 
Bt.16284.1.A1_at 3.30 up  Transcribed sequences 
Bt.3216.1.A1_at 3.29 up  
Transcribed sequence with strong similarity to protein 
ref:NP_057692.1 (H.sapiens)  ALEX1 protein [Homo sapiens] 
Bt.5075.1.S1_at 3.29 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_066925.1 (H.sapiens)  serine protease inhibitor, Kunitz type, 
2; placental bikunin 
Bt.4552.4.A1_at 3.28 up PLCB4 phospholipase C beta 
Bt.8131.1.S1_at 3.27 up ALCAM activated leucocyte cell adhesion molecule 
Bt.22063.1.A1_at 3.26 up  Transcribed sequences 
Bt.13566.1.A1_at 3.26 up  Transcribed sequence 
Bt.6504.1.S1_at 3.26 up  Transcribed sequences 
Bt.20373.1.S1_at 3.25 up  
Transcribed sequence with strong similarity to protein sp:O14786 
(H.sapiens) NRP1_HUMAN Neuropilin-1 precursor 
Bt.22974.1.A1_at 3.20 up SYNE1 spectrin repeat containing, nuclear envelope 1 
Bt.23791.1.A1_at 3.20 up  Transcribed sequence 
Bt.9724.1.S1_at 3.18 up  Transcribed sequences 
Bt.16012.1.S1_at 3.18 up GHR growth hormone receptor 
Bt.8897.1.S1_at 3.17 up C20orf114 von Ebner minor salivary gland protein 
Bt.29378.1.A1_at 3.16 up  Transcribed sequence 
Bt.24997.1.S1_at 3.16 up  Transcribed sequences 
Bt.20064.2.S1_at 3.16 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_005777.2 (H.sapiens)  serologically defined colon cancer 
antigen 33 [Homo sapiens] 
Bt.24434.1.A1_at 3.16 up  Transcribed sequences 
Bt.20064.1.S1_at 3.12 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_005777.2 (H.sapiens)  serologically defined colon cancer 
antigen 33 [Homo sapiens] 
Bt.20295.1.A1_at 3.12 up  Transcribed sequences 
Bt.12765.1.S1_at 3.11 up RDH10 retinol dehydrogenase 10 (all-trans) 
Bt.29350.1.A1_at 3.11 up  
Transcribed sequence with moderate similarity to protein sp:P57059 
(H.sapiens) SN1L_HUMAN Probable serine/threonine protein kinase 
SNF1LK 
Bt.20532.1.S1_at 3.10 up  
Transcribed sequence with strong similarity to protein pir:S27332 
(H.sapiens) S27332 proteasome chain LMP2 - human 
Bt.13039.1.A1_at 3.10 up ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
Bt.19508.1.A1_at 3.09 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_005699.1 (H.sapiens)  glypican 6 precursor [Homo sapiens] 
Bt.26426.1.A1_at 3.09 up  Transcribed sequences 
Bt.24532.1.A1_at 3.06 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_062529.1 (M.musculus)  ecotropic viral integration site 27; 
IL-17B receptor [Mus musculus] 
Bt.26095.1.A1_at 3.05 up  Transcribed sequences 
Bt.22076.1.A1_at 3.05 up  Transcribed sequences 
Bt.10442.2.S1_a_at 3.05 up COL12A1 collagen, type XII, alpha 1 
Bt.29806.1.A1_at 3.05 up  
Clone bghrmv6 growth hormone receptor mRNA, variant 5  UTR and 
partial cds 
Bt.27091.2.S1_at 3.04 up  Transcribed sequences 
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Bt.4167.1.S1_at 3.04 up  
Transcribed sequence with strong similarity to protein pir:S55272 
(H.sapiens) S55272 DNA-binding protein NEFA precursor - human 
Bt.26328.1.A1_at 3.03 up  Transcribed sequence 
Bt.23276.1.S1_at 3.03 up  
Transcribed sequence with strong similarity to protein sp:Q9Y4K1 
(H.sapiens) AIM1_HUMAN Absent in melanoma 1 protein 
Bt.17606.1.A1_at 3.03 up  Transcribed sequence 
Bt.28659.1.A1_at 3.02 up  Transcribed sequences 
Bt.28162.2.A1_at 3.02 up  
Transcribed sequence with strong similarity to protein pir:A40424 
(H.sapiens) A40424 phospholamban - human 
Bt.4263.1.S1_at 3.01 up GPRK5 G protein-coupled receptor kinase 5 
Bt.21924.1.A1_at 3.00 up  Transcribed sequences 
Bt.13482.2.S1_at 3.00 up  
Transcribed sequence with moderate similarity to protein sp:P48745 
(H.sapiens) NOV_HUMAN NOV protein homolog precursor 
Bt.347.1.S1_at 2.97 up CHAD chondroadherin 
Bt.19834.1.A1_at 2.97 up  Transcribed sequence 
Bt.16857.1.A1_at 2.97 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_077024.1 (H.sapiens)  hypothetical protein FLJ11354 [Homo 
sapiens] 
Bt.10565.1.A1_at 2.95 up  
Transcribed sequence with moderate similarity to protein pir:T12520 
(H.sapiens) T12520 hypothetical protein DKFZp434G173.1 - human 
Bt.4586.1.S1_at 2.95 up GNG2 guanine nucleotide binding protein (G protein), gamma 2 
Bt.20226.1.A1_at 2.95 up  Transcribed sequences 
Bt.20490.1.S1_at 2.94 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_036253.2 (H.sapiens)  binder of Rho GTPases 4; Cdc42 
effector protein 4 [Homo sapiens] 
Bt.2519.1.S1_at 2.92 up PLAU plasminogen activator, urokinase 
Bt.23276.2.S1_at 2.92 up  
Transcribed sequence with strong similarity to protein sp:Q9Y4K1 
(H.sapiens) AIM1_HUMAN Absent in melanoma 1 protein 
Bt.17738.1.A1_at 2.91 up  Transcribed sequences 
Bt.6279.1.A1_at 2.91 up  
Transcribed sequence with strong similarity to protein 
ref:NP_004990.1 (H.sapiens)  myosin VI [Homo sapiens] 
Bt.3732.1.A1_at 2.91 up  Transcribed sequences 
Bt.22953.1.S1_at 2.88 up TYRP2 tyrosinase-related protein-2 
Bt.13330.1.S1_at 2.88 up  Transcribed sequences 
Bt.13039.1.S1_at 2.88 up ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
Bt.7130.1.S1_at 2.87 up  
Transcribed sequence with strong similarity to protein sp:Q9Y5Z0 
(H.sapiens) BAE2_HUMAN Beta secretase 2 precursor 
Bt.18689.1.S1_at 2.86 up  Transcribed sequences 
Bt.1433.1.S1_at 2.86 up  Transcribed sequences 
Bt.15939.2.S1_at 2.85 up  Transcribed sequences 
Bt.16510.1.A1_at 2.84 up  Transcribed sequences 
Bt.11017.1.S1_at 2.83 up  
Transcribed sequence with moderate similarity to protein pir:T12520 
(H.sapiens) T12520 hypothetical protein DKFZp434G173.1 - human 
Bt.28393.1.S1_at 2.81 up  
Transcribed sequence with weak  similarity to protein sp:P08174 
(H.sapiens) DAF_HUMAN Complement decay-accelerating factor 
precursor 
Bt.26445.1.A1_at 2.80 up  Transcribed sequence 
Bt.3913.1.S1_at 2.79 up VEGFC vascular endothelial growth factor C 
Bt.15692.1.A1_at 2.78 up  
Transcribed sequence with weak  similarity to protein sp:Q9NV58 
(H.sapiens) RN19_HUMAN RING finger protein 19 
Bt.21924.2.S1_at 2.77 up  Transcribed sequences 
Bt.16769.1.A1_at 2.77 up  Transcribed sequence 
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Bt.17324.1.A1_at 2.76 up  Transcribed sequences 
Bt.10150.1.S1_at 2.76 up  Transcribed sequences 
Bt.22349.2.S1_at 2.74 up  Transcribed sequences 
Bt.10340.1.S1_at 2.74 up  Transcribed sequences 
Bt.10442.2.A1_at 2.72 up COL12A1 collagen, type XII, alpha 1 
Bt.4901.1.S1_at 2.72 up  
Transcribed sequence with strong similarity to protein pir:B46619 
(H.sapiens) B46619 Ca2+/calmodulin-dependent protein kinase 
Bt.20706.1.A1_at 2.71 up  Transcribed sequences 
Bt.10222.1.S1_at 2.71 up  Transcribed sequences 
Bt.22000.1.A1_at 2.71 up  Transcribed sequences 
Bt.19097.2.S1_at 2.70 up  Transcribed sequences 
Bt.28780.2.A1_a_at 2.70 up  
Transcribed sequence with weak  similarity to protein pir:A55380 
(H.sapiens) A55380 faciogenital dysplasia-associated protein FGD1 - 
human 
Bt.19355.1.A1_at 2.70 up  
Transcribed sequence with moderate similarity to protein pir:S41819 
(H.sapiens) S41819 nucleoporin p62 - human 
Bt.13553.2.S1_at 2.70 up  
Transcribed sequence with strong similarity to protein 
ref:NP_068747.1 (H.sapiens)  hypothetical protein FLJ22649 similar 
to signal peptidase SPC22/ [Homo sapiens] 
Bt.27769.1.A1_at 2.69 up  Transcribed sequence 
Bt.19517.1.S1_at 2.69 up  
Transcribed sequence with moderate similarity to protein sp:P21860 
(H.sapiens) ERB3_HUMAN Receptor protein-tyrosine kinase erbB-3 
precursor 
Bt.10076.1.S1_at 2.69 up  Transcribed sequences 
Bt.11315.1.A1_at 2.68 up  Transcribed sequences 
Bt.11324.1.A1_s_at 2.67 up  Transcribed sequence 
Bt.23770.1.A1_at 2.66 up  Transcribed sequences 
Bt.20393.1.S1_at 2.66 up  
Transcribed sequence with strong similarity to protein prf:2121279A 
(H.sapiens) 2121279A protein disulfide isomerase-related protein 
[Homo sapiens] 
Bt.663.1.S1_at 2.65 up  Transcribed sequences 
Bt.5878.1.A1_at 2.65 up  
Transcribed sequence with moderate similarity to protein sp:P20132 
(H.sapiens) SDHL_HUMAN L-serine dehydratase 
Bt.1974.1.S1_at 2.65 up  Transcribed sequences 
Bt.8486.2.S1_at 2.65 up  Transcribed sequences 
Bt.9594.1.S1_at 2.65 up  Transcribed sequences 
Bt.24342.1.A1_at 2.65 up  
Transcribed sequence with strong similarity to protein 
ref:NP_066969.1 (H.sapiens)  angiopoietin-like factor [Homo sapiens] 
Bt.24941.1.S1_at 2.64 up  
Transcribed sequence with weak  similarity to protein sp:P08910 
(H.sapiens) HPS1_HUMAN Protein PHPS1-2 
Bt.6449.1.S1_at 2.64 up  
Transcribed sequence with strong similarity to protein sp:Q9UBX5 
(H.sapiens) FBL5_HUMAN Fibulin-5 precursor 
Bt.21762.2.S1_at 2.62 up  Transcribed sequences 
Bt.19217.1.A1_at 2.62 up  Transcribed sequences 
Bt.20430.1.A1_at 2.62 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_478144.1 (H.sapiens)  HEAT-like repeat-containing protein, 
isoform 1; MGC4163 protein [Homo sapiens] 
Bt.12964.1.A1_at 2.61 up  Transcribed sequence 
Bt.25099.1.A1_at 2.60 up  
Transcribed sequence with strong similarity to protein 
ref:NP_004568.1 (H.sapiens)  phosphoserine phosphatase [Homo 
sapiens] 
Bt.8803.1.A1_at 2.60 up  
Transcribed sequence with moderate similarity to protein sp:P00736 
(H.sapiens) C1R_HUMAN Complement C1r component precursor 
Bt.3580.1.A1_at 2.59 up  
Transcribed sequence with weak  similarity to protein sp:Q99538 
(H.sapiens) LEGU_HUMAN Legumain precursor 
Bt.19295.1.S1_at 2.59 up  Transcribed sequences 
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Bt.13912.1.S1_at 2.58 up  Transcribed sequences 
Bt.21294.1.A1_at 2.57 up  Transcribed sequences 
Bt.12912.1.S2_at 2.56 up COL4A1 collagen, type IV, alpha 1 
Bt.3034.1.S1_at 2.56 up COMP cartilage oligomeric matrix protein 
Bt.29411.2.A1_at 2.56 up  
Transcribed sequence with strong similarity to protein pir:T00352 
(H.sapiens) T00352 hypothetical protein KIAA0701 - human 
Bt.9789.1.S1_at 2.56 up  
Transcribed sequence with strong similarity to protein sp:O14640 
(H.sapiens) DVL1_HUMAN Segment polarity protein dishevelled 
homolog DVL-1 
Bt.26560.1.A1_at 2.55 up  Transcribed sequences 
Bt.3699.1.S1_at 2.55 up  
Transcribed sequence with strong similarity to protein 
ref:NP_004402.1 (H.sapiens)  dynein, cytoplasmic, intermediate 
polypeptide 1 [Homo sapiens] 
Bt.448.1.S1_at 2.55 up PLCB1 phosphoinositide-specific phospholipase C beta1 
Bt.624.1.S1_at 2.54 up  
Transcribed sequence with strong similarity to protein 
ref:NP_055398.1 (H.sapiens)  LIM and cysteine-rich domains 1; 
dyxin [Homo sapiens] 
Bt.11704.1.S1_at 2.54 up  Transcribed sequences 
Bt.23651.1.A1_at 2.54 up  Transcribed sequences 
Bt.24928.1.S1_at 2.54 up  
Transcribed sequence with strong similarity to protein 
ref:NP_055705.1 (H.sapiens)  downregulated in ovarian cancer 1 
[Homo sapiens] 
Bt.26204.1.A1_at 2.53 up  Transcribed sequences 
Bt.27091.1.S1_at 2.53 up  Transcribed sequences 
Bt.19845.1.S1_at 2.53 up  Transcribed sequences 
Bt.20569.3.S1_at 2.52 up  Transcribed sequences 
Bt.19978.1.A1_at 2.52 up  Transcribed sequences 
Bt.9026.1.S1_at 2.51 up ITPR2 inositol 1,4,5-triphosphate receptor, type 2 
Bt.9966.2.S1_a_at 2.51 up  
Transcribed sequence with strong similarity to protein pir:CGHU2V 
(H.sapiens) CGHU2V collagen alpha 2 
Bt.13912.2.A1_at 2.50 up  Transcribed sequences 
Bt.3797.1.S1_at 2.50 up FMOD fibromodulin 
Bt.27379.1.A1_at 2.50 up  Transcribed sequences 
Bt.725.1.S1_at 2.49 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_006198.1 (H.sapiens)  platelet-derived growth factor receptor-
like protein; platelet-derived growth factor-beta-like tumor suppressor 
[Homo sapiens] 
Bt.18689.2.A1_at 2.48 up  Transcribed sequences 
Bt.13871.1.S1_at 2.48 up  Transcribed sequences 
Bt.20596.1.S1_at 2.47 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_005788.1 (H.sapiens)  epithelial V-like antigen 1 precursor 
[Homo sapiens] 
Bt.9412.3.S1_at 2.46 up  
Transcribed sequence with moderate similarity to protein pir:S46657 
(H.sapiens) S46657 collagen alpha 1 
Bt.19100.3.A1_at 2.46 up  Transcribed sequences 
Bt.29411.1.S1_at 2.46 up  
Transcribed sequence with strong similarity to protein pir:T00352 
(H.sapiens) T00352 hypothetical protein KIAA0701 - human 
Bt.23672.1.A1_at 2.45 up  Transcribed sequences 
Bt.8463.1.S1_at 2.44 up  Transcribed sequences 
Bt.19541.1.A1_at 2.44 up  Transcribed sequence 
Bt.5656.1.S1_at 2.42 up  
Transcribed sequence with strong similarity to protein sp:Q99689 
(H.sapiens) FEZ1_HUMAN Fasciculation and elongation protein zeta 
1 
Bt.12455.1.S1_at 2.42 up  Transcribed sequences 
Bt.29806.1.S1_at 2.42 up  
Clone bghrmv6 growth hormone receptor mRNA, variant 5  UTR and 
partial cds 
Bt.20162.1.S1_at 2.42 up  Transcribed sequences 
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Bt.17309.2.A1_at 2.42 up  Transcribed sequences 
Bt.11081.1.S1_at 2.42 up  Transcribed sequences 
Bt.4110.1.S1_at 2.42 up HRH1 histamine H1 receptor 
Bt.4594.1.S1_at 2.42 up NB25 MHC class II (BoLA-DQB) 
Bt.121.1.S1_at 2.41 up FRZB frizzled-related protein 
Bt.26885.1.S1_at 2.41 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_060416.1 (H.sapiens)  hypothetical protein FLJ20731 [Homo 
sapiens] 
Bt.25075.1.A1_at 2.40 up  Transcribed sequences 
Bt.22857.1.S1_at 2.39 up TRB2 TRB-2 protein 
Bt.126.1.S2_at 2.39 up KCNJ2 potassium inwardly-rectifying channel, subfamilyJ, member 2 
Bt.24026.1.A1_at 2.39 up  Transcribed sequences 
Bt.19533.1.A1_at 2.37 up  
Transcribed sequence with weak  similarity to protein sp:P11369 
(M.musculus) POL2_MOUSE Retrovirus-related POL polyprotein 
[Contains: Reverse transcriptase ; Endonuclease] 
Bt.5599.1.S1_at 2.37 up  
Transcribed sequence with strong similarity to protein 
ref:NP_071738.1 (H.sapiens)  17kD fetal brain protein [Homo 
sapiens] 
Bt.14249.1.A1_at 2.37 up  Transcribed sequences 
Bt.29717.1.S1_a_at 2.37 up  
Clone bghrmv8 growth hormone receptor mRNA, variant 5  UTR and 
partial cds 
Bt.16195.2.A1_at 2.36 up  Transcribed sequences 
Bt.29696.1.S1_at 2.35 up  
Partial mRNA for fibroblast growth factor receptor 2 (FGFR2 gene), 
isoform IIIc 
Bt.6778.1.S1_at 2.34 up  Transcribed sequences 
Bt.9966.1.S1_at 2.34 up  
Transcribed sequence with strong similarity to protein pir:CGHU2V 
(H.sapiens) CGHU2V collagen alpha 2 
Bt.10861.2.S1_at 2.33 up  Transcribed sequences 
Bt.28159.1.S1_at 2.33 up  Transcribed sequences 
Bt.22165.1.S1_at 2.32 up  Transcribed sequences 
Bt.19024.1.A1_at 2.32 up  
Transcribed sequence with strong similarity to protein sp:P46934 
(H.sapiens) NED4_HUMAN NEDD-4 protein 
Bt.24255.1.S1_at 2.32 up  Transcribed sequences 
Bt.6087.2.S1_a_at 2.31 up  
Transcribed sequence with moderate similarity to protein pir:A42926 
(H.sapiens) A42926 L6 surface protein - human 
Bt.15712.1.S1_at 2.31 up  
Transcribed sequence with moderate similarity to protein sp:P08236 
(H.sapiens) BGLR_HUMAN Beta-glucuronidase precursor 
Bt.17195.1.A1_at 2.31 up  Transcribed sequences 
Bt.9286.2.S1_at 2.31 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_004853.1 (H.sapiens)  LPS-induced TNF-alpha factor [Homo 
sapiens] 
Bt.13651.2.A1_at 2.31 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_003390.2 (H.sapiens)  X-prolyl aminopeptidase 2, membrane-
bound; aminoacylproline aminopeptidase; aminopeptidase P; X-prolyl 
aminopeptidase 2 
Bt.16555.1.A1_at 2.31 up  Transcribed sequences 
Bt.22082.1.S1_at 2.30 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_064629.1 (H.sapiens)  choline phosphotransferase 1; 
cholinephosphotransferase 1; cholinephosphotransferase 1 alpha 
[Homo sapiens] 
Bt.9412.2.S1_at 2.30 up  
Transcribed sequence with moderate similarity to protein pir:S46657 
(H.sapiens) S46657 collagen alpha 1 
Bt.4552.1.S1_a_at 2.30 up  phospholipase C 
Bt.19167.1.A1_at 2.30 up  Transcribed sequences 
Bt.23171.2.S1_at 2.29 up  
Transcribed sequence with strong similarity to protein sp:P80095 
(H.sapiens) PHS_HUMAN Pterin-4-alpha-carbinolamine dehydratase 
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Bt.23351.1.S1_at 2.29 up  
Transcribed sequence with strong similarity to protein prf:2117157A 
(H.sapiens) 2117157A oligosaccharyltransferase [Homo sapiens] 
Bt.10341.1.S1_at 2.29 up  Transcribed sequences 
Bt.19390.1.S1_at 2.29 up  Transcribed sequences 
Bt.2505.2.S1_at 2.29 up  
Transcribed sequence with strong similarity to protein 
ref:NP_079434.1 (H.sapiens)  hypothetical protein FLJ22251 [Homo 
sapiens] 
Bt.9289.1.S1_at 2.28 up  Transcribed sequences 
Bt.7310.1.S1_at 2.28 up  Transcribed sequences 
Bt.20803.1.A1_at 2.28 up  Transcribed sequences 
Bt.11599.2.S1_at 2.28 up  Transcribed sequences 
Bt.1998.1.S1_at 2.27 up  
Transcribed sequence with strong similarity to protein pir:C35826 
(H.sapiens) C35826 hypothetical 13K protein A - human 
Bt.13906.1.S1_at 2.26 up  Transcribed sequences 
Bt.21164.1.S1_at 2.26 up  
Transcribed sequence with moderate similarity to protein 
prf:1001205A (H.sapiens) 1001205A c-myc gene [Homo sapiens] 
Bt.15540.1.A1_at 2.26 up  Transcribed sequences 
Bt.10077.1.S2_at 2.26 up IRF1 interferon responsive factor 1 
Bt.20226.2.A1_at 2.25 up  Transcribed sequences 
Bt.19329.1.A1_at 2.25 up  Transcribed sequences 
Bt.20327.1.S1_a_at 2.25 up  
Transcribed sequence with weak  similarity to protein pir:JC4343 
(H.sapiens) JC4343 uridine phosphorylase 
Bt.6127.2.S1_at 2.25 up  
Transcribed sequence with moderate similarity to protein pir:B32688 
(H.sapiens) B32688 beta-galactosidase-related protein - human 
Bt.6592.1.S1_at 2.25 up  
Transcribed sequence with strong similarity to protein sp:P55290 
(H.sapiens) CADD_HUMAN Cadherin-13 precursor 
Bt.4105.2.A1_at 2.24 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_112230.1 (H.sapiens)  G protein coupled receptor interacting 
protein, complement-c1q tumor necrosis factor-related [Homo 
sapiens] 
Bt.9124.1.A1_at 2.24 up  Transcribed sequences 
Bt.9286.1.S1_at 2.24 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_004853.1 (H.sapiens)  LPS-induced TNF-alpha factor [Homo 
sapiens] 
Bt.702.1.S1_at 2.23 up  Transcribed sequences 
Bt.4275.2.S1_at 2.23 up  Transcribed sequences 
Bt.20428.2.S1_a_at 2.23 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_003972.1 (H.sapiens)  protein regulator of cytokinesis 1; 
protein regulating cytokinesis 1 [Homo sapiens] 
Bt.22390.2.S1_at 2.23 up  
Transcribed sequence with moderate similarity to protein pir:KUHU 
(H.sapiens) KUHU ferroxidase 
Bt.13336.2.S1_at 2.22 up  
Transcribed sequence with strong similarity to protein pir:T46486 
(H.sapiens) T46486 chromosomal protein CAPC homolog 
DKFZp434F205.1 [similarity] - human 
Bt.27081.1.S1_at 2.22 up  Transcribed sequences 
Bt.12285.3.S1_a_at 2.22 up  
Transcribed sequence with moderate similarity to protein sp:Q13287 
(H.sapiens) NMI_HUMAN N-myc-interactor 
Bt.2726.1.S1_at 2.22 up  Transcribed sequences 
Bt.19811.1.A1_at 2.21 up  Transcribed sequences 
Bt.14370.1.A1_at 2.21 up  Transcribed sequences 
Bt.10043.1.S1_at 2.21 up  Transcribed sequences 
Bt.12728.3.S1_at 2.21 up  Transcribed sequences 
Bt.5576.1.S1_at 2.20 up  Transcribed sequences 
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Bt.13506.1.A1_at 2.20 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_490719.1 (C.elegans)  Y48G1A.3.p [Caenorhabditis elegans] 
Bt.20846.1.A1_a_at 2.20 up  
Transcribed sequence with strong similarity to protein sp:O15194 
(H.sapiens) NIF1_HUMAN Nuclear LIM interactor-interacting factor 
1 
Bt.10816.1.S1_s_at 2.19 up  Transcribed sequences 
Bt.22664.1.A1_at 2.19 up  Transcribed sequences 
Bt.12285.2.S1_a_at 2.19 up  
Transcribed sequence with moderate similarity to protein sp:Q13287 
(H.sapiens) NMI_HUMAN N-myc-interactor 
Bt.4095.1.A1_at 2.18 up  Transcribed sequences 
Bt.7804.1.S1_at 2.18 up GYG glycogenin 
Bt.2388.1.S1_at 2.18 up  Transcribed sequences 
Bt.18325.2.A1_at 2.18 up  
Transcribed sequence with moderate similarity to protein pir:I37356 
(H.sapiens) I37356 epithelial microtubule-associated protein, 115K - 
human 
Bt.8894.1.S1_at 2.18 up  Transcribed sequences 
Bt.21482.3.A1_at 2.17 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_001189.1 (H.sapiens)  B-lymphocyte-induced maturation 
protein 1; positive regulatory domain I-binding factor 1 [Homo 
sapiens] 
Bt.2220.2.A1_a_at 2.17 up selp selenoprotein P 
Bt.17792.1.S1_at 2.17 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_065984.1 (H.sapiens)  zinc finger protein 317; KRAB-
containing zinc finger protein 317 [Homo sapiens] 
Bt.24405.1.S1_at 2.16 up  
Transcribed sequence with strong similarity to protein 
ref:NP_570139.1 (H.sapiens)  similar to uroplakin 1B; tetraspan 
[Homo sapiens] 
Bt.10398.1.S1_at 2.16 up  
Transcribed sequence with strong similarity to protein pir:A44323 
(H.sapiens) A44323 pentaxin PTX3 precursor - human 
Bt.23394.1.S1_at 2.16 up  Transcribed sequences 
Bt.198.1.S1_at 2.16 up ASPH aspartate beta-hydroxylase 
Bt.1976.1.S1_at 2.16 up  
Transcribed sequence with strong similarity to protein pir:A49013 
(H.sapiens) A49013 tumor cell suppression protein HTS1 [imported] - 
human 
Bt.4275.1.S1_at 2.16 up  Transcribed sequences 
Bt.3125.1.S1_at 2.16 up  
Transcribed sequence with strong similarity to protein 
ref:NP_036395.1 (H.sapiens)  tubulin tyrosine ligase-like 1; tubulin-
tyrosine ligase; chromosome 22 open reading frame 7 [Homo sapiens] 
Bt.27811.1.S1_at 2.16 up  
Transcribed sequence with strong similarity to protein pir:I37904 
(H.sapiens) I37904 c-myc promoter-binding protein irlB - human 
Bt.10111.1.S1_at 2.16 up  Transcribed sequences 
Bt.3580.2.S1_at 2.15 up  
Transcribed sequence with weak  similarity to protein sp:Q99538 
(H.sapiens) LEGU_HUMAN Legumain precursor 
Bt.22270.1.S1_at 2.14 up  Transcribed sequences 
Bt.29696.1.A1_at 2.14 up  
Partial mRNA for fibroblast growth factor receptor 2 (FGFR2 gene), 
isoform IIIc 
Bt.25101.1.S1_at 2.14 up  Transcribed sequences 
Bt.6302.1.S1_at 2.14 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_003795.1 (H.sapiens)  receptor 
Bt.27971.1.S1_at 2.14 up CB11 cyanogen bromide 
Bt.3198.2.S1_at 2.14 up  
Transcribed sequence with strong similarity to protein sp:Q01082 
(H.sapiens) SPCO_HUMAN Spectrin beta chain, brain 1 
Bt.20654.1.A1_a_at 2.14 up  Transcribed sequences 
Bt.28614.1.A1_at 2.13 up  Transcribed sequences 
Bt.22869.1.S1_at 2.13 up FABP5 fatty acid binding protein 5 
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Bt.1286.1.S1_a_at 2.13 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_002880.1 (H.sapiens)  retinoic acid receptor responder 
Bt.2129.1.S1_at 2.13 up  
Transcribed sequence with weak  similarity to protein pir:T31613 
(C.elegans) T31613 hypothetical protein Y50E8A.i - Caenorhabditis 
elegans 
Bt.22204.1.A1_at 2.12 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_055164.1 (H.sapiens)  apolipoprotein L, 3; TNF-inducible 
protein CG12-1 [Homo sapiens] 
Bt.22139.1.S1_at 2.11 up  Transcribed sequences 
Bt.21390.1.S1_at 2.11 up LOC404065 pro-alpha 1(II) mRNA 
Bt.18642.1.A1_at 2.11 up  Transcribed sequences 
Bt.24687.1.A1_at 2.11 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_112203.1 (H.sapiens)  exonuclease NEF-sp [Homo sapiens] 
Bt.17883.1.S1_at 2.11 up  Transcribed sequences 
Bt.23586.1.S1_at 2.10 up  
Transcribed sequence with strong similarity to protein 
ref:NP_002950.3 (H.sapiens)  sortilin 1 preproprotein; neurotensin 
receptor 3; neurotensin receptor, 100-kD; 100 kDa NT receptor; 
glycoprotein 95 [Homo sapiens] 
Bt.12714.1.A1_at 2.10 up  
Transcribed sequence with moderate similarity to protein sp:Q92561 
(H.sapiens) Y273_HUMAN Hypothetical protein KIAA0273 
Bt.979.1.A1_at 2.10 up  
Transcribed sequence with weak  similarity to protein sp:Q9UBC5 
(H.sapiens) MYHL_HUMAN Brush border myosin I 
Bt.25052.1.S1_at 2.09 up  
Transcribed sequence with strong similarity to protein 
ref:NP_055104.2 (H.sapiens)  calpain 6; calpain-like protease; 
calpamodulin [Homo sapiens] 
Bt.27957.1.A1_at 2.09 up  
Transcribed sequence with moderate similarity to protein pir:T34522 
(H.sapiens) T34522 hypothetical protein DKFZp566D244.1 - human 
Bt.18080.2.S1_at 2.08 up  
Transcribed sequence with strong similarity to protein 
ref:NP_060369.1 (H.sapiens)  hypothetical protein FLJ20607; 
tescalcin; likely ortholog of mouse tescalcin [Homo sapiens] 
Bt.355.1.S1_at 2.08 up CALD1 caldesmon, smooth muscle 
Bt.4565.1.S1_at 2.08 up  
Transcribed sequence with strong similarity to protein sp:O43623 
(H.sapiens) SLUG_HUMAN Zinc finger protein SLUG 
Bt.15839.1.S1_at 2.08 up  Transcribed sequences 
Bt.7156.1.S1_at 2.08 up SLC4A4 solute carrier family 4, sodium bicarbonatecotransporter, member 4 
Bt.21956.2.A1_at 2.08 up  Transcribed sequences 
Bt.21150.1.A1_at 2.08 up  
Transcribed sequence with weak  similarity to protein sp:Q92889 
(H.sapiens) XPF_HUMAN DNA-repair protein complementing XP-F 
cell 
Bt.28702.1.S1_at 2.07 up  Transcribed sequences 
Bt.1552.1.S1_at 2.07 up SARS seryl-tRNA synthetase 
Bt.21085.1.S1_at 2.07 up  Transcribed sequences 
Bt.28530.1.A1_at 2.07 up  
Transcribed sequence with moderate similarity to protein pdb:1DVM 
(H.sapiens) A Chain A, Active Form Of Human Pai-1 
Bt.26317.1.A1_at 2.06 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_079268.1 (H.sapiens)  hypothetical protein FLJ12547 [Homo 
sapiens] 
Bt.18094.1.A1_at 2.06 up  Transcribed sequences 
Bt.27884.1.S1_at 2.06 up  
Transcribed sequence with weak  similarity to protein sp:Q99536 
(H.sapiens) VAT1_HUMAN Synaptic vesicle membrane protein 
VAT-1 homolog 
Bt.22822.1.S1_at 2.06 up  
Transcribed sequence with strong similarity to protein sp:P00722 (E. 
coli) BGAL_ECOLI Beta-galactosidase 
Bt.16891.1.A1_at 2.06 up  
Transcribed sequence with strong similarity to protein sp:O00141 
(H.sapiens) SGK_HUMAN Serine/threonine-protein kinase Sgk 
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Bt.19583.1.A1_at 2.06 up  Transcribed sequences 
Bt.19845.2.A1_at 2.06 up  Transcribed sequences 
Bt.6374.1.S1_at 2.06 up  Transcribed sequences 
Bt.5120.1.S1_at 2.05 up NNT nicotinamide nucleotide transhydrogenase 
Bt.4818.1.S1_at 2.05 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_116010.1 (H.sapiens)  X-linked protein [Homo sapiens] 
Bt.3278.1.A1_at 2.05 up  Transcribed sequences 
Bt.20479.1.S1_at 2.05 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_057314.1 (H.sapiens)  flavohemoprotein b5+b5R [Homo 
sapiens] 
Bt.23000.2.S1_a_at 2.05 up  
Transcribed sequence with weak  similarity to protein pir:T48686 
(H.sapiens) T48686 hypothetical protein DKFZp761D1823.1 - human 
Bt.28566.1.S1_at 2.05 up  Transcribed sequences 
Bt.727.2.S1_at 2.05 up  
Transcribed sequence with strong similarity to protein sp:Q9Y3C0 
(H.sapiens) AD16_HUMAN Protein AD-016 
Bt.17212.1.A1_at 2.05 up  Transcribed sequences 
Bt.23127.1.S1_at 2.05 up  
Transcribed sequence with moderate similarity to protein sp:P42785 
(H.sapiens) PCP_HUMAN Lysosomal Pro-X carboxypeptidase 
precursor 
Bt.5203.1.S1_at 2.05 up PRDX4 peroxiredoxin 4 
Bt.6377.1.S1_at 2.04 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_005813.1 (H.sapiens)  Down syndrome critical region gene 1-
like 1 protein; thyroid hormone-responsive 
Bt.2765.1.S1_at 2.03 up  Transcribed sequences 
Bt.9325.1.A1_at 2.03 up  Transcribed sequences 
Bt.23779.1.A1_at 2.03 up  Transcribed sequence 
Bt.29306.1.A1_at 2.03 up  Transcribed sequences 
Bt.426.1.S1_at 2.03 up DBT 
component of branched chain keto aciddehydrogenase complex; 
maple syrup urine disease] 
Bt.10543.1.S1_at 2.03 up  Transcribed sequences 
Bt.26444.1.A1_at 2.02 up  Transcribed sequence 
Bt.24228.1.S1_at 2.02 up  Transcribed sequences 
Bt.21800.1.S1_at 2.02 up  
Transcribed sequence with strong similarity to protein sp:O94855 
(H.sapiens) S24D_HUMAN Protein transport protein Sec24D 
Bt.1422.1.S1_at 2.02 up  Transcribed sequences 
Bt.19548.1.A1_at 2.02 up  Transcribed sequence 
Bt.10077.1.S3_at 2.02 up IRF1 interferon responsive factor 1 
Bt.16514.1.S1_at 2.02 up  
Transcribed sequence with weak  similarity to protein 
ref:NP_076433.1 (H.sapiens)  cytochrome P450 isoform 4F12 [Homo 
sapiens] 
Bt.21543.2.S1_at 2.02 up  Transcribed sequences 
Bt.4855.1.S1_a_at 2.02 up SLC6A9 
solute carrier family 6 (neurotransmittertransporter, glycine), member 
9 
Bt.11832.2.A1_at 2.02 up  Transcribed sequences 
Bt.22251.1.A1_at 2.01 up  Transcribed sequence 
Bt.9667.2.S1_at 2.01 up  Transcribed sequences 
Bt.2600.1.A1_at 2.01 up  Transcribed sequences 
Bt.29686.1.S1_at 2.01 up  
Partial mRNA for fibroblast growth factor receptor 2 (FGFR2 gene), 
isoform IIIb 
Bt.231.1.S1_at 2.01 up TXN thioredoxin 
Bt.2052.2.S1_at 2.01 up  Transcribed sequences 
Bt.9004.1.S1_at 2.01 up  
Transcribed sequence with moderate similarity to protein 
ref:NP_001181.1 (H.sapiens)  branched chain aminotransferase 2, 
mitochondrial [Homo sapiens] 
Bt.24778.1.S1_at 2.00 up  Transcribed sequences 
Bt.2046.1.S1_at 2.00 up ext1 sushi repeat-containing protein 
Bt.16142.3.A1_at 2.00 up  Transcribed sequences 
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Bt.22265.1.S1_at 2.00 up  
Transcribed sequence with strong similarity to protein sp:P18146 
(H.sapiens) EGR1_HUMAN Early growth response protein 1 
Bt.20934.1.S1_at 2.00 up  Transcribed sequences 
Bt.29794.1.A1_at 2.00 down  
Glucose induced gene {clone 2C} [cattle, thoracic aorta smooth 
muscle cells, mRNA Partial, 162 nt] 
Bt.16538.2.A1_at 2.00 down  Transcribed sequences 
Bt.24678.1.A1_at 2.00 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_008994.1 (H.sapiens)  vascular Rab-GAP/TBC-containing 
[Homo sapiens] 
Bt.29423.1.A1_at 2.00 down  
Transcribed sequence with weak  similarity to protein sp:P01876 
(H.sapiens) ALC1_HUMAN Ig alpha-1 chain C region 
Bt.7912.1.A1_at 2.00 down  Transcribed sequences 
Bt.16018.1.S2_at 2.00 down CASP4 caspase 4, apoptosis-related cysteine protease 
Bt.21944.1.S1_at 2.01 down  
Transcribed sequence with moderate similarity to protein sp:P18827 
(H.sapiens) SDC1_HUMAN Syndecan-1 precursor 
Bt.4544.1.S1_at 2.01 down  
Transcribed sequence with moderate similarity to protein pir:B36429 
(H.sapiens) B36429 integrin alpha-6 chain form A precursor - human 
Bt.13278.1.S1_at 2.01 down  Transcribed sequences 
Bt.11276.2.A1_at 2.01 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_079345.1 (H.sapiens)  hypothetical protein FLJ14299 [Homo 
sapiens] 
Bt.28644.1.A1_at 2.01 down  Transcribed sequences 
Bt.28208.1.S1_at 2.02 down  
Transcribed sequence with strong similarity to protein sp:O00757 
(H.sapiens) F16Q_HUMAN Fructose-1,6-bisphosphatase isozyme 2 
Bt.23786.1.A1_at 2.02 down  Transcribed sequences 
Bt.24424.1.S1_at 2.02 down  
Transcribed sequence with weak  similarity to protein prf:2124399A 
(H.sapiens) 2124399A transposase-like protein [Homo sapiens] 
Bt.18203.1.A1_at 2.02 down  
Transcribed sequence with strong similarity to protein sp:P57087 
(H.sapiens) JAM2_HUMAN Junctional adhesion molecule 2 
precursor 
Bt.5301.2.S1_a_at 2.02 down THBS thrombospondin 
Bt.8335.1.S1_at 2.03 down  Transcribed sequences 
Bt.15732.1.S1_at 2.03 down  Transcribed sequences 
Bt.20692.1.A1_at 2.03 down  Transcribed sequences 
Bt.27591.1.S1_at 2.04 down  
Transcribed sequence with moderate similarity to protein 
ref:NP_079230.1 (H.sapiens)  hypothetical protein FLJ11807 [Homo 
sapiens] 
Bt.16340.1.A1_at 2.04 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_055886.1 (H.sapiens)  GTPase regulator associated with the 
focal adhesion kinase pp125 [Homo sapiens] 
Bt.26901.1.S1_at 2.05 down  
Transcribed sequence with moderate similarity to protein 
ref:NP_067541.1 (M.musculus)  junctophilin 2 [Mus musculus] 
Bt.9193.1.S1_at 2.05 down  Transcribed sequences 
Bt.28558.1.S1_at 2.05 down  Transcribed sequences 
Bt.25112.1.S1_at 2.05 down  
Transcribed sequence with strong similarity to protein 
ref:NP_057192.1 (H.sapiens)  androgen induced protein; CGI-103 
protein [Homo sapiens] 
Bt.28382.1.S1_at 2.06 down  Transcribed sequences 
Bt.7236.1.S1_at 2.06 down PIK3R1 
phosphoinositide-3-kinase, regulatory subunit,polypeptide 1 (p85 
alpha) 
Bt.303.1.S1_at 2.06 down P2RY1 purinergic receptor P2Y1 
Bt.13608.1.A1_at 2.07 down  Transcribed sequence 
Bt.22010.1.S1_at 2.07 down  Transcribed sequences 
Bt.546.3.S1_a_at 2.07 down KCNMA1 
potassium large conductance calcium-activated channel, subfamily M, 
alpha member 1 
Bt.86.1.S1_at 2.08 down SERPINF2 alpha-2-plasmin inhibitor 
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Bt.27433.2.A1_at 2.08 down  
Transcribed sequence with strong similarity to protein 
ref:NP_071732.1 (H.sapiens)  RAB38; Rab-related GTP-binding 
protein [Homo sapiens] 
Bt.4375.1.S1_at 2.09 down  
Transcribed sequence with strong similarity to protein 
ref:NP_003770.1 (H.sapiens)  UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase 3 
Bt.17939.1.S1_at 2.09 down  
Transcribed sequence with strong similarity to protein sp:P20700 
(H.sapiens) LAM1_HUMAN Lamin B1 
Bt.20880.1.S1_at 2.09 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_003719.2 (H.sapiens)  unc5 
Bt.1969.1.S1_at 2.10 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_066921.1 (H.sapiens)  calcium channel, voltage-dependent, 
alpha 1H subunit [Homo sapiens] 
Bt.16521.2.A1_at 2.10 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_476946.1 (D.melanogaster)  lio-P1; pigeon [Drosophila 
melanogaster] 
Bt.27425.1.A1_a_at 2.10 down  Transcribed sequences 
Bt.8328.1.S1_at 2.10 down  Transcribed sequences 
Bt.17230.1.A1_at 2.11 down  Transcribed sequences 
Bt.18631.1.A1_at 2.11 down  Transcribed sequences 
Bt.5789.1.S1_at 2.11 down  
Transcribed sequence with strong similarity to protein 
ref:NP_076201.1 (M.musculus)  spinster-like protein [Mus musculus] 
Bt.5301.2.A1_at 2.11 down THBS thrombospondin 
Bt.11276.1.A1_at 2.11 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_079345.1 (H.sapiens)  hypothetical protein FLJ14299 [Homo 
sapiens] 
Bt.5432.3.S1_at 2.11 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_005436.1 (H.sapiens)  chondroitin sulfate proteoglycan 6 
Bt.514.1.S1_at 2.12 down DNAJC6 DnaJ (Hsp40) homolog, subfamily C, member 6 
Bt.7901.3.S1_at 2.12 down  Transcribed sequences 
Bt.25294.1.A1_at 2.12 down  Transcribed sequence 
Bt.5038.1.S1_at 2.12 down FGF1 fibroblast growth factor, acidic [endothelial growth factor] 
Bt.22747.1.S1_at 2.12 down  Transcribed sequences 
Bt.15970.1.A1_at 2.13 down  
Transcribed sequence with moderate similarity to protein 
ref:NP_006527.1 (H.sapiens)  calcium activated chloride channel 2 
precursor [Homo sapiens] 
Bt.19462.1.A1_at 2.14 down  Transcribed sequence 
Bt.6963.1.A1_at 2.14 down  
Transcribed sequence with moderate similarity to protein pir:A38445 
(H.sapiens) A38445 EV12B protein precursor - human 
Bt.236.1.S1_at 2.14 down BTC betacellulin 
Bt.11061.1.S1_at 2.14 down  
Transcribed sequence with moderate similarity to protein pir:A32160 
(H.sapiens) A32160 tenascin-C - human 
Bt.4763.1.S1_at 2.15 down CD3Z antigen CD3Z, zeta polypeptide 
Bt.16521.1.S1_at 2.15 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_476946.1 (D.melanogaster)  lio-P1; pigeon [Drosophila 
melanogaster] 
Bt.18444.2.A1_at 2.16 down  Transcribed sequences 
Bt.29880.1.A1_at 2.16 down  
Epidermal growth factor receptor precursor (EGFR) mRNA, partial 
cds 
Bt.5110.1.A1_at 2.17 down  Transcribed sequences 
Bt.3405.1.S1_at 2.17 down  Transcribed sequences 
Bt.10922.1.A1_at 2.17 down  Transcribed sequences 
Bt.19482.1.A1_at 2.18 down  
Transcribed sequence with moderate similarity to protein sp:P02786 
(H.sapiens) TFR1_HUMAN Transferrin receptor protein 1 
Bt.2318.1.A1_at 2.18 down  Transcribed sequences 
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Bt.11030.1.S1_at 2.19 down  
Transcribed sequence with weak  similarity to protein sp:Q9NLA6 
(D.melanogaster) OAF_DROME Out at first protein [Contains: Out at 
first short protein] 
Bt.7641.1.S1_at 2.19 down  
Transcribed sequence with moderate similarity to protein sp:O00764 
(H.sapiens) PDXK_HUMAN Pyridoxine kinase 
Bt.7468.1.S1_at 2.19 down  Transcribed sequences 
Bt.18843.1.A1_at 2.20 down  Transcribed sequences 
Bt.16311.1.A1_at 2.20 down  Transcribed sequences 
Bt.2304.1.A1_at 2.20 down  Transcribed sequences 
Bt.22475.1.S1_at 2.21 down  
Transcribed sequence with strong similarity to protein 
ref:NP_005867.1 (H.sapiens)  nuclear protein, marker for 
differentiated aortic smooth muscle [Homo sapiens] 
Bt.3532.1.A1_at 2.22 down  Transcribed sequences 
Bt.3891.1.S1_at 2.22 down  Transcribed sequences 
Bt.24157.1.A1_at 2.22 down  
Transcribed sequence with weak  similarity to protein pir:T12458 
(H.sapiens) T12458 hypothetical protein DKFZp564O0823.1 - human 
Bt.18083.1.S1_at 2.23 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_057479.1 (H.sapiens)  butyrate-induced transcript 1; 
hypothetical protein; butyrate-induced transcript 1 [Homo sapiens] 
Bt.22339.2.S1_at 2.23 down  Transcribed sequences 
Bt.6771.1.S1_at 2.23 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_116256.1 (H.sapiens)  hypothetical protein FLJ14966 [Homo 
sapiens] 
Bt.9832.1.S1_at 2.24 down  Transcribed sequences 
Bt.9542.1.S1_at 2.24 down  
Transcribed sequence with strong similarity to protein sp:P18031 
(H.sapiens) PTN1_HUMAN Protein-tyrosine phosphatase, non-
receptor type 1 
Bt.7784.1.S1_at 2.24 down  Transcribed sequences 
Bt.5943.2.S1_at 2.24 down  Transcribed sequences 
Bt.18130.1.A1_at 2.24 down  Transcribed sequences 
Bt.10604.1.A1_at 2.24 down  Transcribed sequence 
Bt.19213.1.A1_at 2.25 down  Transcribed sequences 
Bt.13546.1.A1_at 2.25 down  Transcribed sequences 
Bt.18820.1.S1_at 2.26 down  Transcribed sequences 
Bt.11462.1.S1_at 2.26 down  
Transcribed sequence with moderate similarity to protein pir:A33880 
(H.sapiens) A33880 syndecan 2 - human 
Bt.21319.1.A1_at 2.26 down  Transcribed sequences 
Bt.546.2.S1_at 2.27 down  BK potassium ion channel isoform B 
Bt.5432.2.S1_at 2.27 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_005436.1 (H.sapiens)  chondroitin sulfate proteoglycan 6 
Bt.12936.1.S1_at 2.27 down CATHL5 cathelicidin 5 
Bt.4053.1.S1_at 2.28 down TBXA2R thromboxane A2 receptor 
Bt.3533.1.S1_at 2.28 down  
Transcribed sequence with strong similarity to protein sp:P43268 
(H.sapiens) ETV4_HUMAN ADENOVIRUS E1A ENHANCER 
BINDING PROTEIN 
Bt.9925.1.S1_at 2.28 down  Transcribed sequences 
Bt.9833.1.S1_a_at 2.28 down  
Transcribed sequence with moderate similarity to protein 
ref:NP_077276.1 (H.sapiens)  hypothetical protein MGC2217 [Homo 
sapiens] 
Bt.352.5.S1_a_at 2.28 down FP prostaglandin F2alpha receptor isoform-epsiron 
Bt.13026.1.A1_at 2.28 down DAX-1 orphan nuclear receptor DAX-1 
Bt.5336.1.A1_a_at 2.28 down TF transferrin 
Bt.29724.1.S1_at 2.29 down  6-phosphofructo-2-kinase [cattle, brain, mRNA Partial, 1428 nt] 
Bt.25403.1.A1_at 2.29 down  Transcribed sequence 
Bt.26316.1.A1_at 2.29 down  Transcribed sequences 
Bt.5432.1.S1_at 2.30 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_005436.1 (H.sapiens)  chondroitin sulfate proteoglycan 6 
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Bt.546.1.S1_at 2.30 down KCNMA1 
potassium large conductance calcium-activatedchannel, subfamily M, 
alpha member 1 
Bt.16311.2.S1_at 2.31 down  Transcribed sequences 
Bt.8031.2.S1_a_at 2.31 down  
Transcribed sequence with strong similarity to protein sp:Q99687 
(H.sapiens) MEI3_HUMAN Homeobox protein Meis3 
Bt.10124.1.S1_at 2.32 down  
Transcribed sequence with moderate similarity to protein pir:T46910 
(H.sapiens) T46910 hypothetical protein DKFZp761L0424.1 - human 
Bt.1546.1.S1_at 2.32 down  Transcribed sequences 
Bt.15905.1.S1_at 2.32 down  Transcribed sequences 
Bt.13466.1.S1_at 2.32 down  
Transcribed sequence with strong similarity to protein 
ref:NP_115912.1 (H.sapiens)  oxysterol-binding protein-like protein 
6; OSBP-related protein 6 [Homo sapiens] 
Bt.18444.1.A1_at 2.33 down  Transcribed sequences 
Bt.5313.1.S1_at 2.34 down MMP2 matrix metalloproteinase 2 (72 KDa type IVcollagenase) 
Bt.26440.1.A1_at 2.34 down  Transcribed sequences 
Bt.26969.1.A1_at 2.34 down  Transcribed sequences 
Bt.18251.2.A1_at 2.36 down  
Transcribed sequence with moderate similarity to protein pir:T46364 
(H.sapiens) T46364 hypothetical protein DKFZp434P0116.1 - human 
Bt.18845.1.A1_at 2.36 down  Transcribed sequence 
Bt.21981.2.S1_at 2.36 down  Transcribed sequences 
Bt.13071.4.S1_at 2.36 down CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
Bt.26284.1.A1_at 2.36 down  Transcribed sequence 
Bt.10921.1.S1_at 2.37 down  Transcribed sequences 
Bt.22987.1.A1_at 2.37 down PRG4 
proteoglycan 4, (megakaryocyte stimulating factor, articular 
superficial zone protein, camptodactyly, arthropathy, coxa vara, 
pericarditis syndrome) 
Bt.3996.1.S1_at 2.37 down  Transcribed sequences 
Bt.2903.1.S1_at 2.38 down CXADR coxsackie virus and adenovirus receptor 
Bt.17654.1.A1_at 2.38 down  Transcribed sequence 
Bt.21252.2.S1_at 2.39 down  
Transcribed sequence with moderate similarity to protein sp:Q02846 
(H.sapiens) CYGD_HUMAN Retinal guanylyl cyclase 1 precursor 
Bt.15958.3.S1_at 2.40 down  
Transcribed sequence with strong similarity to protein sp:P21439 
(H.sapiens) MDR3_HUMAN Multidrug resistance protein 3 
Bt.17330.1.A1_at 2.40 down  Transcribed sequence 
Bt.27573.1.A1_at 2.41 down  Transcribed sequence 
Bt.25850.1.S1_at 2.42 down  Transcribed sequences 
Bt.18623.1.A1_at 2.43 down  Transcribed sequences 
Bt.27228.1.A1_at 2.43 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_056982.1 (H.sapiens)  HIV-1 inducer of short transcripts 
binding protein [Homo sapiens] 
Bt.1087.1.S1_at 2.44 down  
Transcribed sequence with strong similarity to protein 
ref:NP_004661.1 (H.sapiens)  3-prime-phosphoadenosine 5-prime-
phosphosulfate synthase 2 [Homo sapiens] 
Bt.4506.1.S1_at 2.44 down MYO10 myosin X 
Bt.2494.2.S1_a_at 2.44 down  Transcribed sequences 
Bt.29129.1.S1_at 2.45 down  
Transcribed sequence with strong similarity to protein 
ref:NP_006399.1 (H.sapiens)  anterior gradient 2 homolog 
Bt.16740.1.A1_at 2.46 down  
Transcribed sequence with moderate similarity to protein sp:Q13751 
(H.sapiens) LMB3_HUMAN Laminin beta-3 chain precursor 
Bt.17585.1.S1_at 2.46 down ST3GAL-V alpha2,3-sialyltransferase 
Bt.16088.1.A1_at 2.47 down  
Transcribed sequence with strong similarity to protein sp:Q9NQX4 
(H.sapiens) MY5C_HUMAN Myosin Vc 
Bt.5078.1.S1_at 2.48 down  
Transcribed sequence with moderate similarity to protein sp:Q9UNF1 
(H.sapiens) MGD2_HUMAN Melanoma-associated antigen D2 
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Bt.26198.1.A1_at 2.48 down  Transcribed sequences 
Bt.3857.1.S1_at 2.48 down ENDOG endonuclease G 
Bt.13570.1.S1_at 2.48 down PRKRA 
protein kinase, interferon-inducible double stranded RNA dependent 
activator 
Bt.6838.1.A1_at 2.48 down  Transcribed sequence 
Bt.22637.1.S1_at 2.49 down  Transcribed sequences 
Bt.7641.2.S1_a_at 2.49 down  
Transcribed sequence with moderate similarity to protein sp:O00764 
(H.sapiens) PDXK_HUMAN Pyridoxine kinase 
Bt.18009.1.A1_at 2.49 down  Transcribed sequences 
Bt.7012.1.S1_at 2.49 down  
Transcribed sequence with moderate similarity to protein sp:O75363 
(H.sapiens) BCAS_HUMAN Breast carcinoma amplified sequence 1 
Bt.2359.1.A1_at 2.51 down  
Transcribed sequence with moderate similarity to protein sp:P06241 
(H.sapiens) FYN_HUMAN Proto-oncogene tyrosine-protein kinase 
FYN 
Bt.16567.1.A1_at 2.51 down  Transcribed sequences 
Bt.28773.1.A1_at 2.52 down  Transcribed sequences 
Bt.24477.1.S1_a_at 2.53 down  
Transcribed sequence with strong similarity to protein sp:O60704 
(H.sapiens) TPS2_HUMAN Protein-tyrosine sulfotransferase 2 
Bt.13071.3.S1_at 2.53 down CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
Bt.13570.1.A1_at 2.54 down PRKRA 
protein kinase, interferon-inducible double stranded RNA dependent 
activator 
Bt.13071.1.S1_at 2.55 down CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
Bt.5011.1.S2_at 2.56 down LTBP2 
latent transforming growth factor beta binding protein 2 
(NOTE:redefinition of symbol) 
Bt.7346.1.S1_at 2.57 down  
Transcribed sequence with moderate similarity to protein sp:P19012 
(H.sapiens) K1CO_HUMAN Keratin, type I cytoskeletal 15 
Bt.22854.1.S1_at 2.57 down CA2 carbonic anhydrase II 
Bt.6879.1.S1_at 2.58 down  Transcribed sequences 
Bt.21685.1.A1_at 2.60 down  Transcribed sequences 
Bt.14098.1.S1_at 2.61 down  
Transcribed sequence with strong similarity to protein 
ref:NP_055083.1 (H.sapiens)  microtubule-associated protein, RP/EB 
family, member 2; T-cell activation protein, EB1 family; APC-
binding protein EB1 [Homo sapiens] 
Bt.27441.1.S1_at 2.62 down  Transcribed sequences 
Bt.26735.1.S1_at 2.63 down  Transcribed sequences 
Bt.13878.1.S1_at 2.64 down GCH1 GTP cyclohydrolase 1 (dopa-responsive dystonia) 
Bt.21224.1.S1_at 2.66 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_083061.1 (M.musculus)  RIKEN cDNA 1200017A24 [Mus 
musculus] 
Bt.28708.1.S1_at 2.67 down  Transcribed sequences 
Bt.22987.2.S1_at 2.68 down PRG4 
proteoglycan 4, (megakaryocyte stimulating factor, articular 
superficial zone protein, camptodactyly, arthropathy, coxa vara, 
pericarditis syndrome) 
Bt.28728.1.A1_at 2.68 down  
Transcribed sequence with strong similarity to protein 
ref:NP_116179.1 (H.sapiens)  hypothetical protein FLJ14466 [Homo 
sapiens] 
Bt.4802.1.S1_at 2.69 down LTF lactoferrin [lactotransferrin] 
Bt.18073.1.A1_at 2.69 down  Transcribed sequences 
Bt.19072.1.A1_at 2.70 down  Transcribed sequences 
Bt.13027.1.A1_at 2.70 down  11 beta-hydroxysteroid dehydrogenase type 1 
Bt.15675.1.S1_at 2.70 down ADAMTS4 
a disintegrin-like and metalloprotease(reprolysin type) with 
thrombospondin type 1 motif, 4 
Bt.8667.1.S1_at 2.75 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_569999.1 (D.melanogaster)  EG:BACH48C10.2 gene product 
[Drosophila melanogaster] 
Bt.22050.1.S1_at 2.76 down  
Transcribed sequence with strong similarity to protein pir:TVHUHC 
(H.sapiens) TVHUHC protein-tyrosine kinase 
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Bt.21102.1.S1_at 2.76 down  Transcribed sequences 
Bt.20748.1.A1_at 2.77 down  Transcribed sequences 
Bt.13071.2.S1_at 2.77 down CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
Bt.3513.1.A1_at 2.78 down  Transcribed sequences 
Bt.15554.1.A1_at 2.78 down  Transcribed sequences 
Bt.4199.1.S1_at 2.79 down IL1RN interleukin 1 receptor antagonist 
Bt.13125.1.S1_s_at 2.79 down BNBD-5 neutrophil beta-defensin 5 
Bt.29066.1.A1_at 2.80 down  Transcribed sequence 
Bt.26926.1.S1_at 2.80 down  Transcribed sequences 
Bt.13071.3.A1_at 2.80 down CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
Bt.13159.1.A1_at 2.80 down PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 
Bt.15188.1.S1_at 2.81 down  Transcribed sequences 
Bt.15808.1.S1_at 2.81 down  Transcribed sequences 
Bt.20512.1.S1_at 2.84 down  
Transcribed sequence with moderate similarity to protein pir:A53317 
(H.sapiens) A53317 collagen alpha 1 
Bt.28195.1.S1_at 2.84 down  Transcribed sequences 
Bt.18298.1.A1_at 2.85 down  Transcribed sequences 
Bt.2318.2.S1_at 2.87 down  Transcribed sequences 
Bt.15037.1.S1_at 2.90 down  Transcribed sequences 
Bt.18618.1.A1_at 2.90 down  Transcribed sequences 
Bt.20512.2.S1_at 2.92 down  
Transcribed sequence with moderate similarity to protein pir:A53317 
(H.sapiens) A53317 collagen alpha 1 
Bt.12757.1.S1_at 2.93 down NGFB nerve growth factor, beta polypeptide 
Bt.20942.1.S1_at 2.93 down  Transcribed sequences 
Bt.546.3.A1_at 2.93 down KCNMA1 
potassium large conductance calcium-activated channel, subfamily M, 
alpha member 1 
Bt.26040.1.A1_at 2.94 down  Transcribed sequence 
Bt.16049.1.S1_at 2.95 down  
Transcribed sequence with moderate similarity to protein sp:Q13571 
(H.sapiens) LAM5_HUMAN Lysosomal-associated 
multitransmembrane protein 
Bt.24592.1.S1_at 3.01 down  
Transcribed sequence with moderate similarity to protein pir:A32160 
(H.sapiens) A32160 tenascin-C - human 
Bt.24231.2.S1_at 3.01 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_068509.1 (R.norvegicus)  IP63 protein [Rattus norvegicus] 
Bt.4137.1.A1_at 3.02 down  
Transcribed sequence with weak  similarity to protein sp:P27469 
(H.sapiens) G0S2_HUMAN Putative lymphocyte G0/G1 switch 
protein 2 
Bt.20636.1.A1_at 3.04 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_493307.1 (C.elegans)  F22G12.5.p [Caenorhabditis elegans] 
Bt.11570.1.A1_at 3.04 down  Transcribed sequences 
Bt.155.1.S1_at 3.05 down IL8 interleukin 8 [neutrophil activating peptide 1] 
Bt.24231.1.A1_at 3.06 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_068509.1 (R.norvegicus)  IP63 protein [Rattus norvegicus] 
Bt.22322.1.S1_at 3.06 down  
Transcribed sequence with moderate similarity to protein sp:P02735 
(H.sapiens) SAA_HUMAN Serum amyloid A protein precursor 
Bt.26110.1.A1_at 3.06 down  Transcribed sequence 
Bt.5403.1.S1_at 3.07 down XDH xanthine dehydrogenase 
Bt.8790.1.S1_at 3.08 down  Transcribed sequences 
Bt.23325.1.A1_at 3.09 down  Transcribed sequences 
Bt.21962.1.S1_at 3.09 down  Transcribed sequences 
Bt.15579.1.A1_at 3.11 down  Transcribed sequences 
Bt.352.2.S1_at 3.11 down FP prostaglandin F2alpha receptor isoform-aplpha 
Bt.29152.1.S1_at 3.11 down  Transcribed sequences 
Bt.26365.1.A1_at 3.12 down  Transcribed sequences 
Bt.29208.1.S1_at 3.12 down  Transcribed sequences 
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Bt.19095.1.S1_at 3.14 down  Transcribed sequences 
Bt.23809.1.A1_s_at 3.16 down  Transcribed sequences 
Bt.4013.1.S1_at 3.18 down  platelet-activating factor acetylhydrolase 2 
Bt.17910.2.S1_at 3.19 down  
Transcribed sequence with moderate similarity to protein 
ref:NP_003380.2 (H.sapiens)  coronin, actin-binding protein, 2A; 
coronin 2A; coronin-like protein B; WD-repeat protein 2; WD protein 
IR10 [Homo sapiens] 
Bt.4688.1.S1_a_at 3.20 down  Transcribed sequences 
Bt.11515.1.A1_at 3.21 down  Transcribed sequence 
Bt.5011.1.S1_at 3.22 down LTBP2 
latent transforming growth factor beta bindingprotein 2 
(NOTE:redefinition of symbol) 
Bt.26847.1.S1_at 3.23 down  
Transcribed sequence with weak  similarity to protein sp:O43561 
(H.sapiens) LAT_HUMAN Linker for activation of T cells 
Bt.27339.1.A1_at 3.25 down  
Transcribed sequence with strong similarity to protein sp:P08473 
(H.sapiens) NEP_HUMAN Neprilysin 
Bt.23776.1.A1_at 3.26 down  Transcribed sequences 
Bt.10865.1.S1_at 3.30 down  Transcribed sequences 
Bt.24124.1.A1_at 3.32 down  Transcribed sequences 
Bt.28243.1.S1_a_at 3.34 down  
Transcribed sequence with moderate similarity to protein sp:O95497 
(H.sapiens) VNN1_HUMAN Pantetheinase precursor 
Bt.22339.1.A1_at 3.36 down  Transcribed sequences 
Bt.25307.1.A1_at 3.37 down  Transcribed sequence 
Bt.21798.1.S1_at 3.37 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_570115.1 (H.sapiens)  immunity associated protein 1; ortholog 
of mouse imap38 [Homo sapiens] 
Bt.22080.1.S1_at 3.40 down  Transcribed sequences 
Bt.27240.1.A1_at 3.42 down  
Transcribed sequence with moderate similarity to protein 
ref:NP_057438.1 (H.sapiens)  organic anion transporter OATP-E 
[Homo sapiens] 
Bt.22987.2.A1_at 3.43 down PRG4 
proteoglycan 4, (megakaryocyte stimulating factor, articular 
superficial zone protein, camptodactyly, arthropathy, coxa vara, 
pericarditis syndrome) 
Bt.23664.1.S1_at 3.45 down  
Transcribed sequence with strong similarity to protein pir:T47142 
(H.sapiens) T47142 hypothetical protein DKFZp761P0724.1 - human 
Bt.1756.1.S1_at 3.46 down  
Transcribed sequence with strong similarity to protein pir:BMHU7 
(H.sapiens) BMHU7 bone morphogenetic protein 7 precursor - human 
Bt.352.1.S1_at 3.48 down PTGFR prostaglandin F receptor 
Bt.26847.2.S1_at 3.50 down  
Transcribed sequence with weak  similarity to protein sp:O43561 
(H.sapiens) LAT_HUMAN Linker for activation of T cells 
Bt.19423.2.S1_at 3.51 down  Transcribed sequences 
Bt.13071.2.A1_at 3.59 down CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
Bt.611.1.S2_at 3.65 down CXCL1 chemokine (C-X-C motif) ligand 1 
Bt.16201.1.S1_at 3.68 down  
Transcribed sequence with weak  similarity to protein sp:P06702 
(H.sapiens) S109_HUMAN Calgranulin B 
Bt.20148.1.S1_at 3.69 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_114424.1 (H.sapiens)  MSTP031 protein [Homo sapiens] 
Bt.3681.1.S1_at 3.72 down  
Transcribed sequence with moderate similarity to protein sp:Q99542 
(H.sapiens) MM19_HUMAN Matrix metalloproteinase-19 precursor 
Bt.132.1.S1_at 3.73 down DEFB1 defensin, beta 1 (enteric) 
Bt.28243.2.S1_at 3.73 down  
Transcribed sequence with moderate similarity to protein sp:O95497 
(H.sapiens) VNN1_HUMAN Pantetheinase precursor 
Bt.1647.1.S1_at 3.76 down CRYGS crystallin, gamma polypeptide 8 [crystallin,gamma S] 
Bt.3590.1.A1_at 3.79 down  
Transcribed sequence with weak  similarity to protein pir:B34087 
(H.sapiens) B34087 hypothetical protein 
Bt.17766.1.S1_at 3.79 down  Transcribed sequences 
Bt.24919.1.S1_at 3.84 down  Transcribed sequences 
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Bt.26847.1.S1_a_at 3.84 down  
Transcribed sequence with weak  similarity to protein sp:O43561 
(H.sapiens) LAT_HUMAN Linker for activation of T cells 
Bt.19423.1.S1_at 3.86 down  Transcribed sequences 
Bt.2452.1.S1_at 3.88 down LUM lumican 
Bt.20649.2.S1_at 3.88 down  Transcribed sequences 
Bt.8031.1.S1_at 3.97 down  
Transcribed sequence with strong similarity to protein sp:Q99687 
(H.sapiens) MEI3_HUMAN Homeobox protein Meis3 
Bt.18111.1.A1_at 3.98 down  
Transcribed sequence with moderate similarity to protein pir:B34087 
(H.sapiens) B34087 hypothetical protein 
Bt.8031.3.S1_a_at 3.99 down  
Transcribed sequence with strong similarity to protein sp:Q99687 
(H.sapiens) MEI3_HUMAN Homeobox protein Meis3 
Bt.27339.2.S1_at 4.00 down  
Transcribed sequence with strong similarity to protein sp:P08473 
(H.sapiens) NEP_HUMAN Neprilysin 
Bt.28752.1.A1_at 4.02 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_077816.1 (H.sapiens)  ATPase, Class V, type 10C; ATPase 
type IV, phospholipid transporting 
Bt.23093.1.S1_at 4.04 down  
Transcribed sequence with moderate similarity to protein sp:P19875 
(H.sapiens) MI2A_HUMAN Macrophage inflammatory protein-2-
alpha precursor 
Bt.23126.1.S1_at 4.06 down NOS2A nitric oxide synthase 2A (inducible, hepatocytes) 
Bt.16058.2.S1_at 4.07 down  Transcribed sequences 
Bt.643.1.S1_at 4.07 down  
Transcribed sequence with weak  similarity to protein sp:P55773 
(H.sapiens) SY23_HUMAN Small inducible cytokine A23 precursor 
Bt.16058.1.A1_at 4.11 down  Transcribed sequences 
Bt.16201.2.A1_at 4.11 down  
Transcribed sequence with weak  similarity to protein sp:P06702 
(H.sapiens) S109_HUMAN Calgranulin B 
Bt.4374.1.S1_at 4.13 down  Transcribed sequences 
Bt.3540.1.S1_at 4.20 down  
Transcribed sequence with strong similarity to protein 
ref:NP_003005.1 (H.sapiens)  secreted frizzled-related  protein 4; 
secreted frizzled-related protein 4 [Homo sapiens] 
Bt.13744.1.A1_at 4.20 down  Transcribed sequences 
Bt.9774.1.S1_a_at 4.24 down  
Transcribed sequence with moderate similarity to protein 
ref:NP_115789.1 (H.sapiens)  normal mucosa of esophagus specific 1 
[Homo sapiens] 
Bt.17752.1.A1_at 4.28 down  
Transcribed sequence with weak  similarity to protein pir:B34087 
(H.sapiens) B34087 hypothetical protein 
Bt.15731.1.A1_at 4.30 down  
Transcribed sequence with moderate similarity to protein 
ref:NP_009199.1 (H.sapiens)  Ig superfamily protein [Homo sapiens] 
Bt.8945.1.S1_at 4.35 down TLR2 toll-like receptor 2 
Bt.357.1.S1_at 4.35 down S100A12 S100 calcium binding protein A12 (calgranulinC) 
Bt.15802.2.S1_at 4.41 down  
Transcribed sequence with strong similarity to protein sp:Q13887 
(H.sapiens) KLF5_HUMAN Krueppel-like factor 5 
Bt.3774.1.A1_at 4.55 down  Transcribed sequences 
Bt.19272.1.A1_at 4.57 down  Transcribed sequence 
Bt.15802.1.S1_at 4.73 down  
Transcribed sequence with strong similarity to protein sp:Q13887 
(H.sapiens) KLF5_HUMAN Krueppel-like factor 5 
Bt.13108.1.S1_at 4.79 down ADAMTS5 
a disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 5 (aggrecanase-2) 
Bt.9633.1.S1_at 4.83 down  
Transcribed sequence with weak  similarity to protein 
ref:NP_113630.1 (H.sapiens)  brain cell membrane protein 1 [Homo 
sapiens] 
Bt.1756.2.S1_at 4.95 down  
Transcribed sequence with strong similarity to protein pir:BMHU7 
(H.sapiens) BMHU7 bone morphogenetic protein 7 precursor - human 
Bt.6261.1.S1_at 4.97 down  Transcribed sequences 
Bt.13108.1.A1_at 5.07 down ADAMTS5 
a disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 5 (aggrecanase-2) 
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Bt.310.1.S1_at 5.10 down CATHL1 cathelicidin 1 
Bt.366.2.S2_a_at 5.75 down 
M-CSF 
alpha macrophage-colony stimulating factor alpha 
Bt.4714.1.S1_at 5.85 down MMP9 
matrix metalloproteinase 9 (gelatinase B, 92kDamatrix 
metalloproteinase 9 (gelatinase B, 92kDagelatinase, 92kDa type IV 
collagenase) 
Bt.27605.1.A1_at 6.08 down  
Transcribed sequence with weak  similarity to protein pir:A55119 
(H.sapiens) A55119 potassium channel protein romk-1 - human 
Bt.562.1.S1_at 6.35 down PFKFB1 6-phosphofructo-2 kinase/fructose-2,6-biphosphatase 1 
Bt.11904.1.S1_at 6.36 down  
Transcribed sequence with strong similarity to protein sp:Q9UKU0 
(H.sapiens) LCFF_HUMAN Long-chain-fatty-acid--CoA ligase 6 
Bt.14191.1.A1_at 6.65 down  Transcribed sequence 
Bt.493.1.S1_at 6.79 down LIF leukemia inhibitory factor [cholinergicdifferentiation factor] 
Bt.29580.1.S1_at 7.07 down  Transcribed sequences 
Bt.26268.1.A1_at 7.80 down  Transcribed sequences 
Bt.16077.1.S1_at 7.94 down  
Transcribed sequence with weak  similarity to protein sp:O60896 
(H.sapiens) RMP3_HUMAN Receptor activity-modifying protein 3 
precursor 
Bt.8479.1.A1_at 8.04 down  
Transcribed sequence with moderate similarity to protein 
prf:2019232A (H.sapiens) 2019232A NO synthase [Homo sapiens] 
Bt.5136.1.S1_at 8.61 down TIMP3 
tissue inhibitor of metalloproteinase 3 (Sorsbyfundus dystrophy, 
pseudoinflammatory) 
Bt.4417.1.S1_at 9.58 down CDH2 cadherin 2 [N-cadherin] [N-cadherin 1] 
Bt.10870.1.S1_at 9.80 down  Transcribed sequences 
Bt.13046.1.A1_at 9.95 down AHR aryl hydrocarbon receptor 
Bt.12283.1.A1_at 10.25 down  
Transcribed sequence with weak  similarity to protein sp:O95661 
(H.sapiens) RHOI_HUMAN Rho-related GTP-binding protein RhoI 
Bt.21197.1.A1_at 10.31 down  Transcribed sequences 
Bt.39.1.S1_at 10.53 down MMP13 matrix metalloproteinase 13 (collagenase 3) 
Bt.23126.2.S1_at 10.63 down NOS2A nitric oxide synthase 2A (inducible, hepatocytes) 
Bt.2537.2.S1_at 10.93 down CHRNA3 cholinergic receptor, nicotinic, alpha polypeptide 3 
Bt.23126.2.A1_at 11.04 down NOS2A nitric oxide synthase 2A (inducible, hepatocytes) 
Bt.26231.1.S1_at 12.02 down  Transcribed sequences 
Bt.13046.1.S1_at 14.36 down AHR aryl hydrocarbon receptor 
Bt.26157.1.A1_at 15.09 down  Transcribed sequences 
Bt.3686.1.S1_at 20.08 down IL6 interleukin 6 [interferon, beta 2] 
Bt.262.1.S1_at 21.19 down TKDP3 trophoblast Kunitz domain protein 3 
Bt.27152.1.A1_at 27.60 down  Transcribed sequences 
Bt.9560.1.S1_at 66.77 down CCL20 chemokine (C-C motif) ligand 20 
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Genome-wide microarray results  
 
  
Human articular chondrocytes: IL-1+OSM+IL-4 vs IL-1+OSM 
   
Symbol 
Fold 
Change Gene name 
CCL26 88.98 Homo sapiens chemokine (C-C motif) ligand 26 (CCL26), mRNA. 
SNFT 15.27 Homo sapiens Jun dimerization protein p21SNFT (SNFT), mRNA. 
ANPEP 10.07 
Homo sapiens alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, 
microsomal aminopeptidase, CD13, p150) (ANPEP), mRNA. 
RGS4 8.64 Homo sapiens regulator of G-protein signalling 4 (RGS4), mRNA. 
SELP 6.83 Homo sapiens selectin P (granule membrane protein 140kDa, antigen CD62) (SELP), mRNA. 
 5.95 Homo sapiens clone 25194 mRNA sequence 
IL1RL1 5.57 Homo sapiens interleukin 1 receptor-like 1 (IL1RL1), transcript variant 2, mRNA. 
CSN1S1 5.51 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 2, mRNA. 
POSTN 5.03 Homo sapiens periostin, osteoblast specific factor (POSTN), mRNA. 
NPPB 5.03 Homo sapiens natriuretic peptide precursor B (NPPB), mRNA. 
ISLR 4.95 
Homo sapiens immunoglobulin superfamily containing leucine-rich repeat (ISLR), transcript 
variant 1, mRNA. 
ISLR 4.70 
Homo sapiens immunoglobulin superfamily containing leucine-rich repeat (ISLR), transcript 
variant 2, mRNA. 
SOCS1 4.56 Homo sapiens suppressor of cytokine signaling 1 (SOCS1), mRNA. 
CCL13 4.54 Homo sapiens chemokine (C-C motif) ligand 13 (CCL13), mRNA. 
IGFBP5 4.54 Homo sapiens insulin-like growth factor binding protein 5 (IGFBP5), mRNA. 
IL13RA2 4.53 Homo sapiens interleukin 13 receptor, alpha 2 (IL13RA2), mRNA. 
POSTN 4.45 Homo sapiens periostin, osteoblast specific factor (POSTN), mRNA. 
LPL 4.25 Homo sapiens lipoprotein lipase (LPL), mRNA. 
IGFBP5 3.98 Homo sapiens insulin-like growth factor binding protein 5 (IGFBP5), mRNA. 
FGL2 3.65 Homo sapiens fibrinogen-like 2 (FGL2), mRNA. 
MAOA 3.54 
Homo sapiens monoamine oxidase A (MAOA), nuclear gene encoding mitochondrial protein, 
mRNA. 
SPON1 3.53 Homo sapiens spondin 1, extracellular matrix protein (SPON1), mRNA. 
C1QTNF1 3.39 Homo sapiens C1q and tumor necrosis factor related protein 1 (C1QTNF1), mRNA. 
PCDH18 3.36 Homo sapiens protocadherin 18 (PCDH18), mRNA. 
CH25H 3.33 Homo sapiens cholesterol 25-hydroxylase (CH25H), mRNA. 
CCL11 3.26 Homo sapiens chemokine (C-C motif) ligand 11 (CCL11), mRNA. 
IL1RL1 3.21 Homo sapiens interleukin 1 receptor-like 1 (IL1RL1), transcript variant 2, mRNA. 
ISG20 3.05 Homo sapiens interferon stimulated exonuclease gene 20kDa (ISG20), mRNA. 
RRS1 3.04 Homo sapiens RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) (RRS1), mRNA. 
HAPLN1 2.95 Homo sapiens hyaluronan and proteoglycan link protein 1 (HAPLN1), mRNA. 
CHST7 2.82 Homo sapiens carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 (CHST7), mRNA. 
SPINT2 2.77 Homo sapiens serine peptidase inhibitor, Kunitz type, 2 (SPINT2), mRNA. 
TFPI 2.75 
Homo sapiens tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
(TFPI), transcript variant 1, mRNA. 
ST8SIA1 2.73 
Homo sapiens ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 (ST8SIA1), 
mRNA. 
LOC648517 2.71 
PREDICTED: Homo sapiens similar to Aldo-keto reductase family 1 member C1 (20-alpha-
hydroxysteroid dehydrogenase) (20-alpha-HSD) (Trans-1,2-dihydrobenzene-1,2-diol 
dehydrogenase) (High-affinity hepatic bile acid-binding protein) (HBAB) (Chlordecone 
reductase homolog HAKRC..., transcript variant 1 (LOC648517), mRNA. 
IFI27 2.68 Homo sapiens interferon, alpha-inducible protein 27 (IFI27), mRNA. 
ATF3 2.67 Homo sapiens activating transcription factor 3 (ATF3), transcript variant 4, mRNA. 
GUCY1A3 2.65 Homo sapiens guanylate cyclase 1, soluble, alpha 3 (GUCY1A3), mRNA. 
NET1 2.63 Homo sapiens neuroepithelial cell transforming gene 1 (NET1), mRNA. 
FLJ90166 2.59 Homo sapiens adenomatosis polyposis coli down-regulated 1-like (APCDD1L), mRNA. 
PIM1 2.57 Homo sapiens pim-1 oncogene (PIM1), mRNA. 
CSN1S1 2.57 Homo sapiens casein alpha s1 (CSN1S1), transcript variant 1, mRNA. 
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IL24 2.57 Homo sapiens interleukin 24 (IL24), transcript variant 2, mRNA. 
PPFIBP2 2.55 Homo sapiens PTPRF interacting protein, binding protein 2 (liprin beta 2) (PPFIBP2), mRNA. 
TFPI 2.53 
Homo sapiens tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
(TFPI), transcript variant 2, mRNA. 
ATP1A1 2.50 
Homo sapiens ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1), transcript variant 
1, mRNA. 
PCDH18 2.44 Homo sapiens protocadherin 18 (PCDH18), mRNA. 
TNC 2.44 Homo sapiens tenascin C (hexabrachion) (TNC), mRNA. 
C1QTNF1 2.43 
Homo sapiens C1q and tumor necrosis factor related protein 1 (C1QTNF1), transcript variant 1, 
mRNA. 
HAPLN1 2.40 Homo sapiens hyaluronan and proteoglycan link protein 1 (HAPLN1), mRNA. 
IL18BP 2.39 Homo sapiens interleukin 18 binding protein (IL18BP), transcript variant A, mRNA. 
DBC1 2.37 Homo sapiens deleted in bladder cancer 1 (DBC1), mRNA. 
HIST2H2AA3 2.36 Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3), mRNA. 
SLIT2 2.36 Homo sapiens slit homolog 2 (Drosophila) (SLIT2), mRNA. 
GADD45G 2.36 Homo sapiens growth arrest and DNA-damage-inducible, gamma (GADD45G), mRNA. 
MEOX1 2.35 Homo sapiens mesenchyme homeo box 1 (MEOX1), transcript variant 1, mRNA. 
FKBP1A 2.33 Homo sapiens FK506 binding protein 1A, 12kDa (FKBP1A), transcript variant 12B, mRNA. 
OXTR 2.32 Homo sapiens oxytocin receptor (OXTR), mRNA. 
LRRC17 2.30 Homo sapiens leucine rich repeat containing 17 (LRRC17), transcript variant 1, mRNA. 
GRP 2.29 Homo sapiens gastrin-releasing peptide (GRP), transcript variant 3, mRNA. 
AKR1C2 2.29 
Homo sapiens aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile 
acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) (AKR1C2), transcript 
variant 1, mRNA. XM_943424 XM_943425 XM_943427 
HIST2H2AA3 2.28 Homo sapiens histone cluster 2, H2aa3 (HIST2H2AA3), mRNA. 
TDG 2.25 Homo sapiens thymine-DNA glycosylase (TDG), mRNA. 
CTSC 2.25 Homo sapiens cathepsin C (CTSC), transcript variant 1, mRNA. 
PRP2 2.23 Homo sapiens proline-rich protein PRP2 (PRP2), mRNA. 
SERPINB4 2.23 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 4 (SERPINB4), 
mRNA. 
NET1 2.21 Homo sapiens neuroepithelial cell transforming gene 1 (NET1), mRNA. 
CISH 2.20 Homo sapiens cytokine inducible SH2-containing protein (CISH), mRNA. 
UGP2 2.20 Homo sapiens UDP-glucose pyrophosphorylase 2 (UGP2), transcript variant 1, mRNA. 
MSX1 2.20 Homo sapiens msh homeo box homolog 1 (Drosophila) (MSX1), mRNA. 
IFITM1 2.20 Homo sapiens interferon induced transmembrane protein 1 (9-27) (IFITM1), mRNA. 
COL8A1 2.19 Homo sapiens collagen, type VIII, alpha 1 (COL8A1), transcript variant 1, mRNA. 
BHLHB5 2.18 Homo sapiens basic helix-loop-helix domain containing, class B, 5 (BHLHB5), mRNA. 
IL18R1 2.18 Homo sapiens interleukin 18 receptor 1 (IL18R1), mRNA. 
LOC642489 2.18 PREDICTED: Homo sapiens similar to FK506-binding protein 1A (LOC642489), mRNA. 
IGSF4 2.17 Homo sapiens cell adhesion molecule 1 (CADM1), mRNA. 
PDGFRL 2.16 Homo sapiens platelet-derived growth factor receptor-like (PDGFRL), mRNA. 
MX1 2.15 
Homo sapiens myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 
(mouse) (MX1), mRNA. 
ISLR 2.15 
Homo sapiens immunoglobulin superfamily containing leucine-rich repeat (ISLR), transcript 
variant 1, mRNA. 
SLC2A6 2.15 
Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 6 (SLC2A6), 
mRNA. 
FKBP1A 2.14 Homo sapiens FK506 binding protein 1A, 12kDa (FKBP1A), transcript variant 12A, mRNA. 
FLJ13391 2.13 Homo sapiens transmembrane protein 166 (TMEM166), mRNA. 
TWISTNB 2.13 Homo sapiens TWIST neighbor (TWISTNB), mRNA. 
CFI 2.11 Homo sapiens complement factor I (CFI), mRNA. 
C15orf48 2.10 Homo sapiens chromosome 15 open reading frame 48 (C15orf48), transcript variant 2, mRNA. 
ATP1A1 2.09 
Homo sapiens ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1), transcript variant 
1, mRNA. 
CDC45L 2.08 Homo sapiens CDC45 cell division cycle 45-like (S. cerevisiae) (CDC45L), mRNA. 
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CKLF 2.08 Homo sapiens chemokine-like factor (CKLF), transcript variant 3, mRNA. 
CYB5A 2.08 Homo sapiens cytochrome b5 type A (microsomal) (CYB5A), transcript variant 2, mRNA. 
MYB 2.04 Homo sapiens v-myb myeloblastosis viral oncogene homolog (avian) (MYB), mRNA. 
FKBP1A 2.04 Homo sapiens FK506 binding protein 1A, 12kDa (FKBP1A), transcript variant 12A, mRNA. 
GUCY1A3 2.04 Homo sapiens guanylate cyclase 1, soluble, alpha 3 (GUCY1A3), mRNA. 
PTGIS 2.02 Homo sapiens prostaglandin I2 (prostacyclin) synthase (PTGIS), mRNA. 
CDC42EP2 2.02 Homo sapiens CDC42 effector protein (Rho GTPase binding) 2 (CDC42EP2), mRNA. 
C10orf81 2.01 Homo sapiens chromosome 10 open reading frame 81 (C10orf81), mRNA. 
PRKCZ 2.01 Homo sapiens protein kinase C, zeta (PRKCZ), transcript variant 1, mRNA. 
CYB5A 2.01 Homo sapiens cytochrome b5 type A (microsomal) (CYB5A), transcript variant 1, mRNA. 
HIST2H2AC 2.00 Homo sapiens histone cluster 2, H2ac (HIST2H2AC), mRNA. 
VAMP5 1.99 Homo sapiens vesicle-associated membrane protein 5 (myobrevin) (VAMP5), mRNA. 
LOXL3 1.99 Homo sapiens lysyl oxidase-like 3 (LOXL3), mRNA. 
ARL4 1.98 Homo sapiens ADP-ribosylation factor-like 4 (ARL4), transcript variant 1, mRNA. 
MEIS1 1.98 Homo sapiens Meis homeobox 1 (MEIS1), mRNA. 
MRPS6 1.96 
Homo sapiens mitochondrial ribosomal protein S6 (MRPS6), nuclear gene encoding 
mitochondrial protein, mRNA. 
ARRDC4 1.96 Homo sapiens arrestin domain containing 4 (ARRDC4), mRNA. 
TRPV2 1.96 
Homo sapiens transient receptor potential cation channel, subfamily V, member 2 (TRPV2), 
mRNA. 
CDK5RAP2 1.96 
Homo sapiens CDK5 regulatory subunit associated protein 2 (CDK5RAP2), transcript variant 
2, mRNA. 
PRRX2 1.95 Homo sapiens paired related homeobox 2 (PRRX2), mRNA. 
PSMB9 1.94 
Homo sapiens proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional 
peptidase 2) (PSMB9), transcript variant 1, mRNA. 
C11orf70 1.94 Homo sapiens chromosome 11 open reading frame 70 (C11orf70), mRNA. 
EPSTI1 1.94 Homo sapiens epithelial stromal interaction 1 (breast) (EPSTI1), transcript variant 2, mRNA. 
GNE 1.92 
Homo sapiens glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (GNE), 
mRNA. 
MS4A6A 1.92 
Homo sapiens membrane-spanning 4-domains, subfamily A, member 6A (MS4A6A), transcript 
variant 3, mRNA. 
C11orf70 1.91 Homo sapiens chromosome 11 open reading frame 70 (C11orf70), mRNA. 
ATP1A1 1.91 
Homo sapiens ATPase, Na+/K+ transporting, alpha 1 polypeptide (ATP1A1), transcript variant 
2, mRNA. 
EIF1B 1.91 Homo sapiens eukaryotic translation initiation factor 1B (EIF1B), mRNA. 
IFI35 1.91 Homo sapiens interferon-induced protein 35 (IFI35), mRNA. 
RHBDD2 1.91 Homo sapiens rhomboid domain containing 2 (RHBDD2), transcript variant 1, mRNA. 
C10orf116 1.90 Homo sapiens chromosome 10 open reading frame 116 (C10orf116), mRNA. 
COL6A1 1.90 Homo sapiens collagen, type VI, alpha 1 (COL6A1), mRNA. 
EPHA3 1.90 Homo sapiens EPH receptor A3 (EPHA3), transcript variant 1, mRNA. 
COL24A1 1.89 Homo sapiens collagen, type XXIV, alpha 1 (COL24A1), mRNA. 
MYL9 1.89 Homo sapiens myosin, light chain 9, regulatory (MYL9), transcript variant 1, mRNA. 
GHR 1.89 Homo sapiens growth hormone receptor (GHR), mRNA. 
OAS2 1.88 
Homo sapiens 2'-5'-oligoadenylate synthetase 2, 69/71kDa (OAS2), transcript variant 1, 
mRNA. 
SFRP2 1.88 Homo sapiens secreted frizzled-related protein 2 (SFRP2), mRNA. 
SLC16A4 1.87 
Homo sapiens solute carrier family 16, member 4 (monocarboxylic acid transporter 5) 
(SLC16A4), mRNA. 
KRTCAP2 1.87 Homo sapiens keratinocyte associated protein 2 (KRTCAP2), mRNA. 
COL6A3 1.87 Homo sapiens collagen, type VI, alpha 3 (COL6A3), transcript variant 1, mRNA. 
CDC42EP5 1.86 Homo sapiens CDC42 effector protein (Rho GTPase binding) 5 (CDC42EP5), mRNA. 
FLJ39155 1.86 
Homo sapiens EGF-like, fibronectin type III and laminin G domains (EGFLAM), transcript 
variant 1, mRNA. 
SLC25A25 1.85 
Homo sapiens solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 25 
(SLC25A25), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 
RHBDD2 1.85 Homo sapiens rhomboid domain containing 2 (RHBDD2), mRNA. 
C6orf129 1.85 Homo sapiens chromosome 6 open reading frame 129 (C6orf129), mRNA. 
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PDZK1IP1 1.85 Homo sapiens PDZK1 interacting protein 1 (PDZK1IP1), mRNA. 
ARRDC4 1.85 Homo sapiens arrestin domain containing 4 (ARRDC4), mRNA. 
LOC646786 1.85 PREDICTED: Homo sapiens similar to Afadin (AF-6 protein) (LOC646786), mRNA. 
 1.84 
AGENCOURT_10229596 NIH_MGC_141 Homo sapiens cDNA clone IMAGE:6563923 5, 
mRNA sequence 
PRKCZ 1.84 Homo sapiens protein kinase C, zeta (PRKCZ), transcript variant 1, mRNA. 
C19orf10 1.84 Homo sapiens chromosome 19 open reading frame 10 (C19orf10), mRNA. 
AK2 1.83 Homo sapiens adenylate kinase 2 (AK2), transcript variant AK2A, mRNA. 
SLCO2A1 1.83 
Homo sapiens solute carrier organic anion transporter family, member 2A1 (SLCO2A1), 
mRNA. 
LOC441019 1.83 PREDICTED: Homo sapiens hypothetical LOC441019 (LOC441019), mRNA. 
ANG 1.82 Homo sapiens angiogenin, ribonuclease, RNase A family, 5 (ANG), mRNA. 
ARMET 1.82 Homo sapiens arginine-rich, mutated in early stage tumors (ARMET), mRNA. 
GCNT2 1.81 
Homo sapiens glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) 
(GCNT2), transcript variant 2, mRNA. 
IGSF3 1.81 Homo sapiens immunoglobulin superfamily, member 3 (IGSF3), transcript variant 1, mRNA. 
 1.80 
zx42c01.r1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:789120 5, 
mRNA sequence 
D15Wsu75e 1.80 
Homo sapiens DNA segment, Chr 15, Wayne State University 75, expressed (D15Wsu75e), 
mRNA. 
VAMP8 1.80 Homo sapiens vesicle-associated membrane protein 8 (endobrevin) (VAMP8), mRNA. 
S100A4 1.80 Homo sapiens S100 calcium binding protein A4 (S100A4), transcript variant 1, mRNA. 
AHNAK 1.80 Homo sapiens AHNAK nucleoprotein (AHNAK), transcript variant 2, mRNA. 
DLX5 1.79 Homo sapiens distal-less homeo box 5 (DLX5), mRNA. 
S100A11 1.79 Homo sapiens S100 calcium binding protein A11 (S100A11), mRNA. 
UST 1.79 Homo sapiens uronyl-2-sulfotransferase (UST), mRNA. 
EDG3 1.79 
Homo sapiens endothelial differentiation, sphingolipid G-protein-coupled receptor, 3 (EDG3), 
mRNA. 
RASL11A 1.78 Homo sapiens RAS-like, family 11, member A (RASL11A), mRNA. 
DIXDC1 1.78 Homo sapiens DIX domain containing 1 (DIXDC1), transcript variant 1, mRNA. 
FKBP2 1.77 Homo sapiens FK506 binding protein 2, 13kDa (FKBP2), transcript variant 1, mRNA. 
AKR1C3 1.77 
Homo sapiens aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II) (AKR1C3), mRNA. 
PTGFRN 1.77 Homo sapiens prostaglandin F2 receptor negative regulator (PTGFRN), mRNA. 
SLA 1.77 Homo sapiens Src-like-adaptor (SLA), mRNA. 
OSR2 1.77 Homo sapiens odd-skipped related 2 (Drosophila) (OSR2), mRNA. 
RAG1AP1 1.77 Homo sapiens recombination activating gene 1 activating protein 1 (RAG1AP1), mRNA. 
PRDM1 1.77 
Homo sapiens PR domain containing 1, with ZNF domain (PRDM1), transcript variant 1, 
mRNA. 
NDP 1.76 Homo sapiens Norrie disease (pseudoglioma) (NDP), mRNA. 
SATB2 1.76 Homo sapiens SATB homeobox 2 (SATB2), mRNA. 
TMEM93 1.76 Homo sapiens transmembrane protein 93 (TMEM93), transcript variant 2, mRNA. 
DUSP5 1.75 Homo sapiens dual specificity phosphatase 5 (DUSP5), mRNA. 
TRAFD1 1.75 Homo sapiens TRAF-type zinc finger domain containing 1 (TRAFD1), mRNA. 
BAD 1.75 Homo sapiens BCL2-antagonist of cell death (BAD), transcript variant 1, mRNA. 
KLF2 1.75 Homo sapiens Kruppel-like factor 2 (lung) (KLF2), mRNA. 
S100A4 1.75 Homo sapiens S100 calcium binding protein A4 (S100A4), transcript variant 1, mRNA. 
INSIG1 1.74 Homo sapiens insulin induced gene 1 (INSIG1), transcript variant 2, mRNA. 
FCRLM2 1.74 Homo sapiens Fc receptor-like B (FCRLB), mRNA. 
MSC 1.74 Homo sapiens musculin (activated B-cell factor-1) (MSC), mRNA. 
AHNAK 1.74 Homo sapiens AHNAK nucleoprotein (AHNAK), transcript variant 2, mRNA. 
COPZ2 1.74 Homo sapiens coatomer protein complex, subunit zeta 2 (COPZ2), mRNA. 
IFIT1 1.74 
Homo sapiens interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), transcript 
variant 2, mRNA. 
CGGBP1 1.74 Homo sapiens CGG triplet repeat binding protein 1 (CGGBP1), transcript variant 2, mRNA. 
ZCSL2 1.73 Homo sapiens DPH3, KTI11 homolog (S. cerevisiae) (DPH3), transcript variant 1, mRNA. 
ZNHIT1 1.73 Homo sapiens zinc finger, HIT type 1 (ZNHIT1), mRNA. 
HIST1H2AC 1.73 Homo sapiens histone cluster 1, H2ac (HIST1H2AC), mRNA. 
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PSME2 1.73 
Homo sapiens proteasome (prosome, macropain) activator subunit 2 (PA28 beta) (PSME2), 
mRNA. 
LOC728489 1.73 Homo sapiens similar to CG12379-PA (LOC728489), mRNA. 
LOC255783 1.73 
PREDICTED: Homo sapiens hypothetical protein LOC255783, transcript variant 2 
(LOC255783), misc RNA. 
MATN2 1.73 Homo sapiens matrilin 2 (MATN2), transcript variant 2, mRNA. 
LHFP 1.73 Homo sapiens lipoma HMGIC fusion partner (LHFP), mRNA. 
DSCR1L1 1.72 Homo sapiens regulator of calcineurin 2 (RCAN2), mRNA. 
PTPLA 1.72 
Homo sapiens protein tyrosine phosphatase-like (proline instead of catalytic arginine), member 
a (PTPLA), mRNA. 
MRPS18C 1.71 
Homo sapiens mitochondrial ribosomal protein S18C (MRPS18C), nuclear gene encoding 
mitochondrial protein, mRNA. 
KCNK1 1.71 Homo sapiens potassium channel, subfamily K, member 1 (KCNK1), mRNA. 
APH1B 1.70 Homo sapiens anterior pharynx defective 1 homolog B (C. elegans) (APH1B), mRNA. 
ISG15 1.70 Homo sapiens ISG15 ubiquitin-like modifier (ISG15), mRNA. 
TNFSF12 1.70 Homo sapiens tumor necrosis factor (ligand) superfamily, member 12 (TNFSF12), mRNA. 
AHI1 1.70 Homo sapiens Abelson helper integration site 1 (AHI1), mRNA. 
FABP3 1.70 
Homo sapiens fatty acid binding protein 3, muscle and heart (mammary-derived growth 
inhibitor) (FABP3), mRNA. 
PCBD1 1.70 
Homo sapiens 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte 
nuclear factor 1 alpha (TCF1) (PCBD1), transcript variant 2, mRNA. 
MGC33212 1.70 Homo sapiens hypothetical protein MGC33212 (MGC33212), mRNA. 
MAPRE2 1.69 Homo sapiens microtubule-associated protein, RP/EB family, member 2 (MAPRE2), mRNA. 
EGFL6 1.69 Homo sapiens EGF-like-domain, multiple 6 (EGFL6), mRNA. 
AK2 1.69 Homo sapiens adenylate kinase 2 (AK2), transcript variant AK2A, mRNA. 
FLJ20186 1.69 Homo sapiens hypothetical protein FLJ20186 (FLJ20186), transcript variant 2, mRNA. 
CLTB 1.69 Homo sapiens clathrin, light chain (Lcb) (CLTB), transcript variant 1, mRNA. 
CKLF 1.69 Homo sapiens chemokine-like factor (CKLF), transcript variant 6, mRNA. 
C6orf79 1.69 Homo sapiens chromosome 6 open reading frame 79 (C6orf79), transcript variant 2, mRNA. 
TGFBR3 1.68 Homo sapiens transforming growth factor, beta receptor III (TGFBR3), mRNA. 
ORF1-FL49 1.68 Homo sapiens putative nuclear protein ORF1-FL49 (ORF1-FL49), mRNA. 
AYP1p1 1.68 PREDICTED: Homo sapiens AYP1 pseudogene 1 (AYP1p1), misc RNA. 
SLC5A3 1.68 Homo sapiens solute carrier family 5 (inositol transporters), member 3 (SLC5A3), mRNA. 
 1.68 Homo sapiens cDNA FLJ40058 fis, clone TCOLN1000180 
HIST1H2BD 1.68 Homo sapiens histone cluster 1, H2bd (HIST1H2BD), transcript variant 2, mRNA. 
HSPC023 1.67 Homo sapiens HSPC023 protein (HSPC023), mRNA. 
TDO2 1.67 Homo sapiens tryptophan 2,3-dioxygenase (TDO2), mRNA. 
TFPI 1.67 
Homo sapiens tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
(TFPI), transcript variant 2, mRNA. 
TPD52L1 1.67 Homo sapiens tumor protein D52-like 1 (TPD52L1), transcript variant 3, mRNA. 
SRGN 1.67 Homo sapiens serglycin (SRGN), mRNA. 
NDUFC1 1.66 
Homo sapiens NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa 
(NDUFC1), mRNA. 
TIMP4 1.66 Homo sapiens TIMP metallopeptidase inhibitor 4 (TIMP4), mRNA. 
SSBP2 1.66 Homo sapiens single-stranded DNA binding protein 2 (SSBP2), mRNA. 
KLF6 1.66 Homo sapiens Kruppel-like factor 6 (KLF6), transcript variant 2, mRNA. 
PTMS 1.66 Homo sapiens parathymosin (PTMS), mRNA. 
DPH3 1.66 Homo sapiens DPH3, KTI11 homolog (S. cerevisiae) (DPH3), transcript variant 2, mRNA. 
RBMS1 1.66 
Homo sapiens RNA binding motif, single stranded interacting protein 1 (RBMS1), transcript 
variant 3, mRNA. 
LOC388642 1.65 
PREDICTED: Homo sapiens similar to Triosephosphate isomerase (TIM) (Triose-phosphate 
isomerase), transcript variant 3 (LOC388642), mRNA. 
MGC17839 1.65 Homo sapiens transmembrane protein 136 (TMEM136), mRNA. 
NOD1 1.65 Homo sapiens nucleotide-binding oligomerization domain containing 1 (NOD1), mRNA. 
SUCNR1 1.65 Homo sapiens succinate receptor 1 (SUCNR1), mRNA. 
EIF4E2 1.65 Homo sapiens eukaryotic translation initiation factor 4E family member 2 (EIF4E2), mRNA. 
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ITGB8 1.65 Homo sapiens integrin, beta 8 (ITGB8), mRNA. 
TSPO 1.65 Homo sapiens translocator protein (18kDa) (TSPO), transcript variant PBR-S, mRNA. 
STRA13 1.65 Homo sapiens stimulated by retinoic acid 13 homolog (mouse) (STRA13), mRNA. 
CLEC4A 1.65 
Homo sapiens C-type lectin domain family 4, member A (CLEC4A), transcript variant 4, 
mRNA. 
C17orf58 1.65 
PREDICTED: Homo sapiens chromosome 17 open reading frame 58, transcript variant 3 
(C17orf58), mRNA. 
BOLA3 1.65 Homo sapiens bolA homolog 3 (E. coli) (BOLA3), transcript variant 1, mRNA. 
ARID5A 1.65 Homo sapiens AT rich interactive domain 5A (MRF1-like) (ARID5A), mRNA. 
DBI 1.64 
Homo sapiens diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A 
binding protein) (DBI), transcript variant 2, mRNA. 
SDF2L1 1.64 Homo sapiens stromal cell-derived factor 2-like 1 (SDF2L1), mRNA. 
MAPK1 1.64 Homo sapiens mitogen-activated protein kinase 1 (MAPK1), transcript variant 2, mRNA. 
IFI6 1.64 Homo sapiens interferon, alpha-inducible protein 6 (IFI6), transcript variant 2, mRNA. 
PMCH 1.64 Homo sapiens pro-melanin-concentrating hormone (PMCH), mRNA. 
TDG 1.64 Homo sapiens thymine-DNA glycosylase (TDG), mRNA. 
DRAP1 1.64 Homo sapiens DR1-associated protein 1 (negative cofactor 2 alpha) (DRAP1), mRNA. 
NET1 1.64 Homo sapiens neuroepithelial cell transforming gene 1 (NET1), mRNA. 
PLAUR 1.64 
Homo sapiens plasminogen activator, urokinase receptor (PLAUR), transcript variant 2, 
mRNA. 
OSBPL8 1.64 Homo sapiens oxysterol binding protein-like 8 (OSBPL8), transcript variant 1, mRNA. 
C22orf16 1.63 Homo sapiens chromosome 22 open reading frame 16 (C22orf16), mRNA. 
CA12 1.63 Homo sapiens carbonic anhydrase XII (CA12), transcript variant 1, mRNA. 
CRIP1 1.63 Homo sapiens cysteine-rich protein 1 (intestinal) (CRIP1), mRNA. 
OAS1 1.63 Homo sapiens 2',5'-oligoadenylate synthetase 1, 40/46kDa (OAS1), transcript variant 2, mRNA. 
COX7A1 1.63 Homo sapiens cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) (COX7A1), mRNA. 
PDCD5 1.63 Homo sapiens programmed cell death 5 (PDCD5), mRNA. 
FLJ20186 1.63 Homo sapiens hypothetical protein FLJ20186 (FLJ20186), transcript variant 2, mRNA. 
GPM6B 1.62 Homo sapiens glycoprotein M6B (GPM6B), transcript variant 1, mRNA. 
CUTA 1.62 
Homo sapiens cutA divalent cation tolerance homolog (E. coli) (CUTA), transcript variant 1, 
mRNA. 
MRPS24 1.62 
Homo sapiens mitochondrial ribosomal protein S24 (MRPS24), nuclear gene encoding 
mitochondrial protein, mRNA. 
PCBD1 1.62 
Homo sapiens pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte 
nuclear factor 1 alpha (TCF1) (PCBD1), mRNA. 
PLEKHH2 1.62 
Homo sapiens pleckstrin homology domain containing, family H (with MyTH4 domain) 
member 2 (PLEKHH2), mRNA. 
SNRPB2 1.62 
Homo sapiens small nuclear ribonucleoprotein polypeptide B'' (SNRPB2), transcript variant 1, 
mRNA. 
SH3BGRL3 1.62 Homo sapiens SH3 domain binding glutamic acid-rich protein like 3 (SH3BGRL3), mRNA. 
APOL2 1.62 Homo sapiens apolipoprotein L, 2 (APOL2), transcript variant beta, mRNA. 
FLJ21986 1.62 Homo sapiens hypothetical protein FLJ21986 (FLJ21986), mRNA. 
WFDC3 1.62 Homo sapiens WAP four-disulfide core domain 3 (WFDC3), transcript variant 4, mRNA. 
IL1RN 1.62 Homo sapiens interleukin 1 receptor antagonist (IL1RN), transcript variant 1, mRNA. 
WFDC3 1.62 Homo sapiens WAP four-disulfide core domain 3 (WFDC3), transcript variant 2, mRNA. 
PI3 1.61 Homo sapiens peptidase inhibitor 3, skin-derived (SKALP) (PI3), mRNA. 
LOC51334 1.61 Homo sapiens proline rich 16 (PRR16), mRNA. 
KCNK6 1.61 Homo sapiens potassium channel, subfamily K, member 6 (KCNK6), mRNA. 
FAIM3 1.61 Homo sapiens Fas apoptotic inhibitory molecule 3 (FAIM3), mRNA. 
CDK5RAP2 1.61 
Homo sapiens CDK5 regulatory subunit associated protein 2 (CDK5RAP2), transcript variant 
2, mRNA. 
RIPK2 1.61 Homo sapiens receptor-interacting serine-threonine kinase 2 (RIPK2), mRNA. 
METRNL 1.61 Homo sapiens meteorin, glial cell differentiation regulator-like (METRNL), mRNA. 
SLC38A6 1.61 Homo sapiens solute carrier family 38, member 6 (SLC38A6), mRNA. 
PDK3 1.61 Homo sapiens pyruvate dehydrogenase kinase, isozyme 3 (PDK3), mRNA. 
BATF 1.60 Homo sapiens basic leucine zipper transcription factor, ATF-like (BATF), mRNA. 
PPIC 1.60 Homo sapiens peptidylprolyl isomerase C (cyclophilin C) (PPIC), mRNA. 
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TKT 1.60 Homo sapiens transketolase (Wernicke-Korsakoff syndrome) (TKT), mRNA. 
C17orf58 1.60 Homo sapiens chromosome 17 open reading frame 58 (C17orf58), transcript variant 2, mRNA. 
BAIAP2L2 1.60 Homo sapiens BAI1-associated protein 2-like 2 (BAIAP2L2), mRNA. 
ID2 1.60 
Homo sapiens inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2), 
mRNA. 
CIDEA 1.60 Homo sapiens cell death-inducing DFFA-like effector a (CIDEA), transcript variant 2, mRNA. 
BOLA3 1.60 Homo sapiens bolA-like 3 (E. coli) (BOLA3), mRNA. 
C7orf24 1.60 Homo sapiens chromosome 7 open reading frame 24 (C7orf24), mRNA. 
SLC16A4 1.59 
Homo sapiens solute carrier family 16, member 4 (monocarboxylic acid transporter 5) 
(SLC16A4), mRNA. 
MRPL14 1.59 
Homo sapiens mitochondrial ribosomal protein L14 (MRPL14), nuclear gene encoding 
mitochondrial protein, mRNA. 
MGC40579 1.59 Homo sapiens hypothetical protein MGC40579 (MGC40579), mRNA. 
DYNC2LI1 1.59 
Homo sapiens dynein, cytoplasmic 2, light intermediate chain 1 (DYNC2LI1), transcript variant 
2, mRNA. 
IRF8 1.59 Homo sapiens interferon regulatory factor 8 (IRF8), mRNA. 
C1orf41 1.59 Homo sapiens chromosome 1 open reading frame 41 (C1orf41), mRNA. 
PPAP2B 1.59 Homo sapiens phosphatidic acid phosphatase type 2B (PPAP2B), transcript variant 2, mRNA. 
CIB1 1.59 Homo sapiens calcium and integrin binding 1 (calmyrin) (CIB1), mRNA. 
NRN1 1.59 Homo sapiens neuritin 1 (NRN1), mRNA. 
RNASE4 1.59 Homo sapiens ribonuclease, RNase A family, 4 (RNASE4), transcript variant 1, mRNA. 
TMOD1 1.59 Homo sapiens tropomodulin 1 (TMOD1), mRNA. 
RPP21 1.59 Homo sapiens ribonuclease P/MRP 21kDa subunit (RPP21), mRNA. 
RPL36AL 1.59 Homo sapiens ribosomal protein L36a-like (RPL36AL), mRNA. 
SERTAD3 1.59 Homo sapiens SERTA domain containing 3 (SERTAD3), transcript variant 2, mRNA. 
FLJ39155 1.59 
Homo sapiens EGF-like, fibronectin type III and laminin G domains (EGFLAM), transcript 
variant 4, mRNA. 
RARRES3 1.58 Homo sapiens retinoic acid receptor responder (tazarotene induced) 3 (RARRES3), mRNA. 
COX17 1.58 
Homo sapiens COX17 cytochrome c oxidase assembly homolog (S. cerevisiae) (COX17), 
nuclear gene encoding mitochondrial protein, mRNA. 
FAM14A 1.58 Homo sapiens family with sequence similarity 14, member A (FAM14A), mRNA. 
SEC14L1 1.58 Homo sapiens SEC14-like 1 (S. cerevisiae) (SEC14L1), transcript variant 1, mRNA. 
HSCB 1.58 Homo sapiens HscB iron-sulfur cluster co-chaperone homolog (E. coli) (HSCB), mRNA. 
TSPO 1.58 Homo sapiens translocator protein (18kDa) (TSPO), transcript variant PBR, mRNA. 
TUBB2C 1.58 Homo sapiens tubulin, beta 2C (TUBB2C), mRNA. 
RWDD1 1.58 Homo sapiens RWD domain containing 1 (RWDD1), transcript variant 3, mRNA. 
IL17R 1.58 Homo sapiens interleukin 17 receptor (IL17R), mRNA. 
SEMA4B 1.58 
Homo sapiens sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 4B (SEMA4B), transcript variant 1, mRNA. 
RRAS 1.58 Homo sapiens related RAS viral (r-ras) oncogene homolog (RRAS), mRNA. 
RAB11FIP1 1.58 
Homo sapiens RAB11 family interacting protein 1 (class I) (RAB11FIP1), transcript variant 3, 
mRNA. 
LOC56901 1.58 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 
(NDUFA4L2), mRNA. 
MRPL54 1.58 
Homo sapiens mitochondrial ribosomal protein L54 (MRPL54), nuclear gene encoding 
mitochondrial protein, mRNA. 
C1GALT1C1 1.57 Homo sapiens C1GALT1-specific chaperone 1 (C1GALT1C1), transcript variant 2, mRNA. 
KIAA1434 1.57 Homo sapiens hypothetical protein KIAA1434 (KIAA1434), mRNA. 
LOC653610 1.57 
PREDICTED: Homo sapiens similar to Histone H2A.o (H2A/o) (H2A.2) (H2a-615) 
(LOC653610), mRNA. 
NFE2 1.57 Homo sapiens nuclear factor (erythroid-derived 2), 45kDa (NFE2), mRNA. 
MYL9 1.57 Homo sapiens myosin, light chain 9, regulatory (MYL9), transcript variant 1, mRNA. 
OBFC2A 1.57 
Homo sapiens oligonucleotide/oligosaccharide-binding fold containing 2A (OBFC2A), 
transcript variant 2, mRNA. 
PLP2 1.57 Homo sapiens proteolipid protein 2 (colonic epithelium-enriched) (PLP2), mRNA. 
UXT 1.57 Homo sapiens ubiquitously-expressed transcript (UXT), transcript variant 1, mRNA. 
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NUDT14 1.57 
Homo sapiens nudix (nucleoside diphosphate linked moiety X)-type motif 14 (NUDT14), 
mRNA. 
DCI 1.57 
Homo sapiens dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-Coenzyme A 
isomerase) (DCI), nuclear gene encoding mitochondrial protein, mRNA. 
LOC650298 1.57 PREDICTED: Homo sapiens similar to 40S ribosomal protein S26 (LOC650298), mRNA. 
SCO2 1.57 
Homo sapiens SCO cytochrome oxidase deficient homolog 2 (yeast) (SCO2), nuclear gene 
encoding mitochondrial protein, mRNA. 
GPM6B 1.57 Homo sapiens glycoprotein M6B (GPM6B), transcript variant 4, mRNA. 
BLVRB 1.57 Homo sapiens biliverdin reductase B (flavin reductase (NADPH)) (BLVRB), mRNA. 
EMP3 1.56 Homo sapiens epithelial membrane protein 3 (EMP3), mRNA. 
C1orf50 1.56 Homo sapiens chromosome 1 open reading frame 50 (C1orf50), mRNA. 
C16orf61 1.56 Homo sapiens chromosome 16 open reading frame 61 (C16orf61), mRNA. 
COL8A1 1.56 Homo sapiens collagen, type VIII, alpha 1 (COL8A1), transcript variant 2, mRNA. 
GLRX2 1.56 Homo sapiens glutaredoxin 2 (GLRX2), transcript variant 2, mRNA. 
RP11-529I10.4 1.56 
Homo sapiens deleted in a mouse model of primary ciliary dyskinesia (RP11-529I10.4), 
mRNA. 
BST2 1.56 Homo sapiens bone marrow stromal cell antigen 2 (BST2), mRNA. 
FST 1.56 Homo sapiens follistatin (FST), transcript variant FST344, mRNA. 
GTF2IRD2 1.56 Homo sapiens GTF2I repeat domain containing 2 (GTF2IRD2), mRNA. 
 1.56 AV762101 MDS Homo sapiens cDNA clone MDSEOA03 5, mRNA sequence 
DNAL1 1.56 Homo sapiens dynein, axonemal, light chain 1 (DNAL1), mRNA. 
LOX 1.55 Homo sapiens lysyl oxidase (LOX), mRNA. 
ATOX1 1.55 Homo sapiens ATX1 antioxidant protein 1 homolog (yeast) (ATOX1), mRNA. 
APIP 1.55 Homo sapiens APAF1 interacting protein (APIP), mRNA. 
RPL34 1.55 Homo sapiens ribosomal protein L34 (RPL34), transcript variant 2, mRNA. 
LARP6 1.55 
Homo sapiens La ribonucleoprotein domain family, member 6 (LARP6), transcript variant 2, 
mRNA. 
RNASE4 1.55 Homo sapiens ribonuclease, RNase A family, 4 (RNASE4), transcript variant 1, mRNA. 
FCGR2B 1.55 
Homo sapiens Fc fragment of IgG, low affinity IIb, receptor (CD32) (FCGR2B), transcript 
variant 1, mRNA. 
MRPL27 1.55 
Homo sapiens mitochondrial ribosomal protein L27 (MRPL27), nuclear gene encoding 
mitochondrial protein, transcript variant 1, mRNA. 
SNRPF 1.55 Homo sapiens small nuclear ribonucleoprotein polypeptide F (SNRPF), mRNA. 
SLA 1.55 Homo sapiens Src-like-adaptor (SLA), transcript variant 2, mRNA. 
ZNF593 1.55 Homo sapiens zinc finger protein 593 (ZNF593), mRNA. 
LOC400948 1.55 PREDICTED: Homo sapiens similar to CG33774-PA (LOC400948), mRNA. 
PSMB10 1.55 Homo sapiens proteasome (prosome, macropain) subunit, beta type, 10 (PSMB10), mRNA. 
MS4A6A 1.55 
Homo sapiens membrane-spanning 4-domains, subfamily A, member 6A (MS4A6A), transcript 
variant 2, mRNA. 
C9orf89 1.55 Homo sapiens chromosome 9 open reading frame 89 (C9orf89), mRNA. 
SCNM1 1.55 Homo sapiens sodium channel modifier 1 (SCNM1), mRNA. 
BOLA2 1.55 Homo sapiens bolA homolog 2 (E. coli) (BOLA2), mRNA. 
NDUFA11 1.54 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 14.7kDa 
(NDUFA11), mRNA. 
MGC71993 1.54 
Homo sapiens similar to DNA segment, Chr 11, Brigham & Womens Genetics 0434 expressed 
(MGC71993), mRNA. 
C17orf58 1.54 Homo sapiens chromosome 17 open reading frame 58 (C17orf58), transcript variant 2, mRNA. 
FKBP1A 1.54 Homo sapiens FK506 binding protein 1A, 12kDa (FKBP1A), transcript variant 12A, mRNA. 
DCXR 1.54 Homo sapiens dicarbonyl/L-xylulose reductase (DCXR), mRNA. 
HCFC1R1 1.54 
Homo sapiens host cell factor C1 regulator 1 (XPO1 dependent) (HCFC1R1), transcript variant 
2, mRNA. 
TUBB6 1.54 PREDICTED: Homo sapiens tubulin, beta 6 (TUBB6), mRNA. 
ZCD1 1.54 Homo sapiens zinc finger, CDGSH-type domain 1 (ZCD1), mRNA. 
ATPIF1 1.54 
Homo sapiens ATPase inhibitory factor 1 (ATPIF1), nuclear gene encoding mitochondrial 
protein, transcript variant 1, mRNA. 
NDUFB8 1.54 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19kDa (NDUFB8), 
mRNA. 
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ATP5I 1.54 
Homo sapiens ATP synthase, H+ transporting, mitochondrial F0 complex, subunit E (ATP5I), 
nuclear gene encoding mitochondrial protein, mRNA. 
EBPL 1.54 Homo sapiens emopamil binding protein-like (EBPL), mRNA. 
 1.54 Homo sapiens cDNA clone IMAGE:30530513 
PSMB6 1.54 Homo sapiens proteasome (prosome, macropain) subunit, beta type, 6 (PSMB6), mRNA. 
NDUFB6 1.54 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa (NDUFB6), 
nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 
 1.54 Homo sapiens mRNA; cDNA DKFZp686F09166 (from clone DKFZp686F09166) 
SNAPC2 1.54 
Homo sapiens small nuclear RNA activating complex, polypeptide 2, 45kDa (SNAPC2), 
mRNA. 
RRBP1 1.53 
Homo sapiens ribosome binding protein 1 homolog 180kDa (dog) (RRBP1), transcript variant 
1, mRNA. 
SNRPC 1.53 Homo sapiens small nuclear ribonucleoprotein polypeptide C (SNRPC), mRNA. 
LOC205251 1.53 Homo sapiens hypothetical protein LOC205251 (LOC205251), mRNA. 
YIF1B 1.53 
Homo sapiens Yip1 interacting factor homolog B (S. cerevisiae) (YIF1B), transcript variant 4, 
mRNA. 
PSMB2 1.53 Homo sapiens proteasome (prosome, macropain) subunit, beta type, 2 (PSMB2), mRNA. 
PMAIP1 1.53 Homo sapiens phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1), mRNA. 
ATP5D 1.53 
Homo sapiens ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit 
(ATP5D), nuclear gene encoding mitochondrial protein, transcript variant 2, mRNA. 
NHP2L1 1.53 
Homo sapiens NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) (NHP2L1), 
transcript variant 1, mRNA. 
UGP2 1.53 Homo sapiens UDP-glucose pyrophosphorylase 2 (UGP2), transcript variant 1, mRNA. 
C20orf35 1.53 Homo sapiens chromosome 20 open reading frame 35 (C20orf35), transcript variant 1, mRNA. 
KHSRP 1.53 
Homo sapiens KH-type splicing regulatory protein (FUSE binding protein 2) (KHSRP), 
mRNA. 
DDIT3 1.53 Homo sapiens DNA-damage-inducible transcript 3 (DDIT3), mRNA. 
RIT1 1.53 Homo sapiens Ras-like without CAAX 1 (RIT1), mRNA. 
LOC285016 1.53 Homo sapiens hypothetical protein LOC285016 (LOC285016), mRNA. 
CTSC 1.53 Homo sapiens cathepsin C (CTSC), transcript variant 1, mRNA. 
MGC2574 1.53 Homo sapiens coiled-coil domain containing 86 (CCDC86), mRNA. 
MRPL55 1.53 
Homo sapiens mitochondrial ribosomal protein L55 (MRPL55), nuclear gene encoding 
mitochondrial protein, transcript variant 6, mRNA. 
GAS2L3 1.53 Homo sapiens growth arrest-specific 2 like 3 (GAS2L3), mRNA. 
LOC440928 1.53 PREDICTED: Homo sapiens hypothetical LOC440928 (LOC440928), mRNA. 
C20orf24 1.53 Homo sapiens chromosome 20 open reading frame 24 (C20orf24), transcript variant 4, mRNA. 
C9orf21 1.53 Homo sapiens chromosome 9 open reading frame 21 (C9orf21), mRNA. 
RAB38 1.53 Homo sapiens RAB38, member RAS oncogene family (RAB38), mRNA. 
HRAS 1.53 
Homo sapiens v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS), transcript variant 
2, mRNA. 
LOC652545 1.53 PREDICTED: Homo sapiens similar to Protein C21orf70 homolog (LOC652545), mRNA. 
USMG5 1.52 
Homo sapiens upregulated during skeletal muscle growth 5 homolog (mouse) (USMG5), 
mRNA. 
PRKCA 1.52 Homo sapiens protein kinase C, alpha (PRKCA), mRNA. 
LOC650832 1.52 
PREDICTED: Homo sapiens similar to mitogen-activated protein kinase kinase 3 isoform A 
(LOC650832), mRNA. 
C17orf61 1.52 Homo sapiens chromosome 17 open reading frame 61 (C17orf61), mRNA. 
QP-C 1.52 
Homo sapiens low molecular mass ubiquinone-binding protein (9.5kD) (QP-C), nuclear gene 
encoding mitochondrial protein, mRNA. 
EGFLAM 1.52 
Homo sapiens EGF-like, fibronectin type III and laminin G domains (EGFLAM), transcript 
variant 3, mRNA. 
COX8A 1.52 Homo sapiens cytochrome c oxidase subunit 8A (ubiquitous) (COX8A), mRNA. 
LOC650982 1.52 PREDICTED: Homo sapiens similar to DC2 protein (LOC650982), mRNA. 
PCBD1 1.52 
Homo sapiens 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte 
nuclear factor 1 alpha (TCF1) (PCBD1), transcript variant 2, mRNA. 
C1orf53 1.52 Homo sapiens chromosome 1 open reading frame 53 (C1orf53), mRNA. 
IBRDC3 1.52 Homo sapiens IBR domain containing 3 (IBRDC3), mRNA. 
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MRPL36 1.52 
Homo sapiens mitochondrial ribosomal protein L36 (MRPL36), nuclear gene encoding 
mitochondrial protein, mRNA. 
LRIG1 1.52 Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1), mRNA. 
RRAD 1.52 Homo sapiens Ras-related associated with diabetes (RRAD), mRNA. 
MAGOH 1.52 Homo sapiens mago-nashi homolog, proliferation-associated (Drosophila) (MAGOH), mRNA. 
CLEC4A 1.52 
Homo sapiens C-type lectin domain family 4, member A (CLEC4A), transcript variant 4, 
mRNA. 
AHNAK 1.52 Homo sapiens AHNAK nucleoprotein (AHNAK), transcript variant 1, mRNA. 
QIL1 1.52 Homo sapiens hypothetical protein P117 (P117), mRNA. 
HSPC176 1.52 Homo sapiens trafficking protein particle complex 2-like (TRAPPC2L), mRNA. 
ANXA2 1.52 Homo sapiens annexin A2 (ANXA2), transcript variant 2, mRNA. 
C15orf48 1.52 Homo sapiens chromosome 15 open reading frame 48 (C15orf48), transcript variant 2, mRNA. 
LOC286016 1.52 Homo sapiens hypothetical protein LOC286016 (LOC286016) on chromosome 7. 
METRNL 1.51 
PREDICTED: Homo sapiens meteorin, glial cell differentiation regulator-like (METRNL), 
mRNA. 
GALNAC4S-6ST 1.51 Homo sapiens B cell RAG associated protein (GALNAC4S-6ST), mRNA. 
NDUFB2 1.51 
Homo sapiens NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa (NDUFB2), 
nuclear gene encoding mitochondrial protein, mRNA. 
MGC3731 1.51 Homo sapiens hypothetical protein MGC3731 (MGC3731), mRNA. 
CDC25B 1.51 
Homo sapiens cell division cycle 25 homolog B (S. pombe) (CDC25B), transcript variant 2, 
mRNA. 
BCYRN1 1.51 Homo sapiens brain cytoplasmic RNA 1, Bc1 analog (mouse) (BCYRN1) on chromosome 2. 
SERPINH1 1.51 
Homo sapiens serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen 
binding protein 1) (SERPINH1), mRNA. 
DUSP6 1.51 Homo sapiens dual specificity phosphatase 6 (DUSP6), transcript variant 2, mRNA. 
DPM3 1.51 
Homo sapiens dolichyl-phosphate mannosyltransferase polypeptide 3 (DPM3), transcript 
variant 2, mRNA. 
LOC51255 1.51 Homo sapiens ring finger protein 181 (RNF181), mRNA. 
H2BFS 1.51 Homo sapiens H2B histone family, member S (H2BFS), mRNA. 
C10orf72 1.51 Homo sapiens chromosome 10 open reading frame 72 (C10orf72), transcript variant 1, mRNA. 
DCTN3 1.51 Homo sapiens dynactin 3 (p22) (DCTN3), transcript variant 2, mRNA. 
C21orf34 1.51 Homo sapiens chromosome 21 open reading frame 34 (C21orf34), transcript variant 1, mRNA. 
 1.51 
BX093329 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone 
IMAGp998A124183 ; IMAGE:1648403, mRNA sequence 
FAM96B 1.51 Homo sapiens family with sequence similarity 96, member B (FAM96B), mRNA. 
ECGF1 1.51 Homo sapiens endothelial cell growth factor 1 (platelet-derived) (ECGF1), mRNA. 
TIMP2 1.51 Homo sapiens TIMP metallopeptidase inhibitor 2 (TIMP2), mRNA. 
ALG13 1.51 Homo sapiens asparagine-linked glycosylation 13 homolog (S. cerevisiae) (ALG13), mRNA. 
SHFM1 1.51 Homo sapiens split hand/foot malformation (ectrodactyly) type 1 (SHFM1), mRNA. 
NPEPL1 1.51 Homo sapiens aminopeptidase-like 1 (NPEPL1), mRNA. 
MRPS12 1.51 
Homo sapiens mitochondrial ribosomal protein S12 (MRPS12), nuclear gene encoding 
mitochondrial protein, transcript variant 3, mRNA. 
LOC653566 1.51 
Homo sapiens similar to Signal peptidase complex subunit 2 (Microsomal signal peptidase 25 
kDa subunit) (SPase 25 kDa subunit) (LOC653566), mRNA. 
GPR64 1.51 Homo sapiens G protein-coupled receptor 64 (GPR64), mRNA. 
TMPIT 1.50 Homo sapiens transmembrane protein 120A (TMEM120A), mRNA. 
CCBE1 1.50 Homo sapiens collagen and calcium binding EGF domains 1 (CCBE1), mRNA. 
S100A13 1.50 Homo sapiens S100 calcium binding protein A13 (S100A13), transcript variant 3, mRNA. 
LOC84661 1.50 Homo sapiens dpy-30-like protein (HDPY-30), mRNA. 
SSNA1 1.50 Homo sapiens Sjogren's syndrome nuclear autoantigen 1 (SSNA1), mRNA. 
 1.50 Homo sapiens cDNA clone IMAGE:5277162 
CCDC68 1.50 Homo sapiens coiled-coil domain containing 68 (CCDC68), mRNA. 
FKBP11 1.50 Homo sapiens FK506 binding protein 11, 19 kDa (FKBP11), mRNA. 
HBXIP 1.50 Homo sapiens hepatitis B virus x interacting protein (HBXIP), mRNA. 
TRG20 1.50 Homo sapiens mediator complex subunit 10 (MED10), mRNA. 
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COBLL1 1.50 Homo sapiens COBL-like 1 (COBLL1), mRNA. 
ZMYND11 -1.50 
Homo sapiens zinc finger, MYND domain containing 11 (ZMYND11), transcript variant 1, 
mRNA. 
BACE2 -1.50 Homo sapiens beta-site APP-cleaving enzyme 2 (BACE2), transcript variant c, mRNA. 
AGL -1.50 
Homo sapiens amylo-1, 6-glucosidase, 4-alpha-glucanotransferase (glycogen debranching 
enzyme, glycogen storage disease type III) (AGL), transcript variant 5, mRNA. 
CACHD1 -1.50 Homo sapiens cache domain containing 1 (CACHD1), mRNA. 
WSB2 -1.50 Homo sapiens WD repeat and SOCS box-containing 2 (WSB2), mRNA. 
NXT2 -1.50 Homo sapiens nuclear transport factor 2-like export factor 2 (NXT2), mRNA. 
ARHGEF3 -1.50 Homo sapiens Rho guanine nucleotide exchange factor (GEF) 3 (ARHGEF3), mRNA. 
TOM1 -1.50 Homo sapiens target of myb1 (chicken) (TOM1), mRNA. 
CHES1 -1.50 Homo sapiens checkpoint suppressor 1 (CHES1), mRNA. 
NTN4 -1.51 Homo sapiens netrin 4 (NTN4), mRNA. 
TMEM154 -1.51 Homo sapiens transmembrane protein 154 (TMEM154), mRNA. 
C8orf52 -1.51 Homo sapiens integrator complex subunit 8 (INTS8), mRNA. 
HDGFRP3 -1.51 Homo sapiens hepatoma-derived growth factor, related protein 3 (HDGFRP3), mRNA. 
LOC648695 -1.51 
PREDICTED: Homo sapiens similar to retinoblastoma binding protein 4, transcript variant 4 
(LOC648695), mRNA. 
HNMT -1.51 Homo sapiens histamine N-methyltransferase (HNMT), transcript variant 2, mRNA. 
ZNF148 -1.51 Homo sapiens zinc finger protein 148 (ZNF148), mRNA. 
KIAA1754 -1.51 Homo sapiens KIAA1754 (KIAA1754), mRNA. 
ZNF503 -1.51 Homo sapiens zinc finger protein 503 (ZNF503), mRNA. 
DUSP10 -1.51 Homo sapiens dual specificity phosphatase 10 (DUSP10), transcript variant 3, mRNA. 
IRF2BP2 -1.51 Homo sapiens interferon regulatory factor 2 binding protein 2 (IRF2BP2), mRNA. 
ZNF265 -1.51 
Homo sapiens zinc finger, RAN-binding domain containing 2 (ZRANB2), transcript variant 2, 
mRNA. 
SLC4A7 -1.51 
Homo sapiens solute carrier family 4, sodium bicarbonate cotransporter, member 7 (SLC4A7), 
mRNA. 
GPR177 -1.51 Homo sapiens G protein-coupled receptor 177 (GPR177), transcript variant 2, mRNA. 
SRPX2 -1.51 Homo sapiens sushi-repeat-containing protein, X-linked 2 (SRPX2), mRNA. 
GPR177 -1.52 Homo sapiens G protein-coupled receptor 177 (GPR177), transcript variant 2, mRNA. 
RBM25 -1.52 Homo sapiens RNA binding motif protein 25 (RBM25), mRNA. 
TCF12 -1.52 
Homo sapiens transcription factor 12 (HTF4, helix-loop-helix transcription factors 4) (TCF12), 
transcript variant 2, mRNA. 
CROP -1.52 
Homo sapiens cisplatin resistance-associated overexpressed protein (CROP), transcript variant 
1, mRNA. 
VPS41 -1.52 
Homo sapiens vacuolar protein sorting 41 homolog (S. cerevisiae) (VPS41), transcript variant 
1, mRNA. 
SNAPC1 -1.52 
Homo sapiens small nuclear RNA activating complex, polypeptide 1, 43kDa (SNAPC1), 
mRNA. 
RAB23 -1.52 Homo sapiens RAB23, member RAS oncogene family (RAB23), transcript variant 1, mRNA. 
SESN3 -1.52 Homo sapiens sestrin 3 (SESN3), mRNA. 
PDE1A -1.52 
Homo sapiens phosphodiesterase 1A, calmodulin-dependent (PDE1A), transcript variant 2, 
mRNA. 
CERK -1.52 Homo sapiens ceramide kinase (CERK), transcript variant 2, mRNA. 
ITPR3 -1.52 Homo sapiens inositol 1,4,5-triphosphate receptor, type 3 (ITPR3), mRNA. 
PPP3CA -1.52 
Homo sapiens protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (PPP3CA), 
mRNA. 
PCM1 -1.52 Homo sapiens pericentriolar material 1 (PCM1), mRNA. 
SLC35F2 -1.53 Homo sapiens solute carrier family 35, member F2 (SLC35F2), mRNA. 
SLC25A37 -1.53 Homo sapiens solute carrier family 25, member 37 (SLC25A37), transcript variant 1, mRNA. 
VLDLR -1.53 Homo sapiens very low density lipoprotein receptor (VLDLR), transcript variant 2, mRNA. 
CXCL5 -1.53 Homo sapiens chemokine (C-X-C motif) ligand 5 (CXCL5), mRNA. 
PLD1 -1.53 Homo sapiens phospholipase D1, phosphatidylcholine-specific (PLD1), mRNA. 
YTHDF3 -1.53 Homo sapiens YTH domain family, member 3 (YTHDF3), mRNA. 
ADFP -1.53 Homo sapiens adipose differentiation-related protein (ADFP), mRNA. 
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C4orf18 -1.53 Homo sapiens chromosome 4 open reading frame 18 (C4orf18), transcript variant 2, mRNA. 
CBX1 -1.53 Homo sapiens chromobox homolog 1 (HP1 beta homolog Drosophila ) (CBX1), mRNA. 
MYH9 -1.53 Homo sapiens myosin, heavy polypeptide 9, non-muscle (MYH9), mRNA. 
ZMPSTE24 -1.53 Homo sapiens zinc metallopeptidase (STE24 homolog, yeast) (ZMPSTE24), mRNA. 
GALNT10 -1.53 
Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 (GalNAc-T10) (GALNT10), transcript variant 1, mRNA. 
NAT13 -1.53 Homo sapiens N-acetyltransferase 13 (NAT13), mRNA. 
TMEM38B -1.53 Homo sapiens transmembrane protein 38B (TMEM38B), mRNA. 
PXDN -1.53 
Homo sapiens peroxidasin homolog (Drosophila) (PXDN), mRNA. XM_935184 XM_936786 
XM_942966 XM_942982 XM_942986 XM_942994 XM_943000 
DEK -1.53 Homo sapiens DEK oncogene (DNA binding) (DEK), mRNA. 
POFUT1 -1.54 Homo sapiens protein O-fucosyltransferase 1 (POFUT1), transcript variant 1, mRNA. 
TMEM106B -1.54 Homo sapiens transmembrane protein 106B (TMEM106B), mRNA. 
FAT -1.54 Homo sapiens FAT tumor suppressor homolog 1 (Drosophila) (FAT), mRNA. 
XPO4 -1.54 Homo sapiens exportin 4 (XPO4), mRNA. 
TMEM106B -1.54 Homo sapiens transmembrane protein 106B (TMEM106B), mRNA. 
 -1.54 AV737943 CB Homo sapiens cDNA clone CBDAEG06 5, mRNA sequence 
FLJ12649 -1.54 
PREDICTED: Homo sapiens hypothetical protein FLJ12649, transcript variant 1 (FLJ12649), 
mRNA. 
SNAPC4 -1.54 
Homo sapiens small nuclear RNA activating complex, polypeptide 4, 190kDa (SNAPC4), 
mRNA. 
C1orf24 -1.54 Homo sapiens chromosome 1 open reading frame 24 (C1orf24), transcript variant 1, mRNA. 
PABPC1 -1.54 Homo sapiens poly(A) binding protein, cytoplasmic 1 (PABPC1), mRNA. 
CTSO -1.55 Homo sapiens cathepsin O (CTSO), mRNA. 
TIMP3 -1.55 
Homo sapiens TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, 
pseudoinflammatory) (TIMP3), mRNA. 
MTDH -1.55 Homo sapiens metadherin (MTDH), mRNA. 
ALS2CR13 -1.55 
Homo sapiens amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 13 
(ALS2CR13), mRNA. 
MAP4K4 -1.55 
Homo sapiens mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), transcript 
variant 3, mRNA. 
ITGB5 -1.55 PREDICTED: Homo sapiens integrin, beta 5, transcript variant 8 (ITGB5), mRNA. 
FZD2 -1.55 Homo sapiens frizzled homolog 2 (Drosophila) (FZD2), mRNA. 
ALDH1B1 -1.55 
Homo sapiens aldehyde dehydrogenase 1 family, member B1 (ALDH1B1), nuclear gene 
encoding mitochondrial protein, mRNA. 
NBPF11 -1.55 Homo sapiens neuroblastoma breakpoint family, member 11 (NBPF11), mRNA. 
CTNNB1 -1.55 
PREDICTED: Homo sapiens catenin (cadherin-associated protein), beta 1, 88kDa, transcript 
variant 4 (CTNNB1), mRNA. 
BBX -1.55 Homo sapiens bobby sox homolog (Drosophila) (BBX), mRNA. 
CRTAC1 -1.55 Homo sapiens cartilage acidic protein 1 (CRTAC1), mRNA. 
BHLHB3 -1.56 Homo sapiens basic helix-loop-helix domain containing, class B, 3 (BHLHB3), mRNA. 
SIPA1L2 -1.56 Homo sapiens signal-induced proliferation-associated 1 like 2 (SIPA1L2), mRNA. 
PDXK -1.56 Homo sapiens pyridoxal (pyridoxine, vitamin B6) kinase (PDXK), mRNA. 
NAV2 -1.56 Homo sapiens neuron navigator 2 (NAV2), transcript variant 2, mRNA. 
ZNF302 -1.56 Homo sapiens zinc finger protein 302 (ZNF302), transcript variant 1, mRNA. 
GAS6 -1.56 Homo sapiens growth arrest-specific 6 (GAS6), mRNA. 
TNS3 -1.56 Homo sapiens tensin 3 (TNS3), mRNA. 
LPP -1.56 Homo sapiens LIM domain containing preferred translocation partner in lipoma (LPP), mRNA. 
ABCC4 -1.56 Homo sapiens ATP-binding cassette, sub-family C (CFTR/MRP), member 4 (ABCC4), mRNA. 
COL16A1 -1.56 Homo sapiens collagen, type XVI, alpha 1 (COL16A1), mRNA. 
LOC642934 -1.56 PREDICTED: Homo sapiens hypothetical protein LOC642934 (LOC642934), mRNA. 
DHFRL1 -1.56 Homo sapiens dihydrofolate reductase-like 1 (DHFRL1), mRNA. 
NMD3 -1.56 Homo sapiens NMD3 homolog (S. cerevisiae) (NMD3), mRNA. 
SMAD4 -1.57 Homo sapiens SMAD family member 4 (SMAD4), mRNA. 
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NOL8 -1.57 Homo sapiens nucleolar protein 8 (NOL8), mRNA. 
ABCA1 -1.57 Homo sapiens ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1), mRNA. 
DDEFL1 -1.57 Homo sapiens development and differentiation enhancing factor-like 1 (DDEFL1), mRNA. 
FMO4 -1.57 Homo sapiens flavin containing monooxygenase 4 (FMO4), mRNA. 
WDFY1 -1.57 Homo sapiens WD repeat and FYVE domain containing 1 (WDFY1), mRNA. 
NISCH -1.57 Homo sapiens nischarin (NISCH), mRNA. 
GAS6 -1.57 PREDICTED: Homo sapiens growth arrest-specific 6, transcript variant 2 (GAS6), mRNA. 
TCEA1 -1.57 Homo sapiens transcription elongation factor A (SII), 1 (TCEA1), transcript variant 2, mRNA. 
JMJD1C -1.57 Homo sapiens jumonji domain containing 1C (JMJD1C), mRNA. 
MUM1 -1.57 Homo sapiens melanoma associated antigen (mutated) 1 (MUM1), mRNA. 
EFEMP1 -1.57 
Homo sapiens EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1), transcript 
variant 1, mRNA. 
FHL2 -1.57 Homo sapiens four and a half LIM domains 2 (FHL2), transcript variant 2, mRNA. 
FNDC3A -1.57 
Homo sapiens fibronectin type III domain containing 3A (FNDC3A), transcript variant 1, 
mRNA. 
CYFIP2 -1.58 Homo sapiens cytoplasmic FMR1 interacting protein 2 (CYFIP2), mRNA. 
MCM4 -1.58 
Homo sapiens MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) (MCM4), 
transcript variant 1, mRNA. 
MMP11 -1.58 Homo sapiens matrix metallopeptidase 11 (stromelysin 3) (MMP11), mRNA. 
GPNMB -1.58 Homo sapiens glycoprotein (transmembrane) nmb (GPNMB), transcript variant 1, mRNA. 
TNFRSF10B -1.58 
Homo sapiens tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B), 
transcript variant 1, mRNA. 
LUM -1.58 Homo sapiens lumican (LUM), mRNA. 
PPM2C -1.58 
Homo sapiens protein phosphatase 2C, magnesium-dependent, catalytic subunit (PPM2C), 
nuclear gene encoding mitochondrial protein, mRNA. 
CD14 -1.58 Homo sapiens CD14 molecule (CD14), transcript variant 2, mRNA. 
ZNF91 -1.58 Homo sapiens zinc finger protein 91 (HPF7, HTF10) (ZNF91), mRNA. 
LANCL1 -1.58 Homo sapiens LanC lantibiotic synthetase component C-like 1 (bacterial) (LANCL1), mRNA. 
ZBTB33 -1.58 Homo sapiens zinc finger and BTB domain containing 33 (ZBTB33), mRNA. 
SP3 -1.58 Homo sapiens Sp3 transcription factor (SP3), transcript variant 2, mRNA. 
DACT1 -1.59 
Homo sapiens dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) (DACT1), 
mRNA. 
 -1.59 
BX099724 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone 
IMAGp998F201004, mRNA sequence 
C5orf13 -1.59 Homo sapiens chromosome 5 open reading frame 13 (C5orf13), mRNA. 
C1orf71 -1.59 Homo sapiens chromosome 1 open reading frame 71 (C1orf71), mRNA. 
C1orf24 -1.59 Homo sapiens chromosome 1 open reading frame 24 (C1orf24), transcript variant 2, mRNA. 
DPP4 -1.59 
Homo sapiens dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2) 
(DPP4), mRNA. 
IRX3 -1.59 Homo sapiens iroquois homeobox 3 (IRX3), mRNA. 
THBS2 -1.59 Homo sapiens thrombospondin 2 (THBS2), mRNA. 
NGFB -1.60 Homo sapiens nerve growth factor, beta polypeptide (NGFB), mRNA. 
ZNF295 -1.60 Homo sapiens zinc finger protein 295 (ZNF295), mRNA. 
CD24 -1.60 Homo sapiens CD24 molecule (CD24), mRNA. 
DKFZP686A01247 -1.60 Homo sapiens LIM and calponin homology domains 1 (LIMCH1), mRNA. 
RPA1 -1.60 Homo sapiens replication protein A1, 70kDa (RPA1), mRNA. 
APP -1.60 
Homo sapiens amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease) 
(APP), transcript variant 3, mRNA. 
PLAU -1.60 Homo sapiens plasminogen activator, urokinase (PLAU), mRNA. 
ITGB1 -1.60 
Homo sapiens integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes 
MDF2, MSK12) (ITGB1), transcript variant 1E, mRNA. 
COLEC12 -1.60 Homo sapiens collectin sub-family member 12 (COLEC12), mRNA. 
ITGB2 -1.60 
Homo sapiens integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; 
macrophage antigen 1 (mac-1) beta subunit) (ITGB2), mRNA. 
COL5A1 -1.60 Homo sapiens collagen, type V, alpha 1 (COL5A1), mRNA. 
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CTNNB1 -1.60 
Homo sapiens catenin (cadherin-associated protein), beta 1, 88kDa (CTNNB1), mRNA. 
XM_945653 XM_945654 XM_945655 XM_945657 
ZNF195 -1.60 Homo sapiens zinc finger protein 195 (ZNF195), mRNA. 
CTSK -1.60 Homo sapiens cathepsin K (CTSK), mRNA. 
PRKAA1 -1.60 
Homo sapiens protein kinase, AMP-activated, alpha 1 catalytic subunit (PRKAA1), transcript 
variant 2, mRNA. 
PCNA -1.60 Homo sapiens proliferating cell nuclear antigen (PCNA), transcript variant 2, mRNA. 
ADAMTS5 -1.61 
Homo sapiens ADAM metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2) 
(ADAMTS5), mRNA. 
SPOCK -1.61 
Homo sapiens sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 
(SPOCK), mRNA. 
RECK -1.61 Homo sapiens reversion-inducing-cysteine-rich protein with kazal motifs (RECK), mRNA. 
FUT8 -1.61 
Homo sapiens fucosyltransferase 8 (alpha (1,6) fucosyltransferase) (FUT8), transcript variant 2, 
mRNA. 
TPM1 -1.61 Homo sapiens tropomyosin 1 (alpha) (TPM1), transcript variant 3, mRNA. 
SGCD -1.61 
Homo sapiens sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) (SGCD), 
transcript variant 1, mRNA. 
KIAA0194 -1.61 PREDICTED: Homo sapiens KIAA0194 protein (KIAA0194), mRNA. 
NBPF20 -1.61 Homo sapiens neuroblastoma breakpoint family, member 20 (NBPF20), mRNA. 
PDLIM3 -1.61 Homo sapiens PDZ and LIM domain 3 (PDLIM3), mRNA. 
ENAH -1.62 Homo sapiens enabled homolog (Drosophila) (ENAH), transcript variant 2, mRNA. 
SEMA3C -1.62 
Homo sapiens sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3C (SEMA3C), mRNA. 
F13A1 -1.62 Homo sapiens coagulation factor XIII, A1 polypeptide (F13A1), mRNA. 
CD55 -1.62 
Homo sapiens CD55 molecule, decay accelerating factor for complement (Cromer blood group) 
(CD55), mRNA. 
C17orf70 -1.62 Homo sapiens chromosome 17 open reading frame 70 (C17orf70), mRNA. 
ENAH -1.62 Homo sapiens enabled homolog (Drosophila) (ENAH), transcript variant 2, mRNA. 
FLJ12716 -1.62 Homo sapiens FLJ12716 protein (FLJ12716), transcript variant 2, mRNA. 
LAMA1 -1.62 Homo sapiens laminin, alpha 1 (LAMA1), mRNA. 
VGLL4 -1.62 Homo sapiens vestigial like 4 (Drosophila) (VGLL4), mRNA. 
TCF12 -1.62 
Homo sapiens transcription factor 12 (HTF4, helix-loop-helix transcription factors 4) (TCF12), 
transcript variant 1, mRNA. 
ITGB5 -1.62 Homo sapiens integrin, beta 5 (ITGB5), mRNA. XM_944688 XM_944693 
TNPO1 -1.62 Homo sapiens transportin 1 (TNPO1), transcript variant 1, mRNA. 
UBQLN2 -1.63 Homo sapiens ubiquilin 2 (UBQLN2), mRNA. 
OSR1 -1.63 Homo sapiens odd-skipped related 1 (Drosophila) (OSR1), mRNA. 
ALOX5 -1.63 Homo sapiens arachidonate 5-lipoxygenase (ALOX5), mRNA. 
VAV3 -1.63 Homo sapiens vav 3 guanine nucleotide exchange factor (VAV3), transcript variant 1, mRNA. 
PAWR -1.63 Homo sapiens PRKC, apoptosis, WT1, regulator (PAWR), mRNA. 
ATP2B1 -1.64 
Homo sapiens ATPase, Ca++ transporting, plasma membrane 1 (ATP2B1), transcript variant 1, 
mRNA. 
SH3BP4 -1.64 Homo sapiens SH3-domain binding protein 4 (SH3BP4), mRNA. 
NT5E -1.64 Homo sapiens 5'-nucleotidase, ecto (CD73) (NT5E), mRNA. 
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NBPF10 -1.64 
Homo sapiens neuroblastoma breakpoint family, member 10 (NBPF10), mRNA. XM_930727 
XM_930739 XM_930751 XM_930759 XM_930766 XM_930776 XM_930785 XM_930797 
XM_930808 XM_930830 XM_930841 XM_930850 XM_930862 XM_930872 XM_930880 
XM_930889 XM_930897 XM_930903 XM_930910 XM_930917 XM_930926 XM_930936 
XM_930943 XM_930951 XM_930954 XM_930961 XM_930967 XM_930975 XM_930985 
XM_930993 XM_931003 XM_931009 XM_931015 XM_931021 XM_931027 XM_931033 
XM_931038 XM_931044 XM_931049 XM_931055 XM_931060 XM_931066 XM_931069 
XM_931072 XM_931076 XM_931080 XM_931084 XM_931090 XM_931096 XM_931102 
XM_931110 XM_931119 XM_931125 XM_931131 XM_931137 XM_931138 XM_931145 
XM_931149 XM_931157 XM_931161 XM_931164 XM_931169 XM_931174 XM_931178 
XM_931183 XM_931188 XM_931191 XM_931196 XM_931202 XM_931208 XM_931213 
XM_931221 XM_931229 XM_931234 XM_931240 XM_931245 XM_931251 XM_931255 
XM_931259 XM_931264 XM_931269 XM_931277 XM_931282 XM_931291 XM_931299 
XM_931308 XM_931317 XM_931322 XM_931328 XM_931335 
GAS6 -1.64 Homo sapiens growth arrest-specific 6 (GAS6), mRNA. 
ARHGAP1 -1.64 Homo sapiens Rho GTPase activating protein 1 (ARHGAP1), mRNA. 
PAPLN -1.64 Homo sapiens papilin, proteoglycan-like sulfated glycoprotein (PAPLN), mRNA. 
VPS26 -1.64 Homo sapiens vacuolar protein sorting 26 (yeast) (VPS26), mRNA. 
FLJ11259 -1.65 Homo sapiens hypothetical protein FLJ11259 (FLJ11259), mRNA. 
SLC24A3 -1.65 
Homo sapiens solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 
(SLC24A3), mRNA. 
ABI3BP -1.65 Homo sapiens ABI gene family, member 3 (NESH) binding protein (ABI3BP), mRNA. 
SRGAP1 -1.65 Homo sapiens SLIT-ROBO Rho GTPase activating protein 1 (SRGAP1), mRNA. 
PDGFC -1.65 Homo sapiens platelet derived growth factor C (PDGFC), mRNA. 
HOM-TES-103 -1.65 Homo sapiens hypothetical protein LOC25900 (HOM-TES-103), transcript variant 2, mRNA. 
BMP4 -1.66 Homo sapiens bone morphogenetic protein 4 (BMP4), transcript variant 1, mRNA. 
PIGQ -1.66 
Homo sapiens phosphatidylinositol glycan anchor biosynthesis, class Q (PIGQ), transcript 
variant 2, mRNA. 
DYRK2 -1.66 
Homo sapiens dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2), 
transcript variant 1, mRNA. 
TMEPAI -1.66 
Homo sapiens transmembrane, prostate androgen induced RNA (TMEPAI), transcript variant 2, 
mRNA. 
SPP1 -1.66 
Homo sapiens secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte 
activation 1) (SPP1), transcript variant 1, mRNA. 
SLC27A1 -1.66 Homo sapiens solute carrier family 27 (fatty acid transporter), member 1 (SLC27A1), mRNA. 
TPM1 -1.66 Homo sapiens tropomyosin 1 (alpha) (TPM1), transcript variant 6, mRNA. 
CABC1 -1.66 Homo sapiens chaperone, ABC1 activity of bc1 complex like (S. pombe) (CABC1), mRNA. 
AOX1 -1.67 Homo sapiens aldehyde oxidase 1 (AOX1), mRNA. 
TBL1XR1 -1.67 Homo sapiens transducin (beta)-like 1X-linked receptor 1 (TBL1XR1), mRNA. 
CMAH -1.67 
Homo sapiens cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-N-
acetylneuraminate monooxygenase) (CMAH) on chromosome 6. 
CLCN7 -1.67 Homo sapiens chloride channel 7 (CLCN7), mRNA. 
NMB -1.68 Homo sapiens neuromedin B (NMB), transcript variant 1, mRNA. 
C21orf66 -1.68 Homo sapiens chromosome 21 open reading frame 66 (C21orf66), transcript variant 1, mRNA. 
DPYSL3 -1.68 Homo sapiens dihydropyrimidinase-like 3 (DPYSL3), mRNA. 
RAB23 -1.68 Homo sapiens RAB23, member RAS oncogene family (RAB23), transcript variant 1, mRNA. 
Sep-11 -1.69 Homo sapiens septin 11 (SEPT11), mRNA. 
LASS6 -1.69 Homo sapiens LAG1 homolog, ceramide synthase 6 (LASS6), mRNA. 
IRXL1 -1.69 Homo sapiens mohawk homeobox (MKX), mRNA. 
RPS6KA2 -1.69 
Homo sapiens ribosomal protein S6 kinase, 90kDa, polypeptide 2 (RPS6KA2), transcript 
variant 1, mRNA. 
CXorf6 -1.69 Homo sapiens chromosome X open reading frame 6 (CXorf6), mRNA. 
DFNA5 -1.69 Homo sapiens deafness, autosomal dominant 5 (DFNA5), mRNA. 
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A2M -1.70 Homo sapiens alpha-2-macroglobulin (A2M), mRNA. 
PLS3 -1.70 Homo sapiens plastin 3 (T isoform) (PLS3), mRNA. 
SLC43A3 -1.70 Homo sapiens solute carrier family 43, member 3 (SLC43A3), mRNA. 
GREM1 -1.71 
Homo sapiens gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) (GREM1), 
mRNA. 
CCL3L3 -1.71 Homo sapiens chemokine (C-C motif) ligand 3-like 3 (CCL3L3), mRNA. 
ZSCAN2 -1.71 
Homo sapiens zinc finger and SCAN domain containing 2 (ZSCAN2), transcript variant 1, 
mRNA. 
PAQR3 -1.71 Homo sapiens progestin and adipoQ receptor family member III (PAQR3), mRNA. 
PSD3 -1.71 Homo sapiens pleckstrin and Sec7 domain containing 3 (PSD3), transcript variant 2, mRNA. 
ARNT2 -1.71 Homo sapiens aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2), mRNA. 
DBN1 -1.72 Homo sapiens drebrin 1 (DBN1), transcript variant 2, mRNA. 
CMAH -1.72 
Homo sapiens cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMP-N-
acetylneuraminate monooxygenase) (CMAH) on chromosome 6. 
HIF1A -1.72 
Homo sapiens hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription 
factor) (HIF1A), transcript variant 1, mRNA. 
C20orf82 -1.72 PREDICTED: Homo sapiens chromosome 20 open reading frame 82 (C20orf82), mRNA. 
SVEP1 -1.72 
Homo sapiens sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 
(SVEP1), mRNA. 
 -1.73 Homo sapiens mRNA; cDNA DKFZp779O0231 (from clone DKFZp779O0231) 
ZSWIM4 -1.73 Homo sapiens zinc finger, SWIM-type containing 4 (ZSWIM4), mRNA. 
BCAT1 -1.73 Homo sapiens branched chain aminotransferase 1, cytosolic (BCAT1), mRNA. 
SPP1 -1.73 
Homo sapiens secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte 
activation 1) (SPP1), transcript variant 2, mRNA. 
BNIP3L -1.73 Homo sapiens BCL2/adenovirus E1B 19kDa interacting protein 3-like (BNIP3L), mRNA. 
PDZRN3 -1.74 
PREDICTED: Homo sapiens PDZ domain containing RING finger 3, transcript variant 3 
(PDZRN3), mRNA. 
OGN -1.75 
Homo sapiens osteoglycin (osteoinductive factor, mimecan) (OGN), transcript variant 2, 
mRNA. 
GJA1 -1.75 Homo sapiens gap junction protein, alpha 1, 43kDa (connexin 43) (GJA1), mRNA. 
TPM1 -1.75 Homo sapiens tropomyosin 1 (alpha) (TPM1), transcript variant 6, mRNA. 
PLS3 -1.75 Homo sapiens plastin 3 (T isoform) (PLS3), mRNA. 
CLIC4 -1.75 Homo sapiens chloride intracellular channel 4 (CLIC4), mRNA. 
HIF1A -1.76 
Homo sapiens hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription 
factor) (HIF1A), transcript variant 2, mRNA. 
GPR177 -1.76 Homo sapiens G protein-coupled receptor 177 (GPR177), transcript variant 1, mRNA. 
C4orf18 -1.76 Homo sapiens chromosome 4 open reading frame 18 (C4orf18), transcript variant 2, mRNA. 
GNPTAB -1.76 
Homo sapiens N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 
(GNPTAB), mRNA. 
PTX3 -1.76 Homo sapiens pentraxin-related gene, rapidly induced by IL-1 beta (PTX3), mRNA. 
COL11A1 -1.76 Homo sapiens collagen, type XI, alpha 1 (COL11A1), transcript variant B, mRNA. 
KCNMA1 -1.76 
Homo sapiens potassium large conductance calcium-activated channel, subfamily M, alpha 
member 1 (KCNMA1), transcript variant 2, mRNA. 
LANCL1 -1.76 Homo sapiens LanC lantibiotic synthetase component C-like 1 (bacterial) (LANCL1), mRNA. 
C6orf69 -1.77 Homo sapiens potassium channel tetramerisation domain containing 20 (KCTD20), mRNA. 
 -1.78 AV737317 CB Homo sapiens cDNA clone CBCAQH03 5, mRNA sequence 
HTRA4 -1.79 Homo sapiens HtrA serine peptidase 4 (HTRA4), mRNA. 
BDKRB1 -1.79 Homo sapiens bradykinin receptor B1 (BDKRB1), mRNA. 
GAS7 -1.79 Homo sapiens growth arrest-specific 7 (GAS7), transcript variant b, mRNA. 
 -1.80 Homo sapiens cDNA clone IMAGE:5261213 
SLC43A3 -1.80 Homo sapiens solute carrier family 43, member 3 (SLC43A3), mRNA. 
PABPC4 -1.80 Homo sapiens poly(A) binding protein, cytoplasmic 4 (inducible form) (PABPC4), mRNA. 
TMEPAI -1.80 
Homo sapiens transmembrane, prostate androgen induced RNA (TMEPAI), transcript variant 2, 
mRNA. 
SSPN -1.81 Homo sapiens sarcospan (Kras oncogene-associated gene) (SSPN), mRNA. 
ADCY4 -1.81 Homo sapiens adenylate cyclase 4 (ADCY4), mRNA. 
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RHOBTB3 -1.82 Homo sapiens Rho-related BTB domain containing 3 (RHOBTB3), mRNA. 
MTSS1 -1.82 Homo sapiens metastasis suppressor 1 (MTSS1), mRNA. 
RECK -1.83 Homo sapiens reversion-inducing-cysteine-rich protein with kazal motifs (RECK), mRNA. 
DACT1 -1.83 
Homo sapiens dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) (DACT1), 
transcript variant 1, mRNA. 
PLTP -1.83 Homo sapiens phospholipid transfer protein (PLTP), transcript variant 1, mRNA. 
ZCCHC14 -1.83 Homo sapiens zinc finger, CCHC domain containing 14 (ZCCHC14), mRNA. 
ARHGAP22 -1.84 Homo sapiens Rho GTPase activating protein 22 (ARHGAP22), mRNA. 
VGLL3 -1.84 Homo sapiens vestigial like 3 (Drosophila) (VGLL3), mRNA. 
RASD1 -1.84 Homo sapiens RAS, dexamethasone-induced 1 (RASD1), mRNA. 
ZMAT3 -1.84 Homo sapiens zinc finger, matrin type 3 (ZMAT3), transcript variant 2, mRNA. 
ANKRD10 -1.84 Homo sapiens ankyrin repeat domain 10 (ANKRD10), mRNA. 
SLITRK4 -1.84 Homo sapiens SLIT and NTRK-like family, member 4 (SLITRK4), mRNA. 
ANGPTL7 -1.85 Homo sapiens angiopoietin-like 7 (ANGPTL7), mRNA. 
BMP2 -1.85 Homo sapiens bone morphogenetic protein 2 (BMP2), mRNA. 
CCND1 -1.85 Homo sapiens cyclin D1 (PRAD1: parathyroid adenomatosis 1) (CCND1), mRNA. 
MCM7 -1.86 
Homo sapiens minichromosome maintenance complex component 7 (MCM7), transcript 
variant 2, mRNA. 
KLHL24 -1.86 Homo sapiens kelch-like 24 (Drosophila) (KLHL24), mRNA. 
CRISPLD2 -1.86 
Homo sapiens cysteine-rich secretory protein LCCL domain containing 2 (CRISPLD2), 
mRNA. 
LPXN -1.86 Homo sapiens leupaxin (LPXN), mRNA. 
FAM107B -1.86 Homo sapiens family with sequence similarity 107, member B (FAM107B), mRNA. 
HNMT -1.87 Homo sapiens histamine N-methyltransferase (HNMT), transcript variant 1, mRNA. 
PLXDC2 -1.87 Homo sapiens plexin domain containing 2 (PLXDC2), mRNA. 
LRRC20 -1.88 Homo sapiens leucine rich repeat containing 20 (LRRC20), transcript variant 1, mRNA. 
SPOCD1 -1.89 Homo sapiens SPOC domain containing 1 (SPOCD1), mRNA. 
LAMB1 -1.90 Homo sapiens laminin, beta 1 (LAMB1), mRNA. 
CDH11 -1.90 Homo sapiens cadherin 11, type 2, OB-cadherin (osteoblast) (CDH11), mRNA. 
 -1.92 Homo sapiens mRNA; cDNA DKFZp564O0862 (from clone DKFZp564O0862) 
CXCL12 -1.92 
Homo sapiens chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) (CXCL12), 
transcript variant 1, mRNA. 
FRMD6 -1.94 Homo sapiens FERM domain containing 6 (FRMD6), mRNA. 
EVI2A -1.94 Homo sapiens ecotropic viral integration site 2A (EVI2A), transcript variant 2, mRNA. 
TMEM119 -1.94 Homo sapiens transmembrane protein 119 (TMEM119), mRNA. 
IL33 -1.95 Homo sapiens interleukin 33 (IL33), mRNA. 
LOC654103 -1.95 
PREDICTED: Homo sapiens similar to solute carrier family 25, member 37 (LOC654103), 
mRNA. 
CCDC14 -1.95 Homo sapiens coiled-coil domain containing 14 (CCDC14), mRNA. 
CXCL12 -1.96 
Homo sapiens chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) (CXCL12), 
transcript variant 2, mRNA. 
CYP27A1 -1.97 
Homo sapiens cytochrome P450, family 27, subfamily A, polypeptide 1 (CYP27A1), nuclear 
gene encoding mitochondrial protein, mRNA. 
LOXL4 -1.99 Homo sapiens lysyl oxidase-like 4 (LOXL4), mRNA. 
FLJ14054 -2.01 Homo sapiens hypothetical protein FLJ14054 (FLJ14054), mRNA. 
GREM1 -2.02 
Homo sapiens gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) (GREM1), 
mRNA. 
MYLK -2.02 Homo sapiens myosin, light polypeptide kinase (MYLK), transcript variant 6, mRNA. 
PDE5A -2.06 Homo sapiens phosphodiesterase 5A, cGMP-specific (PDE5A), transcript variant 3, mRNA. 
HNMT -2.06 Homo sapiens histamine N-methyltransferase (HNMT), transcript variant 1, mRNA. 
LOC653778 -2.08 
PREDICTED: Homo sapiens similar to solute carrier family 25, member 37 (LOC653778), 
mRNA. 
SOX4 -2.08 Homo sapiens SRY (sex determining region Y)-box 4 (SOX4), mRNA. 
GALNT1 -2.08 
Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 1 (GalNAc-T1) (GALNT1), mRNA. 
HIF1A -2.09 
Homo sapiens hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription 
factor) (HIF1A), transcript variant 2, mRNA. 
LAMB1 -2.09 Homo sapiens laminin, beta 1 (LAMB1), mRNA. 
MMP13 -2.10 Homo sapiens matrix metallopeptidase 13 (collagenase 3) (MMP13), mRNA. 
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ANTXR1 -2.12 Homo sapiens anthrax toxin receptor 1 (ANTXR1), transcript variant 1, mRNA. 
SLC38A2 -2.14 Homo sapiens solute carrier family 38, member 2 (SLC38A2), mRNA. 
ENPP2 -2.15 
Homo sapiens ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) (ENPP2), 
mRNA. 
FBXO32 -2.15 Homo sapiens F-box protein 32 (FBXO32), transcript variant 1, mRNA. 
SFRP4 -2.16 Homo sapiens secreted frizzled-related protein 4 (SFRP4), mRNA. 
THBS1 -2.16 Homo sapiens thrombospondin 1 (THBS1), mRNA. 
IL26 -2.19 Homo sapiens interleukin 26 (IL26), mRNA. 
GDF15 -2.19 Homo sapiens growth differentiation factor 15 (GDF15), mRNA. 
CXCL12 -2.21 
Homo sapiens chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) (CXCL12), 
transcript variant 3, mRNA. 
ENPP2 -2.21 
Homo sapiens ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) (ENPP2), 
transcript variant 2, mRNA. 
KIAA0564 -2.24 Homo sapiens KIAA0564 protein (KIAA0564), transcript variant 1, mRNA. 
ANKRD1 -2.31 Homo sapiens ankyrin repeat domain 1 (cardiac muscle) (ANKRD1), mRNA. 
MYLK -2.32 Homo sapiens myosin, light chain kinase (MYLK), transcript variant 2, mRNA. 
ALPL -2.32 Homo sapiens alkaline phosphatase, liver/bone/kidney (ALPL), mRNA. 
SCG5 -2.34 Homo sapiens secretogranin V (7B2 protein) (SCG5), mRNA. 
EVI2A -2.35 Homo sapiens ecotropic viral integration site 2A (EVI2A), transcript variant 2, mRNA. 
ADAMTS1 -2.52 
Homo sapiens ADAM metallopeptidase with thrombospondin type 1 motif, 1 (ADAMTS1), 
mRNA. 
SDC1 -2.57 Homo sapiens syndecan 1 (SDC1), transcript variant 2, mRNA. 
FBXO32 -2.58 Homo sapiens F-box protein 32 (FBXO32), transcript variant 2, mRNA. 
GEM -2.72 
Homo sapiens GTP binding protein overexpressed in skeletal muscle (GEM), transcript variant 
1, mRNA. 
GEM -2.85 
Homo sapiens GTP binding protein overexpressed in skeletal muscle (GEM), transcript variant 
2, mRNA. 
GAS1 -3.06 Homo sapiens growth arrest-specific 1 (GAS1), mRNA. 
GAS1 -4.13 Homo sapiens growth arrest-specific 1 (GAS1), mRNA. 
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Genome-wide microarray results  
   
SW1353 cells: IL-1+OSM+IL-4 vs IL-1+OSM 
   
Symbol Fold change Gene name 
CCL26 21.07 Homo sapiens chemokine (C-C motif) ligand 26 (CCL26), mRNA. 
FST 5.13 Homo sapiens follistatin (FST), transcript variant FST344, mRNA. 
RGS4 4.77 Homo sapiens regulator of G-protein signalling 4 (RGS4), mRNA. 
SNFT 4.67 Homo sapiens Jun dimerization protein p21SNFT (SNFT), mRNA. 
FST 4.30 Homo sapiens follistatin (FST), transcript variant FST317, mRNA. 
VCAM1 4.09 
Homo sapiens vascular cell adhesion molecule 1 (VCAM1), transcript variant 1, 
mRNA. 
PPFIBP2 4.08 
Homo sapiens PTPRF interacting protein, binding protein 2 (liprin beta 2) (PPFIBP2), 
mRNA. 
LOC653671 4.08 
PREDICTED: Homo sapiens similar to Beta-defensin 103A precursor (Beta-defensin 
3) (DEFB-3) (BD-3) (hBD-3) (HBD3) (Defensin-like protein) (LOC653671), mRNA. 
TNC 3.99 Homo sapiens tenascin C (hexabrachion) (TNC), mRNA. 
DEFB103A 3.75 Homo sapiens defensin, beta 103A (DEFB103A), mRNA. 
SERPINB4 3.59 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 4 
(SERPINB4), mRNA. 
SERPINB3 3.36 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 3 
(SERPINB3), mRNA. 
ADCY8 3.08 Homo sapiens adenylate cyclase 8 (brain) (ADCY8), mRNA. 
INHBE 2.96 Homo sapiens inhibin, beta E (INHBE), mRNA. 
CISH 2.86 Homo sapiens cytokine inducible SH2-containing protein (CISH), mRNA. 
CDKN1A 2.84 
Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript 
variant 2, mRNA. 
ARRDC4 2.76 Homo sapiens arrestin domain containing 4 (ARRDC4), mRNA. 
DCBLD2 2.67 Homo sapiens discoidin, CUB and LCCL domain containing 2 (DCBLD2), mRNA. 
IL13RA2 2.66 Homo sapiens interleukin 13 receptor, alpha 2 (IL13RA2), mRNA. 
FAM101A 2.65 Homo sapiens family with sequence similarity 101, member A (FAM101A), mRNA. 
IL1F5 2.62 
Homo sapiens interleukin 1 family, member 5 (delta) (IL1F5), transcript variant 2, 
mRNA. 
PMP22 2.60 Homo sapiens peripheral myelin protein 22 (PMP22), transcript variant 3, mRNA. 
GADD45A 2.59 Homo sapiens growth arrest and DNA-damage-inducible, alpha (GADD45A), mRNA. 
SOCS1 2.59 Homo sapiens suppressor of cytokine signaling 1 (SOCS1), mRNA. 
SERPINB3 2.57 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 3 
(SERPINB3), mRNA. 
CENTA1 2.53 Homo sapiens centaurin, alpha 1 (CENTA1), mRNA. 
NIPA1 2.45 Homo sapiens non imprinted in Prader-Willi/Angelman syndrome 1 (NIPA1), mRNA. 
DCUN1D3 2.44 
Homo sapiens DCN1, defective in cullin neddylation 1, domain containing 3 (S. 
cerevisiae) (DCUN1D3), mRNA. 
HAS2 2.42 Homo sapiens hyaluronan synthase 2 (HAS2), mRNA. 
DEFB103A 2.41 Homo sapiens defensin, beta 103A (DEFB103A), mRNA. 
KITLG 2.38 Homo sapiens KIT ligand (KITLG), transcript variant b, mRNA. 
KAL1 2.34 Homo sapiens Kallmann syndrome 1 sequence (KAL1), mRNA. 
LBH 2.34 Homo sapiens limb bud and heart development homolog (mouse) (LBH), mRNA. 
PMP22 2.30 Homo sapiens peripheral myelin protein 22 (PMP22), transcript variant 2, mRNA. 
GADD45A 2.29 Homo sapiens growth arrest and DNA-damage-inducible, alpha (GADD45A), mRNA. 
IGFBP3 2.28 
Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript variant 
1, mRNA. 
CCL5 2.27 Homo sapiens chemokine (C-C motif) ligand 5 (CCL5), mRNA. 
LOX 2.27 Homo sapiens lysyl oxidase (LOX), mRNA. 
LOXL3 2.21 Homo sapiens lysyl oxidase-like 3 (LOXL3), mRNA. 
TNC 2.20 Homo sapiens tenascin C (hexabrachion) (TNC), mRNA. 
KITLG 2.17 Homo sapiens KIT ligand (KITLG), transcript variant b, mRNA. 
NPPB 2.11 Homo sapiens natriuretic peptide precursor B (NPPB), mRNA. 
MESP1 2.11 Homo sapiens mesoderm posterior 1 homolog (mouse) (MESP1), mRNA. 
KLF2 2.11 Homo sapiens Kruppel-like factor 2 (lung) (KLF2), mRNA. 
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MAPKAPK3 2.07 
Homo sapiens mitogen-activated protein kinase-activated protein kinase 3 
(MAPKAPK3), mRNA. 
ITGAX 2.06 
Homo sapiens integrin, alpha X (complement component 3 receptor 4 subunit) 
(ITGAX), mRNA. 
LOC652481 2.05 
PREDICTED: Homo sapiens similar to Mitochondrial import inner membrane 
translocase subunit Tim23 (LOC652481), mRNA. 
TRIB3 1.98 Homo sapiens tribbles homolog 3 (Drosophila) (TRIB3), mRNA. 
ANXA8 1.98 Homo sapiens annexin A8-like 2 (ANXA8L2), mRNA. 
SLC3A2 1.97 
Homo sapiens solute carrier family 3 (activators of dibasic and neutral amino acid 
transport), member 2 (SLC3A2), transcript variant 6, mRNA. 
HAS2 1.94 Homo sapiens hyaluronan synthase 2 (HAS2), mRNA. 
SUSD2 1.94 Homo sapiens sushi domain containing 2 (SUSD2), mRNA. 
SERPINB13 1.94 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 13 
(SERPINB13), mRNA. 
KLF6 1.92 Homo sapiens Kruppel-like factor 6 (KLF6), transcript variant 1, mRNA. 
SHC4 1.92 
Homo sapiens SHC (Src homology 2 domain containing) family, member 4 (SHC4), 
mRNA. 
C1QTNF1 1.91 Homo sapiens C1q and tumor necrosis factor related protein 1 (C1QTNF1), mRNA. 
PMAIP1 1.90 Homo sapiens phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1), mRNA. 
ORF1-FL49 1.90 Homo sapiens putative nuclear protein ORF1-FL49 (ORF1-FL49), mRNA. 
ITGB3 1.89 
Homo sapiens integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) (ITGB3), 
mRNA. 
PDCD1LG2 1.88 Homo sapiens programmed cell death 1 ligand 2 (PDCD1LG2), mRNA. 
CCL5 1.88 Homo sapiens chemokine (C-C motif) ligand 5 (CCL5), mRNA. 
ARL4C 1.88 Homo sapiens ADP-ribosylation factor-like 4C (ARL4C), mRNA. 
CHST7 1.87 
Homo sapiens carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 (CHST7), 
mRNA. 
CTSL 1.87 Homo sapiens cathepsin L (CTSL), transcript variant 1, mRNA. 
C1orf24 1.86 
Homo sapiens chromosome 1 open reading frame 24 (C1orf24), transcript variant 2, 
mRNA. 
DEFB104A 1.85 Homo sapiens defensin, beta 104A (DEFB104A), mRNA. 
ENC1 1.85 Homo sapiens ectodermal-neural cortex (with BTB-like domain) (ENC1), mRNA. 
FLJ40504 1.85 Homo sapiens hypothetical protein FLJ40504 (FLJ40504), mRNA. 
IL17R 1.83 Homo sapiens interleukin 17 receptor (IL17R), mRNA. 
FLNB 1.82 Homo sapiens filamin B, beta (actin binding protein 278) (FLNB), mRNA. 
SGPL1 1.82 Homo sapiens sphingosine-1-phosphate lyase 1 (SGPL1), mRNA. 
SLC35D2 1.82 Homo sapiens solute carrier family 35, member D2 (SLC35D2), mRNA. 
GAS2L3 1.82 Homo sapiens growth arrest-specific 2 like 3 (GAS2L3), mRNA. 
ACN9 1.81 Homo sapiens ACN9 homolog (S. cerevisiae) (ACN9), mRNA. 
GNE 1.81 
Homo sapiens glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase 
(GNE), mRNA. 
PGM2 1.80 Homo sapiens phosphoglucomutase 2 (PGM2), mRNA. 
SBDSP 1.80 
Homo sapiens Shwachman-Bodian-Diamond syndrome pseudogene (SBDSP) on 
chromosome 7. 
SERPINB7 1.79 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 7 
(SERPINB7), mRNA. 
WNT5B 1.79 
Homo sapiens wingless-type MMTV integration site family, member 5B (WNT5B), 
transcript variant 1, mRNA. 
PRRX1 1.78 Homo sapiens paired related homeobox 1 (PRRX1), transcript variant pmx-1b, mRNA. 
PRKDC 1.78 
Homo sapiens protein kinase, DNA-activated, catalytic polypeptide (PRKDC), 
transcript variant 1, mRNA. 
SERPINB2 1.78 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 2 
(SERPINB2), mRNA. 
GLIPR1 1.77 Homo sapiens GLI pathogenesis-related 1 (glioma) (GLIPR1), mRNA. 
TXNRD1 1.77 Homo sapiens thioredoxin reductase 1 (TXNRD1), transcript variant 1, mRNA. 
COL6A1 1.77 Homo sapiens collagen, type VI, alpha 1 (COL6A1), mRNA. 
PAPPA 1.76 Homo sapiens pregnancy-associated plasma protein A, pappalysin 1 (PAPPA), mRNA. 
CAMTA1 1.76 Homo sapiens calmodulin binding transcription activator 1 (CAMTA1), mRNA. 
KIAA1913 1.74 Homo sapiens KIAA1913 (KIAA1913), mRNA. 
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MRPS6 1.74 
Homo sapiens mitochondrial ribosomal protein S6 (MRPS6), nuclear gene encoding 
mitochondrial protein, mRNA. 
EGR1 1.73 Homo sapiens early growth response 1 (EGR1), mRNA. 
TXNRD1 1.72 Homo sapiens thioredoxin reductase 1 (TXNRD1), transcript variant 4, mRNA. 
LMNA 1.72 Homo sapiens lamin A/C (LMNA), transcript variant 2, mRNA. 
ANXA2 1.72 Homo sapiens annexin A2 (ANXA2), transcript variant 2, mRNA. 
LOC651348 1.72 
PREDICTED: Homo sapiens similar to tropomyosin 3, gamma isoform 2, transcript 
variant 2 (LOC651348), mRNA. 
CDC45L 1.72 Homo sapiens CDC45 cell division cycle 45-like (S. cerevisiae) (CDC45L), mRNA. 
TRIB1 1.71 Homo sapiens tribbles homolog 1 (Drosophila) (TRIB1), mRNA. 
MAP3K8 1.71 Homo sapiens mitogen-activated protein kinase kinase kinase 8 (MAP3K8), mRNA. 
AK5 1.71 Homo sapiens adenylate kinase 5 (AK5), transcript variant 2, mRNA. 
DLX5 1.71 Homo sapiens distal-less homeo box 5 (DLX5), mRNA. 
DEFB104B 1.70 Homo sapiens defensin, beta 104B (DEFB104B), mRNA. 
IL18R1 1.70 Homo sapiens interleukin 18 receptor 1 (IL18R1), mRNA. 
TUBB 1.70 Homo sapiens tubulin, beta (TUBB), mRNA. 
TPM3 1.69 Homo sapiens tropomyosin 3 (TPM3), transcript variant 2, mRNA. 
CTNS 1.69 Homo sapiens cystinosis, nephropathic (CTNS), transcript variant 2, mRNA. 
LOC57149 1.69 Homo sapiens hypothetical protein A-211C6.1 (LOC57149), mRNA. 
TWISTNB 1.68 Homo sapiens TWIST neighbor (TWISTNB), mRNA. 
MAP1B 1.68 
Homo sapiens microtubule-associated protein 1B (MAP1B), transcript variant 2, 
mRNA. 
FER1L3 1.68 
Homo sapiens fer-1-like 3, myoferlin (C. elegans) (FER1L3), transcript variant 1, 
mRNA. 
RRAS2 1.67 Homo sapiens related RAS viral (r-ras) oncogene homolog 2 (RRAS2), mRNA. 
IGFBP3 1.67 
Homo sapiens insulin-like growth factor binding protein 3 (IGFBP3), transcript variant 
1, mRNA. 
PTPN4 1.67 
Homo sapiens protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) 
(PTPN4), mRNA. 
PGRMC2 1.66 Homo sapiens progesterone receptor membrane component 2 (PGRMC2), mRNA. 
DCBLD2 1.66 Homo sapiens discoidin, CUB and LCCL domain containing 2 (DCBLD2), mRNA. 
DCI 1.66 
Homo sapiens dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-Coenzyme A 
isomerase) (DCI), nuclear gene encoding mitochondrial protein, mRNA. 
UFD1L 1.66 Homo sapiens ubiquitin fusion degradation 1-like (UFD1L), mRNA. 
PPFIBP1 1.66 
Homo sapiens PTPRF interacting protein, binding protein 1 (liprin beta 1) (PPFIBP1), 
transcript variant 1, mRNA. 
FNDC1 1.66 Homo sapiens fibronectin type III domain containing 1 (FNDC1), mRNA. 
SPANXB1 1.65 Homo sapiens SPANX family, member B1 (SPANXB1), mRNA. 
SLC25A4 1.65 
Homo sapiens solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 4 (SLC25A4), nuclear gene encoding mitochondrial protein, 
mRNA. 
HERPUD1 1.65 
Homo sapiens homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 (HERPUD1), transcript variant 3, mRNA. 
NRP1 1.65 Homo sapiens neuropilin 1 (NRP1), transcript variant 1, mRNA. 
RHBDD2 1.65 Homo sapiens rhomboid domain containing 2 (RHBDD2), mRNA. 
PLOD2 1.64 
Homo sapiens procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), transcript 
variant 1, mRNA. 
WDRPUH 1.64 Homo sapiens WD40-repeat protein upregulated in HCC (WDRPUH), mRNA. 
LOC389286 1.64 Homo sapiens similar to FKSG62 (LOC389286), mRNA. 
CANT1 1.63 Homo sapiens calcium activated nucleotidase 1 (CANT1), mRNA. 
SERPINB8 1.63 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 8 
(SERPINB8), transcript variant 1, mRNA. 
ATP2B4 1.63 
Homo sapiens ATPase, Ca++ transporting, plasma membrane 4 (ATP2B4), transcript 
variant 2, mRNA. 
AXL 1.63 Homo sapiens AXL receptor tyrosine kinase (AXL), transcript variant 2, mRNA. 
SBDSP 1.63 
Homo sapiens Shwachman-Bodian-Diamond syndrome pseudogene (SBDSP) on 
chromosome 7. 
LOC644743 1.63 PREDICTED: Homo sapiens hypothetical protein LOC644743 (LOC644743), mRNA. 
CAT 1.62 Homo sapiens catalase (CAT), mRNA. 
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COMT 1.62 
Homo sapiens catechol-O-methyltransferase (COMT), transcript variant MB-COMT, 
mRNA. 
AIM1 1.62 Homo sapiens absent in melanoma 1 (AIM1), mRNA. 
LOC399942 1.62 
PREDICTED: Homo sapiens similar to Tubulin alpha-2 chain (Alpha-tubulin 2), 
transcript variant 5 (LOC399942), mRNA. 
DUSP5 1.62 Homo sapiens dual specificity phosphatase 5 (DUSP5), mRNA. 
C3orf58 1.62 Homo sapiens chromosome 3 open reading frame 58 (C3orf58), mRNA. 
LOC162073 1.62 
PREDICTED: Homo sapiens hypothetical protein LOC162073, transcript variant 4 
(LOC162073), mRNA. 
FGG 1.61 Homo sapiens fibrinogen gamma chain (FGG), transcript variant gamma-A, mRNA. 
MED8 1.61 
Homo sapiens mediator of RNA polymerase II transcription, subunit 8 homolog (S. 
cerevisiae) (MED8), transcript variant 3, mRNA. 
CTNS 1.61 Homo sapiens cystinosis, nephropathic (CTNS), transcript variant 2, mRNA. 
 1.61 Homo sapiens mRNA; cDNA DKFZp686F1546 (from clone DKFZp686F1546) 
PLEKHF1 1.61 
Homo sapiens pleckstrin homology domain containing, family F (with FYVE domain) 
member 1 (PLEKHF1), mRNA. 
KLF6 1.61 Homo sapiens Kruppel-like factor 6 (KLF6), transcript variant 2, mRNA. 
RGS3 1.61 Homo sapiens regulator of G-protein signalling 3 (RGS3), transcript variant 5, mRNA. 
SERPINB7 1.61 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 7 
(SERPINB7), mRNA. 
PALM2-AKAP2 1.61 
Homo sapiens PALM2-AKAP2 protein (PALM2-AKAP2), transcript variant 2, 
mRNA. 
STRN3 1.60 Homo sapiens striatin, calmodulin binding protein 3 (STRN3), mRNA. 
NFE2 1.60 Homo sapiens nuclear factor (erythroid-derived 2), 45kDa (NFE2), mRNA. 
FLJ13391 1.60 Homo sapiens transmembrane protein 166 (TMEM166), mRNA. 
DTX3L 1.60 Homo sapiens deltex 3-like (Drosophila) (DTX3L), mRNA. 
C18orf55 1.60 Homo sapiens chromosome 18 open reading frame 55 (C18orf55), mRNA. 
FER1L3 1.59 
Homo sapiens fer-1-like 3, myoferlin (C. elegans) (FER1L3), transcript variant 1, 
mRNA. 
SLC7A11 1.59 
Homo sapiens solute carrier family 7, (cationic amino acid transporter, y+ system) 
member 11 (SLC7A11), mRNA. 
METRNL 1.59 
PREDICTED: Homo sapiens meteorin, glial cell differentiation regulator-like 
(METRNL), mRNA. 
PITRM1 1.59 Homo sapiens pitrilysin metallopeptidase 1 (PITRM1), mRNA. 
MGLL 1.58 Homo sapiens monoglyceride lipase (MGLL), transcript variant 1, mRNA. 
ANXA8L1 1.58 
Homo sapiens annexin A8 (ANXA8), mRNA. XM_931361 XM_931369 XM_931374 
XM_931375 XM_931378 XM_931383 XM_931388 XM_931391 XM_931399 
XM_931404 XM_931411 
DDIT3 1.58 Homo sapiens DNA-damage-inducible transcript 3 (DDIT3), mRNA. 
CSF2 1.58 Homo sapiens colony stimulating factor 2 (granulocyte-macrophage) (CSF2), mRNA. 
PFKP 1.58 Homo sapiens phosphofructokinase, platelet (PFKP), mRNA. 
 1.58 Homo sapiens HGC6.3 mRNA, complete cds 
MRPS18A 1.57 
Homo sapiens mitochondrial ribosomal protein S18A (MRPS18A), nuclear gene 
encoding mitochondrial protein, mRNA. 
TUBB4Q 1.57 Homo sapiens tubulin, beta polypeptide 4, member Q (TUBB4Q), mRNA. 
MME 1.57 
Homo sapiens membrane metallo-endopeptidase (neutral endopeptidase, 
enkephalinase, CALLA, CD10) (MME), transcript variant 2a, mRNA. 
TGM2 1.57 
Homo sapiens transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) (TGM2), transcript variant 1, mRNA. 
PDZK1IP1 1.57 Homo sapiens PDZK1 interacting protein 1 (PDZK1IP1), mRNA. 
ARPC1B 1.57 
Homo sapiens actin related protein 2/3 complex, subunit 1B, 41kDa (ARPC1B), 
mRNA. 
TUBB 1.57 Homo sapiens tubulin, beta polypeptide (TUBB), mRNA. 
UXT 1.57 Homo sapiens ubiquitously-expressed transcript (UXT), transcript variant 1, mRNA. 
WARS 1.57 Homo sapiens tryptophanyl-tRNA synthetase (WARS), transcript variant 4, mRNA. 
ASNS 1.57 Homo sapiens asparagine synthetase (ASNS), transcript variant 1, mRNA. 
CAV2 1.57 Homo sapiens caveolin 2 (CAV2), transcript variant 1, mRNA. 
SPANXA1 1.56 
Homo sapiens sperm protein associated with the nucleus, X-linked, family member A1 
(SPANXA1), mRNA. 
HSPA1B 1.56 Homo sapiens heat shock 70kDa protein 1B (HSPA1B), mRNA. 
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FOXD1 1.56 Homo sapiens forkhead box D1 (FOXD1), mRNA. 
ATP2B4 1.56 
Homo sapiens ATPase, Ca++ transporting, plasma membrane 4 (ATP2B4), transcript 
variant 2, mRNA. 
ATF3 1.56 Homo sapiens activating transcription factor 3 (ATF3), transcript variant 4, mRNA. 
RHBDD2 1.56 Homo sapiens rhomboid domain containing 2 (RHBDD2), transcript variant 1, mRNA. 
THBS1 1.56 Homo sapiens thrombospondin 1 (THBS1), mRNA. 
C2orf18 1.56 Homo sapiens chromosome 2 open reading frame 18 (C2orf18), mRNA. 
LOC653506 1.56 
PREDICTED: Homo sapiens similar to meteorin, glial cell differentiation regulator-
like (LOC653506), mRNA. 
CARS 1.56 Homo sapiens cysteinyl-tRNA synthetase (CARS), transcript variant 4, mRNA. 
LOC652846 1.55 
PREDICTED: Homo sapiens similar to Annexin A8 (Annexin VIII) (Vascular 
anticoagulant-beta) (VAC-beta) (LOC652846), mRNA. 
KRT18 1.55 Homo sapiens keratin 18 (KRT18), transcript variant 2, mRNA. 
KRT16 1.55 
Homo sapiens keratin 16 (focal non-epidermolytic palmoplantar keratoderma) 
(KRT16), mRNA. 
LOC650611 1.55 
PREDICTED: Homo sapiens similar to Keratin, type I cytoskeletal 16 (Cytokeratin-
16) (CK-16) (Keratin-16) (K16), transcript variant 1 (LOC650611), mRNA. 
PLOD2 1.55 
Homo sapiens procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), transcript 
variant 1, mRNA. 
IER3 1.55 Homo sapiens immediate early response 3 (IER3), transcript variant long, mRNA. 
LOC653743 1.55 
PREDICTED: Homo sapiens similar to hypothetical protein DKFZp566J091 
(LOC653743), mRNA. 
PPID 1.55 Homo sapiens peptidylprolyl isomerase D (cyclophilin D) (PPID), mRNA. 
SLC26A6 1.55 
Homo sapiens solute carrier family 26, member 6 (SLC26A6), transcript variant 3, 
mRNA. 
FLJ20366 1.55 Homo sapiens hypothetical protein FLJ20366 (FLJ20366), mRNA. 
BST2 1.54 Homo sapiens bone marrow stromal cell antigen 2 (BST2), mRNA. 
LRRFIP2 1.54 
Homo sapiens leucine rich repeat (in FLII) interacting protein 2 (LRRFIP2), transcript 
variant 1, mRNA. 
TMEM16K 1.54 Homo sapiens transmembrane protein 16K (TMEM16K), mRNA. 
UFD1L 1.54 
Homo sapiens ubiquitin fusion degradation 1 like (yeast) (UFD1L), transcript variant 
2, mRNA. 
SLC25A25 1.54 
Homo sapiens solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 25 (SLC25A25), nuclear gene encoding mitochondrial protein, transcript 
variant 1, mRNA. 
C1orf24 1.54 
Homo sapiens chromosome 1 open reading frame 24 (C1orf24), transcript variant 1, 
mRNA. 
CAPN2 1.54 Homo sapiens calpain 2, (m/II) large subunit (CAPN2), mRNA. 
ATP5G1 1.54 
Homo sapiens ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C1 
(subunit 9) (ATP5G1), nuclear gene encoding mitochondrial protein, transcript variant 
1, mRNA. 
LOC644330 1.54 
PREDICTED: Homo sapiens similar to tropomyosin 3 isoform 2, transcript variant 2 
(LOC644330), mRNA. 
SAMD4A 1.53 Homo sapiens sterile alpha motif domain containing 4A (SAMD4A), mRNA. 
MYO1C 1.53 Homo sapiens myosin IC (MYO1C), mRNA. 
LOC51334 1.53 Homo sapiens proline rich 16 (PRR16), mRNA. 
CDKN2A 1.53 
Homo sapiens cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 
(CDKN2A), transcript variant 3, mRNA. 
CTTN 1.53 Homo sapiens cortactin (CTTN), transcript variant 2, mRNA. 
HSD3B1 1.53 
Homo sapiens hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 1 (HSD3B1), mRNA. 
RUVBL1 1.53 PREDICTED: Homo sapiens RuvB-like 1 (E. coli) (RUVBL1), mRNA. 
SERPINB8 1.53 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 8 
(SERPINB8), transcript variant 3, mRNA. 
HAPLN1 1.53 Homo sapiens hyaluronan and proteoglycan link protein 1 (HAPLN1), mRNA. 
TUBB6 1.53 Homo sapiens tubulin, beta 6 (TUBB6), mRNA. 
RAP1GDS1 1.52 Homo sapiens RAP1, GTP-GDP dissociation stimulator 1 (RAP1GDS1), mRNA. 
SH3PXD2A 1.52 Homo sapiens SH3 and PX domains 2A (SH3PXD2A), mRNA. 
SPHK1 1.52 Homo sapiens sphingosine kinase 1 (SPHK1), transcript variant 1, mRNA. 
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LOC650034 1.52 
PREDICTED: Homo sapiens similar to uncharacterized protein family UPF0227 
member RGD1359682 (LOC650034), mRNA. 
ARL4 1.52 Homo sapiens ADP-ribosylation factor-like 4 (ARL4), transcript variant 1, mRNA. 
DNAJB6 1.52 
Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 6 (DNAJB6), transcript 
variant 2, mRNA. 
MAP1B 1.52 
Homo sapiens microtubule-associated protein 1B (MAP1B), transcript variant 1, 
mRNA. 
PCK2 1.52 
Homo sapiens phosphoenolpyruvate carboxykinase 2 (mitochondrial) (PCK2), nuclear 
gene encoding mitochondrial protein, transcript variant 2, mRNA. 
UPP1 1.52 Homo sapiens uridine phosphorylase 1 (UPP1), transcript variant 2, mRNA. 
SARS 1.51 Homo sapiens seryl-tRNA synthetase (SARS), mRNA. 
MFHAS1 1.51 
Homo sapiens malignant fibrous histiocytoma amplified sequence 1 (MFHAS1), 
mRNA. 
TUBB2A 1.51 Homo sapiens tubulin, beta 2A (TUBB2A), mRNA. 
KTN1 1.51 Homo sapiens kinectin 1 (kinesin receptor) (KTN1), transcript variant 4, mRNA. 
MMD 1.51 Homo sapiens monocyte to macrophage differentiation-associated (MMD), mRNA. 
SPRY2 1.51 Homo sapiens sprouty homolog 2 (Drosophila) (SPRY2), mRNA. 
CSPG4 1.51 
Homo sapiens chondroitin sulfate proteoglycan 4 (melanoma-associated) (CSPG4), 
mRNA. 
TUBA1A 1.51 Homo sapiens tubulin, alpha 1a (TUBA1A), mRNA. 
NFIL3 1.51 Homo sapiens nuclear factor, interleukin 3 regulated (NFIL3), mRNA. 
LMCD1 1.51 Homo sapiens LIM and cysteine-rich domains 1 (LMCD1), mRNA. 
ISG20 1.51 Homo sapiens interferon stimulated exonuclease gene 20kDa (ISG20), mRNA. 
EXT1 1.51 Homo sapiens exostoses (multiple) 1 (EXT1), mRNA. 
HNRPA3 1.50 Homo sapiens heterogeneous nuclear ribonucleoprotein A3 (HNRPA3), mRNA. 
NBPF20 1.50 Homo sapiens neuroblastoma breakpoint family, member 20 (NBPF20), mRNA. 
PLK2 1.50 Homo sapiens polo-like kinase 2 (Drosophila) (PLK2), mRNA. 
LSM12 1.50 Homo sapiens LSM12 homolog (S. cerevisiae) (LSM12), mRNA. 
NFS1 1.50 
Homo sapiens NFS1 nitrogen fixation 1 (S. cerevisiae) (NFS1), nuclear gene encoding 
mitochondrial protein, transcript variant 2, mRNA. 
LOC645074 1.50 
PREDICTED: Homo sapiens similar to Keratin, type I cytoskeletal 16 (Cytokeratin-
16) (CK-16) (Keratin-16) (K16) (LOC645074), mRNA. 
IL1F8 1.50 
Homo sapiens interleukin 1 family, member 8 (eta) (IL1F8), transcript variant 2, 
mRNA. 
TRADD 1.50 
Homo sapiens TNFRSF1A-associated via death domain (TRADD), transcript variant 
1, mRNA. 
UQCRH -1.50 Homo sapiens ubiquinol-cytochrome c reductase hinge protein (UQCRH), mRNA. 
HCG2P7 -1.50 Homo sapiens HLA complex group 2 pseudogene 7 (HCG2P7) on chromosome 6. 
 -1.50 
full-length cDNA clone CS0DI004YB08 of Placenta Cot 25-normalized of Homo 
sapiens (human) 
LSM5 -1.50 
Homo sapiens LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
(LSM5), mRNA. 
SAA4 -1.50 Homo sapiens serum amyloid A4, constitutive (SAA4), mRNA. 
PTTG3 -1.50 Homo sapiens pituitary tumor-transforming 3 (PTTG3) on chromosome 8. 
PPP3CA -1.50 
Homo sapiens protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform 
(PPP3CA), mRNA. 
SHROOM4 -1.50 Homo sapiens shroom family member 4 (SHROOM4), mRNA. 
ASCIZ -1.50 
Homo sapiens ATM/ATR-Substrate Chk2-Interacting Zn2+-finger protein (ASCIZ), 
mRNA. 
FEZ1 -1.50 
Homo sapiens fasciculation and elongation protein zeta 1 (zygin I) (FEZ1), transcript 
variant 1, mRNA. 
CAMK2N1 -1.51 
Homo sapiens calcium/calmodulin-dependent protein kinase II inhibitor 1 
(CAMK2N1), mRNA. 
KIAA0391 -1.51 Homo sapiens KIAA0391 (KIAA0391), mRNA. 
C14orf106 -1.51 Homo sapiens chromosome 14 open reading frame 106 (C14orf106), mRNA. 
C20orf108 -1.51 Homo sapiens chromosome 20 open reading frame 108 (C20orf108), mRNA. 
GNAI1 -1.51 
Homo sapiens guanine nucleotide binding protein (G protein), alpha inhibiting activity 
polypeptide 1 (GNAI1), mRNA. 
APPBP1 -1.51 
Homo sapiens amyloid beta precursor protein binding protein 1 (APPBP1), transcript 
variant 3, mRNA. 
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LOC653226 -1.51 
PREDICTED: Homo sapiens similar to Signal recognition particle 9 kDa protein 
(SRP9) (LOC653226), mRNA. 
CAST1 -1.51 Homo sapiens ELKS/RAB6-interacting/CAST family member 2 (ERC2), mRNA. 
MCM7 -1.51 
Homo sapiens minichromosome maintenance complex component 7 (MCM7), 
transcript variant 2, mRNA. 
OIP5 -1.51 Homo sapiens Opa interacting protein 5 (OIP5), mRNA. 
LOC375449 -1.51 
Homo sapiens similar to microtubule associated testis specific serine/threonine protein 
kinase (LOC375449), mRNA. 
CDKN3 -1.51 
Homo sapiens cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity 
phosphatase) (CDKN3), mRNA. 
CPE -1.51 Homo sapiens carboxypeptidase E (CPE), mRNA. 
DUSP19 -1.52 Homo sapiens dual specificity phosphatase 19 (DUSP19), mRNA. 
SDCBP -1.52 
Homo sapiens syndecan binding protein (syntenin) (SDCBP), transcript variant 2, 
mRNA. 
RGS17 -1.52 Homo sapiens regulator of G-protein signalling 17 (RGS17), mRNA. 
CTDSP1 -1.52 
Homo sapiens CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) 
small phosphatase 1 (CTDSP1), transcript variant 1, mRNA. 
ZNF69 -1.52 Homo sapiens zinc finger protein 69 (ZNF69), mRNA. 
LRP10 -1.52 Homo sapiens low density lipoprotein receptor-related protein 10 (LRP10), mRNA. 
LOC399900 -1.52 Homo sapiens hypothetical gene supported by AK093779 (LOC399900), mRNA. 
 -1.52 
xj89b12.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:2664383 3, 
mRNA sequence 
NINJ1 -1.52 Homo sapiens ninjurin 1 (NINJ1), mRNA. 
MBTD1 -1.52 Homo sapiens mbt domain containing 1 (MBTD1), mRNA. 
MARCKS -1.52 
Homo sapiens myristoylated alanine-rich protein kinase C substrate (MARCKS), 
mRNA. 
FAS -1.52 
Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 7, 
mRNA. 
C14orf153 -1.52 Homo sapiens chromosome 14 open reading frame 153 (C14orf153), mRNA. 
ATP1B3 -1.52 
Homo sapiens ATPase, Na+/K+ transporting, beta 3 polypeptide (ATP1B3), mRNA. 
XM_945518 
NFKBIZ -1.52 
Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, zeta (NFKBIZ), transcript variant 2, mRNA. 
ARHGEF3 -1.53 Homo sapiens Rho guanine nucleotide exchange factor (GEF) 3 (ARHGEF3), mRNA. 
THBS2 -1.53 Homo sapiens thrombospondin 2 (THBS2), mRNA. 
C6orf160 -1.53 
PREDICTED: Homo sapiens chromosome 6 open reading frame 160, transcript variant 
4 (C6orf160), mRNA. 
TBC1D9 -1.53 
Homo sapiens TBC1 domain family, member 9 (with GRAM domain) (TBC1D9), 
mRNA. 
C14orf143 -1.53 Homo sapiens chromosome 14 open reading frame 143 (C14orf143), mRNA. 
FLJ21062 -1.53 Homo sapiens hypothetical protein FLJ21062 (FLJ21062), mRNA. 
SSTR2 -1.53 Homo sapiens somatostatin receptor 2 (SSTR2), mRNA. 
MAN1A1 -1.53 Homo sapiens mannosidase, alpha, class 1A, member 1 (MAN1A1), mRNA. 
SDFR1 -1.53 
Homo sapiens stromal cell derived factor receptor 1 (SDFR1), transcript variant beta, 
mRNA. 
FUT8 -1.53 
Homo sapiens fucosyltransferase 8 (alpha (1,6) fucosyltransferase) (FUT8), transcript 
variant 2, mRNA. 
LOC642989 -1.54 
PREDICTED: Homo sapiens similar to 40S ribosomal protein S25 (LOC642989), 
mRNA. 
TRIM13 -1.54 Homo sapiens tripartite motif-containing 13 (TRIM13), transcript variant 4, mRNA. 
LMO4 -1.54 Homo sapiens LIM domain only 4 (LMO4), mRNA. 
APBB3 -1.54 
Homo sapiens amyloid beta (A4) precursor protein-binding, family B, member 3 
(APBB3), transcript variant 2, mRNA. 
SMC4 -1.54 
Homo sapiens structural maintenance of chromosomes 4 (SMC4), transcript variant 2, 
mRNA. 
C2orf33 -1.54 Homo sapiens chromosome 2 open reading frame 33 (C2orf33), mRNA. 
ITGB3BP -1.54 Homo sapiens integrin beta 3 binding protein (beta3-endonexin) (ITGB3BP), mRNA. 
PTGS2 -1.54 
Homo sapiens prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and 
cyclooxygenase) (PTGS2), mRNA. 
KIAA0564 -1.54 Homo sapiens KIAA0564 protein (KIAA0564), transcript variant 1, mRNA. 
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HIF1A -1.54 
Homo sapiens hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) (HIF1A), transcript variant 2, mRNA. 
SMC2 -1.54 
Homo sapiens structural maintenance of chromosomes 2 (SMC2), transcript variant 1, 
mRNA. 
 -1.54 Homo sapiens cDNA clone IMAGE:5277415, partial cds 
LOC441087 -1.54 Homo sapiens hypothetical gene supported by AK125735 (LOC441087), mRNA. 
RGS2 -1.55 Homo sapiens regulator of G-protein signalling 2, 24kDa (RGS2), mRNA. 
YIPF5 -1.55 Homo sapiens Yip1 domain family, member 5 (YIPF5), transcript variant 2, mRNA. 
MAD2L1 -1.55 Homo sapiens MAD2 mitotic arrest deficient-like 1 (yeast) (MAD2L1), mRNA. 
PSMA2 -1.55 
Homo sapiens proteasome (prosome, macropain) subunit, alpha type, 2 (PSMA2), 
mRNA. 
HYPK -1.55 Homo sapiens Huntingtin interacting protein K (HYPK), mRNA. 
PNN -1.55 Homo sapiens pinin, desmosome associated protein (PNN), mRNA. 
 -1.55 Homo sapiens cDNA: FLJ21027 fis, clone CAE07110 
WSB1 -1.55 
Homo sapiens WD repeat and SOCS box-containing 1 (WSB1), transcript variant 3, 
mRNA. 
CREB1 -1.55 
Homo sapiens cAMP responsive element binding protein 1 (CREB1), transcript variant 
A, mRNA. 
RPA3 -1.56 Homo sapiens replication protein A3, 14kDa (RPA3), mRNA. 
PDPR -1.56 
Homo sapiens pyruvate dehydrogenase phosphatase regulatory subunit (PDPR), 
mRNA. 
EID2B -1.56 Homo sapiens EP300 interacting inhibitor of differentiation 2B (EID2B), mRNA. 
PILRB -1.56 
Homo sapiens paired immunoglobin-like type 2 receptor beta (PILRB), transcript 
variant 2, mRNA. 
MTSS1 -1.57 Homo sapiens metastasis suppressor 1 (MTSS1), mRNA. 
GIMAP8 -1.57 Homo sapiens GTPase, IMAP family member 8 (GIMAP8), mRNA. 
PRICKLE1 -1.57 Homo sapiens prickle homolog 1 (Drosophila) (PRICKLE1), mRNA. 
DEFB4 -1.57 Homo sapiens defensin, beta 4 (DEFB4), mRNA. 
HAT1 -1.57 Homo sapiens histone acetyltransferase 1 (HAT1), transcript variant 1, mRNA. 
KIAA0672 -1.57 Homo sapiens KIAA0672 gene product (KIAA0672), mRNA. 
GRK5 -1.57 Homo sapiens G protein-coupled receptor kinase 5 (GRK5), mRNA. 
MBD4 -1.57 Homo sapiens methyl-CpG binding domain protein 4 (MBD4), mRNA. 
GYPC -1.57 PREDICTED: Homo sapiens glycophorin C (Gerbich blood group) (GYPC), mRNA. 
SLC43A3 -1.57 Homo sapiens solute carrier family 43, member 3 (SLC43A3), mRNA. 
CTSO -1.57 Homo sapiens cathepsin O (CTSO), mRNA. 
LPXN -1.57 Homo sapiens leupaxin (LPXN), mRNA. 
LOC389787 -1.57 
PREDICTED: Homo sapiens similar to Translationally-controlled tumor protein 
(TCTP) (p23) (Histamine-releasing factor) (HRF) (Fortilin) (LOC389787), mRNA. 
ALG5 -1.57 
Homo sapiens asparagine-linked glycosylation 5 homolog (S. cerevisiae, dolichyl-
phosphate beta-glucosyltransferase) (ALG5), mRNA. 
TMED7 -1.57 
Homo sapiens transmembrane emp24 protein transport domain containing 7 (TMED7), 
mRNA. 
IL7R -1.57 PREDICTED: Homo sapiens interleukin 7 receptor (IL7R), mRNA. 
LOC654194 -1.58 PREDICTED: Homo sapiens similar to ribosomal protein S27 (LOC654194), mRNA. 
 -1.58 
we85a04.x1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:2347854 3, 
mRNA sequence 
KNTC2 -1.58 
Homo sapiens NDC80 homolog, kinetochore complex component (S. cerevisiae) 
(NDC80), mRNA. 
KIAA1794 -1.59 Homo sapiens KIAA1794 (KIAA1794), mRNA. 
TNIP3 -1.59 Homo sapiens TNFAIP3 interacting protein 3 (TNIP3), mRNA. 
LRAP -1.59 Homo sapiens leukocyte-derived arginine aminopeptidase (LRAP), mRNA. 
PLCL2 -1.59 Homo sapiens phospholipase C-like 2 (PLCL2), mRNA. 
C7orf11 -1.60 Homo sapiens chromosome 7 open reading frame 11 (C7orf11), mRNA. 
CCL7 -1.60 Homo sapiens chemokine (C-C motif) ligand 7 (CCL7), mRNA. 
CKAP2 -1.60 Homo sapiens cytoskeleton associated protein 2 (CKAP2), mRNA. 
LOC130355 -1.60 Homo sapiens hypothetical protein LOC130355 (LOC130355), mRNA. 
TGFBI -1.60 Homo sapiens transforming growth factor, beta-induced, 68kDa (TGFBI), mRNA. 
HMMR -1.61 
Homo sapiens hyaluronan-mediated motility receptor (RHAMM) (HMMR), transcript 
variant 1, mRNA. 
GAS1 -1.61 Homo sapiens growth arrest-specific 1 (GAS1), mRNA. 
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CHRNA5 -1.61 Homo sapiens cholinergic receptor, nicotinic, alpha 5 (CHRNA5), mRNA. 
LRRFIP1 -1.61 Homo sapiens leucine rich repeat (in FLII) interacting protein 1 (LRRFIP1), mRNA. 
FLJ38451 -1.61 Homo sapiens FLJ38451 protein (FLJ38451), mRNA. 
CCNB1 -1.61 Homo sapiens cyclin B1 (CCNB1), mRNA. 
NEK2 -1.62 Homo sapiens NIMA (never in mitosis gene a)-related kinase 2 (NEK2), mRNA. 
SUB1 -1.62 Homo sapiens SUB1 homolog (S. cerevisiae) (SUB1), mRNA. 
LUM -1.62 Homo sapiens lumican (LUM), mRNA. 
GMNN -1.62 Homo sapiens geminin, DNA replication inhibitor (GMNN), mRNA. 
CCDC14 -1.62 Homo sapiens coiled-coil domain containing 14 (CCDC14), mRNA. 
HIGD1A -1.62 Homo sapiens HIG1 domain family, member 1A (HIGD1A), mRNA. 
FAM113A -1.62 Homo sapiens family with sequence similarity 113, member A (FAM113A), mRNA. 
LOC649518 -1.62 
PREDICTED: Homo sapiens similar to 40S ribosomal protein S26 (LOC649518), 
mRNA. 
BMP2 -1.63 Homo sapiens bone morphogenetic protein 2 (BMP2), mRNA. 
GIMAP4 -1.63 Homo sapiens GTPase, IMAP family member 4 (GIMAP4), mRNA. 
CXCL5 -1.63 Homo sapiens chemokine (C-X-C motif) ligand 5 (CXCL5), mRNA. 
GBP2 -1.63 Homo sapiens guanylate binding protein 2, interferon-inducible (GBP2), mRNA. 
DDX17 -1.64 
Homo sapiens DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 (DDX17), transcript 
variant 2, mRNA. 
HRSP12 -1.64 Homo sapiens heat-responsive protein 12 (HRSP12), mRNA. 
EPAS1 -1.64 Homo sapiens endothelial PAS domain protein 1 (EPAS1), mRNA. 
BMP6 -1.65 Homo sapiens bone morphogenetic protein 6 (BMP6), mRNA. 
GGH -1.65 
Homo sapiens gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl 
hydrolase) (GGH), mRNA. 
APBB3 -1.65 
Homo sapiens amyloid beta (A4) precursor protein-binding, family B, member 3 
(APBB3), transcript variant 4, mRNA. 
C10orf80 -1.65 Homo sapiens chromosome 10 open reading frame 80 (C10orf80), mRNA. 
SLC27A1 -1.65 
Homo sapiens solute carrier family 27 (fatty acid transporter), member 1 (SLC27A1), 
mRNA. 
MCM10 -1.65 
Homo sapiens minichromosome maintenance complex component 10 (MCM10), 
transcript variant 2, mRNA. 
LIMK2 -1.65 Homo sapiens LIM domain kinase 2 (LIMK2), transcript variant 1, mRNA. 
SMARCC2 -1.65 
Homo sapiens SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 2 (SMARCC2), transcript variant 1, mRNA. 
MTE -1.65 Homo sapiens metallothionein E (MTE), mRNA. 
C1orf176 -1.66 Homo sapiens chromosome 1 open reading frame 176 (C1orf176), mRNA. 
FLJ23657 -1.66 Homo sapiens chromosome 4 open reading frame 26 (C4orf26), mRNA. 
CD163 -1.66 Homo sapiens CD163 molecule (CD163), transcript variant 2, mRNA. 
LYN -1.66 
Homo sapiens v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (LYN), 
mRNA. 
C12orf35 -1.66 Homo sapiens chromosome 12 open reading frame 35 (C12orf35), mRNA. 
TP53TG3 -1.66 Homo sapiens TP53TG3 protein (TP53TG3), transcript variant 2, mRNA. 
GGH -1.66 
Homo sapiens gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl 
hydrolase) (GGH), mRNA. 
ZNF549 -1.66 Homo sapiens zinc finger protein 549 (ZNF549), mRNA. 
HCAP-G -1.67 Homo sapiens non-SMC condensin I complex, subunit G (NCAPG), mRNA. 
PFKFB3 -1.67 
Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), 
mRNA. 
RAB27A -1.67 
Homo sapiens RAB27A, member RAS oncogene family (RAB27A), transcript variant 
1, mRNA. 
PTMA -1.67 Homo sapiens prothymosin, alpha (gene sequence 28) (PTMA), mRNA. 
NUSAP1 -1.67 
Homo sapiens nucleolar and spindle associated protein 1 (NUSAP1), transcript variant 
1, mRNA. 
SAA1 -1.67 Homo sapiens serum amyloid A1 (SAA1), transcript variant 1, mRNA. 
GLT8D2 -1.67 Homo sapiens glycosyltransferase 8 domain containing 2 (GLT8D2), mRNA. 
PPM2C -1.67 
Homo sapiens protein phosphatase 2C, magnesium-dependent, catalytic subunit 
(PPM2C), nuclear gene encoding mitochondrial protein, mRNA. 
FAM119A -1.68 Homo sapiens family with sequence similarity 119, member A (FAM119A), mRNA. 
MMP9 -1.68 
Homo sapiens matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type 
IV collagenase) (MMP9), mRNA. 
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SBSN -1.68 Homo sapiens suprabasin (SBSN), mRNA. 
MMP12 -1.69 Homo sapiens matrix metallopeptidase 12 (macrophage elastase) (MMP12), mRNA. 
 -1.69 MR1-GN0172-061100-005-h03 GN0172 Homo sapiens cDNA, mRNA sequence 
STC1 -1.69 Homo sapiens stanniocalcin 1 (STC1), mRNA. 
TNFRSF1B -1.69 
Homo sapiens tumor necrosis factor receptor superfamily, member 1B (TNFRSF1B), 
mRNA. 
HRSP12 -1.69 Homo sapiens heat-responsive protein 12 (HRSP12), mRNA. 
MYLK -1.70 Homo sapiens myosin, light chain kinase (MYLK), transcript variant 2, mRNA. 
OLFML3 -1.70 Homo sapiens olfactomedin-like 3 (OLFML3), mRNA. 
TNFAIP6 -1.70 Homo sapiens tumor necrosis factor, alpha-induced protein 6 (TNFAIP6), mRNA. 
MYLIP -1.71 Homo sapiens myosin regulatory light chain interacting protein (MYLIP), mRNA. 
ST3GAL6 -1.71 Homo sapiens ST3 beta-galactoside alpha-2,3-sialyltransferase 6 (ST3GAL6), mRNA. 
GCH1 -1.71 
Homo sapiens GTP cyclohydrolase 1 (dopa-responsive dystonia) (GCH1), transcript 
variant 2, mRNA. 
EDG2 -1.71 
Homo sapiens endothelial differentiation, lysophosphatidic acid G-protein-coupled 
receptor, 2 (EDG2), transcript variant 1, mRNA. 
KLHL24 -1.71 Homo sapiens kelch-like 24 (Drosophila) (KLHL24), mRNA. 
KIF11 -1.71 Homo sapiens kinesin family member 11 (KIF11), mRNA. 
HMGB2 -1.71 Homo sapiens high-mobility group box 2 (HMGB2), mRNA. 
FKBP14 -1.72 Homo sapiens FK506 binding protein 14, 22 kDa (FKBP14), mRNA. 
SS18 -1.72 
Homo sapiens synovial sarcoma translocation, chromosome 18 (SS18), transcript 
variant 2, mRNA. 
RAD51AP1 -1.72 Homo sapiens RAD51 associated protein 1 (RAD51AP1), mRNA. 
OCA2 -1.72 
Homo sapiens oculocutaneous albinism II (pink-eye dilution homolog, mouse) 
(OCA2), mRNA. 
GRIPAP1 -1.73 Homo sapiens GRIP1 associated protein 1 (GRIPAP1), transcript variant 2, mRNA. 
ORM2 -1.73 Homo sapiens orosomucoid 2 (ORM2), mRNA. 
SAA1 -1.73 Homo sapiens serum amyloid A1 (SAA1), transcript variant 2, mRNA. 
PTPLB -1.74 
Homo sapiens protein tyrosine phosphatase-like (proline instead of catalytic arginine), 
member b (PTPLB), mRNA. 
KCNK1 -1.74 Homo sapiens potassium channel, subfamily K, member 1 (KCNK1), mRNA. 
FAM20C -1.74 Homo sapiens family with sequence similarity 20, member C (FAM20C), mRNA. 
FLJ11259 -1.74 Homo sapiens hypothetical protein FLJ11259 (FLJ11259), mRNA. 
SLC30A3 -1.74 
Homo sapiens solute carrier family 30 (zinc transporter), member 3 (SLC30A3), 
mRNA. 
ASPM -1.75 
Homo sapiens asp (abnormal spindle)-like, microcephaly associated (Drosophila) 
(ASPM), mRNA. 
C4orf18 -1.75 
Homo sapiens chromosome 4 open reading frame 18 (C4orf18), transcript variant 2, 
mRNA. 
CD82 -1.76 Homo sapiens CD82 molecule (CD82), transcript variant 2, mRNA. 
TNFAIP3 -1.76 Homo sapiens tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), mRNA. 
C12orf35 -1.76 Homo sapiens chromosome 12 open reading frame 35 (C12orf35), mRNA. 
STAT1 -1.76 
Homo sapiens signal transducer and activator of transcription 1, 91kDa (STAT1), 
transcript variant beta, mRNA. 
TSC22D1 -1.76 
Homo sapiens TSC22 domain family, member 1 (TSC22D1), transcript variant 1, 
mRNA. 
RPLP1 -1.77 Homo sapiens ribosomal protein, large, P1 (RPLP1), transcript variant 1, mRNA. 
LSM3 -1.77 
Homo sapiens LSM3 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
(LSM3), mRNA. 
MMP12 -1.77 Homo sapiens matrix metallopeptidase 12 (macrophage elastase) (MMP12), mRNA. 
ZNF503 -1.77 Homo sapiens zinc finger protein 503 (ZNF503), mRNA. 
SLC25A37 -1.78 
Homo sapiens solute carrier family 25, member 37 (SLC25A37), transcript variant 1, 
mRNA. 
SLC39A8 -1.78 
Homo sapiens solute carrier family 39 (zinc transporter), member 8 (SLC39A8), 
mRNA. 
FLJ20701 -1.79 Homo sapiens phosphotyrosine interaction domain containing 1 (PID1), mRNA. 
PNKD -1.79 
Homo sapiens paroxysmal nonkinesiogenic dyskinesia (PNKD), transcript variant 2, 
mRNA. 
GABARAPL2 -1.80 Homo sapiens GABA(A) receptor-associated protein-like 2 (GABARAPL2), mRNA. 
FAM9C -1.80 Homo sapiens family with sequence similarity 9, member C (FAM9C), mRNA. 
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STOM -1.81 Homo sapiens stomatin (STOM), transcript variant 1, mRNA. 
VGF -1.82 Homo sapiens VGF nerve growth factor inducible (VGF), mRNA. 
DSCR1L1 -1.82 Homo sapiens regulator of calcineurin 2 (RCAN2), mRNA. 
ADD3 -1.82 Homo sapiens adducin 3 (gamma) (ADD3), transcript variant 1, mRNA. 
MGC17330 -1.83 Homo sapiens phosphoinositide-3-kinase interacting protein 1 (PIK3IP1), mRNA. 
TDP1 -1.83 Homo sapiens tyrosyl-DNA phosphodiesterase 1 (TDP1), transcript variant 1, mRNA. 
PABPC1 -1.83 Homo sapiens poly(A) binding protein, cytoplasmic 1 (PABPC1), mRNA. 
CXCL13 -1.84 
Homo sapiens chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant) 
(CXCL13), mRNA. 
GJA1 -1.85 Homo sapiens gap junction protein, alpha 1, 43kDa (connexin 43) (GJA1), mRNA. 
PDGFC -1.86 Homo sapiens platelet derived growth factor C (PDGFC), mRNA. 
VNN2 -1.86 Homo sapiens vanin 2 (VNN2), transcript variant 1, mRNA. 
GDF15 -1.87 Homo sapiens growth differentiation factor 15 (GDF15), mRNA. 
ANTXR1 -1.87 Homo sapiens anthrax toxin receptor 1 (ANTXR1), transcript variant 1, mRNA. 
 -1.88 
xr14b10.x1 NCI_CGAP_Lu28 Homo sapiens cDNA clone IMAGE:2760091 3, mRNA 
sequence 
GAS1 -1.88 Homo sapiens growth arrest-specific 1 (GAS1), mRNA. 
ANGPTL2 -1.91 Homo sapiens angiopoietin-like 2 (ANGPTL2), mRNA. 
HCK -1.91 Homo sapiens hemopoietic cell kinase (HCK), mRNA. 
SLC1A3 -1.92 
Homo sapiens solute carrier family 1 (glial high affinity glutamate transporter), 
member 3 (SLC1A3), mRNA. 
C3orf34 -1.93 Homo sapiens chromosome 3 open reading frame 34 (C3orf34), mRNA. 
ZNF91 -1.94 Homo sapiens zinc finger protein 91 (HPF7, HTF10) (ZNF91), mRNA. 
HSD11B1 -1.94 
Homo sapiens hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), transcript 
variant 2, mRNA. 
FCAR -1.95 Homo sapiens Fc fragment of IgA, receptor for (FCAR), transcript variant 9, mRNA. 
CA2 -1.96 Homo sapiens carbonic anhydrase II (CA2), mRNA. 
MT1E -1.96 Homo sapiens metallothionein 1E (MT1E), mRNA. 
SLPI -1.97 Homo sapiens secretory leukocyte peptidase inhibitor (SLPI), mRNA. 
EFNA1 -1.97 Homo sapiens ephrin-A1 (EFNA1), transcript variant 1, mRNA. 
SEMA3E -2.00 
Homo sapiens sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3E (SEMA3E), mRNA. 
MAFB -2.00 
Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 
(MAFB), mRNA. 
HEY1 -2.00 Homo sapiens hairy/enhancer-of-split related with YRPW motif 1 (HEY1), mRNA. 
CMKOR1 -2.01 Homo sapiens chemokine orphan receptor 1 (CMKOR1), mRNA. 
LAMB1 -2.01 Homo sapiens laminin, beta 1 (LAMB1), mRNA. 
PPAP2B -2.02 
Homo sapiens phosphatidic acid phosphatase type 2B (PPAP2B), transcript variant 1, 
mRNA. 
DUSP23 -2.06 Homo sapiens dual specificity phosphatase 23 (DUSP23), mRNA. 
KIAA1754 -2.07 Homo sapiens KIAA1754 (KIAA1754), mRNA. 
MRGPRX3 -2.08 Homo sapiens MAS-related GPR, member X3 (MRGPRX3), mRNA. 
NFIX -2.09 
Homo sapiens nuclear factor I/X (CCAAT-binding transcription factor) (NFIX), 
mRNA. 
WISP1 -2.13 
Homo sapiens WNT1 inducible signaling pathway protein 1 (WISP1), transcript 
variant 1, mRNA. 
BCL6 -2.13 
Homo sapiens B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6), transcript 
variant 1, mRNA. 
SNX10 -2.13 Homo sapiens sorting nexin 10 (SNX10), mRNA. 
MMP8 -2.13 Homo sapiens matrix metallopeptidase 8 (neutrophil collagenase) (MMP8), mRNA. 
HSD11B1 -2.17 
Homo sapiens hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), transcript 
variant 1, mRNA. 
CD163 -2.20 Homo sapiens CD163 molecule (CD163), transcript variant 2, mRNA. 
MT1G -2.20 Homo sapiens metallothionein 1G (MT1G), mRNA. 
ACSL4 -2.23 
Homo sapiens acyl-CoA synthetase long-chain family member 4 (ACSL4), transcript 
variant 1, mRNA. 
LOC441019 -2.23 PREDICTED: Homo sapiens hypothetical LOC441019 (LOC441019), mRNA. 
OLFM1 -2.26 Homo sapiens olfactomedin 1 (OLFM1), transcript variant 1, mRNA. 
MT1H -2.26 Homo sapiens metallothionein 1H (MT1H), mRNA. 
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KCNMB4 -2.29 
Homo sapiens potassium large conductance calcium-activated channel, subfamily M, 
beta member 4 (KCNMB4), mRNA. 
SAA2 -2.40 Homo sapiens serum amyloid A2 (SAA2), mRNA. 
PI3 -2.40 Homo sapiens peptidase inhibitor 3, skin-derived (SKALP) (PI3), mRNA. 
MT1F -2.40 Homo sapiens metallothionein 1F (MT1F), mRNA. 
DNER -2.44 
Homo sapiens delta-notch-like EGF repeat-containing transmembrane (DNER), 
mRNA. 
CA2 -2.44 Homo sapiens carbonic anhydrase II (CA2), mRNA. 
HSD11B1 -2.60 
Homo sapiens hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), transcript 
variant 2, mRNA. 
MMP13 -2.63 Homo sapiens matrix metallopeptidase 13 (collagenase 3) (MMP13), mRNA. 
CXCL5 -2.82 Homo sapiens chemokine (C-X-C motif) ligand 5 (CXCL5), mRNA. 
LOC654103 -2.85 
PREDICTED: Homo sapiens similar to solute carrier family 25, member 37 
(LOC654103), mRNA. 
LOC653778 -2.97 
PREDICTED: Homo sapiens similar to solute carrier family 25, member 37 
(LOC653778), mRNA. 
MT1B -3.15 Homo sapiens metallothionein 1B (MT1B), mRNA. 
COL10A1 -3.25 
Homo sapiens collagen, type X, alpha 1(Schmid metaphyseal chondrodysplasia) 
(COL10A1), mRNA. 
S100A8 -3.80 Homo sapiens S100 calcium binding protein A8 (S100A8), mRNA. 
LBP -3.93 Homo sapiens lipopolysaccharide binding protein (LBP), mRNA. 
CCL20 -4.17 Homo sapiens chemokine (C-C motif) ligand 20 (CCL20), mRNA. 
ORM1 -4.43 Homo sapiens orosomucoid 1 (ORM1), mRNA. 
S100A9 -4.82 Homo sapiens S100 calcium binding protein A9 (calgranulin B) (S100A9), mRNA. 
CRP -8.97 Homo sapiens C-reactive protein, pentraxin-related (CRP), mRNA. 
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